0001033905-21-000012.txt : 20210226 0001033905-21-000012.hdr.sgml : 20210226 20210226110446 ACCESSION NUMBER: 0001033905-21-000012 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 73 CONFORMED PERIOD OF REPORT: 20201231 FILED AS OF DATE: 20210226 DATE AS OF CHANGE: 20210226 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LUMINEX CORP CENTRAL INDEX KEY: 0001033905 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 742747608 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-30109 FILM NUMBER: 21685264 BUSINESS ADDRESS: STREET 1: 12212 TECHNOLOGY BLVD STREET 2: 512-219-8020 CITY: AUSTIN STATE: TX ZIP: 78727 BUSINESS PHONE: 5122494741 MAIL ADDRESS: STREET 1: 12212 TECHNOLOGY BLVD CITY: AUSTIN STATE: TX ZIP: 78727 10-K 1 lmnx-20201231.htm 10-K lmnx-20201231
December 31, 2020000103390512/312020FYfalse46,688,3091,344,295,984December 31, 20200.0010.001200,000,000200,000,00045,682,68744,325,36945,682,68744,325,3690.0010.0015,000,0005,000,000————1,140843117,46799,84990,424109,519106,060111,39340,07839,83842,67946,94950,34669,68163,38164,44448,70550,90551,85553,9441,64118,77611,52610,50065412,5101,7672390.010.270.040.010.010.270.040.010.090.090.090.1082,40883,05678,67390,50136,60137,82936,83340,63645,80745,22741,84049,86549,39150,98347,56246,8823,5845,7565,7222,9832,9604,9315,2503,3830.070.110.120.080.070.110.120.070.060.060.090.0900010339052020-01-012020-12-31iso4217:USD00010339052020-06-30xbrli:shares00010339052021-02-2600010339052020-12-3100010339052019-12-31iso4217:USDxbrli:shares00010339052019-01-012019-12-3100010339052018-01-012018-12-3100010339052020-01-012020-03-3100010339052020-04-012020-06-3000010339052020-07-012020-09-3000010339052020-10-012020-12-3100010339052019-01-012019-03-3100010339052019-04-012019-06-3000010339052019-07-012019-09-3000010339052019-10-012019-12-3100010339052018-12-3100010339052017-12-310001033905us-gaap:CommonStockMember2017-12-310001033905us-gaap:AdditionalPaidInCapitalMember2017-12-310001033905us-gaap:AccumulatedOtherComprehensiveIncomeMember2017-12-310001033905us-gaap:RetainedEarningsMember2017-12-310001033905us-gaap:CommonStockMember2018-01-012018-12-310001033905us-gaap:AdditionalPaidInCapitalMember2018-01-012018-12-310001033905us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-01-012018-12-310001033905us-gaap:RetainedEarningsMember2018-01-012018-12-310001033905us-gaap:CommonStockMember2018-12-310001033905us-gaap:AdditionalPaidInCapitalMember2018-12-310001033905us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-310001033905us-gaap:RetainedEarningsMember2018-12-310001033905us-gaap:CommonStockMember2019-01-012019-12-310001033905us-gaap:AdditionalPaidInCapitalMember2019-01-012019-12-310001033905us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-12-310001033905us-gaap:RetainedEarningsMember2019-01-012019-12-310001033905us-gaap:CommonStockMember2019-12-310001033905us-gaap:AdditionalPaidInCapitalMember2019-12-310001033905us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001033905us-gaap:RetainedEarningsMember2019-12-310001033905us-gaap:CommonStockMember2020-01-012020-12-310001033905us-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-310001033905us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-310001033905us-gaap:RetainedEarningsMember2020-01-012020-12-310001033905us-gaap:CommonStockMember2020-12-310001033905us-gaap:AdditionalPaidInCapitalMember2020-12-310001033905us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001033905us-gaap:RetainedEarningsMember2020-12-310001033905us-gaap:LicensingAgreementsMember2020-12-310001033905us-gaap:LicensingAgreementsMember2019-12-310001033905us-gaap:FairValueInputsLevel1Member2020-12-310001033905us-gaap:FairValueInputsLevel2Member2020-12-310001033905us-gaap:FairValueInputsLevel3Member2020-12-310001033905us-gaap:FairValueInputsLevel1Member2019-12-310001033905us-gaap:FairValueInputsLevel2Member2019-12-310001033905us-gaap:FairValueInputsLevel3Member2019-12-310001033905us-gaap:TechnologyBasedIntangibleAssetsMember2018-12-310001033905us-gaap:CustomerRelatedIntangibleAssetsMember2018-12-310001033905us-gaap:OtherIntangibleAssetsMember2018-12-310001033905us-gaap:TechnologyBasedIntangibleAssetsMember2019-01-012019-12-310001033905us-gaap:CustomerRelatedIntangibleAssetsMember2019-01-012019-12-310001033905us-gaap:OtherIntangibleAssetsMember2019-01-012019-12-310001033905us-gaap:TechnologyBasedIntangibleAssetsMember2019-12-310001033905us-gaap:CustomerRelatedIntangibleAssetsMember2019-12-310001033905us-gaap:OtherIntangibleAssetsMember2019-12-310001033905us-gaap:TechnologyBasedIntangibleAssetsMember2020-01-012020-12-310001033905us-gaap:CustomerRelatedIntangibleAssetsMember2020-01-012020-12-310001033905us-gaap:OtherIntangibleAssetsMember2020-01-012020-12-310001033905us-gaap:TechnologyBasedIntangibleAssetsMember2020-12-310001033905us-gaap:CustomerRelatedIntangibleAssetsMember2020-12-310001033905us-gaap:OtherIntangibleAssetsMember2020-12-31xbrli:pureutr:Rate0001033905us-gaap:EmployeeStockOptionMember2019-12-310001033905us-gaap:EmployeeStockOptionMember2020-01-012020-12-310001033905us-gaap:EmployeeStockOptionMember2020-12-310001033905us-gaap:RestrictedStockMember2020-01-012020-12-310001033905us-gaap:RestrictedStockMember2019-01-012019-12-310001033905us-gaap:RestrictedStockMember2018-01-012018-12-310001033905us-gaap:RestrictedStockMember2019-12-310001033905us-gaap:RestrictedStockMember2020-12-310001033905us-gaap:RestrictedStockUnitsRSUMember2019-12-310001033905us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-12-310001033905us-gaap:RestrictedStockUnitsRSUMember2020-12-310001033905us-gaap:RestrictedStockUnitsRSUMember2019-01-012019-12-310001033905us-gaap:RestrictedStockUnitsRSUMember2018-01-012018-12-310001033905us-gaap:EmployeeStockOptionMember2019-01-012019-12-310001033905us-gaap:EmployeeStockOptionMember2018-01-012018-12-31



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-K
☑Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended
December 31, 2020or
☐Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from __ to __.
lmnx-20201231_g1.jpg 
LUMINEX CORPORATION
(Exact name of registrant as specified in its charter)
Delaware000-3010974-2747608
(State or other jurisdiction of incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
12212 Technology Blvd.,Austin,Texas78727
(Address of principal executive offices)(Zip Code)
(512)219-8020
Registrant’s Telephone Number, Including Area Code
None
Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of exchange on which registered
Common Stock, $0.001 par valueLMNXThe Nasdaq Global Select Market
Securities registered pursuant to Section 12(g) of the Act: NONE
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
☑Yes☐No
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
☐Yes☑No
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
☑Yes☐No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
☑Yes☐No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☑Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
Emerging growth company☐



If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.
☑
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
☐Yes☑No

Based on the closing sale price of common stock on The Nasdaq Global Select Market on June 30, 2020, the aggregate market value of the voting stock held by non-affiliates of the Registrant was $1,344,295,984 as of such date, which assumes, for purposes of this calculation only, that all shares of common stock beneficially held by officers and directors are shares owned by “affiliates.”

There were 46,688,309 shares of the Company’s Common Stock, par value $0.001 per share, outstanding on February 25, 2021.


DOCUMENTS INCORPORATED BY REFERENCE

Portions of the Registrant’s Proxy Statement for its 2021 Annual Meeting of Stockholders are incorporated by reference into Part III hereof.


LUMINEX CORPORATION

FORM 10-K
FOR THE YEAR ENDED DECEMBER 31, 2020

TABLE OF CONTENTS
PAGE
 
Item 1A.
Risk Factors
Item 3.
Legal Proceedings

SAFE HARBOR CAUTIONARY STATEMENT

    This annual report on Form 10-K contains statements that are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide our current expectations of forecasts of future events. All statements other than statements of current or historical fact contained in this annual report, including statements regarding our future financial position, business strategy, impact of the reimbursement landscape, products including ARIES, VERIGENE, NxTAG, Muse, Guava, easyCyte, InCyte, Amnis, ImageStream, Flowsight and CellStream, assay sales, consumable sales patterns and bulk purchases, budgets, system sales, anticipated gross margins, liquidity, cash flows, projected costs and expenses, taxes, deferred tax assets, regulatory approvals or the impact of laws or regulations applicable to us, plans and objectives of management for future operations, and impact of prior acquisitions or future acquisitions, integration and the expected benefit of our acquisitions are all forward-looking statements. The words “anticipate,” “believe,” “continue,” “should,” “estimate,” “expect,” “intend,” “may,” “plan,” “projects,” “will” and similar expressions as they relate to us, are intended to identify forward-looking statements. These statements are based on our current plans and actual future activities, and our financial condition and results of operations may be materially different from those set forth in the forward-looking statements as a result of known or unknown risks and uncertainties, including, among other things:

•the ongoing uncertainty caused by the COVID-19 pandemic, including uncertainty regarding its extent, duration and impact, the uncertainty regarding the long-term impacts of the COVID-19 pandemic on our and our customers’, suppliers’, partners’ and other business relations’ business, prospects, financial condition, operating results, liquidity and personnel, as well as its impacts on capital markets and general economic conditions, and the actions by government officials at the federal, state or local level in connection with the COVID-19 pandemic;

•concentration of our revenue in a limited number of direct customers and strategic partners, some of which may be experiencing decreased demand for their products utilizing or incorporating our technology, budget or finance constraints in the current economic environment, or periodic variability in their purchasing patterns or practices as a result of internal resource planning challenges;

•risks and uncertainties relating to market demand and acceptance of our products and technology, including ARIES, MultiCode, xMAP, xMAP INTELLIFLEX, VERIGENE, VERIGENE II, Guava, Muse, Amnis, and NxTAG products;

•timing of and process for regulatory approvals;

•our ability to scale manufacturing operations (particularly with respect to our products that recently received U.S. Food and Drug Administration (FDA) EUA clearance) and manage operating expenses, gross margins and inventory levels;

•potential shortages, or increases in costs, of components or other disruptions to our manufacturing operations;

•our ability to obtain and enforce intellectual property protections on our products and technologies;

•our ability to successfully develop and launch new products in a timely manner;

•competition and competitive technologies utilized by our competitors;

•dependence on strategic partners for development, commercialization and distribution of products;

•reliance upon the accuracy and completeness of the information received from strategic partners to determine the appropriate financial reporting;

•risks and uncertainties associated with implementing our acquisition strategy, and our challenge to identify acquisition targets, including our ability to obtain financing on acceptable terms;

•our ability to integrate acquired companies or selected assets into our consolidated business operations, and the ability to fully realize the benefits of our acquisitions;

•fluctuations in quarterly results due to a lengthy and unpredictable sales cycle, fluctuations in bulk purchases of consumables, fluctuations in product mix and the seasonal nature of some of our assay products;


•our ability to comply with applicable laws, regulations, policies and procedures;

•the impact of the ongoing uncertainty in global finance markets and changes in governmental and governmental agency funding, including its effects on the capital spending policies of our partners and end users and their ability to finance purchases of our products;

•changes in principal members of our management staff;

•our increasing dependency on information technology to enable us to improve the effectiveness of our operations and to monitor financial accuracy and efficiency;

•implementation, including any modification, of our strategic operating plans;

•uncertainty regarding the outcome or expense of any litigation brought against or initiated by us;

•risks relating to our foreign operations, including fluctuations in exchange rates, tariffs, customs and other barriers to importing/exporting materials and products in a cost-effective and timely manner; difficulties in accounts receivable collections; our ability to monitor and comply with foreign and international laws and treaties; and our ability to comply with changes in international taxation policies;

•budget or finance constraints in the current economic environment, or periodic variability in customer purchasing patterns or practices as a result of material resource planning challenges;

•reliance on third party distributors for distribution of specific Luminex-developed and manufactured assay products; and

•risks related to the issuance of our Convertible Senior Notes due in May 2025 (the Notes) and with respect to the Convertible Note Hedge Transactions.

    Many of these risks, uncertainties and other factors are beyond our control and are difficult to predict. Any or all of our forward-looking statements in this annual report may turn out to be inaccurate. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. New factors could also emerge from time to time that could adversely affect our business. The forward-looking statements herein can be affected by inaccurate assumptions we might make or by known or unknown risks, uncertainties and assumptions, including the risks, uncertainties and assumptions outlined above and described in Item 1A “Risk Factors” below. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this annual report may not occur and actual results could differ materially from those anticipated or implied in the forward-looking statements. When you consider these forward-looking statements, you should keep in mind these risk factors and other cautionary statements in this annual report including in Item 7 “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and in Item 1A “Risk Factors.”
 
Our forward-looking statements speak only as of the date made. We undertake no obligation to publicly update or revise forward-looking statements, whether as a result of new information, future events or otherwise. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements contained in this annual report.
 
    Unless the context requires otherwise, references in this Annual Report on Form 10-K to “Luminex,” the “Company,” “we,” “us” and “our” refer to Luminex Corporation and its subsidiaries.
___________________

Amnis®, ARIES®, CellStream®, easyCheck™, easyCyte™, Flex®, FLEXMAP 3D®, FlowCellect®, FlowSight®, Guava®, GuavaSoft™, Guava Express®, Guava Nexin®, IDEAS®, ImageStream®, InCyte™, INSPIRE™, LumAvidin®, Luminex®, Luminex 100™, Luminex 200™, SD™, MAGPIX®, MagPlex®, MagPlex-TAG™, MicroPlex®, MultiCode®, Muse®, NxTAG®, SeroMAP™, SpeedBead®, SYNCT™, VERIGENE®, ViaCount™, xMAP®, xMAP INTELLIFLEX™, xPONENT®, xTAG®, and XYP™ are trademarks of Luminex Corporation or one of its subsidiaries. This report also refers to trademarks, service marks and trade names of other organizations. Our use or display of other parties’ trademarks, trade dress or products in this Annual Report does not imply that we have a relationship with, or the endorsement or sponsorship of, the trademark or trade dress owners.

PART I
ITEM 1. BUSINESS

Overview
We develop, manufacture and sell proprietary biological testing technologies and products with applications throughout the life sciences industries, including diagnostics, pharmaceutical and research. These industries depend on a broad range of tests, called assays, to perform diagnostic testing and conduct life science research. We have established a position in several segments of the life sciences industries by developing and delivering products that satisfy a variety of customer needs in specific market segments, including multiplexing, accuracy, precision, sensitivity, specificity, reduction of labor and ability to test for proteins and nucleic acids. These needs are addressed by our proprietary technologies.

Multiplexing, the foundation of our Company, allows the end user in a laboratory to generate multiple laboratory results from a single sample with a single assay. This is important because our end user customers, which include laboratory professionals performing discovery and research, and clinical laboratories performing tests on patients as ordered by physicians and other laboratories, have a fundamental need to perform high quality testing as efficiently as possible. Until the availability of multiplexing technology, the laboratory professional had to perform one assay at a time in a sequential manner, and if additional testing was required on a sample, a second assay would be performed to generate the second result, and so on until all the necessary tests were performed.

Business Strategy

Our Company’s current focus is both on solidifying our leadership position as a provider of effective tools for diagnostic and research use, as well as establishing Luminex as a market leader in the molecular diagnostic market. To achieve these objectives, we have implemented and are pursuing the following strategies:

•Focus on key markets

We have identified the following goals in our key market segments: (i) expanding usage of our automated molecular infectious disease testing solutions, (ii) enabling and expanding end markets for our xMAP technologies through our partnership arrangements, and (iii) developing and expanding the image-based flow cytometry market. We will continue to employ a combination of a product-driven direct sales model focused on select market segments and assay applications and a partnership-driven business model to achieve our goals.

•Develop and deliver market-leading molecular diagnostic platforms and assays

Our research and development and our acquisition activity have expanded the breadth of technologies and solutions we offer our customers to meet their needs. In addition, we collaborate with industry participants, biomedical research institutions and government entities to develop additional products on our platforms, and we continuously consider other adjacent markets where our platforms and assay offerings would be beneficial.

In March 2020, the Biomedical Advanced Research and Development Authority (BARDA) awarded the Company two milestone-based contracts related to the development of diagnostics for SARS-COV-2, with a value of $642,450 each, funding approximately 36% of the overall cost of development. The Company’s management believes these two contracts helped to enable an expansion of the Company’s current portfolio of diagnostics for SARS-CoV-2 (the virus that causes COVID-19). In September 2020, BARDA awarded the Company two additional milestone-based contracts valued at $5,389,813 and $683,500, respectively, related to completing a 510(k) filing for Luminex’s expanded NxTAG Respiratory Pathogen Panel (RPP), which will include the SARS-CoV-2 virus for COVID-19 testing and to support the enhancement of the Company’s xMAP SARS-CoV-2 Multi-Antigen IgG Assay. The Company intends to submit this enhanced serology assay for an Emergency Use Authorization (EUA) when this project is completed.

Based upon our understanding of the needs of our customers to address the impacts of COVID-19, in addition to the above, the Company intends to include diagnostics for SARS-CoV-2 in future syndromic panels.

1

We also offer our VERIGENE System, which provides automated, cost-effective multiplex capabilities that rapidly and accurately detect infectious pathogens and drug resistance markers, without relying on time-consuming culture methods. We believe the VERIGENE System delivers better outcomes, improved patient care, earlier optimization for patient treatment and improved laboratory and hospital efficiency, all at a lower cost than competing systems. We currently offer assays on the VERIGENE platform in the categories of Bloodstream Infection Tests, Gastrointestinal Infection Tests and a Respiratory Infection Test.

We also are developing the VERIGENE II System, having initiated clinical studies on the system and its first assay in 2018. We currently expect to commercially launch the VERIGENE II System in 2021.

In addition, we have improved the simplicity and ease-of-use of our xMAP-based multiplex products through the development of a version of our multiplex PCR technology. This NxTAG chemistry streamlines workflow without sacrificing throughput, preserving the ability to process 1 to 96 patient samples in a single batch. This throughput flexibility and capacity is a crucial aspect for tests like our NxTAG Respiratory Pathogen Panel (RPP), in which seasonality and local outbreaks can cause testing volumes to surge unpredictably. We continue to pursue projects such as development of consumables, automation, software and the expansion and enhancement of our multiplexing capabilities to advance our technologies and improve market acceptance.

We are working on the development of the xMAP INTELLIFLEX instrument, a next generation bead-based multiplexing system. This new system will provide the opportunity to address both expanding and evolving market needs, plus offer an opportunity for existing users to upgrade to a modernized version of bead-based multiplexing. We currently expect to commercially launch this system in the first half of 2021.

We have developed a full range of multiplexing instruments and consumables to cover a broad range of customer applications and budgets. We have developed, and continue to improve, our proprietary chemistries for our multiplex assays in areas such as infectious disease testing, human genetic testing and personalized medicine testing. All of these technology solutions provide our customers with a breadth of innovative solutions to meet their many testing needs.

We have plans to submit additional assays to regulatory authorities in 2021, including the FDA and foreign equivalents, for market authorization in order to comply with established guidelines across the jurisdictions in which we compete.

Additionally, we intend to expand our presence in the image-based, flow cytometry market with our proprietary technology that provides microscopy-quality images of individual cells. The new product will evolve our flagship Amnis ImageStream platform to deliver a simplified user experience with enhanced performance and functionality. The improvements made with this new product should both further advance scientific discovery and expand adoption. Advances in instrument design should also improve image definition, accelerate data acquisition, and increase system flexibility. Finally, new data analysis capabilities should improve system usability to enable a greater range of applications with less user effort.

•Actively pursue acquisitions to accelerate our business strategies

We actively assess potential acquisition targets to accelerate our business strategies in the key markets described above. This approach led to several successful acquisitions historically, including GenturaDx, which is the foundation of our ARIES System, Nanosphere, which is the foundation of the VERIGENE System and EMD Millipore Corporation’s flow cytometry portfolio. We actively evaluate opportunities to enhance our capabilities or our access to targeted markets and technologies, to provide us other advantages in executing our business strategies in our key markets.

•Continue to develop the partnership channel focused on select key markets

As of December 31, 2020, 54 of our 82 strategic partners have developed and commercialized xMAP-based assays and are paying royalties to us. We also have strategic partners who distribute Luminex products. During 2020, the 54 strategic partners who have commercialized xMAP-based assays accounted for approximately 31% of our total revenue and all of our strategic partners represented approximately 33% of our total revenue. Of these 54 strategic partners, 27 principally serve the clinical diagnostics market and 27 principally serve the life science research market. We intend to continue pursuing opportunities to expand market acceptance of xMAP technology through development, marketing and distribution partnerships with leading companies in the life sciences markets. By leveraging our strategic partners’ market positions and utilizing their distribution channels and marketing infrastructure, we believe we can continue to expand our installed instrument base.
2
Furthermore, our partners’ investments in research and development for xMAP applications provide customers vastly more assay solutions than we could develop and commercialize individually.
    
    We continue to focus our commercialization efforts through our strategic partners covering large sectors of the life science research market, where Luminex believes it has competitive advantages over alternative technologies and approaches. We define strategic partners as those companies in the life sciences markets that develop and distribute assays and tests on xMAP technology or that may only distribute our xMAP technology-based systems and consumables. With our partners’ support and through our direct commercial efforts in the molecular diagnostics clinical laboratory segment, we have targeted major pharmaceutical companies, large clinical laboratories, research institutions and major medical institutions for our principal marketing efforts. We believe that these customers provide the greatest opportunity for maximizing the use of xMAP-based products and that continued adoption by these industry leaders will promote wider market acceptance of our xMAP technology.

Market Approach / Sales and Marketing

Our three primary focus areas for continued revenue growth, as well as our sales and marketing strategies to achieve such growth, are as follows:

1. Molecular Diagnostics: the development and sale of molecular diagnostic assays utilizing our proprietary MultiCode, xMAP and VERIGENE technologies for use on our installed base of automated and non-automated systems. Our molecular diagnostic assay sales and marketing strategy is to expand the installed base and utilization of xMAP, xTAG, NxTAG, ARIES and VERIGENE product lines. We sell the xTAG, NxTAG, MultiCode, ARIES and VERIGENE product lines primarily through a direct sales channel. Building a direct relationship with customers is a critical component of our sales and marketing strategy to launch innovative products such as our VERIGENE Systems, NxTAG Respiratory Pathogen Panel (RPP) and ARIES Systems. In addition, we market and sell our clinical diagnostics products to group purchasing organizations (GPOs) and integrated healthcare delivery networks. These efforts support and enable our selling efforts to individual laboratories, for example, by contracting with GPOs to provide standardized pricing and terms for member hospitals. Our assays are primarily focused on multiplexed applications for the human molecular clinical diagnostics market and are also focused on three segments of the molecular diagnostic testing market: infectious disease, human genetics and personalized medicine.

2. Licensed Technologies Group (LTG): the sustained expansion of our partnership revenues through the introduction of an innovative new xMAP system and continued fulfillment of our partner's needs in their respective fields of use, as well as supporting the kit development and testing services developed or performed by partners who generate royalties. Our strategic partners include market leaders in immune/clinical diagnostics, protein diagnostic, pharmaceutical and life sciences companies that develop applications and/or provide testing services using our xMAP technology platforms. Some partners also distribute xMAP Systems to their customers. Our LTG sales and marketing strategy also includes generating recurring revenues from the sale of Luminex developed assays, microspheres and other consumables,

We continue to work with these strategic partners as the primary distribution channel for our xMAP Systems, and we will continue to pursue new partnerships focusing on partners with market presence in the key partner segments described below. Some of our strategic partners develop application-specific kits for use on our xMAP Systems that they, in turn, sell to their customers, thereby generating royalties for us. Certain strategic partners also perform testing services for third parties using our xMAP products, which also result in royalty revenue. We also contract with distributors to purchase and resell xMAP Systems and consumables in geographic or application-specific areas not covered by strategic partners.

We update our LTG listing regularly to reflect partner consolidations resulting from mergers and acquisitions, commercial sales inactivity, as well as termination or expiration of existing non-performing partner agreements. We also believe our strategic partners provide us with complementary capabilities in product development, regulatory expertise and sales and marketing. By leveraging our strategic partners’ assay development capabilities, customer relationships and distribution channels, we believe that we can continue to achieve measurable market penetration and product adoption. Our current partners are in various stages of development and commercialization of products that incorporate our technology.

We also serve as an original equipment manufacturer (OEM) for certain strategic partners who choose to sell components of the xMAP product line as an embedded system under their own branding and marketing efforts. Luminex and these partners have sold more than 17,900 xMAP-based instruments in laboratories worldwide as of December 31, 2020, some of which may be retired or otherwise not in use.
3

3. Flow Cytometry: the continued innovation of our proprietary image-based flow cytometry technology, and expansion of all of our platforms into existing and additional markets. Our flow cytometry sales and marketing strategy is to become a global leader in flow cytometry, competing in all markets with disruptive and differentiated solutions by expanding our position in the research markets, building our diagnostic capabilities and increasing content generation. We are pursuing this strategy by leveraging our pipeline of new product launches and expanding our positions in the pharma, academic, diagnostics and industrial markets, which we believe will allow us to grow our recurring revenue in service, research and clinical reagents, and clinical trial solutions and drive geographic expansion in both established and developing markets.

We sell the Amnis and Guava Flow Cytometry Systems through a direct sales channel in developed markets in North America, Europe, the Middle East, Africa and the Asia-Pacific region, and through distribution partners in emerging markets in Southeast Asia, Africa and Latin America. Our flow cytometry business has built healthy relationships with its customer base and has a reputation for quality customer support through its sales team and field application scientists, as well as technical service and instrument repair teams. We anticipate continuing to leverage these strengths to expand our installed base of instruments and concomitant recurring sales of reagents, software licenses and services.

Products

The table below briefly describes our key systems and technologies:
SYSTEMSTECHNOLOGIES
Luminex 100/200xMAP Technology
FLEXMAP 3DxMAP Technology
MAGPIXxMAP Technology
ARIES and ARIES M1xTAG and MultiCode Technologies
VERIGENENanoGrid Technology
Amnis FlowSight
Amnis CCD-TDI Technology
Amnis ImageStream
Amnis CCD-TDI Technology
Amnis CellStream
Amnis CCD-TDI Technology
Guava easyCyteGuava Microcapillary Technology
Muse Cell AnalyzerGuava Microcapillary Technology

Products

xMAP Products

Our xMAP products are based on an open architecture, multiplexing technology that combines existing biological testing techniques with illumination, advanced digital signal processing, detection and proprietary software. This technology is multi-analyte and multi-format, flexible and scalable and able to analyze both proteins and nucleic acids on a single platform, all while providing high throughput utilizing a process that is designed to be simple to use and cost-effective for customers compared to competitive techniques and technologies. These products can simultaneously perform up to 500 tests in a single well, permitting up to 96,000 tests to be detected in approximately one hour with only a small amount of sample. We have a full range of instruments built on this technology, leveraging proprietary optics, digital signal processors and software to automate data acquisition and analysis in real-time. Our products based on this technology are currently used within various segments of the life sciences industries, including the fields of drug discovery and development, and for clinical diagnostics, COVID-19 testing, bio-defense, food safety and biomedical research.

xMAP Instruments

Luminex 100/200. Luminex 100/200 Systems are compact analyzers that integrate fluidics, optics and digital signal processing to measure up to 100 analytes simultaneously in a single tube or well of a microtiter plate using only a small amount of sample. By combining lasers with digital signal processors and microcontrollers, these systems perform rapid, multi-analyte profiles under the control of a Windows-based personal computer and our proprietary software.

4

MAGPIX. The MAGPIX System is a versatile multiplexing analyzer capable of performing qualitative and quantitative analyses of proteins and nucleic acids in a variety of sample matrices. This system can measure up to 50 analytes in a single reaction volume, reducing sample input, reagents and labor, while simultaneously improving productivity. The MAGPIX System is based on an innovative detection mechanism that uses LEDs and a charge-coupled device (CCD) imaging system, rather than the lasers and detection mechanisms used in our FLEXMAP 3D and Luminex 100/200 instruments.

FLEXMAP 3D. The FLEXMAP 3D System is intended for use as a general laboratory instrument in the life sciences, diagnostics, and associated markets. This device can simultaneously measure up to 500 analytes from a single sample and offers increased speed and enhanced ease-of-use and serviceability. Like our Luminex 100/200 Systems, the FLEXMAP 3D System combines lasers with digital signal processors and microcontrollers and these systems perform rapid, multi-analyte profiles under the control of a Windows-based personal computer and our proprietary software.

xMAP Consumables

MicroPlex Microspheres. Our Luminex 100/200, FLEXMAP 3D and MAGPIX Systems use polystyrene microspheres that are approximately 5.6 microns in diameter. We dye the microspheres in sets with varying intensities of a red and a near infrared dye to achieve up to 100 distinct color sets. Each microsphere can be coupled with proteins, nucleic acids or other molecules to enable biological assays.

MagPlex Microspheres. Our MagPlex microspheres feature super-paramagnetic properties that make them ideal for running automated xMAP-based assays. We dye the microspheres in sets with varying intensities of a red and a near infrared dye to achieve up to 500 distinct color sets. These microspheres can be moved or held in place by a magnetic field. Many automated systems utilize magnetic properties to automate the performance of the assay. Automating sample testing using MagPlex microspheres on a robotic sample preparation system decreases hands-on technician time, improves precision and streamlines workflow.

xTAG Microspheres. Our xTAG microspheres are dyed microspheres that are linked to a set of 100 proprietary nucleic acid capture sequences providing a “universal array” for DNA and RNA work. They are designed for conducting genotyping and other nucleic acid-based experiments in the life sciences, pharmaceutical and clinical diagnostic markets. When used in conjunction with our Luminex systems, xTAG microspheres are designed to simplify the molecular assay development process and increase assay flexibility. xTAG microspheres may be used by customers to develop LDT assays and are used in Luminex’s xTAG assay kits.

SeroMAP Microspheres. Our SeroMAP microspheres represent 100 distinct sets of microspheres that are designed for specific protein-based serological applications. Certain Luminex partners use this product for enhanced sensitivity in serum-based assays.

Calibration and Control Microspheres. Calibration microspheres are microspheres of known fluorescent light intensities used to calibrate the settings for the classification and reporter channel for the Luminex systems. Control microspheres are microspheres that are used to verify the calibration and optical integrity for both the classification and reporter channels for the various systems.

xMAP Software

xPONENT. Our xPONENT Software is included in all of our xMAP instruments and is designed to enhance both ease-of-use and automation capabilities, expanding xMAP functionality in our core markets. The software suite incorporates important features, all designed to simplify laboratory workflow and increase productivity, including enhanced security (21 CFR Part 11 compliance and electronic signatures), integration capabilities that allow customers to transmit and receive data from Laboratory Information Systems (LIS/LIMS), integration with the most popular automated sample preparation systems, the ability to run magnetic bead applications and touchscreen capability. xPONENT is sold on new Luminex 100/200, FLEXMAP 3D, and MAGPIX Systems and is available as an upgrade to existing Luminex systems in the marketplace.

TDAS. Our TDAS Software is an analysis program designed to complement our xTAG Technology, which uses a proprietary universal tag system that allows for the development and optimization of nucleic acid assays. TDAS Software simplifies workflow and increases productivity by helping to accurately identify pathogens associated with infectious diseases and genetic mutations. TDAS Software produces non-subjective results, which can be viewed in the software, integrated with LIS, and exported or printed into reports.
5
xTAG Assays and Product Family

Our xTAG family of products includes infectious disease panels and genetic testing panels that utilize Luminex xMAP bead-based detection platforms in combination with proprietary molecular chemistries. xTAG infectious disease IVD products enable our laboratory end users to identify the causative agent for respiratory and gastrointestinal infections, which are major causes of illness and mortality globally. xTAG Assays for genetic testing include several IVD kits for cystic fibrosis (CF) genotyping and a number of pharmacogenetic assays that may be used to profile genetic mutations related to drug metabolism. NxTAG chemistry, a streamlined version of the xTAG chemistry, described above, includes assays for both respiratory and gastrointestinal infections. This product family includes our FDA-cleared and CE-marked NxTAG CoV Extended Panel, NxTAG Respiratory Pathogen Panel (RPP), xMAP SARS-CoV-2 Multi-Antigen IgG Assay, xTAG CYP2C19 Kit v3, xTAG CYP2D6 Kit v3, xTAG Cystic Fibrosis (CFTR) 39 Kit v2, xTAG Cystic Fibrosis (CFTR) 60 Kit v2, xTAG Cystic Fibrosis (CFTR) 71 Kit v2, xTAG Gastrointestinal Pathogen Panel (GPP), xTAG Respiratory Viral Panel (RVP), and xTAG Respiratory Viral Panel (RVP) FAST v2.

ARIES Products

The ARIES System, available in single-module or double-module configurations, is our sample-to-answer real-time PCR platform for our MultiCode-RTx technology, including In Vitro Diagnostic (IVD) assays. The ARIES System is used with specific assays to measure multiple analytes indicative of infectious disease. The ARIES System uses internal barcode scanning and other advanced features to minimize operator errors. Each independent module supports from one to six cassettes, allowing both short turn around testing (STAT) and batch testing. The ARIES System can run IVD, MultiCode Analyte Specific Reagents (ASRs), and LDTs using the ARIES Exo+ Ready Mix and extraction cassettes with a common Universal Assay Protocol. An integrated touchscreen computer eliminates the need for a separate computer, stand-alone keyboard and mouse, thus maximizing valuable bench space.

SYNCT. Our SYNCT data management software solution can compile data from multiple ARIES Systems, or multiple MAGPIX Systems (NxTAG-enabled), assisting laboratories to better leverage their data to decrease laboratory costs and improve patient care. In addition, SYNCT Standard Curve Analysis Software enables labs to create quantitative LDTs.

ARIES Assays and Product Family

ARIES Cassettes. ARIES Cassettes are self-contained assay consumables designed to run a fully automated, sample-to-answer molecular assay on the ARIES System. The cassettes make use of proprietary injection-molded parts, as well as MultiCode and other reagents, to perform automated extraction, purification, elution, amplification and analysis of nucleic acid testing from a variety of different sample types.

Our ARIES product family includes our FDA-cleared and CE-marked ARIES HSV 1&2 Assay, ARIES Flu A/B & RSV Assay, ARIES Group B Streptococcus Assay, ARIES Group A Strep Assay, ARIES Bordetella Assay, ARIES Norovirus Assay, ARIES C. difficile Assay, and ARIES MRSA Assay in 2019. In addition, we launched an EUA-cleared SARS-CoV-2 Assay in 2020.

VERIGENE Products

The VERIGENE System is a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market that rapidly and accurately detects infectious pathogens and drug resistance markers. The VERIGENE System consists of: (i) VERIGENE Test Cartridges, which are single-use, self-contained test units, and (ii) VERIGENE instruments, including the VERIGENE Processor SP, which is a modular benchtop analyzer, that combines automated nucleic acid extraction, purification, amplification (if needed), and hybridization in each module, as well as the VERIGENE Reader, which manages sample information and reads results from processed cartridges. Tests that run on the VERIGENE System are primarily designed to identify infections in the bloodstream, respiratory tract, and gastrointestinal tract. Customers using this system will have the ability to select both individual and groups of targets on assays using Flex pricing. This approach to target selection allows customers to save money by only paying for the targets they wish to see, which will often align with healthcare standard of care guidelines, where applicable. If these results do not provide a conclusive diagnosis, additional targets that were tested for but not released can immediately be viewed for an incremental charge.


6
VERIGENE Assays and Product Family

VERIGENE Cartridges. VERIGENE test cartridges are single-use, self-contained test units comprised of (i) a reagent pack, which is a microfluidic cassette that contains all of the hybridization reagents needed for a single test that also captures the waste materials generated during test processing, and (ii) a substrate holder, which contains a glass slide that serves as a solid support for the microarray used to capture targeted nucleic acids. Each test cartridge is designed for multiplex analyses of one patient sample.

Our VERIGENE product family includes our FDA-cleared and CE-marked VERIGENE Bloodstream Infection tests, VERIGENE Gastrointestinal Infection tests, including the VERIGENE C. difficile Test and the VERIGENE Enteric Pathogens Test, and the VERIGENE Respiratory Pathogens Flex Test, as well as other VERIGENE next generation assays in development.

Amnis/Guava Products

Our Amnis and Guava products provide technology that powers flow-based detection systems. Amnis Systems are a family of imaging flow cytometry products for cell-based analysis. FlowSight and ImageStream imaging flow cytometers combine the speed and sensitivity of flow cytometry with the functional detail and spatial information of microscopy. The Guava portfolio of products, which are versatile, easy-to-use cytometry systems based on microcapillary fluidics technology, include the Muse Cell Analyzer, a simple, compact, and affordable system for absolute cell counting, viability, and basic cell health analyses, and the Guava easyCyte System, a versatile benchtop platform for additional, multi-dimensional cell health and biological assessments.

Amnis FlowSight Imaging Flow Cytometer. The FlowSight imaging flow cytometer provides high-sensitivity flow cytometry and imagery with up to twelve 20X multi-color images of every cell, including side scatter and brightfield, at up to 5,000 events per second. It is upgradeable to 4 lasers, offers automated sample loading for walk-away operations and is supported with image analysis software with fluorescence compensation and analysis wizards.

Amnis ImageStream Mark II Imaging Flow Cytometer. The ImageStream System is a benchtop, multispectral, imaging flow cytometer designed for the acquisition of up to 12 channels of cellular imagery at up to 60X magnification. By collecting large numbers of digital images per sample and providing a numerical representation of image-based features, the ImageStream System combines the per cell information content provided by standard microscopy with the statistical significance afforded by large sample sizes common to standard flow cytometry. With the ImageStream System, fluorescence intensity measurements are acquired as with a conventional flow cytometer; however, the best applications for the ImageStream System take advantage of the system’s imaging abilities to locate and quantify the distribution of signals on, in or between cells.

Amnis CellStream. The CellStream Flow Cytometer delivers high sensitivity and flexibility for cell and particle analysis. This compact system may be configured with up to seven lasers to adapt to a wide range of analytical requirements. With highly sensitive and configurable optics, researchers benefit from multiparameter detection capabilities, while maintaining the flexibility to tailor and expand the system according to their research needs and budget.

Guava easyCyte Benchtop Flow Cytometer. The Guava easyCyte line includes compact benchtop flow cytometer models that offer up to 3 lasers and 14 parameters with excellent sensitivity and optional high throughput auto-sampling capabilities. Guava easyCyte Systems use patented, microcapillary, laser-based technology capable of detecting mammalian and microbial cells, particles and beads. The instruments are supported by a line of 13 reagent FlowCellect Kits and elegant InCyte acquisition and analysis software.

Muse Cell Analyzer. The Muse Cell Analyzer is a simple, compact, easy-to-use benchtop device that uses patented miniaturized fluorescent detection and microcapillary technology to deliver accurate, precise and quantitative cell analysis. It is versatile enough to analyze both suspension and adherent cells 2–60 μm in diameter and includes a user-friendly touchscreen interface, intuitive software and optimized “Mix-and-Read” assays.


7
IDEAS. Our IDEAS image analysis software for our Amnis Flow Cytometers provides detailed analysis of intensity, location and co-location of probes. IDEAS offers powerful tools for high content, statistically robust analysis of images, as well as standard flow cytometry graphing tools and statistics for hundreds of morphological features in addition to intensity.

Customers

In 2020, top five customers accounted for 22% of our total revenues as compared to 30% in 2019 and approximately 43% in 2018. No other customer or partner accounted for more than 3% of our total revenues in 2020, 2019 and 2018.

International Operations

    We currently ship products to a number of customers outside the United States, primarily including customers in Canada, Europe and the Asia-Pacific region. For the annual periods ended December 31, 2020, 2019 and 2018, foreign shipments to customers totaled $91.6 million, $82.3 million and $54.1 million, respectively, representing 22%, 25% and 17%, respectively, of our total revenues for such periods. We have foreign subsidiaries in Canada, the Netherlands, the United Kingdom, Germany, France the People’s Republic of China, Japan, and Hong Kong, which increase our international support, service and marketing capabilities. Sales to territories outside of the U.S. are primarily denominated in U.S. dollars. We believe that our activities in some countries outside the U.S. involve greater risk than our domestic business due to foreign economic conditions, exchange rate fluctuations, local commercial and economic policies and political uncertainties. See Note 16 to our Consolidated Financial Statements.

Customer Operations

    Our Customer Operations Group provides technical support, field service and assistance to our customers, our distributors, our strategic partners and their customers. Most of our customer operations personnel have experience as biologists, biochemists or electrical engineers and have extensive experience in academic, industrial and commercial settings. Cross-training is a major focus, as is empowering group members to solve problems outside of their primary assignment.

Remote Support

    Our Technical Support department assists users primarily through a toll-free hotline, internet interface and e-mail communications. We deliver “24/7” remote technical support with our staff based at our Austin, Northbrook and Toronto locations and from our European, Chinese and Japanese subsidiaries to better serve our customer base. Personnel assist our distributors, strategic partners and customers in inquiry and complaint management related to Luminex products, system implementation and development of their assays. A comprehensive software and database system is utilized to track customer interactions, follow trends and measure utilization. The information is categorized and presented to management for regular review.

Training

    We offer comprehensive programs in basic system training, advanced assay development, instrument field service and technical support functions. A portion of our training material is web-based and available online. Customers have the option to receive training on-site at their location or locally, with our staff based at our Austin, Texas, Northbrook, Illinois, European, Chinese or Japanese offices.

Field Support

    We currently have field service and field application personnel based across North America, Europe, China and Japan in areas of our more significant system concentration. In addition, several of our distributors and strategic partners provide their own field service and field application support. As we continue to expand our installed base, we believe a strong, reliable, efficient field support organization is crucial to maintaining a high level of customer satisfaction.

8
Research and Development

    Our research and development groups work to develop next generation systems, chemistries, assays and software to provide new, innovative products to our customers. Our research and development expense for the years ended December 31, 2020, 2019 and 2018, was $53.7 million, $56.2 million and $47.2 million, respectively.

    Our current research and development projects include:

•New platform and technology development

We are working on the development of the next generation, sample-to-answer, molecular diagnostic, automated VERIGENE II platform. This involves the final design and development of the instrument, consumables and software as well as the development of a menu of assays for this system. We currently expect to commercially launch the VERIGENE II System in 2021.

•New sample-to-answer menu development

We have a pipeline of new syndromic assays for use on the next generation VERIGENE II platform. These automated assays are primarily in the area of infectious disease testing.

•xMAP INTELLIFLEX system

Our Next-Generation xMAP system is nearing testing with partners and we expect will be ready for commercial launch in the first half of 2021. Among other activities, our partners will need to validate the backward capability of previously developed kits and plan their launches of new kits that will be able to take advantage of the increased sensitivity of this next generation xMAP System.

Manufacturing

    We have approximately 150,000 square feet of leased manufacturing space, including space located at our principal executive offices in Austin, Texas (84,000 square feet), in Madison, Wisconsin (13,000 square feet), in Toronto, Canada (10,000 square feet), in Northbrook, Illinois (34,000 square feet) and in Seattle, Washington (10,000 square feet). In addition, we have signed a purchase agreement for the building in Northbrook, Illinois that is expected to close in the first quarter of 2021 and a lease agreement for an additional 50,000 square feet of manufacturing space in Austin, Texas to commence in the middle of 2021.
    We initially certified our Quality Management System (QMS) to the ISO 9001:2000 standard and in 2010 updated our certification to ISO 9001:2008. ISO is an internationally recognized standard for quality management systems. Subsequent audits by the registrar have been and will continue to be carried out at regular intervals to ensure we are maintaining our system in compliance with ISO standards. Recertification is required every three years and we have been successfully recertified in each applicable year since obtaining our original ISO certification. Also, we have our QMS certified to the ISO 13485:2012 Quality Management Standard and the Canadian Medical Devices Regulation (CMDR). These standards include a special set of requirements specifically related to the supply of medical devices and related services. Additionally, we manufacture to current FDA “Good Manufacturing Practice” requirements and our QMS is implemented in accordance with FDA Quality System Regulations (21 CFR 820).

Supply Chain

    We have historically purchased many of the components and raw materials used in our products from numerous suppliers worldwide. For reasons of quality assurance, sole source availability and cost-effectiveness, certain components and raw materials used in the manufacture of our products are available only from one supplier. We have worked closely with our suppliers to develop contingency plans to assure continuity of supply while maintaining high quality and reliability, and in some cases, we have established long-term supply contracts with our suppliers. Due to the high standards and FDA requirements applicable to the manufacturing of our products, we may not be able to quickly establish additional or replacement sources for certain components or materials. In the event that we are unable to obtain sufficient quantities of raw materials or components on commercially reasonable terms or in a timely manner, our ability to manufacture our products on a timely and cost-competitive basis may be compromised, which may have a material adverse effect on our business, financial condition and results of operations.

9
Instruments

    Component suppliers and contract manufacturers provide certain components and component assemblies of our xMAP and ARIES Systems. The remaining assembly and manufacturing of our systems are performed at our facilities in Austin, Texas and Northbrook, Illinois. The quality control and quality assurance protocols are all performed at our facilities. Parts and component assemblies that comprise our technology systems are obtained from a number of sources. We have identified alternate sources of supply for several of our strategic parts and component assemblies. Additionally, we have entered into supply agreements with most of our suppliers of strategic parts and component subassemblies to help ensure component availability and flexible purchasing terms with respect to the purchase of such components. As of December 31, 2020, approximately 17,900 Luminex multiplexing analyzers have been shipped since 1999, some of which may be retired or otherwise not in use.

Microspheres

    We procure our undyed, standard MicroPlex microspheres and manufacture our magnetic MagPlex carboxylated polystyrene microspheres. We synthesize our dyes and manufacture our dyed microspheres using a proprietary method in our Austin, Texas manufacturing facility in large lots. We dye the microspheres with varying intensities of red and near infrared dyes to produce our distinctly colored microsphere sets. We currently purchase the standard polystyrene microspheres from one supplier, in accordance with a supply agreement. We believe this agreement will help ensure microsphere availability and flexible purchasing terms with respect to the purchase of such microspheres. While we believe the microspheres will continue to be available from our supplier in quantities sufficient to meet our production needs, we believe our in-house manufacturing capabilities along with other potential suppliers would provide sufficient microspheres for us if given adequate lead-time to manufacture the microspheres to our specifications.

Assays and Reagents

    Component suppliers and contract manufacturers produce certain components of our developed reagents. The remaining assembly and manufacturing of our on-market kits are performed at one of our facilities in Austin, Texas, Toronto, Canada, Madison, Wisconsin, Northbrook, Illinois, or Seattle, Washington. The quality control and quality assurance protocols are all performed at our facilities. Reagents, consumables and other raw material that comprise our kits are obtained from a number of sources.

    In addition to developed assay kits, increasing regulatory requirements coupled with rising demand for new clinical applications are driving demand for laboratory developed tests. Our proprietary technologies and platforms offer a unique combination of flexibility and throughput, as our systems’ open architecture, software and standard protocols allow our customers the ability to use our proprietary reagents to validate and verify a new test, while being able to utilize the same system to handle increasing volumes once the assay is commercialized.

Competition

    We design our xMAP Systems and consumables for use by customers across the various segments of the life sciences, pharmaceutical and clinical diagnostic industries. Our xTAG, NxTAG, MultiCode, ARIES and VERIGENE products are developed specifically for the molecular diagnostic segment. Our competition includes companies marketing conventional testing products based on established technologies such as ELISA, real-time PCR, mass spectrometry, gene sequencing, biochips, arrays and flow-based technologies, as well as next generation sequencing and companies developing their own advanced testing technologies.

    The pharmaceutical industry is a large market for the genomic, protein and high-throughput screening applications supported by xMAP Technology. In each application area, Luminex faces a different set of competitors. Genomic and protein testing can be performed by products available from Affymetrix, Inc. (a Thermo Fisher Scientific Inc. brand), Life Technologies Corporation (a Thermo Fisher Scientific Inc. brand), Becton, Dickinson and Company, Illumina, Inc., Qiagen N.V., Meso Scale Discovery (a division of Meso Scale Diagnostics LLC), Quanterix Corporation, PerkinElmer, Inc., Bio-Rad Laboratories, Inc., and others.

10
    Our diagnostic market competitors include, among others, Abbott Laboratories, Life Technologies Corporation (a Thermo Fisher Scientific Inc. brand), BioFire Diagnostics, LLC (a bioMérieux company), Cepheid (a Danaher Corporation company), GenMark Dx, Roche Diagnostics, Siemens Medical Solutions, Hologic, Inc., Alere (now part of Abbott Laboratories), Quidel Corporation, Focus Diagnostics (DiaSorin S.p.A), T2 Biosystems, Inc., Accelerate Diagnostics, Inc., Meridian Bioscience, Inc., and Illumina, Inc. Some of these companies have technologies that can run a variety of established assays. In addition, certain of these companies offer integrated systems and laboratory automation that are designed to meet the need for improved work efficiencies in the clinical laboratory.

    Competition within the academic biomedical research market is highly fragmented. There are hundreds of suppliers to this market including, among others, Amersham Pharmacia Biotech, a part of GE Healthcare, Life Technologies Corporation (a Thermo Fisher Scientific Inc. brand) and Becton, Dickinson and Company.

    Flow cytometry is a well-established field that has grown into a multi-billion dollar market, including research and clinical systems and applications. Competition for our flow cytometry systems is expanding as established competitors consolidate their positions and new competitors and technologies enter and grow within the field. BD Biosciences and Beckman Coulter are long-time leaders in the field and hold the majority of the market share. Mid-term competitors include Miltenyi Biotec, Bio-Rad, Sony Biotechnology, and Attune (part of ThermoFisher Scientific). Newer competitors include ACEA Biosciences, Cytek Biosciences. Our imaging flow cytometry systems cross over into both imaging and microscopy areas and face a number of competitors in these fields, as well as new competitors developing imaging-in-flow systems.

Intellectual Property

    To establish and protect our proprietary technologies and products, we rely on a combination of patent, copyright, trademark and trade secret laws and confidentiality agreements. We have filed for registration or obtained registration for trademarks used with our products and key technologies.

    We have implemented a strategy designed to optimize our intellectual property rights. For core intellectual property, we are pursuing patent coverage in the United States and those foreign countries that correspond to the majority of our current and anticipated customer base. We currently own 821 issued patents worldwide directed to various aspects and applications of our products and technology, including 237 issued patents in the United States. Other countries in which we have issued patents directed to various aspects and applications of our products and technology include, among others, France, Germany, the United Kingdom, Australia, Japan, the Netherlands, Canada, Hong Kong, China and South Korea. Our patent portfolio also includes 110 pending patent applications in the United States and other foreign jurisdictions. We believe our patents and pending patent applications provide, or will provide, protection for systems and technologies that allow real-time multiplexed analytical techniques for the detection and quantification of many analytes from a single sample. We also hold patents covering the fluorescently dyed, magnetically responsive microspheres. In addition, multiple granted patents and pending applications describe aspects of MultiCode technology, xTAG technology, nanoparticle technology, the ARIES and VERIGENE Systems, NxTAG technology, imaging flow cytometry technology and capillary flow cytometry technology.

    The source code for our proprietary software is protected as a trade secret and/or as a copyrighted work. Aspects of the software also are covered by issued patents.

    We also rely on trade secret protection of our intellectual property. We attempt to protect our trade secrets by entering into confidentiality agreements with strategic partners, third parties, employees and consultants. Our employees and third-party consultants also sign agreements requiring that they assign to us their interests in inventions and original works of expression and any corresponding patents and copyrights arising from their work for us. See Item 1A, Risk Factors - “The property rights we rely upon to protect the technologies underlying our products may not be adequate to maintain market exclusivity. Inadequate intellectual property protection could enable third parties to exploit our technologies or use very similar technologies and could reduce our ability to distinguish our products in the market.”

Government Regulation

    Our products are generally considered medical devices and are subject to regulation by numerous government agencies, including the FDA and similar agencies outside the United States. To varying degrees, each of these agencies requires us to comply with laws and regulations governing the development, testing, manufacturing, labeling, marketing and distribution of our medical devices. Our business is also affected by the United States and foreign patient privacy laws, cost containment initiatives and environmental health and safety laws and regulations. The primary laws and regulations that are particularly relevant to our business are described below.

11
Food and Drug Administration

    In general, the products that we manufacture are considered to be medical devices and are subject to regulation in the United States by the FDA. We also manufacture versions of the Luminex instruments for use with diagnostic assay kits that are available through our strategic partners. For FDA purposes, Luminex systems are considered components of our partners’ kit products. Kits manufactured by our strategic partners used in conjunction with our technology may be subject to clearance or approval requirements and other FDA regulations.

    The FDA classifies medical devices into one of three classes on the basis of the intended use of the device, the risk associated with the use of the device for that indication, as determined by the FDA, and on the controls deemed by the FDA to be necessary to reasonably ensure their safety and effectiveness. Class I devices, which have the lowest level of risk associated with them, are subject to general controls. Class II devices are subject to general controls and special controls, including performance standards. Class III devices, which have the highest level of risk associated with them, are subject to general controls and premarket approval. Most Class I devices and some Class II devices are exempt from a requirement that the manufacturer submit a premarket notification, or 510(k), and receive clearance from the FDA, which is otherwise a premarketing requirement for a Class II device. Class III devices may not be commercialized until a premarket approval application (PMA) is submitted to and approved by the FDA.

510(k) Clearance Pathway

    To obtain 510(k) clearance, a sponsor must submit to the FDA a premarket notification demonstrating that the device is substantially equivalent (SE) to a device legally marketed in the U.S. for which a PMA was not required. The FDA is supposed to make a SE determination within 90 days of FDA’s receipt of the 510(k), but it often takes longer if the FDA requests additional information. After a device receives 510(k) clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, will require a new clearance or possibly a pre-market approval.

Emergency Use Authorization

In emergency situations, such as a pandemic, the FDA has the authority to allow unapproved medical products or unapproved uses of cleared or approved medical products to be used in an emergency to diagnose, treat or prevent serious or life-threatening diseases or conditions caused by chemical, biological, radiological or nuclear warfare threat agents when there are no adequate, approved and available alternatives.

Under this authority, the FDA may issue an EUA for an unapproved device if the following four statutory criteria have been met: (1) a serious or life-threatening condition exists; (2) evidence of effectiveness of the device exists; (3) a risk-benefit analysis shows that the benefits of the product outweigh the risks; and (4) no other alternatives exist for diagnosing, preventing or treating the disease or condition. Evidence of effectiveness includes medical devices that “may be effective” to prevent, diagnose or treat the disease or condition identified in a declaration of emergency issued by the Secretary of the Department of Health and Human Services, or HHS. The “may be effective” standard for EUAs requires a lower level of evidence than the “effectiveness” standard that the FDA uses for product clearances or approvals in non-emergency situations. The FDA assesses the potential effectiveness of a possible EUA product on a case-by-case basis using a risk-benefit analysis. In determining whether the known and potential benefits of the product outweigh the known and potential risks, the FDA examines the totality of the scientific evidence to make an overall risk-benefit determination. Such evidence, which could arise from a variety of sources, may include (but is not limited to) results of domestic and foreign clinical trials, in vivo efficacy data from animal models, in vitro data, as well as the quality and quantity of the available evidence.

Once granted, an EUA will remain in effect and generally terminate on the earlier of (1) the determination by the Secretary of HHS that the public health emergency has ceased or (2) a change in the approval status of the product such that the authorized use(s) of the product are no longer unapproved. After the EUA is no longer valid, the product is no longer considered to be legally marketed and one of the FDA’s non-emergency premarket pathways would be necessary to resume or continue distribution of the subject product.

The FDA also may revise or revoke an EUA if the circumstances justifying its issuance no longer exist, the criteria for its issuance are no longer met, or other circumstances make a revision or revocation appropriate to protect the public health or safety.

12

On January 31, 2020, the Secretary of HHS issued a declaration of a public health emergency related to COVID-19. On February 4, 2020, HHS determined that COVID-19 represents a public health emergency that has a significant potential to affect national security or the health and security of U.S. citizens living abroad and, subsequently, declared on March 24, 2020, that circumstances exist to justify the authorization of emergency use of medical devices, including alternative products used as medical devices, during the COVID-19 pandemic, subject to the terms of any authorization as issued by the FDA. On February 29, 2020, the FDA issued an immediately in effect guidance with policy specific to development of in vitro diagnostic tests during the COVID-19 public health emergency. This guidance was updated on March 16, 2020, May 4, 2020 and May 11, 2020.

Clinical Trials

    Clinical trials are usually required to support a PMA and are sometimes required for a 510(k). In the U.S., if the device is determined to present a “significant risk,” the manufacturer may not begin a clinical trial until it submits an investigational device exemption application (IDE) and obtains approval of the IDE from the FDA. These clinical trials are also subject to the review, approval and oversight of an institutional review board (IRB) at each clinical trial site. The clinical trials must be conducted in accordance with the FDA’s IDE regulations and good clinical practices. A clinical trial may be suspended by the FDA, the sponsor or an IRB at its institution at any time for various reasons, including a belief that the risks to the study participants outweigh the benefits of participation in the trial. Even if a clinical trial is completed, the results may not demonstrate the safety and efficacy of a device to the satisfaction of the FDA, or may be equivocal or otherwise not be sufficient to obtain approval of a device.

FDA Enforcement

    After a medical device is placed on the market, numerous regulatory requirements apply. These include among other things:

•establishment registration and device listing;

•the QSR, which requires manufacturers, including third-party manufacturers, to follow stringent design, testing, control, documentation and other quality assurance procedures during all aspects of the manufacturing process;

•labeling regulations and the FDA prohibitions against the promotion of products for uncleared, unapproved or “off-label” uses and other requirements related to promotional activities;

•medical device reporting regulations, which require that manufacturers report to the FDA if their device may have caused or contributed to a death or serious injury, or if their device malfunctioned and the device or a similar device marketed by the manufacturer would be likely to cause or contribute to a death or serious injury if the malfunction were to recur;

•corrections and removal reporting regulations, which require that manufacturers report to the FDA field corrections or removals if undertaken to reduce a risk to health posed by a device or to remedy a violation of the Federal Food, Drug and Cosmetic Act (FDC Act) that may present a risk to health; and

•post-market surveillance regulations, which apply to certain Class II or III devices when necessary to protect the public health or to provide additional safety and effectiveness data for the device.

    To ensure compliance with regulatory requirements, medical device manufacturers are subject to market surveillance and periodic, pre-scheduled and unannounced inspections by the FDA. Failure to comply with applicable regulatory requirements can result in enforcement action by the FDA, which may include sanctions, including but not limited to, warning letters; fines, injunctions, consent decrees and civil penalties; recall or seizure of the device; operating restrictions, partial suspension or total shutdown of production; refusal to grant 510(k) clearance or PMA approvals of new devices; withdrawal of 510(k) clearance or PMA approvals; and civil or criminal prosecution.

13
On June 26, 2020, the Company received a warning letter (Warning Letter) from the FDA relating to the operations of the Company’s Austin, Texas and Northbrook, Illinois facilities (Facilities) and the Company’s VERIGENE Processor SP System. The Warning Letter resulted from inspections held at the Facilities from February 10, 2020 to February 14, 2020. The company submitted a comprehensive response to each of these inspections. The subsequently issued Warning Letter primarily relates to the Company’s VERIGENE SP instrument and its hybridization heater in connection with certain FDA requirements under the Quality System Regulation (21 C.F.R. Part 820) and the regulation of Medical Device Corrections and Removals (21 C.F.R. Part 806).

The Company timely submitted a response and corrective action plan to the FDA regarding the issues raised in the Warning Letter, as requested by the FDA, and continues working diligently and expeditiously to resolve the issues raised by the FDA. The Warning Letter did not restrict the manufacture, production or shipment of any of the Company’s products, nor require the withdrawal of any product from the marketplace. The Company believes it has taken, and is continuing to take, appropriate measures to address the items identified by the FDA with respect to the VERIGENE SP instrument and its hybridization heater, and the Company included communication of these measures in its response to the Warning Letter. Specifically, we recalled affected products from the field and replaced them with new units. Additionally, we are executing a field action to re-calibrate all VERIGENE SP instruments deployed in the field with in-house built and verified temperature verification fixtures by March 18, 2021. In addition, the Company continues to evaluate what further corrective or preventive actions may be required.

The Company has responded to the FDA’s concerns raised in the Warning Letter but cannot give assurances that the FDA will be satisfied with its response to the Warning Letter or that such actions will sufficiently resolve the issues identified in the Warning Letter. Failure to promptly and fully address the issues raised in the Warning Letter to the FDA’s satisfaction or to comply with U.S. medical device regulatory requirements in general could result in further regulatory and enforcement actions being initiated by the FDA. These actions could result in, among other things, product recalls, product seizures, injunctions, civil monetary penalties, further delays in obtaining marketing authorization for products, an impact on federal contracts, limitations on our ability to export products and criminal enforcement actions. Any such actions could disrupt our ongoing business and operations and potentially have a material adverse effect on our business, financial condition and results of operations.

Research Use Only Products

    Some of our products are currently intended for research use only (RUO) applications, although our customers may use our products to develop their own products that are separately subject to regulation by the FDA. Although most products intended for RUO are not currently subject to clearance or approval by the FDA, RUO products fall under the FDA’s jurisdiction if they are used for clinical rather than research purposes. Consequently, these products are labeled “For Research Use Only.”

    On November 25, 2013, the FDA issued Final Guidance for Industry and Food and Drug Administration Staff on “Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only,” (the RUO/IUO Guidance). The purpose of an FDA guidance document is to provide the FDA’s current thinking on when IVD products are properly labeled for RUO or for Investigational Use Only (IUO), but as with all FDA guidance documents, this guidance does not establish legally enforceable responsibilities and should be viewed as recommendations unless specific regulatory or statutory requirements are cited. The RUO/IUO Guidance explains that the FDA will review the totality of the circumstances when evaluating whether equipment and testing components are properly labeled as RUO. Merely including a labeling statement that a product is intended for research use only will not necessarily exempt the device from the FDA’s 510(k) clearance, premarket approval, or other requirements, if the circumstances surrounding the distribution of the product indicate that the manufacturer intends its product to be used for clinical diagnostic use. These circumstances may include written or verbal marketing claims or links to articles regarding a product’s performance in clinical applications, a manufacturer’s provision of technical support for clinical validation or clinical applications, or solicitation of business from clinical laboratories, all of which could be considered evidence of intended uses that conflict with RUO labeling. Consequently, these Luminex products are labeled “For Research Use Only” and meet the intent of the RUO/IUO Guidance.

14
Clinical Laboratory Improvement Amendments of 1988

    Laboratories that purchase certain of our products are subject to extensive regulation under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), which applies to all clinical laboratory testing performed on humans in the United States (with the exception of clinical trials and basic research). A clinical laboratory is defined by CLIA as any facility that performs laboratory testing on specimens obtained from humans for the purpose of providing information for health assessment or for the diagnosis, prevention, or treatment of disease. CLIA requires laboratories to meet specified standards in areas such as personnel qualifications, administration, participation in proficiency testing, patient test management, quality control, quality assurance and inspections. Certification through the CLIA program is generally a prerequisite to be eligible to bill state and federal health care programs, as well as many private insurers, for laboratory testing services. As a condition of CLIA certification, laboratories are subject to survey and inspection every other year, in addition to being subject to additional random inspections. The biennial survey is conducted by the Centers for Medicare & Medicaid Services (CMS), a CMS agent (typically a state agency), or a CMS‑approved accreditation organization. High complexity, CLIA-certified laboratories frequently develop testing procedures to provide diagnostic results to customers.

     These tests have been traditionally offered by nearly all complex laboratories for the last few decades as LDTs, which are subject to CMS oversight through its enforcement of CLIA. The FDA also has claimed that it has regulatory authority over LDTs, but has not exercised enforcement with respect to most LDTs offered by high complexity laboratories, and has not sought to require these laboratories to comply with FDA regulations regarding medical devices. During 2010, the FDA publicly announced that it had decided to exercise regulatory authority over these LDTs, and that it planned to issue guidance to the industry regarding its regulatory approach. At that time, the FDA indicated that it would use a risk-based approach to regulation and would direct more resources to tests with wider distribution and with the highest risk of injury, but that it would be sensitive to the need to not adversely impact patient care or innovation. In September 2014, the FDA announced its framework and timetable for implementing this guidance. On November 18, 2016, the FDA announced it would not release final guidance at that time and instead would continue to work with stakeholders, the new administration and Congress to determine the right approach. On January 3, 2017, the FDA released a discussion paper outlining a possible risk-based approach for FDA and CMS oversight of LDTs. Later in 2017, the FDA indicated that Congress should enact legislation to address improved oversight of diagnostics, including LDTs, rather than the FDA addressing the issue through administrative proposals. Several legislative proposals have been described in separate bills (including, for example, the Diagnostic Accuracy and Innovation Act (DAIA) in 2017 and the Verifying Accurate, Leading-edge IVCT Development (VALID) Act in 2018), but none of these legislative approaches have been enacted. We cannot predict the ultimate timing or form of any such guidance or regulation or their potential impact. If adopted, such a regulatory approach by the FDA may lead to an increased regulatory burden, including additional costs and delays in introducing new tests. While the ultimate impact of the FDA’s approach is unknown, it may be extensive and may result in significant change.

Radiological Health Regulations

    Certain of our instruments use lasers to detect assay results. Therefore, we are required to ensure that these products comply with FDA regulations pertaining to the performance of laser products. The Radiation Control for Health and Safety Act, administered by the FDA, imposes performance standards and record keeping, reporting, product testing and product labeling requirements for devices that emit radiation. These regulations are intended to ensure the safety of laser products by establishing standards to prevent exposure to excessive levels of laser radiation. There can be no assurance that the FDA will agree with our interpretation and implementation of these regulations.

Foreign Jurisdictions

    Our products are also subject to certification or approval and regulation by foreign regulatory, safety agencies and notified bodies. For example, the EU has adopted the In Vitro Diagnostic Regulation (IVDR), which is scheduled to go into effect on May 26, 2022. This new regulation will impose stricter requirements for the marketing and sale of in vitro diagnostic medical devices, including in the area of clinical evaluation requirements, quality systems and post-market surveillance. As of now, manufacturers of currently approved in vitro diagnostic medical devices will have until May 26, 2022 to meet the IVDR. Complying with the requirements of this regulation may require us to incur significant expenditures. Failure to meet these requirements could adversely impact our business in the EU and other regions that tie their product registrations to the EU requirements.

15

Medical device laws and regulations are also in effect in many countries outside of the United States, ranging from comprehensive pre-approval or pre-certification requirements for medical products, to simpler requests for product data or certification. The number and scope of these requirements is increasing. There can be no assurance that we, and our strategic partners, will be able to obtain any approvals that may be required to market xMAP or other technology products outside the United States. In addition, we may incur significant initial and/or ongoing costs in obtaining or maintaining our foreign regulatory approvals or certifications. Further, the export by us of products that have not yet been cleared for domestic commercial distribution is subject to FDA and other export requirements and/or restrictions.

    We have agreements relating to the sale of our products to government entities and, as a result, we are subject to various statutes and regulations that apply to companies doing business with the government. A failure to comply with these regulations could result in suspension of these contracts, or administrative or other penalties, and could have a material adverse effect on our ability to compete for future government contracts and programs.

    We produce CE marked products, which are subject to a number of different EU Directives, including, but not limited to, the In Vitro Diagnostic Medical Devices Directive 98/79/EC (IVDD). CE marking of our products is currently by self-assessment based on the intended uses of our products. There is currently no need for intervention in the assessment process by a notified body. A product that is not CE marked is non-compliant with applicable EU rules. Enforcement is ensured through market surveillance by the competent authorities of the EEA Member States. Imported products into the EU are checked for compliance at customs offices.

EU Regulation of Medical Devices

As a general rule, demonstration of conformity of medical devices and their manufacturers with the Essential Requirements must be based, among other things, on the evaluation of clinical data supporting the safety and performance of the products during normal conditions of use. Specifically, a manufacturer must demonstrate that the device achieves its intended performance during normal conditions of use and that the known and foreseeable risks, and any adverse events, are minimized and acceptable when weighed against the benefits of its intended performance, and that any claims made about the performance and safety of the device (e.g., product labeling and instructions for use) are supported by suitable evidence. This assessment must be based on clinical data, which can be obtained from results of domestic and foreign clinical trials, in vivo efficacy data from animal models, in vitro data, as well as the quality and quantity of the available evidence. The conduct of clinical studies in the EEA is governed by detailed regulatory obligations. These may include the requirement of prior authorization by the Competent Authorities of the country in which the study takes place and the requirement to obtain a positive opinion from a competent Ethics Committee. This process can be expensive and time-consuming.

On May 26, 2021, the current EU legislation applicable to medical devices is scheduled to be replaced by the Medical Device Regulation (Regulation (EU) 2017/745) (MDR).

EU Regulation of In Vitro Diagnostic Medical Devices

In the EEA, in vitro diagnostic medical devices (IVDs) are regulated under the In Vitro Diagnostic Medical Devices Directive 98/79/EC (the IVDD). IVD manufacturers are required to comply with the Essential Requirements laid down in Annex I to the IVDD. Compliance with these requirements entitles manufacturers to affix the CE mark on products, without which they cannot be placed on the EU market. To demonstrate compliance with the Essential Requirements laid down in Annex I to the IVDD and obtain the right to affix the CE mark, IVD manufacturers must undergo a conformity assessment procedure, which varies according to the type of IVDs. The IVDD groups IVDs into four categories based on the risks associated with relative dangers to public health and / or patient treatment by an IVD failing to perform as intended:

•General IVDs;
•IVDs for self-testing;
•IVDs falling within the scope of Annex II, List A;
•IVDs falling within the scope of Annex II, List B.

Following determination of the appropriate category for an IVD, manufacturers are required to follow the related conformity assessment procedures laid down in Article 9 of the IVDD.

For general IVDs, a self-assessment process in accordance with Annex III of the IVDD and a related Declaration of Conformity by the manufacturer prior to affixing the CE mark is sufficient. In the Declaration of Conformity, the manufacturer certifies that its product complies with the Essential Requirements provided for in Annex I to the IVDD.

16
For IVDs for self-testing and those falling within List A or B of Annex II to the IVD, a notified body must undertake an assessment of the conformity of the manufacturer and/or the device with the applicable provisions of the IVDD.

The notified body will commonly audit and examine a product's Technical File and the quality management system for the manufacture, design, and final inspection of a medical device before issuing a CE Certificate of Conformity demonstrating compliance with the requirements of the IVDD. Following the issuance of a CE Certificate of Conformity, manufacturers can draw up the Declaration of Conformity and affix the CE mark to the products covered by the CE Certificate of Conformity and the Declaration of Conformity.

CE marking of our products is currently by self-assessment, not issued by a third party, based on the intended uses of our products. The involvement of a notified body during the conformity assessment procedure is not, therefore, currently required. This situation may, however, change with the new Regulation on In Vitro Diagnostic Medical Devices (IVDR), which are scheduled to go into effect May 26, 2022. The Regulation, which will replace the previous IVDD, will substantially impact IVD manufacturers.

There can be no assurance that the Competent Authorities of the EEA Member States will agree with our interpretation and implementation of these regulations as it pertains to classification of our products. The failure by us or our strategic partners to comply with the IVDD could have a material adverse effect on our business.

Regulation of our products in China

The State Food and Drug Administration, P.R. China (SFDA), is the government regulation authority in charge of safety management of drug, food, health food and cosmetics for the People’s Republic of China. The SFDA issues certificates that are required for registration and approval to import our products into China. Certificates are also subject to periodic recertification requirements. We have received certificates for the “Luminex System,” which combines the Luminex 100 and Luminex 200 into one product, and for our MAGPIX System.

Failure by us, or our strategic partners, to comply with applicable current federal, state and foreign medical product laws and regulations could have a material adverse effect on our business. Federal, state and foreign regulations regarding the manufacture and sale of medical devices and components of such devices are continually subject to future changes. We cannot predict what impact, if any, such changes might have on our business, but any such changes could have a material impact.

WEEE

Directive 2012/19/EU on Waste Electrical and Electronic Equipment (WEEE Directive) outlines the responsibility for the disposal of waste electrical and electronic equipment. Compliance with the WEEE Directive is placed with the manufacturers of such equipment. Those manufacturers are required to establish an infrastructure for collecting WEEE, in such a way that users of electrical and electronic equipment from private households should have the ability of returning WEEE at least free of charge. All Luminex-manufactured equipment is in compliance with this directive. Since August 13, 2005, we have been in compliance with the requirements regarding the labeling and disposal of our products containing electronic devices in each of the EEA Member States where our regulated products are distributed.

RoHS

Directive 2011/65/EU on the restriction of the use of certain hazardous substances in electrical and electronic equipment (RoHS Directive) restricts the placing on the EU market of electrical and electronic equipment (EEE) containing specific hazardous substances in quantities above the maximum concentrations specified in Annex II to the RoHS Directive. Restricted substances include lead, cadmium, mercury, hexavalent chromium, polybrominated biphenyl (PBB) and polybrominated diphenyl ether (PBDE). Maximum concentration levels have also been set for Bis(2-ethylhexyl) phthalate (DEHP), Butyl benzyl phthalate (BBP), Dibutyl phthalate (DBP), Diisobutyl phthalate (DIBP) following Commission Delegated Directive (EU) 2015/863 of 31 March 2015 amending Annex II to Directive 2011/65/EU as regards the list of restricted substances The restriction of DEHP, BBP, DBP and DIBP will be applicable to in vitro medical devices from July 22, 2021.
The Directive directly affects manufacturers, importers and distributors of EEE placing their products on the EEA market. The Directive applies to EEE falling within the categories set out in Annex I to the RoHS Directive, including medical devices and IVDs. Manufacturers of EEE are required to comply with the requirements set out in Article 4 of the RoHS. Article 4 of the RoHS Directive restricts the presence of substances referred to in Annex II to the RoHS Directive above the maximum concentrations detailed for each substance in Annex II to the RoHS Directive in EEE. Exemptions for applications are provided in Annex III to the RoHS Directive. Further exemptions for specific applications to medical devices and monitoring and control instruments are set out in Annex IV to the RoHS Directive.
17

In the EEA, EEE manufacturers must comply with the requirements of Article 4 of the RoHS Directive. Compliance with these requirements entitles manufacturers to affix the CE mark on products, without which they cannot be placed on the EU market. To demonstrate compliance with the requirements of Article 4 of the RoHS Directive and obtain the right to affix the CE mark on products, manufacturers must undergo a conformity assessment procedure. For EEE, a self-assessment process in accordance with module A of Annex II to Decision No 768/2008/EC and a related Declaration of Conformity by the manufacturer prior to affixing the CE mark is sufficient. In the Declaration of Conformity, the manufacturer certifies that its product complies with the requirements of Article 4 of the RoHS Directive.

If the EEE also falls under other EU legislation requiring the application of a conformity assessment procedure which is at least as stringent, compliance with the requirements of Article 4 of the RoHS Directive may be demonstrated within the context of that procedure and a single technical documentation may be drawn up.


Environmental

    We are subject to federal, state and local laws and regulations relating to the protection of human health and the environment. In the course of our business, we are involved in the handling, storage and disposal of certain chemicals and biohazards. The laws and regulations applicable to our operations include provisions that regulate the discharge of materials into the environment. Some of these environmental laws and regulations impose “strict liability,” rendering a party liable without regard to negligence or fault on the part of such party. Such environmental laws and regulations may expose us to liability for environmental contamination, including remediation costs, natural resource damages and other damages as a result of the conduct of, or conditions caused by, us or others or for acts that were in compliance with all applicable laws at the time such acts were performed. In addition, where contamination may be present, it is not uncommon for neighboring landowners and other third parties to file claims for personal injury, property damage and recovery of response costs. Although it is our policy to use generally accepted operating and disposal practices in accordance with applicable environmental laws and regulations, hazardous substances or wastes may have been disposed or released on, under or from properties owned, leased or operated by us or on, under or from other locations where such substances or wastes have been taken for disposal. These properties may be subject to investigation, remediation and monitoring requirements under federal, state and local environmental laws and regulations. We believe that our operations are in substantial compliance with applicable environmental laws and regulations. However, failure to comply with these environmental laws and regulations may result in the imposition of administrative, civil and criminal penalties or other liabilities. We do not believe that we have been required to expend material amounts in connection with our efforts to comply with environmental requirements or that compliance with such requirements will have a material adverse effect upon our capital expenditures, results of operations or competitive position. Because the requirements imposed by such laws and regulations may frequently change and new environmental laws and regulations may be adopted, we are unable to predict the cost of compliance with such requirements in the future, or the effect of such laws on our capital expenditures, results of operations or competitive position. Moreover, the modification or interpretation of existing environmental laws or regulations, the more vigorous enforcement of existing environmental laws or regulations or the adoption of new environmental laws or regulations may also negatively impact our strategic partners, which in turn could have a material adverse effect on us and other similarly situated component companies.

Other Government Regulations

    Our operations in the United States are subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute, the Eliminating Kickbacks in Recovery Act of 2018, and state and federal marketing compliance laws. These laws may impact our operations directly or indirectly through our customers and may impact, among other things, our proposed sales, marketing and education programs. In addition, we may be subject to or impacted by patient and consumer privacy regulation by both the federal government and the states in which we conduct our business. We are also subject to statutes in foreign jurisdictions that prohibit commercial bribery and certain activities with customers or potential customers. The laws that may affect our ability to operate include the following foreign laws, federal laws and their counterparts at the state level in addition to various implementing regulations:

•the federal Anti-Kickback Statute and state anti-kickback prohibitions;

•the federal physician self-referral prohibition, commonly known as the Stark Law, and state equivalents;

•the federal Health Insurance Portability and Accountability Act of 1996, as amended, and implementing privacy, security and breach notification regulations, and similar state laws;

•the Civil Monetary Penalties Law and related exclusion provisions;
18

•the federal False Claims Act and state equivalents;

•the U.K. Bribery Act of 2010;

•the Foreign Corrupt Practices Act, which applies to our international activities; and

•the Physician Payment Sunshine Act.

The legislative and regulatory landscape for privacy and data security continues to evolve. There has been increased attention to privacy and data security issues that could potentially affect our business, including the EU General Data Protection Regulation (GDPR), which entered into effect on May 25, 2018 and imposes penalties up to 4% of annual global turnover. In addition, laws and regulations enacted in the United States, Europe, Asia and Latin America, including the new California Consumer Privacy Act of 2018, which went into effect January 1, 2020, increases potential enforcement and litigation activity.

In the event we enroll subjects in our ongoing or future clinical investigations in the EEA, we may be subject to additional privacy restrictions, including restrictions relating to the collection, use, storage, transfer, and other processing of personal data, including personal health data, regarding individuals in the European Economic Area as governed by the General Data Protection Regulation, or GDPR. The GDPR imposes several requirements on companies that process personal data, strict rules on the transfer of personal data out of the European Economic Area, including to the U.S and fines and penalties for failure to comply with the requirements of the GDPR and the related national data protection laws of the EU Member States. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. The obligations under the GDPR may be onerous and adversely affect our business, financial condition, results of operations and prospects. Compliance with the GDPR will be a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation, and reputational harm in connection with any European activities. Furthermore, the United Kingdom’s exit of the EU, often referred to as Brexit, has created uncertainty with regard to data protection regulation in the United Kingdom. In particular, it is unclear how data transfers to and from the United Kingdom will be regulated.

Because of the remote work policies we implemented due to the COVID-19 pandemic, information that is normally protected, including company confidential information, may be less secure. Cybersecurity and data security threats continue to evolve and raise the risk of an incident that could affect our operations or compromise our business information or sensitive personal information, including health data.

We may also need to collect more extensive health-related information from our employees to manage our workforce. If we or our third-party partners fail to comply or are alleged to have failed to comply with applicable data protection and privacy laws and regulations, and related employment rules, or if we were to experience a data breach involving personal information, we could be subject to government enforcement actions or private lawsuits.

In addition, our business could be adversely impacted if our ability to transfer personal data outside of the EEA or Switzerland is restricted, which could adversely impact our operating results. For example, in July 2020, the Court of Justice of the European Union, or the Court of Justice, declared the Privacy Shield Decision (Decision 2018/1250) invalid, which could adversely impact our ability to transfer personal data from the EU to the U.S. The Court of Justice further ruled that in order to transfer data outside of the EU, under the existing mechanism known as the Standard Contractual Clauses, or SCCs, the importing country’s level of protection must be adequate.

On September 8, 2020, the Federal Data Protection and Information Commissioner, or FDPIC, of Switzerland issued an opinion concluding that the Swiss-U.S. Privacy Shield Framework does not provide an adequate level of protection for data transfers from Switzerland to the United States. The FDPIC also found that SCCs may still be legally adequate at an individual level, provided that they can pass a risk assessment conducted by the FDPIC. If the level of protection in the U.S. or any other importing country is called into question under the SCCs, this could further impact our ability to transfer data outside of the EU or Switzerland.

19

Health Care Reform

    Over the last decade, the U.S. Congress and certain state legislatures have introduced and passed a large number of laws and regulations designed to make major changes in the healthcare system, including changes intended to increase access to health insurance. The most prominent of these efforts, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (Affordable Care Act), has resulted in extensive changes across the healthcare system and affects how healthcare services are covered, delivered and reimbursed. However, there is substantial uncertainty regarding the future of the Affordable Care Act. The law has been subject to legislative and regulatory changes and court challenges, and certain members of Congress have expressed their intent to repeal or make significant changes to the Affordable Care Act, its implementation or its interpretation. Effective January 2019, Congress eliminated the financial penalty associated with the individual mandate to maintain health insurance coverage. As a result of this change, a federal court in Texas ruled that the individual mandate was unconstitutional, and determined that the rest of the law was, therefore, invalid. In December 2019, the Fifth Circuit Court of Appeals upheld this decision with respect to the individual mandate, but remanded for further consideration of how this affects the rest of the law. The law remains in place pending appeal. It is possible that the Affordable Care Act, uncertainty regarding its repeal, the ultimate outcome and impact of court challenges, significant changes to the law or other health reform efforts, such as single-payor proposals, will adversely affect our customers and strategic partners, which could cause them to reduce or delay the purchase of our systems or to demand reduced fees.

Human Capital Management

Our People

We believe that our talented workforce and culture of collaboration is one of our key strengths and that our continued success is built on the empowerment of our employees to develop and deliver reliable products for the diagnostic and life science industries we serve. As a global company in a highly competitive industry, we have designed our human capital strategy, including our employee compensation programs, to attract, develop, engage and retain talented employees who will allow us to continue to deliver on our business strategy.

As of December 31, 2020, we employed approximately 1,325 team members in 18 countries. 1,058 of our team members are employed in the United States and the remaining 267 are employed in foreign countries, primarily in Canada, China, Japan, The Netherlands, Germany and the United Kingdom. Nearly 90% of our team members work full time, while approximately 7% are limited assignment team members who work primarily in our manufacturing facilities. Less than 5% are part-time workers. In 2020 we classified less than 5% of our turnover as “regrettable,” which is the classification term we use generally to describe an employee who voluntarily resigns without any associated disciplinary or performance issues pending. None of our team members in the United States are subject to collective bargaining agreements.

Culture of Inclusion

Creating a culture where all colleagues feel supported and valued is paramount to our corporate values. We encourage all of our team members to bring their entire self to Luminex and to feel valued for the distinct contributions they bring to the growth of our business. As a global company, we embrace diversity and collaboration in our workforce and in how we operate. Our talent strategy is focused on attracting the best diverse talent, as well as developing and rewarding our team members' performance to increase retention and performance. We are an affirmative action employer and in addition to our focus on diversity, we prioritize the hiring of our veterans and seek out ways to provide opportunities for our disabled team members. Our recruiters are trained in diversity sourcing strategies and partner with external organizations that develop and supply diverse talent. As of December 31, 2020, approximately 40% of our workforce self-identified as female and approximately 35% of our workforce self-identified as racial minorities. The average age of our team members is forty-two and 21% of our workforce are managers.

In addition to our focus in hiring, we seek to foster a diverse and inclusive workplace that encourages engagement and development of our team members and drives retention. We provide diversity and inclusion training for leaders across our organization and utilize Employee Resource Groups (“ERG”) programs, which are staffed by volunteer team members with diverse backgrounds, experiences, or characteristics who share a common interest in professional development, improving corporate culture and delivering sustained business results.

We currently have four ERGs:

1.xTreme Team, which promotes and organizes events to keep all team members engaged with Luminex and keep it a fun environment where employees want to be part of a great team;
2.Women@Luminex, which focuses on the growth and development of our female team members by providing educational opportunities, mentoring programs and other activities to provide growth and development of our talented women and to encourage community development for women and girls to choose a career in life sciences;
20
3.Diversity Council, which embraces the diversity and inclusion of our team members, customers, partners and stakeholders, including their unique backgrounds, experiences, thoughts and talents; and
4.Community Involvement Committee, which promotes our commitment to corporate social responsibility and improving the world for current and future generations, as well as our collective values rooted in trust, respect, innovation and execution.

We believe that our rich culture of diversity and inclusion and our continuous focus on developing and training our global workforce, enable us to create, develop and fully leverage the strengths of our workforce to exceed customer expectations.

Compensation

The primary objective of our compensation programs, which we design with oversight from senior management and the compensation committee of our board of directors, as appropriate, is to provide incentives that attract, retain, motivate and reward superior performance by team members who must perform in a highly competitive and technologically challenging environment. The compensation programs for our team members align with the compensation programs for our executives, which the compensation committee of our board of directors reviews annually. We seek to identify top talent and then provide incentives for these talented team members to grow their careers with us. We review total compensation and benefits with reference to both external comparisons and internal comparisons and believe that our compensation programs support our corporate strategic priorities and align our team members’ economic interests with those of our stockholders. We base annual changes in compensation on our overall performance, as well as each individual’s contribution to the results achieved, and we grant equity awards, not only to our executives but also to our key team members and certain top performers. Annual bonus decisions are significantly tied to our overall achievement of financial goals and key development projects so that our employees’ incentives track our performance and align with our key business priorities. We believe that our compensation programs encourage an innovative, collaborative working environment and incentivize our team members to drive our overall success.

Compliance and Ethics

Compliance and ethics are deeply embedded in our values and business processes. Our compliance programs are designed around global standards with appropriate variations addressing the multiple jurisdictions in which we operate. We strive to create a culture of compliance for every team member, with a responsibility to always “do the right thing.” We have a Code of Compliance that applies to all of the team members, officers and directors and regularly conduct compliance and regulatory training at all of our locations. We also maintain an ethics reporting hotline for both team members and customers to provide any compliance, regulatory or discrimination concerns. We believe that fostering a workforce committed to compliance and ethics is an important part of our overall success.

Wellness and Safety

We strive to ensure the health, safety and general well-being of all of our team members. We maintain a safety environment that seeks to eliminate workplace incidents, risk, hazards and transmission of any illnesses. We also continue to evolve our programs to meet our team members’ health and wellness needs, which we believe is essential to attract and retain high-caliber employees. In addition, as we have sought to manage the impact of the COVID-19 pandemic on our workforce, we have undertaken a number of new initiatives, including working remotely when possible, increasing the amount of communication from senior management, providing mental health programs and online training for our remote employees and offering COVID-19 and serology testing to our manufacturing and R&D team members and their support organizations who must physically report to the office.

We also monitor the overall engagement of our team members with the use of on-boarding surveys and recently implemented a new tool to allow more frequent surveys to measure the morale and ongoing concerns of our team members. We understand that the work environment has changed because of the COVID-19 pandemic and are committed to working in tandem with our leaders and team members to assess how the shifts brought on by the pandemic may change our flexible working policies in the future.

Seasonality

    Worldwide sales, including U.S. sales, do not reflect any significant degree of seasonality; however, sales of our Respiratory Viral products have demonstrated seasonal fluctuations consistent with the onset and decline of influenza-like illnesses.

21
    Financial information relating to our business for the years ended December 31, 2020, 2019 and 2018 can be found in Item 7 “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and Item 8 “Financial Statements and Supplementary Data.”

Available Information

    Our shares of common stock are traded on the Nasdaq Global Select Market under the symbol “LMNX.” Our principal executive offices are located at 12212 Technology Blvd., Austin, Texas 78727, and our telephone number is (512) 219-8020. Our website address is luminexcorp.com. Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to these reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, are available free of charge through our website as soon as reasonably practicable after such material is electronically filed with, or furnished to, the Securities and Exchange Commission (SEC). Information contained or accessible on our website is not incorporated by reference into this report and such information should not be considered to be part of this report except as expressly incorporated herein. The public may read and copy these materials on the SEC’s website at www.sec.gov. The SEC’s website contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.

    Luminex was incorporated under the laws of the State of Texas in May 1995 and reincorporated in the State of Delaware in February 2000.

Information About Our Executive Officers
NameAgePosition
Nachum Shamir67Chairman, President and Chief Executive Officer
Harriss T. Currie59Chief Financial Officer, Senior Vice President, Finance and Treasurer
Todd C. Bennett 51Senior Vice President, Global Sales and Customer Operations
Chuck Collins44Senior Vice President, Research and Development
Nancy M. Fairchild67Senior Vice President, Human Resources
Randall J. Myers59Senior Vice President, Global Manufacturing and Quality
Richard W. Rew II53Senior Vice President, General Counsel and Corporate Secretary
Eric S. Shapiro57Senior Vice President, Global Marketing
    
Nachum Shamir. Mr. Shamir joined the Company on October 14, 2014 as President and Chief Executive Officer and was elected to our Board. Mr. Shamir assumed the responsibilities of Chairman of the Board on August 3, 2020. From 2006 to 2014, Mr. Shamir was the President, Chief Executive Officer and Director of Given Imaging Ltd. (Given), a developer of the PillCam capsule and manufacturer and marketer of diagnostic products for the visualization and detection of disorders of the gastrointestinal tract, which was acquired by Covidien PLC in early 2014. Mr. Shamir currently serves on the board of directors of Strata Skin Sciences, Inc. (Nasdaq: SSKN), a medical technology company which focuses on the dermatology market. Mr. Shamir holds a Bachelor of Science from the Hebrew University of Jerusalem and a Masters of Public Administration from Harvard University.

    Harriss T. Currie. Mr. Currie served the Company as Vice President, Finance, Treasurer and Chief Financial Officer since October of 2002 and was appointed Senior Vice President, Finance (as well as Chief Financial Officer and Treasurer) of the Company in March 2013. Since joining the Company in November of 1998, Mr. Currie previously served in the capacities of Controller and Treasurer. Prior to joining us, he was employed as the chief financial officer, secretary and treasurer of SpectraCell Laboratories, a specialized clinical testing laboratory company, from 1993 to 1998 where he also served as vice president of finance for two subsidiary companies. Mr. Currie earned his B.B.A. from Southwestern University and his M.B.A. in Finance and Marketing from the University of Texas at Austin. Prior to returning to graduate school for his M.B.A., Mr. Currie was a certified public accountant with Deloitte & Touche LLP.

22
    Todd C. Bennett. Mr. Bennett joined the Company in October 2012 as General Manager, Americas. Mr. Bennett was promoted to Vice President, Global Sales and Customer Operations in July 2015 and to Senior Vice President, Global Sales and Customer Operations in November 2016. From January 2007 through March 2012, Mr. Bennett was the Vice President of Sales and then promoted to Vice President of Commercial Operations at Immucor, Inc., a provider of transfusion and transplantation products, where he was responsible for Commercial Operations (Sales, Global Marketing, Customer Service functions). Prior to Immucor, Mr. Bennett held various commercial leadership roles at Roche Diagnostics and Abbott Laboratories dating to 1994. Mr. Bennett holds a B.S. in Business Administration with an emphasis in finance from the Max M. Fisher College of Business at The Ohio State University in Columbus, Ohio.

    Chuck Collins. Dr. Collins joined the Company in January 2006 as Senior Scientist. Dr. Collins was promoted to Director, Advanced Technology Group in January of 2008, and to Senior Director, Advanced Technology Group in August 2010. Dr. Collins then expanded his role with a promotion to Vice President, Systems R&D in May of 2012 and to Senior Vice President, R&D in January 2018. From August 2002 to January 2006, Dr. Collins was a Research Scientist at The U.S. Army Research Laboratory, developing ultraviolet LEDs, laser diodes, and photodetectors. Dr. Collins earned his BS in Electrical Engineering from Trinity University and received his Masters and PhD degrees in Electrical Engineering from The University of Texas at Austin.

    Nancy M. Fairchild. Ms. Fairchild joined the Company as Senior Director, Human Resources in March 2010. She was promoted to Vice President, Human Resources in August 2012 and to Senior Vice President, Human Resources in January 2015. Prior to joining the Company, Ms. Fairchild served from 2006 to 2010 as Chief Administrative Officer and Vice President of Human Resources and Organizational Development for the Electric Reliability Council of Texas, which provides the energy grid services for Texas. In this role, she managed Strategic Planning, Project Management, Facilities and Human Resources. Earlier in her career, she served as Vice President, Human Resources for Esoterix, Inc., an international healthcare company specializing in laboratory services, from 2001 to 2006, the Senior Vice President of Human Resources for Southern Union Company, a large natural gas conglomerate, from 1989 to 2001, and President of EnergyWorX, a training subsidiary, from 1996 to 2000. Ms. Fairchild is currently a member of the Board of Directors and Chair of the Audit Committee for Workforce Solutions, a local workforce development board in Texas, representing the biotech sector. She graduated with highest honors from Texas State University with a B.S. degree in Math Education and an M.S. degree in Counseling.

    Randall J. Myers. Mr. Myers joined the Company as Senior Vice President, Global Manufacturing and Quality, in March 2015. Prior to joining the Company, Mr. Myers accepted an early retirement from Applied Materials, Inc. (Applied Materials), a supplier of equipment services and software to enable the manufacture of semiconductor, flat panel display, glass, WEB and solar products, in 2012 and had been consulting in supply chain and manufacturing operations since that time. Prior to his retirement from Applied Materials, Mr. Myers held various positions at Applied Materials in manufacturing and operations from 1995-2012. In his final position with Applied Materials, Mr. Myers was Vice President of the Silicon Systems Group Global Planning & Business Operations. Mr. Myers attended Kettering University where he obtained a B.S. in Electrical Engineering.

    Richard W. Rew II. Mr. Rew joined the Company as Senior Vice President, General Counsel and Corporate Secretary in March 2015. Prior to joining the Company, Mr. Rew served as Senior Vice President, General Counsel and Secretary at ArthroCare Corporation (ArthroCare), a medical device company, from December 2008 until it was acquired by Smith & Nephew in 2014. Mr. Rew joined ArthroCare in 2006 as its Vice President, Legal Affairs. Mr. Rew previously served as General Counsel of Activant Solutions Inc. from 2000 to 2006 and as General Counsel of EZCORP, Inc. from 1996 to 2000. Mr. Rew earned a B.A. in the Plan II Honors Program from the University of Texas at Austin and a J.D. from the University of Oklahoma College of Law. Mr. Rew is a member of the State Bar of Texas.

    Eric S. Shapiro. Mr. Shapiro joined Luminex in October 2015 as the Vice President of Global Marketing, and was promoted to Senior Vice President, Global Marketing in February 2018. Prior to joining the Company on a full-time basis, Mr. Shapiro was the Principal at ESS Strategic Consulting, LLC, which he founded in 2014. In his role there, he worked on a variety of global strategic and operational projects, including serving as the General Manager for the Market Launch of ARIES and NxTAG RPP, from May 2015 to September 2015. Mr. Shapiro has previously served as a Vice President of Marketing for Given, from 2009 to 2014, and held numerous leadership positions at Kinetic Concepts, Inc., from 1993 to 2007, including Vice President of Marketing, Vice President of Patient Administration, Director of Corporate Development, and Director of Mergers and Acquisitions. Mr. Shapiro began his career working in both office and hospital-based Sales positions with Merrell Dow and Marion Merrell Dow. Mr. Shapiro holds a B.S. degree from Syracuse University, with an emphasis in Marketing and Telecommunications Management, and an M.B.A. from the J.L. Kellogg Graduate School of Management, with an emphasis in Marketing, Healthcare, Organizational Behavior, and Economics.


23
ITEM 1A. RISK FACTORS

Risk Factor Summary

We are providing the following summary of the risk factors contained in this Annual Report on Form 10-K to enhance the readability and accessibility of our risk factor disclosures. We encourage you to carefully review the full risk factors contained in this Annual Report on Form 10-K in their entirety for additional information. Our business is subject to numerous risks and uncertainties, discussed in more detail in the following section. These risks include, among others, the following:

•Our business relies upon our ability to maintain the technological advances and resources to compete in the rapidly-changing life sciences and diagnostics industry. Our profitability in this industry depends on many other industry-related factors, including the success of our acquisition strategy, maintenance and expansion of our manufacturing operations, protection of cybersecurity and proprietary rights, development of our technology infrastructure and the success of our products in the market, all of which are unpredictable and may adversely impact our business.
•Our business and products, as well as those of our strategic partners and suppliers, are subject to extensive regulation by the FDA and may require other industry clearances and approvals. Changes to U.S. legislative, FDA or global regulations may make it more difficult for us to obtain regulatory approval of our products and/or manufacture our products. We are subject to evolving legislative, regulatory, judicial and ethical standards on use of technology and biotechnology.
•Our revenue depends significantly upon a limited number of direct customers and strategic partners, as well as the establishment and maintenance of relationships with other direct customers and strategic partners. Our business also depends on our ability to attract and retain our management and staff.
•If our products contribute to a death or a serious injury, or malfunction in certain ways, we will be subject to medical device reporting regulations, which can result in voluntary corrective actions or agency enforcement actions. If we become subject to product liability claims, we may be required to pay damages that exceed our insurance coverage. If we become subject to claims relating to improper handling, storage or disposal of hazardous materials, we could incur significant cost and time to comply.
•We face business disruption and related risks resulting from the recent pandemic of the novel coronavirus 2019 virus (COVID-19) and related preventative vaccines, which could have a material adverse effect on our business. Uncertain economic conditions, particularly during the COVID-19 pandemic, may adversely affect our business. We expect our operating results, sales and stock price to fluctuate from quarter to quarter.
•Our effective tax rate may fluctuate and we may incur obligations in tax jurisdictions in excess of amounts that have been accrued. We hold cash and cash equivalents at various foreign subsidiaries that may not be readily available to meet domestic cash requirements.
•We incurred indebtedness by issuing Notes and entering Convertible Note Hedge and Warrant Transactions, which may affect our cash, financial condition and operating results and value of our common stock and other securities

Risk Factors Relating to Growth and Profitability of Our Business

The life sciences and diagnostics industries are highly competitive and subject to rapid technological change, and we may not have the technologies and resources necessary to compete successfully.

    We compete with companies in the United States and abroad that are engaged in the development and production of similar products. We will continue to face intense competition from existing competitors and other companies seeking to develop and commercialize new technologies. Many of our competitors have access to greater financial, technical, scientific, research, marketing, sales, distribution, service and other resources than we do and may have longer operating histories or more recognizable brand names. These companies may develop technologies that are superior alternatives to our technologies or may be more effective at commercializing their technologies in products.

24
    The life sciences and diagnostics industries are characterized by rapid and continuous technological innovation. We may need to develop new technologies for our products to remain competitive. One or more of our current or future competitors could render our present or future products or those of our partners obsolete or uneconomical by technological advances, including the introduction or existence of, competing products or technologies that may be more effective, cheaper or easier to use than our products and technologies. In addition, the introduction or announcement of new products by us or others could result in a delay of or decrease in sales of existing products as we await regulatory approvals, while customers evaluate these new products, or if customers choose to purchase the new products instead of legacy products. We may also encounter other problems in the process of delivering new products to the marketplace such as problems related to design, development, supply chain or manufacturing of such products, and as a result, we may be unsuccessful in selling such products. Our future success depends on our ability to compete effectively against current technologies, as well as to respond effectively to technological advances by developing and marketing products that are competitive in the continually changing technological landscape.

    Several companies provide systems and reagents for DNA amplification or detection. Life Technologies Corporation (a Thermo Fisher Scientific Inc. brand) and F. Hoffman-La Roche Ltd. (Roche) sell systems integrating DNA amplification and detection (sequence detection systems) to the commercial market. Life Technologies Corporation (a Thermo Fisher Scientific Inc. brand), Roche, Abbott Laboratories, Becton Dickinson and Company, Danaher Corporation, Qiagen N.V., Hologic, Inc., Meridian Bioscience, Inc., bioMérieux S.A., Illumina, Inc. and Quidel Corporation sell sequence detection systems, some with separate robotic batch DNA purification systems, and they also sell reagents to the clinical diagnostics market. Other companies offer molecular diagnostic tests. Additionally, we anticipate that in the future, additional competitors will emerge and offer a broad range of competing products, including increasing adoption of competitive products based on mass spectrometry and next generation sequencing test technologies.
               
    There are also a number of companies that provide flow cytometry instruments and reagents for research and clinical flow cytometry applications. BD Biosciences and Beckman Coulter sell systems for cell analysis and cell sorting in both the clinical and research markets. Miltenyi Biotec markets systems focused on cell separation, some of which integrate their magnetic separation technology for cell enrichment/depletion. Bio-Rad sells flow analyzers and sorters designed and manufactured by Propel Labs. Attune (part of ThermoFisher Scientific) markets flow cytometers that use acoustic focusing for high cell throughput for rare event analysis. Sony Biotechnology sells cell sorters and analyzers and has recently developed a spectral flow cytometry system that expands the detection of simultaneous fluorescent parameters. Cytek Biosciences has grown from a third-party field service provider to launch its own spectral flow cytometry system. ACEA Biosciences is a relatively new provider of benchtop flow cytometry analyzers. A few companies are reportedly working on systems to compete directly with our Amnis imaging flow cytometers. We anticipate additional competitors will emerge in the future who will offer a broad range of competing products, which will likely both increase awareness and adoption of spectral flow cytometry and imaging flow cytometry.

25
If we do not introduce new products in a timely manner, we may lose market share and be unable to achieve revenue growth targets.

    We sell many of our products in industries characterized by rapid technological change, frequent new product and service introductions and evolving customer needs and industry standards. Many of the businesses competing with us in these industries have significant financial and other resources to invest in new technologies, substantial intellectual property portfolios, substantial experience in new product development, regulatory expertise, manufacturing capabilities and established distribution channels to deliver products to customers. Our products could become technologically obsolete over time, or we may invest in technologies that do not lead to revenue growth or continue to sell products for which the demand from our customers is declining, in which case we may lose market share or not achieve our revenue growth targets. The success of our new product offerings will depend upon several factors, including our ability to:

•accurately anticipate customer needs;

•innovate and develop new technologies and applications;

•obtain required regulatory clearances;

•successfully commercialize new technologies in a timely manner;

•price our products competitively, and manufacture and deliver our products in sufficient volumes and on time; and

•differentiate our offerings from our competitors’ offerings.

    Many of our products are used by our customers to develop, test and manufacture their products. We must anticipate industry trends and consistently develop new products to meet our customers’ expectations. In developing new products, we may be required to make significant investments before we can determine the commercial viability of a new product. If we fail to accurately foresee our customers’ needs and future activities, we may invest heavily in research and development of products that do not lead to significant revenue. We may also suffer a loss in market share and potential revenue if we are unable to commercialize our products in a timely and efficient manner.

We may be unsuccessful in implementing our acquisition strategy. We may face difficulties integrating acquired entities with our existing businesses. Our business may be harmed by prior or future acquisitions.

    Acquisitions of assets or entities designed to accelerate the implementation of our strategic plan are an important element of our long-term strategy. We may be unable to identify and complete appropriate future acquisitions in a timely manner, or at all, and no assurance can be provided that the market price of potential business acquisitions will be acceptable. In addition, many of our competitors have greater financial resources than we have and may be willing to pay more for these businesses or selected assets. In the future, should we identify suitable acquisition targets, we may be unable to complete acquisitions or obtain the financing, if necessary, for these acquisitions on terms favorable to us. Potential acquisitions pose a number of risks, including, among others, that:

•we may not be able to accurately estimate the financial effect of acquisitions on our business;

•future acquisitions may require us to incur debt or other obligations, issue additional securities, incur large and immediate write-offs, issue capital stock potentially dilutive to our stockholders or spend significant cash, or may negatively affect our operating results and financial condition;

•if we spend significant funds or incur additional debt or other obligations, our ability to obtain financing for working capital or other purposes could decline, and we may be more vulnerable to economic downturns and competitive pressures;

•technological advancement or worse than expected performance of acquired businesses may result in the impairment of intangible assets;

26
•we may be unable to realize the anticipated benefits and synergies from acquisitions, as a result of inherent risks and uncertainties, including difficulties integrating acquired businesses or retaining their key personnel, partners, customers or other key relationships, entering market segments in which we have no or limited experience, and risks that acquired entities may not operate profitably or that acquisitions may not result in improved operating performance;

•we may fail to successfully obtain appropriate regulatory approval or clearance for products under development of our acquired businesses;

•we may be assuming liability for unresolved regulatory risks of our acquired businesses;

•we may fail to effectively enhance acquired technologies and products to develop new products relating to acquired businesses;

•our customers may not accept products of our acquired businesses;

•we may fail to effectively coordinate sales and marketing efforts of our acquired businesses;

•we may fail to combine product offerings and product lines of our acquired businesses quickly and effectively;

•we may fail to successfully manage relationships with customers, distributors and suppliers of our acquired businesses;

•an acquisition may involve unexpected costs or liabilities, including as a result of pending and future shareholder lawsuits relating to acquisitions or exercise by shareholders of their statutory appraisal rights, or the effects of purchase accounting may be different from our expectations;

•an acquisition may involve significant contingent payments that may adversely affect our future liquidity or capital resources;

•acquisitions and subsequent integration of these companies may disrupt our business and distract our management from other responsibilities; and

•the costs of unsuccessful acquisition efforts may adversely affect our financial performance.

    Other risks of integration of acquired businesses include:

•disparate information technology, internal control, financial reporting and record-keeping systems;

•differences in accounting policies, including those requiring judgment or complex estimation processes;

•new partners or customers who may operate on terms and programs different than ours;

•additional employees not familiar with our operations;

•unanticipated additional transaction and integration-related costs;

•our current and prospective customers and suppliers may experience uncertainty associated with an acquisition, including with respect to current or future business relationships with us, and may attempt to negotiate changes in existing business;

•facilities or operations of acquired businesses in remote locations or potentially foreign jurisdictions and the inherent risks of operating in unfamiliar legal and regulatory environments; and

•new products, including the risk that any underlying intellectual property associated with such products, may not have been adequately protected or that such products may infringe on the proprietary rights of others.
27

Epidemic diseases could negatively affect various aspects of our business, make it more difficult to meet our obligations to our customers, and could result in reduced demand from our customers. These could have a material adverse effect on our business, financial condition, results of operations, or cash flows.

Parts of our business have been and continue to be adversely affected by the effects of the COVID-19 pandemic and may be further affected by the recent availability and distribution of a preventative vaccines. In an effort to halt the outbreak of COVID-19, many countries have placed significant restrictions on travel and congregation, including “shelter-in-place” or similar orders, leading to extended business closures. Individuals who contract the virus may be unavailable to work, and in certain jurisdictions, individuals exposed to the virus, as well as their families and co-workers, may be placed in mandatory quarantines. The spread of the virus, as well as restrictions and business closures implemented in an effort to minimize its spread, can adversely impact our operations, including delaying or suspending our ability to sell or distribute our products, causing temporary closures of our offices and manufacturing operations, or those of our suppliers, customers, distributors and other business partners. Any disruption of our suppliers, customers or distributors could continue to adversely impact our global sales and operating results and harm our reputation. While many businesses have re-opened as the pandemic eased in particular locations, a resurgence of COVID-19 cases in those geographies could cause additional closures. Likewise, we may be subject to public and private litigation based upon, arising out of or related to COVID-19 and our actions and responses thereto, including any determinations that we may make to continue to operate or to re-open our facilities where permitted by local law. We cannot at this time accurately predict what effects these conditions will continue to have on our operations longer-term due to uncertainties relating to the ultimate geographic spread of the virus, the severity of the disease, the duration of the outbreak, the extent and effectiveness of responsive actions by authorities of impacted countries and the impact of these and other factors on our employees, customers and suppliers. In addition, a significant outbreak of a contagious disease in the human population could result in a widespread health crisis that could adversely affect the economies and financial markets of many countries for an extended period of time, resulting in economic uncertainty and volatility that could affect demand for our products, and likely adversely impact our business, operations, financial conditions and results of operations for an indefinite period of time.

Despite the authorization and distribution of preventative COVID-19 vaccines, there are still uncertainties surrounding the effectiveness, availability and extent of distribution of such vaccines. We cannot predict the effect of such vaccines on us and our vendors, suppliers, and potential sublicensees; the global economy and political conditions; and the health of our personnel, consultants, and their families; all of which will affect how quickly and to what extent normal economic and operating activities can resume. Even after the COVID-19 pandemic has subsided, we may continue to experience an adverse effect on our business as a result of its global economic impact, including any resulting and ongoing recession. All of these circumstances likely exert similar hardships on those with which we deal, such as vendors, shippers, distributors, and sublicensees. As a result, we have made adjustments to, and will need to continue to adjust, our business and expenditures in an effort to correlate our activities with business exigencies, including restrictions of executive and employee travel, hiring freezes or delays, and limitations on marketing. The ultimate financial impact and duration of all of the foregoing cannot now be predicted and may well exceed our expectations or our ability to cope with them. Any, or all, of the foregoing uncertainties could continue to have a material adverse effect on our business, operations, financial conditions and results of operations for an indefinite period of time.

Risks Affecting Our Product Development and Manufacturing Operations

As we continue to expand our business, we may experience problems in scaling our manufacturing operations, or delays or component shortages that could limit the growth of our revenue.

    As we continue to expand our manufacturing capabilities in order to meet our growth objectives, we may not be able to produce sufficient quantities of products or maintain consistency between differing lots of consumables. If we encounter difficulties in scaling our manufacturing operations as a result of, among other things, quality control and quality assurance issues and availability of components and raw material supplies, we will likely experience reduced sales of our products, increased repair or re-engineering costs due to product returns and defects and increased expenses due to switching to alternate suppliers, any of which could reduce our revenues and gross margins.

28
Our ability to continue to operate without any significant negative operational impact from the COVID-19 pandemic will, in part, depend on our ability to protect our employees and maintain our supply chain. Continued rapid expansion of capacity may be constrained by long lead-time purchased items and capital equipment needs. We continue to endeavor to follow the recommended actions of government and health authorities to protect our employees, with particular measures in place for employees who manufacture our products. However, the complications resulting from the pandemic could result in unforeseen disruptions to our workforce and supply chain, including an inability of a key supplier or transportation supplier to source, transport and supply materials to the Company that are necessary for continued operations, that could individually or in combination with other factors, have a material adverse effect on our business, operations, financial conditions and results of operations.

    We presently outsource certain aspects of the assembly of our systems to contract manufacturers. Because of a long lead-time to delivery, we are required to place orders for a variety of items well in advance of scheduled production runs. We have increased our flexibility to purchase strategic components within shorter lead times by entering into supply agreements with the suppliers of these components. Although we attempt to match our parts inventory and production capabilities to estimates of marketplace demand, to the extent system orders materially vary from our estimates, we may experience continued constraints in our systems production and delivery capacity, which could adversely impact revenue in a given fiscal period. Should our need for raw materials and components used in production continue to fluctuate, we could incur additional costs associated with either expediting or postponing delivery of those materials. In an effort to control costs, we have implemented a lean production system. Managing the change from discrete to continuous flow production requires time and management commitment. Lean initiatives and limitations in our supply chain capabilities may result in parts shortages that delay shipments and cause fluctuations in revenue.

    We currently purchase certain key components of our product line from a limited number of outside sources and, in the case of some components, a single source, and these components may only be available through a limited number of providers. We do not have agreements with all of our suppliers. While we currently believe that we will be able to satisfy our forecasted demand for our products, the failure to find alternative suppliers in the event of any type of supply failure at any of our current vendors at reasonably comparable prices could have a material adverse effect on our business, financial condition and results of operations. Additionally, we have entered into supply agreements with most of our suppliers of strategic reagents and component subassemblies to help ensure component availability, and flexible purchasing terms with respect to the purchase of such components. If our suppliers discontinue production of a key component, we will be required to revalidate an affected product and may be required to resubmit a previously cleared product.  Our reliance on our suppliers and contract manufacturers exposes us to risks including:

•the possibility that one or more of our suppliers or our assemblers that do not have supply agreements with us could terminate their services at any time without penalty;

•natural disasters such as earthquakes, tsunamis and floods that impact our suppliers;

•the potential obsolescence and/or inability of our suppliers to obtain required components;

•the potential delays and expenses of seeking alternate sources of supply or manufacturing services;

•the inability to qualify alternate sources without impacting performance claims of our products;

•reduced control over pricing, quality and timely delivery due to the difficulties in switching to alternate suppliers or assemblers; and

◦increases in prices of raw materials and key components.

    Consequently, in the event that supplies of components or work performed by any of our assemblers are delayed or interrupted, our ability to produce and supply our products could be impaired.


29
If a catastrophe strikes our manufacturing or warehousing facilities, we may be unable to manufacture or distribute our products for a substantial amount of time and we may experience inventory shortfalls, which would cause us to experience lost revenues.

Our manufacturing facilities are located in Austin, Madison, Northbrook, Toronto and Seattle. Although we have business interruption insurance, our facilities and some pieces of manufacturing equipment are difficult to replace and could require substantial replacement lead time. Various types of disasters, including tornadoes, fires, floods and acts of terrorism, may affect our manufacturing facilities. In the event our existing manufacturing facilities or equipment are affected by man-made or natural disasters, we may be unable to manufacture products for sale or meet customer demands or sales projections. If our manufacturing operations were curtailed or ceased, it would seriously harm our business.

The property rights we rely upon to protect the technologies underlying our products may not be adequate to maintain market exclusivity. Inadequate intellectual property protection could enable third parties to exploit our technologies or use very similar technologies and could reduce our ability to distinguish our products in the market.

    Our success depends, in part, on our ability to obtain, protect and enforce patents on our technologies and products and to protect our trade secrets, including the intellectual property of entities we may acquire. Any patents we own may not afford full protection for our technologies and products. Other parties may challenge the validity of our patents and, as a result, our patents could be narrowed or invalidated in administrative or judicial proceedings. In addition, our current and future patent applications may not result in the issuance of patents in the United States or foreign countries. Competitors may develop products that are not covered by our patents. Furthermore, there is a substantial backlog of patent applications at the U.S. Patent and Trademark Office and certain patent offices in foreign jurisdictions, and the approval or rejection of patent applications may take several years.

    We currently own 821 issued patents worldwide, including 237 issued patents in the United States. Other countries in which we have issued patents directed to various aspects and applications of our products and technologies include France, Germany, the United Kingdom, Australia, Japan, Netherlands, Canada, Hong Kong, China and South Korea, amongst others. In addition, our patent portfolio includes 110 pending patent applications in the United States and other foreign jurisdictions. We also have patents covering key aspects of MultiCode technology, xTAG technology, and nanoparticle technology, utilized in our assays as well as our ARIES and VERIGENE Systems, NxTAG technology imaging flow cytometry technology and capillary flow cytometry technology.

    We seek to require employees, consultants, strategic partners and other third parties to execute confidentiality agreements. Our employees and third-party consultants also sign agreements requiring that they assign to us their interests in inventions and original expressions and any corresponding patents and copyrights arising from their work for us. In addition, we have implemented a patent process to file patent applications on our key technologies. However, we cannot guarantee that these agreements or this patent process will provide us with adequate ownership rights, protection against improper use of our intellectual property, or disclosure of confidential information. In addition, in some situations, these agreements may conflict with, or be subject to, the rights of third parties with whom our employees, consultants or advisers have prior employment or consulting relationships. Further, others may independently develop substantially equivalent proprietary technologies, techniques and products or counterfeit versions of our products or otherwise gain access to our trade secrets. Our failure to protect our proprietary information and techniques may inhibit or limit our ability to distinguish our products in the market.

    In order to protect or enforce our patent rights, we may have to initiate legal proceedings against third parties, such as infringement suits or interference proceedings. These legal proceedings could be expensive, take significant time and/or divert management’s attention from other business concerns. These proceedings may cause us to lose the benefit of some of our intellectual property rights, the loss of which may inhibit or preclude our ability to distinguish our products in the market. These proceedings also may provoke these third parties to assert claims against us. Moreover, a series of decisions from the Supreme Court of the United States have arguably weakened United States patent rights, including the Impression Products v. Lexmark case, which expands the scope of the patent exhaustion doctrine to sales of patented products outside of the United States and limits a patent holder’s ability to enforce post-sale restrictions under patent law. The patent position of companies like ours generally is highly uncertain, involves complex legal and factual questions, and has recently been the subject of much litigation. No consistent policy has emerged from the U.S. Patent and Trademark Office or the courts regarding the breadth of claims allowed or the degree of protection afforded under patents like ours.
30

If our current products and our products under development do not become widely used in the life sciences and clinical diagnostics industries, we may not be able to maintain or increase profitability.

    Life sciences and clinical diagnostic service provider companies have historically conducted biological tests using a variety of technologies, including bead-based analysis. The commercial success of our products depends upon widespread adoption of our systems as methods to perform assays. In order to be successful, we must convince potential partners and customers to utilize our systems instead of other competing products. Market acceptance depends on many factors, including our ability to:

•timely and successfully launch our products under development;

•manage trends relating to, or the introduction or existence of, competing products or technologies that may be more effective, cheaper or easier to use than our products and technologies;

•operate in a highly competitive marketplace, including in the presence of competing products sold by companies with longer operating histories, more recognizable names and more established distribution networks;

•convince prospective strategic partners and customers that our products are an attractive alternative to others for research, clinical, biomedical and genetic testing and analysis;

•encourage these partners to develop and market products using our technologies;

•manufacture products in sufficient quantities with acceptable quality and at an acceptable cost;

•obtain and maintain sufficient pricing and royalties from partners on such Luminex products; and

•place and service sufficient quantities of our products at the level of service required in the life science and clinical diagnostics market segments.

    In the molecular diagnostics sector, we must recognize significant market uptake in order to gain operational efficiencies and reduce costs based on increased volume.

    Because of these and other factors, our products may not gain or sustain sufficient market acceptance to maintain or increase profitability. Additionally, we may have to write off excess or obsolete inventory if sales of our products are not consistent with our expectations or if the demand for our products changes.

Risks Related to Customers and Partners

Currently, a limited number of customers account for a significant portion of our revenue and the loss of any one of these or their inability to perform to expectations could have a material adverse effect on our business, financial condition, and results of operations. Our success depends significantly on the establishment and maintenance of successful relationships with our customers.

Our two largest customers accounted for 14% of total revenue in the twelve months ended December 31, 2020, with one of the customers accounting for 10%. In the twelve months ended December 31, 2019 and 2018, our two largest customers accounted for 17% and 29% of total revenue, respectively. No other customer accounted for more than 4% of total revenue during the twelve months ended December 31, 2020. In total, for the years ended December 31, 2020 and 2019, our top five customers accounted for 22% and 30%, respectively, of our total revenue. The loss of any of our significant direct customers, strategic partners, or the loss of a material portion of the sales to these customers or partners could have a material adverse effect on our growth and future results of operations.
31

If third-party payors continue to increasingly restrict payments for healthcare expenses or fail to adequately pay for multi-analyte testing, we may experience reduced sales, which would hurt our business and our business prospects.

    Third-party payors, government-sponsored healthcare programs (e.g., Medicare, Medicaid and Tricare), health maintenance organizations, preferred provider organizations and other private or commercial insurers are continually seeking to reduce healthcare expenses. Payors are challenging the utilization of, and prices charged for, medical services, including clinical diagnostic tests. The federal government has implemented cost-cutting strategies for government-sponsored healthcare programs, including coverage limitations and reimbursement rate reductions required by the Affordable Care Act. As a result of regulations issued pursuant to the Protecting Access to Medicare Act, payment rates for most tests included in the Clinical Laboratory Fee Schedule used by Medicare are based on commercial insurance rates, which certain laboratories are required to report. The payment reductions resulting from this revised reimbursement methodology are capped at 10% for 2020 and 15% for each of 2021 through 2023. We expect reimbursement rates to trend down over time. Coverage and reimbursement from commercial payors may also reflect these reductions.

    Further cost containment initiatives by governmental or educational entities or programs may reduce funding for genetic research and development activities and slow the growth of the genetic testing market.  Lack of adequate coverage or reimbursement for our products could affect consumer demand, reducing volumes or adding additional cost pressures, resulting in lowered prices for our products. Efforts by group purchasing organizations and other large purchasers to reduce costs may also result in lowered prices or deeper discounts on our products. Reduced sales or margins by us, or our direct customers, and strategic partners, would adversely affect our business, profitability and business prospects. In addition, failure to secure appropriate reimbursement in foreign jurisdictions could severely limit our ability to expand sales within these markets.

Delays in implementation, delays in obtaining regulatory approval, changes in strategy, or the financial difficulty of our strategic partners for any reason could have a material adverse effect on our business, financial condition, and results of operations.

    Our ability to enter into agreements with additional strategic partners depends in part on convincing them that our products can help achieve and accelerate their goals or efforts. We expend substantial funds and management efforts with no assurance that any additional strategic relationships will result. We cannot guarantee that we will be able to negotiate additional strategic agreements in the future on acceptable terms, if at all, or that current or future strategic partners will not pursue or develop alternative technologies either on their own or in collaboration with others. Some of the companies we are targeting as strategic partners offer products competitive with our xMAP Technology, which may hinder or prevent strategic relationships. Delays in implementation of new products by our strategic partners, changes in their strategy, financial difficulties they experience, or delays in obtaining or their inability to obtain regulatory approval for their products, including as a result of the COVID-19 pandemic, could negatively affect our business. Termination of strategic relationships, the failure to enter into a sufficient number of additional strategic relationships on favorable terms, or disputes with our partners could reduce sales of our products, lower margins on our products and limit the market demand for and acceptance of our products.

    As we pursue the development and registration of products, regulation by governmental authorities in the United States and other countries will be a significant factor in the development, testing, production, and marketing of such products. Products that we develop in the molecular diagnostic markets will be regulated as medical devices by the FDA and other global governmental authorities and may require receipt of clearance following a pre-market notification process prior to marketing. Obtaining the requisite regulatory approvals can be expensive and may involve considerable delay. Changes to the current regulatory framework, including additional or new regulations, could arise at any time during the development or marketing of our products, which may negatively affect our ability to obtain regulatory approval of our products.

32
If the quality or delivery of our products does not meet our customers’ expectations, our reputation could suffer and ultimately our sales and operating earnings could be negatively impacted.

    In the course of conducting our business, we must adequately address quality issues associated with our products and services, including defects in our engineering, design, manufacturing and delivery processes, as well as defects in third-party components included in our products. Because our instruments and consumables are highly complex, the occurrence of defects may increase as we continue to introduce new products and services and as we rapidly scale up manufacturing to meet increased demand for our products and services. Although we have established internal procedures to minimize risks that may arise from product quality issues, there can be no assurance that we will be able to eliminate or mitigate occurrences of these issues and associated liabilities. In addition, identifying the root cause of quality issues, particularly those affecting reagents and third-party components, may be difficult, which increases the time needed to address quality issues as they arise and increases the risk that similar problems could recur. Finding solutions to quality issues can be expensive and we may incur significant costs or lost revenue in connection with, for example, shipment holds, product recalls and warranty or other service obligations. In addition, quality issues can impair our relationships with new or existing customers and adversely affect our brand image, and our reputation as a producer of high quality products could suffer, which could adversely affect our business, financial condition or results of operations.

If our direct selling efforts for our products are less successful than anticipated, our business expansion plans could suffer and our ability to generate revenues could be diminished.

    If our direct sales force is not successful, or additions to our sales team fail to gain traction among our customers, we may not be able to increase market awareness and sales of our products, or to maintain historical sales levels. If we fail to establish our systems in the marketplace, it could have a negative effect on our ability to sell subsequent systems and hinder the planned expansion of our business.

    The commercial launch of the ARIES System was the first Luminex system launch that was not channeled through a partner. The successful execution of our product launch and adoption by our direct customers has been and will continue to be critical to establishing an installed base of satisfied customers. To the extent that these customers do not continue to adopt the menu of ARIES Assays that have been a significant focus of our research and development efforts over the last five years, there is a significant risk that our investment in these assays may not pay off. Additionally, we have made a significant investment in our customer service, support and direct sales force to support the launches of ARIES Systems. Our ability to service, support and sell the ARIES and VERIGENE Systems directly, and not through a partner, may also fail to meet ongoing market expectations, which could have a material adverse effect on our business, financial condition and results of operations.

Our success depends on our ability to service and support our products directly or in collaboration with our strategic partners.

    To the extent that we or our strategic partners fail to maintain a high quality level of service and support for xMAP products, there is a risk that the perceived quality of our xMAP products will be diminished in the marketplace. Likewise, we may fail to provide the level, quantity or quality of service expected by the marketplace. This could result in slower adoption rates and lower than anticipated utilization of xMAP products, which could have a material adverse effect on our business, financial condition and results of operations.

33
In most of our strategic partnerships, we have granted non-exclusive rights with respect to commercialization of our products and technologies. 

    We expect that a significant portion of our future revenues will come from sales of our systems and the development and sale of kits utilizing our xMAP consumables by our strategic partners and from use of our xMAP products by our strategic partners in performing services offered to third parties. We believe that our strategic partners will have economic incentives to develop and market these products, but we cannot accurately predict future sales and royalty revenues because some of our existing strategic partner agreements do not include minimum purchase requirements or minimum royalty commitments. Some of our existing strategic partner agreements contain minimum purchase requirements for certain years, but unless renegotiated, these minimum purchase requirements could and will expire. In addition, we have no control with respect to our strategic partners’ sales personnel and how they prioritize products based on xMAP technology, nor can we control the timing of the development or release of products by our strategic partners. The amount of these revenues depends on a variety of factors that are outside our control, including the amount and timing of resources that current and future strategic partners devote to developing and marketing products incorporating our technology. Furthermore, the development and marketing of certain kits will require our strategic partners to obtain governmental approvals, which could delay or prevent their commercialization efforts. If our current or future strategic partners do not successfully develop and market products based on our technology and obtain necessary government approvals, our revenues from product sales and royalties could be significantly reduced.

Our reliance on strategic partnerships makes forecasting difficult.

    As a result of our reliance on our strategic relationships, it can be difficult to accurately forecast future operating results. Estimating the timing and amount of sales of our products is particularly difficult for the following reasons (among others):

•we do not control the timing or extent of product development, marketing or sale of our products by our strategic partners;

•we do not control the incentives provided by our strategic partners and distributors to their sales personnel;

•we utilize a limited number of geographically focused distributors for a portion of our sales, including sales of several of our key assays, and the loss of or nonperformance by these distributors could harm our revenues in the territories serviced by these distributors;

•a significant number of our strategic partners intend to produce clinical diagnostic applications that may need to be approved by the FDA or other regulatory bodies in jurisdictions outside of the United States;

•certain strategic partners may have unique requirements for their applications and systems. Assisting the various strategic partners may strain our research and development and manufacturing resources. To the extent that we are unable to timely assist our strategic partners, the commercialization of their products will likely be delayed;

•certain strategic partners may fail to deliver products that satisfy market requirements, or such products may fail to perform properly;

•we have limited access to partner and distributor confidential corporate information. A sudden unexpected change in ownership or strategy or other material event due to information of which we are not currently aware could adversely impact partner purchases of our products; and

•partners tend to order in bulk prior to the production of new lots of their products and prior to major product development initiatives. The frequency of these bulk purchases is difficult to predict and may cause large fluctuations in microsphere sales quarter to quarter.

34
The capital spending policies of our customers have a significant effect on the demand for our products.

    Our customers include clinical diagnostic, pharmaceutical, biotechnological, research institutions, chemical and industrial companies, and the capital spending policies of these companies can have a significant effect on the demand for our products. These policies are based on a wide variety of factors, including general or local economic conditions, governmental regulation or price controls, resources available for purchasing research equipment, government funding, grants, spending priorities among various types of analytical equipment manufacturers and policies regarding capital expenditures during recessionary periods. Any decrease in capital spending by life sciences companies could cause our revenues to decline. As a result, we are subject to significant volatility in revenue. Therefore, our operating results can be materially affected (negatively and positively) by the spending policies and priorities of our customers.

Adjustments of previously recognized royalty revenue from LTG partners could impact our results of operations and result in our restating financial results for certain fiscal periods.

The Company through its LTG enters into contractual arrangements with customers and other third parties, a component of which are royalty arrangements. Such royalty obligations are typically self-reported, paid in the regular course of business and recorded by the Company accordingly. These royalty arrangements may be subject to inspection (either directly by the Company or by a third-party) to seek to assure that the counterparty has made sufficient payment to the Company. Generally, if the Company has inspection rights, the Company may exercise these rights every three years.

With respect to royalty reporting, the Company significantly relies upon the accuracy and completeness of the information it receives from its counterparties to determine the appropriate financial reporting. The Company is regularly involved in negotiations, disputes and other discussions regarding these arrangements and the calculation of any royalties. Should differences between submitted royalties and due royalties be claimed or identified, the Company makes a determination as to the proper way to account for such claim or difference. Any claims or differences with respect to previously recognized royalty revenue could result in the Company recording reserves, making a current period adjustment or correcting or potentially restating the Company’s prior financial statements and its related Exchange Act reports during the relevant historical periods (or in prospective periods during which claims are made). The cost and distraction of any such claim, any necessary adjustments or restatement of amounts previously reported and/or any prospective changes to royalty calculations could harm our operating results and adversely impact our business and stock price.

We rely on the innovation and resources of larger industry participants and public programs in our partnership business to advance genomic research and educate physicians/clinicians on genetic diagnostics.

    The linkages between genetic anomalies that our products detect and the underlying disease states are not always fully medically correlated. Additionally, the availability of correlated genetic markers is dependent on significant investment in genomic research, often funded through public programs, for which there are no assurances of ongoing support. Should any government limit patent rights to specific genetic materials, private investment in this area could also be significantly curtailed. In addition, the adoption of genetic diagnostics is dependent to a great extent on the education and training of physicians and clinicians. We do not have the resources to undertake such training, and are relying on larger industry participants and professional medical colleges to establish, communicate and educate physicians and clinicians on best practices related to genetic diagnostics.

35
Risks Relating to Regulation of Our Products

Our products are subject to extensive regulation by the FDA, the Competent Authorities of EEA Member States and foreign governmental authorities, the Competent Authorities of EEA Member States and foreign governmental authorities, the Competent Authorities of EEA Member States and foreign governmental authorities, including the requirement to obtain premarket approval and the requirement to report adverse events and violations of the FDC Act that could present significant risk of injury to patients. We will continue to be subject to extensive FDA regulatory oversight.

Our products are subject to rigorous regulation by the FDA and numerous other federal, state and foreign governmental authorities. The process of obtaining regulatory clearances to market a medical device can be costly and time consuming, and we may not be able to obtain these clearances or approvals on a timely basis, if at all. In general, the FDA permits commercial distribution of a new medical device only after the device has received clearance under Section 510(k) of the FDC Act, or is the subject of an approved premarket approval application (PMA), unless the device is specifically exempt from those requirements. The FDA will clear marketing of a lower risk medical device through the 510(k) process if the manufacturer demonstrates that the new product is substantially equivalent to other pre-amendment, 510(k)-exempt, 510(k) cleared products, or PMA-approved products that have subsequently been down-classified. If the FDA determines that the device is not “substantially equivalent” to a predicate device, or if the device is automatically classified into Class III, the device sponsor must then fulfill the much more rigorous premarketing requirements of the PMA approval process, or seek reclassification of the device through the de novo process. Pursuant to amendments to the statute in 2012, a manufacturer can also submit a petition for a direct de novo review if the manufacturer is unable to identify an appropriate predicate device and the new device or new use of the device presents a moderate or low risk.

High risk devices deemed to pose the greatest risk, such as life-sustaining, life-supporting, or implantable devices, or devices not deemed substantially equivalent to a previously cleared device, require the approval of a PMA. The PMA process is more costly, lengthy and uncertain than the 510(k) clearance process. A PMA application must be supported by extensive data, including, but not limited to, technical, preclinical, clinical trial, manufacturing and labeling data, to demonstrate to the FDA’s satisfaction the safety and efficacy of the device for its intended use. Currently, all of our products requiring FDA clearance or approval are Class II and have been cleared through the 510(k) process.

In emergency situations, such as a pandemic, the FDA has the authority to issue an EUA for an unapproved device if the following four statutory criteria have been met: (1) a serious or life-threatening condition exists; (2) evidence of effectiveness of the device exists; (3) a risk-benefit analysis shows that the benefits of the product outweigh the risks; and (4) no other alternatives exist for diagnosing, preventing or treating the disease or condition. Once granted, an EUA will remain in effect and generally terminate on the earlier of (1) the determination by the Secretary of HHS that the public health emergency has ceased or (2) a change in the approval status of the product such that the authorized use(s) of the product are no longer unapproved. After the EUA is no longer valid, the product is no longer considered to be legally marketed and one of the FDA’s non-emergency premarket pathways would be necessary to resume or continue distribution of the subject product. The FDA also may revise or revoke an EUA if the circumstances justifying its issuance no longer exist, the criteria for its issuance are no longer met, or other circumstances make a revision or revocation appropriate to protect the public health or safety.

    Our failure to comply with U.S. federal, state and foreign governmental regulations could lead to the issuance of additional warning letters or untitled letters, the imposition of injunctions, suspensions or loss of regulatory clearance or approvals, product recalls, termination of distribution, product seizures or civil penalties. In the most extreme cases, criminal sanctions or closure of our manufacturing facilities are possible.

The recent COVID-19 pandemic has introduced additional strain on the FDA. We are unable to fully understand the impact this may cause on regulations or the related timeframes pertaining to communication with, or clearances by, the FDA.

Our products are also subject to approval, certification and regulation by foreign regulatory and safety agencies. For example, the EU has adopted the In Vitro Diagnostic Regulation (the IVDR), which will impose stricter requirements for the marketing and sale of in vitro diagnostic medical devices, including in the area of clinical evaluation requirements, quality systems and post-market surveillance. Manufacturers of currently approved medical devices, as of now, will have until May 26, 2022 to meet the requirements imposed by the IVDR. Complying with the requirements of these regulations may require us to incur significant expenditures. Failure to meet these requirements could adversely impact our business in the EU and other regions that tie their product registrations to the EU requirements.

    Foreign governmental authorities that regulate the manufacture and sale of medical devices have become increasingly stringent and, to the extent we market and sell our products internationally, we may be subject to rigorous international regulation in the future. In these circumstances, we would rely significantly on our foreign independent distributors to comply with the varying regulations, and any failures on their part could result in restrictions on the sale of our products in foreign countries.
36

Marketing of our COVID-19 tests under Emergency Use Authorizations (EUAs) from FDA is subject to certain limitations and we are required to maintain compliance with the terms of the EUA, among other things, and the continuance of our EUAs is subject to government discretion.

On February 4, 2020, then U.S. Secretary of Health and Human Services (HHS) Alex Azar issued a declaration that the threat to public health posed by COVID-19 justified the emergency use of unapproved in vitro diagnostics for the detection or diagnosis of the novel coronavirus (SARS-CoV-2). Under Section 564 of the Food, Drug, and Cosmetic Act (FDCA), because HHS issued this declaration, the FDA Commissioner was authorized to issue EUAs to permit certain developers of SARS-CoV-2 diagnostics to begin offering the tests for detection and diagnosis of COVID-19 without having completed the normally applicable FDA review and clearance or approval process for marketing authorization (with the related standards that would apply to demonstrate safety and effectiveness). The issuance of an EUA at that time reflected an FDA conclusion that, based on the totality of scientific evidence available to the FDA, it was reasonable to believe that the product may be effective in diagnosing COVID-19, and that the known potential benefits of the product outweighed the known and potential risks, and there was no adequate, approved, and available alternative to the emergency use of the product.

On March 27, 2020 we received an EUA for our NxTAG CoV Extended Panel Assay for the qualitative detection of nucleic acid from the SARS-CoV-2 virus in nasopharyngeal swab specimens from individuals suspected of having COVID-19. We received an EUA on April 3, 2020 for our ARIES SARS-CoV-2 Assay for the same indication, but in this case, tests are permitted to be conducted by CLIA laboratories certified to perform moderate complexity tests, as well as those certified for high complexity tests. We also received an EUA on July 16, 2020 for our xMAP SARS-CoV-2 Multi-Antigen IgG Assay, a serology assay to identify the presence of antibodies in people who have been infected with the virus that causes COVID-19. Although there are certain regulatory requirements that the FDA has waived for the duration of the EUA, we remain subject to specific conditions of the authorization, including ensuring appropriate labeling as approved by the FDA specifically for purposes of the EUA, maintaining records of distribution to authorized laboratories, collecting data on occurrences of any false positives or false negatives, and tracking any adverse events.

As with other FDA-regulated products, issues could emerge during the course of the marketing and use of our products under an EUA that could impact our ability to continue the sale and distribution of these products (e.g., compliance and product performance issues).

Our EUAs remain effective only until the HHS declaration is terminated or revoked, and the FDA may also revoke an EUA if it determines the criteria for issuance are no longer met or other circumstances make such revocation appropriate to protect public health or safety. Once our EUA is revoked or terminated, we will be required to stop commercial distribution of our COVID-19 test kit immediately unless we can obtain FDA clearance for our COVID-19 test kit under a traditional regulatory pathway, which is lengthy and expensive, which could harm our future business prospects. We also would be subject to the full and usual regulatory obligations for device manufacturers, including the FDA’s quality system regulations (QSR) under 21 CFR Part 820.

If we or our suppliers fail to comply with ongoing FDA or foreign regulatory authority requirements, or if we experience unanticipated problems with our products, these products could be subject to restrictions or withdrawal from the market.

Any product for which we obtain clearance, and the manufacturing processes, reporting requirements, post-market clinical data and promotional activities for such product, are subject to continued regulatory review, oversight and periodic inspections by the FDA and other domestic and foreign regulatory bodies and notified bodies. In particular, we and our strategic partners who manufacture medical devices are required to comply with the QSR in the US. The QSR covers the methods and documentation of the design, testing, production, control, quality assurance, labeling, packaging, sterilization, storage and shipping of our products. Compliance with applicable regulatory requirements is subject to continual review and is monitored rigorously through periodic inspections by the FDA. If we, or our strategic partners, fail to adhere to QSR requirements in the U.S. or experience delays in obtaining necessary regulatory approvals or clearances, this could delay production of our products and lead to fines, difficulties in obtaining regulatory approvals or clearances, recalls, enforcement actions, including injunctive relief or consent decrees, or other consequences, such as the Warning Letter, which could, in turn, have a material adverse effect on our financial condition and results of operations. We must comply with equivalent standards in third countries. in obtaining regulatory approvals or clearances, recalls, enforcement actions, including injunctive relief or consent decrees, or other consequences, such as the Warning Letter, which could, in turn, have a material adverse effect on our financial condition and results of operations.

In addition, the FDA audits compliance with the QSR through periodic announced and unannounced inspections of manufacturing and other facilities. Any failure to comply with applicable statutes and regulations administered by the FDA, or the failure to timely and adequately respond to any adverse inspection observations or product safety issues, could result in any of the following enforcement actions:
37

•untitled letters, warning letters, such as the Warning Letter, fines, injunctions, consent decrees and civil penalties;
•unanticipated expenditures to address or defend such actions;
•customer notifications or repair, replacement, refunds, recall, detention or seizure of our products;
•operating restrictions, partial suspension or total shutdown of production;
•refusing or delaying our requests for regulatory approvals or clearances of new products or modified products;
•refusal to grant export approval for our products; or
•criminal prosecution.

Any of these sanctions could have a material adverse effect on our reputation, business, results of operations and financial condition. Furthermore, our key component suppliers may not currently be or may not continue to be in compliance with all applicable regulatory requirements, which could result in a failure to produce our products on a timely basis and in the required quantities, if at all.

Our products and operations are required to comply with standards set by foreign regulatory bodies, and those standards, types of evaluation and scope of review differ among foreign regulatory bodies. If we fail to comply with any of these standards adequately or if changes to our manufacturing or supply practices require additional regulatory approval, a foreign regulatory body may take adverse actions or cause delays within their jurisdiction similar to those within the power of the FDA. Any such action or circumstance may harm our reputation and business, and could have an adverse effect on our business, results of operations and financial condition.

On June 26, 2020, we received a Warning Letter from the FDA relating to the operations of our Austin, Texas and Northbrook, Illinois facilities and our VERIGENE Processor SP System. The Warning Letter resulted from inspections held at the Facilities from February 10, 2020 to February 14, 2020. The Warning Letter primarily relates to the Company’s VERIGENE SP instrument and its hybridization heater. We timely submitted a response to the FDA regarding the issues raised in the Warning Letter and are working diligently and expeditiously to resolve the issues raised by the FDA. The Warning Letter does not restrict the manufacture, production or shipment of any of the Company’s products, nor require the withdrawal of any product from the marketplace. The Company believes it is taking appropriate measures to address the items identified by the FDA with respect to the VERIGENE SP instrument and its hybridization heater, and the Company included communication of these measures in its response to the Warning Letter.

The Company has responded to the FDA’s concerns raised in the Warning Letter, but cannot give assurances that the FDA will be satisfied with its response to the Warning Letter or that such response will resolve the issues identified in the Warning Letter. Failure to promptly and fully address the issues raised in the Warning Letter to the FDA’s satisfaction or to comply with U.S. medical device regulatory requirements in general could result in further regulatory and enforcement actions being initiated by the FDA. These actions could result in, among other things, product recalls, product seizures, injunctions, civil monetary penalties, delays in obtaining marketing authorization for products, an impact on federal contracts, limitations on our ability to export products, and criminal enforcement action. Any such actions could disrupt our ongoing business and operations and potentially have a material adverse effect on our business, financial condition and results of operations.

In addition, we may be required to conduct costly post-market testing and surveillance to monitor the safety or effectiveness of our products in the EEA. We must comply with medical device reporting requirements, including the reporting of adverse events and malfunctions related to our products. Later discovery of previously unknown problems with our products, including unanticipated adverse events or adverse events of unanticipated severity or frequency, manufacturing problems, or failure to comply with regulatory requirements may result in changes to labeling, restrictions on such products or manufacturing processes, withdrawal of the products from the market, voluntary or mandatory recalls, a requirement to repair, replace or refund the cost of any medical device we manufacture or distribute, fines, suspension of regulatory clearances or approvals, product seizures, injunctions or the imposition of civil or criminal penalties which would adversely affect our business, operating results and prospects.


38
Modifications to our marketed products may require new 510(k) or de novo clearances or PMA approvals or equivalent steps in third countries, including the EEA, or may require us to cease marketing or recall the modified products until clearances or approvals are obtained.

    Modifications to our products may require new regulatory approvals or clearances, including 510(k) or de novo clearances or premarket approvals, or require us to recall or cease marketing the modified devices until these clearances or approvals are obtained. The FDA requires device manufacturers to initially make and document a determination of whether or not a modification requires a new approval, supplement or clearance. For example, a manufacturer may determine that a modification does not significantly affect safety or efficacy and does not represent a major change in its intended use, so that no new 510(k) clearance is necessary. However, the FDA can review a manufacturer’s decision and may disagree. The FDA may also on its own initiative determine that a new clearance or approval is required. We have made modifications to our products in the past and may make additional modifications in the future that we believe do not or will not require additional clearances or approvals. If the FDA disagrees and requires new clearances or approvals for the modifications, we may be required to recall or to stop marketing our products as modified, which could require us to redesign our products and harm our operating results. In these circumstances, we may be subject to significant enforcement actions.

    For those products sold in the EEA, we must notify our EU notified body if significant changes are made to the products or if there are substantial changes to our quality assurance systems affecting those products. Obtaining certification can be a time-consuming process, and delays in obtaining required future clearances or approvals would adversely affect our ability to introduce new or enhanced products in a timely manner, which in turn would harm our future growth.

If our products contribute to a death or a serious injury, or malfunction in certain ways, we will be subject to medical device reporting regulations, which can result in voluntary corrective actions or agency enforcement actions.

    Under the FDA medical device reporting regulations, medical device manufacturers are required to report to the FDA information that a device has or may have caused or contributed to a death or serious injury or has malfunctioned in a way that would likely cause or contribute to death or serious injury if the malfunction of the device were to recur. As required per the FDA Code of Federal Regulations (21 CFR) Part 803, we have established procedures and processes for documentation and evaluation of all complaints relative to reporting requirements. As with all device manufacturers, we have 30 days from “becoming aware” of an incident to submit to the FDA a medical device report for an event that reasonably suggests that a device has or may have caused or contributed to the incident, or five working days for an event designated by FDA or an event that requires remedial action to prevent an unreasonable risk of substantial harm to the public health. If we fail to report these events to the FDA within the required timeframes, or at all, the FDA could take enforcement action against us. Any adverse event involving our products also could result in future voluntary corrective actions, such as recalls or customer notifications, or agency action, such as inspection or enforcement action. Any corrective action, whether voluntary or involuntary, as well as defending ourselves in a lawsuit, would require the dedication of our time and capital, distract management from operating our business, and may harm our reputation and financial results.

All manufacturers placing medical devices on the market in the EEA are legally bound to report incidents involving devices they produce or sell to the regulatory agency, or Competent Authority, in whose jurisdiction the incident occurred. Under the IVDD an incident is defined as any malfunction, failure or deterioration in the characteristics and/or performance of a device, as well as any inadequacy in the labeling or the instructions for use which, directly or indirectly, might lead to or might have led to the death of a patient, or user or of other persons or to a serious deterioration in their state of health; any technical or medical reason in relation to the characteristics or performance of a device for the reasons referred to above, leading to systematic recall of devices of the same type by the manufacturer.

Malfunction of our products could result in future voluntary corrective actions, such as recalls, including corrections, or customer notifications, or agency action, such as inspection or enforcement actions. If malfunctions do occur, we may be unable to correct the malfunctions adequately or prevent further malfunctions, in which case we may need to cease manufacture and distribution of the affected products, initiate voluntary recalls, and redesign the products. Regulatory authorities may also take actions against us, such as ordering recalls, imposing fines, or seizing the affected products. Any corrective action, whether voluntary or involuntary, will require the dedication of our time and capital, distract management from operating our business, and may harm our reputation and financial results.

39
Our products may in the future be subject to product recalls that could harm our reputation, business and financial results.

    The FDA, Competent Authorities of EEA Member States and similar foreign governmental authorities have the authority to require the recall of commercialized products in the event of material deficiencies or defects in design or manufacture. In the case of the FDA, the authority to require a recall must be based on an FDA finding that there is a reasonable probability that the device would cause serious injury or death. In addition, foreign governmental bodies have the authority to require the recall of our products in the event of material deficiencies or defects in design or manufacture. Manufacturers may, under their own initiative, recall a product if any material deficiency in a device is found. A government-mandated or voluntary recall by us or one of our distributors could occur as a result of component failures, manufacturing errors, design or labeling defects or other deficiencies and issues. Recalls of any of our products would divert managerial and financial resources and have an adverse effect on our financial condition and results of operations. The FDA requires that certain classifications of recalls be reported to the FDA within 10 working days after the recall is initiated. Competent Authorities of foreign countries impose similar deadlines. Companies are required to maintain certain records of recalls, even if they are not reportable to the FDA or to the Competent Authorities of foreign countries. We may initiate voluntary recalls involving our products in the future that we determine do not require notification of the FDA. If the FDA disagrees with our determinations, they could require us to report those actions as recalls. A future recall announcement could harm our reputation with customers and negatively affect our sales. In addition, the FDA could take enforcement action for failing to report the recalls when they were conducted.

The misuse or off-label use of our products may harm our reputation or the image of our test kits in the marketplace, or result in injuries that lead to product liability suits, which could be costly to our business. Moreover, we could be subject to FDA sanctions if we are deemed to have engaged in off-label promotion.

Our promotional materials and training methods must comply with FDA and other applicable laws and regulations, including the prohibition on the promotion of a medical device for an indication that has not been approved or cleared by the FDA, referred to as an off-label use. The FDA does not restrict or regulate a physician’s use of a medical device within the practice of medicine, and we cannot prevent a physician from using our test kits for an off-label use. If the FDA determines that our promotional materials constitute the unlawful promotion of an off-label use, it could subject us to regulatory or enforcement actions, including additional civil money penalties, criminal fines and penalties, and exclusion from participation in federal health programs, among others. Other federal, state or foreign governmental authorities might also take action if they consider our promotional or training materials to constitute promotion of an off-label use, which could result in significant fines or penalties under other statutory authorities. In that event, our reputation could be damaged and the use of our products in the marketplace could be impaired.

Furthermore, the use of our products for indications other than those that have been approved or cleared by the FDA may lead to performance issues or produce erroneous results, which could harm our reputation in the marketplace among physicians and patients and increase the risk of product liability. Product liability claims are expensive to defend and could divert our management’s attention from our primary business and result in substantial damage awards against us. Any of these events could harm our business, results of operations and financial condition.

The advertising and promotion of our products in the EEA is subject to EEA Member States’ national laws implementing the IVDD and, in the future, applying the IVDR Directive 2006/114/EC concerning misleading and comparative advertising, and Directive 2005/29/EC on unfair commercial practices, as well as other national legislation of individual EEA Member States governing the advertising and promotion of medical devices. EEA member state legislation may also restrict or impose limitations on our ability to advertise our products directly to the general public. In addition, voluntary EU and national Codes of Conduct provide guidelines on the advertising and promotion of our products to the general public and may impose limitations on our promotional activities with healthcare professionals.
Clinical trials necessary to support future product submissions will be expensive and may require the enrollment of large numbers of subjects, and suitable subjects may be difficult to identify and recruit. Delays or failures in our clinical trials will prevent us from commercializing any modified or new test kits and will adversely affect our business, operating results and prospects.

Initiating and completing clinical trials necessary to support a future EUA, 510(k), PMA, or de novo submission, will be time consuming and expensive and the outcome uncertain. Moreover, the results of early clinical trials are not necessarily predictive of future results, and any test kit we advance into clinical trials may not have favorable results in later clinical trials.

Conducting successful clinical trials will require the enrollment of large numbers of subjects, and suitable subjects may be difficult to identify and recruit. Subject enrollment in clinical trials and completion of subject participation depends on many factors, including the nature of the trial protocol, the attractiveness of, or the discomforts and risks associated with, the indication of the underlying test kit, the availability of appropriate clinical trial investigators, support staff, and proximity of subjects to clinical sites and ability to comply with the eligibility and exclusion criteria for participation in the clinical trial and subject compliance. In addition, subjects may not participate in our clinical trials if they choose to participate in contemporaneous clinical trials of competitive products.
40

In addition, our clinical trials may in the future be affected by the COVID-19 pandemic. We are unable to predict with confidence the duration of such potential subject enrollment delays and difficulties, whether related to COVID-19 or otherwise. Delays in subject enrollment or failure of subjects to continue to participate in a clinical trial may cause an increase in costs and delays in the approval and attempted commercialization of our test kits or result in the failure of the clinical trial.

Development of sufficient and appropriate clinical protocols to demonstrate safety and efficacy are required and we may not adequately develop such protocols to support clearance and approval. Further, the FDA may require us to submit data on a greater number of subjects than we originally anticipated and/or for a longer follow-up period or change the data collection requirements or data analysis applicable to our clinical trials. In addition, despite considerable time and expense invested in our clinical trials, the FDA may not consider our data adequate for approval. Such increased costs and delays or failures could adversely affect our business, operating results and prospects.

Even if our products are approved or cleared in the United States and CE marked in the EEA, comparable regulatory authorities of additional foreign countries must also approve the manufacturing and marketing of our products in those countries. Approval and clearance procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States or the EEA, including additional preclinical studies or clinical trials. Any of these occurrences may harm our business, financial condition and prospects significantly.

U.S. legislative, FDA or global regulatory reforms may make it more difficult and costly for us to obtain regulatory approval of our product candidates and to manufacture, market and distribute our products after approval is obtained.

    From time to time, legislation is drafted and introduced in Congress that could significantly change the statutory provisions governing the regulatory approval, manufacture and marketing of regulated products or the reimbursement thereof. Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of future products. In addition, FDA regulations and guidance are often revised or reinterpreted by the agency in ways that may significantly affect our business and our products. It is impossible to predict whether legislative changes will be enacted or FDA regulations, guidance or interpretations changed, and what the impact of such changes, if any, may be.

    Moreover, leadership, personnel and structural changes within the FDA as well as recent and future federal election outcomes could result in significant legislative and regulatory reforms impacting the FDA’s regulation of our products. Any change in the laws, regulations or policies that govern the clearance and approval processes relating to our current and future products could make it more difficult and costly to obtain clearance or approval for new products, or to produce, market and distribute existing products. Significant delays in receiving clearance or approval, or the failure to receive clearance or approval, for our new products would have an adverse effect on our ability to expand our business.

    In addition, on May 25, 2017, the new MDR entered into force for medical devices marketed in the EU. Implementation of the MDR was delayed by one year due to the COVID-19 pandemic. Following its entry into application in May, 2021, the MDR will introduce substantial changes to the obligations with which medical device manufacturers must comply in the EU. High risk medical devices will be subject to additional scrutiny during the conformity assessment procedure. Specifically, the MDR repeals and replaces the EU Medical Devices Directive. Unlike directives, which must be implemented into the national laws of the European Economic Area (EEA) Member States, the regulations would be directly applicable, i.e., without the need for adoption of EEA Member State laws implementing them, in all EEA Member States and are intended to eliminate current differences in regulation of medical devices among EEA Member States. The MDR, among other things, is intended to establish a uniform, transparent, predictable and sustainable regulatory framework across the EEA for medical devices to ensure a high level of safety and health while supporting innovation. The MDR will enter into application on May 26, 2021. Once applicable, the new regulation will among other things:

•strengthen the rules on placing devices on the market and reinforce surveillance once they are available;

•establish explicit provisions on manufacturers’ responsibilities for the follow-up of the quality, performance and safety of devices placed on the market;

•improve the traceability of medical devices throughout the supply chain to the end-user or patient through a unique identification number;

•set up a central database to provide patients, healthcare professionals and the public with comprehensive information on products available in the EU; and

•strengthen rules for the assessment of certain high-risk devices which may have to undergo an additional check by experts before they are placed on the market.

41
    The MDR imposes a number of new requirements on manufacturers of medical devices. It will be necessary for notified bodies to be accredited by the EU Member States' accreditation bodies to conduct assessment procedures for medical devices in accordance with the Regulation. There are currently a relatively small number of notified bodies that have been accredited to conduct these assessments. This may delay conformity assessment procedures in the future in the EU. This may impact our activities in the EEA and the UK, the renewal of our existing CE Certificates of Conformity and conformity assessment related to future bodies.

Once applicable, the MDR may impose increased compliance obligations for us to access the EU market.
In April 2017, the EU Regulation on In Vitro Diagnostic Medical Devices (Regulation (EU) 2017/746) (IVDR) was adopted. The IVDR repeals and replaces Directive 98/79/EC, the IVDD. Unlike directives, which must be implemented into the national laws of the individual EU Member States, the IVDR will be directly applicable in the EU Member States and on the basis of the EEA agreement in Iceland, Liechtenstein and Norway. The IVDR is, among other things, intended to establish a uniform, transparent, predictable and sustainable regulatory framework across the EEA for in vitro diagnostic medical devices and ensure a high level of safety and health while supporting innovation. The IVDR will apply beginning on May 26, 2022. Once applicable, the IVDR will introduce new classification rules for in vitro diagnostic medical devices and new regulatory requirements. The IVDR will also impose increased compliance obligations for manufacturers of in vitro diagnostic medical devices to access the EEA market. Moreover, the scrutiny imposed by notified bodies for the technical documentation related these devices will increase considerably. Complying with the requirements of this regulation may require us to incur significant expenditures.

In order to continue to sell our products in the EEA, we must maintain our CE marks and continue to comply with certain EU directives and, beginning in May 2021, with the MDR.

Our failure to continue to comply with applicable foreign regulatory requirements, including those administered by authorities of the EEA countries, could result in enforcement actions against us, including refusal, suspension, variation or withdrawal of our CE Certificates of Conformity by our EU notified body, which could impair our ability to market products in the EEA in the future. Any changes to the membership of the EU, such as the recent departure of the United Kingdom (Brexit), may impact the regulatory requirements for the impacted countries and impair our business operations and our ability to market products in such countries.

The UK’s withdrawal from the EU on January 31, 2020, commonly referred to as Brexit, has created significant uncertainty concerning the future relationship between the UK and the EU. On December 24, 2020, the EU and UK reached an agreement in principle on the framework for their future relationship, the EU-UK Trade and Cooperation Agreement. The Agreement primarily focuses on ensuring free trade between the EU and the UK in relation to goods. The Agreement does not however, specifically address medical devices. The Agreement seeks to ensure that the parties ensure “regulatory cooperation.” Among the changes that will now occur are that Great Britain (England, Scotland and Wales) will be treated as a third country. Northern Ireland will, with regard to EU regulations, continue to follow the EU regulatory rules. In light of the fact that the CE marking process is set out in EU law, which no longer applies in the UK, the UK has devised a new route to market culminating in a UK Conformity Assessed (UKCA) mark to replace the CE mark. Northern Ireland will, however, continue to be covered by the regulations governing CE marks. As part of the Agreement, the EU and the UK have agreed to continue to recognize declarations of conformity based on a self-assessment in the other territory.

Given the lack of comparable precedent to Brexit, it is unclear what the financial, regulatory, and legal implications of Brexit will be and how it will affect us. However, potentially changing regulatory schemes and tariffs engendered by Brexit may add additional complexity, cost and delays in marketing or selling our products in the United Kingdom. Our revenue and profit, supply and demand for our products, and customer retention and acquisition in both the long-term and short-term could be adversely affected.


42
If the governmental laws and regulations change in ways that we do not anticipate or if we fail to comply with existing laws and regulations that affect our business, we could be subject to enforcement actions, injunctions and civil and criminal penalties or otherwise be subject to increased costs that could delay or prevent marketing of our products.

    Medical device laws and regulations are in effect within the United States and also in many countries outside the United States. These range from comprehensive device clearance requirements for some or all of our medical device products to requests for product data or certifications regarding the hazardous material content of our products. As a device manufacturer, we are required to report annually to the CMS any payments or transfers of value we have made to physicians and teaching hospitals and any physician ownership or investment interest in the company. This data is published in a publicly searchable database. As part of the European Council Directive 2002/96 of February 13, 2003, we are expected to comply with certain requirements regarding the collection, recycling and labeling of our products containing electronic devices in each of the EU Member States where our regulated products are distributed. While we are taking steps to comply with the requirements of WEEE, we cannot be certain that we will comply with the national stage implementation of WEEE in all Member States. We continue to evaluate the necessary steps for compliance with regulations as they are enacted. These regulations include, for example, the Registration, Evaluation, Authorization and Restriction of Chemical substances Regulation (REACH), the RoHS Directive and the WEEE Directive enacted in the EU, which regulate the use of certain chemical substance and hazardous substances in, and require the collection, reuse and recycling of waste from, certain products we manufacture. This and similar legislation that has been or is in the process of being enacted in various countries may require us to redesign our products to ensure compliance with the applicable standards. These redesigns may impact the performance of our products, add greater testing lead times for product introductions or have other similar effects. We believe we comply with all such legislation where our products are sold and we will continue to monitor these laws and the regulations being adopted under them to determine our responsibilities. In addition, the State of California adopted the Electronic Waste Recycling Act, effective January 1, 2007, which requires the California Department of Toxic Substances Control to adopt regulations to prohibit the sale of electronic devices in California if they are also prohibited from sale in the EU under the RoHS Directive because they contain certain heavy metals. The number and scope of these requirements are increasing and we will likely become subject to similar laws in other jurisdictions. Failure to comply with applicable federal, state and foreign medical device laws and regulations may harm our business, financial condition and results of operations. We are also subject to a variety of other laws and regulations relating to, among other things, environmental protection and workplace health and safety.

Our strategic partners and customers expect our organization to operate on an established quality management system compliant with FDA Quality System Regulations and industry standards, the In Vitro Diagnostic Directive 98/79/EC of 27 October 1998 (Directive) as implemented nationally in the EU Member States and industry standards, such as ISO 9000. We became ISO 9001:2000 certified in March 2002 and issued a Declaration of Conformity based on a self-assessment for our Luminex 100/200, FLEXMAP 3D and MAGPIX instruments. Our devices are in conformity with Article 1, Article 9, Annex I (Essential Requirements), Annex III and the additional provisions of the Directive as of December 7, 2003. Subsequent audits are carried out annually to ensure we maintain our system in substantial compliance with ISO and other applicable regulations and industry standards. We became ISO 13485:2003 and Canadian Medical Devices Conformity Assessment System (CMDCAS) certified in July 2005. Failure to maintain compliance with FDA, CMDCAS and EU regulations and other medical device laws, or to obtain applicable registrations, where required, could reduce our competitive position in the markets in which we compete and also decrease satisfaction and confidence levels with our partners.

In addition, our operations in the United States are subject to federal, state, and local laws addressing, among other issues, fraud and abuse, privacy and security, and environmental protection. These laws may impact our operations directly or indirectly through our customers and may affect, for example, our sales and marketing programs. We are also subject to laws in foreign jurisdictions, including those that prohibit commercial bribery and certain activities with customers or potential customers. If we fail to comply with applicable laws and regulations, we may be subject to criminal penalties and civil sanctions, including restrictions on our ability to contract with Medicare and Medicaid providers. Evolving interpretations or enforcement of these laws and regulations could subject our current practices to allegations of impropriety or illegality or could require us to make changes to our operations. For further discussion of these matters, see “Government Regulation - Other Government Regulations” in Part I of this Form 10-K.

Risks Relating to Our Common Stock

There can be no assurance that we will continue to pay dividends.

    In February 2017, the Board of Directors initiated a cash dividend program under which the Company will pay a regular quarterly cash dividend. The declaration, amount and timing of such dividends are subject to capital availability and determinations by our Board of Directors that cash dividends are in the best interest of our stockholders and are in compliance with all respective laws and our agreements applicable to the declaration and payment of cash dividends. Our continuing ability to pay dividends will depend upon, among other factors, our cash balances and potential future capital requirements for strategic transactions, including acquisitions, debt service requirements, results of operations, financial condition and other factors beyond our control that our Board of Directors may deem relevant. A reduction in or elimination of our dividend payments, or our dividend program could have a negative effect on our stock price.
43

Our stock price has been and is likely to continue to be volatile.

    The trading price of our common stock has been and is likely to continue to be highly volatile and subject to wide fluctuations in price. This volatility is in response to various factors, many of which are beyond our control, including:

•actual or anticipated variations in quarterly operating results from historical results or estimates of results prepared by securities analysts

•announcements related to the COVID-19 pandemic and related updates on the development, commercialization, distribution and use of vaccines worldwide;

•developments in patents or other intellectual property rights and litigation;

•new, or changes in, recommendations, guidelines or studies that could affect the use of our products;

•announcements of technological innovations or new products or services by us or our competitors;

•announcements by us of significant acquisitions, strategic partnerships, joint ventures or capital commitments;

•developments in relationships with our partners, customers and suppliers;

•additions or departures of key personnel;

•conditions or trends in the life science, biotechnology and pharmaceutical industries, including the regulatory environment;

•published studies and reports relating to the comparative efficacy of products and markets in which we participate;

•changes in financial estimates by securities analysts;

•general worldwide economic conditions and interest rates;

•the success or lack of success of integrating our acquisitions;

•instability in the United States and other financial markets, including, but not limited to, effects resulting from the 2020 elections in the United States, and the ongoing and possible escalation of unrest internationally, other armed hostilities or further acts or threats of terrorism in the United States or elsewhere;

•sales of our common stock; and

◦the potential adverse impact of the secondary trading of our stock on foreign exchanges, without our permission, which exchanges are subject to less regulatory oversight than the Nasdaq Global Select Market, and the activity of the market makers of our stock on such exchanges, including the risk that such market makers may engage in naked short sales and/or other deceptive trading practices which may artificially depress or otherwise affect the price of our common stock on the Nasdaq Global Select Market.

    In addition, the stock market in general, and the Nasdaq Global Select Market and the market for technology companies in particular, has experienced significant price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies. Further, there has been particular volatility in the market prices of securities of life sciences companies. These broad market and industry factors may seriously harm the market price of our common stock, regardless of our operating performance. In the past, following periods of volatility in the market price of a company’s securities, securities class action litigation has often been instituted. A securities class action suit against us could result in substantial costs, potential liabilities and the diversion of management’s attention and resources.


44
Anti-takeover provisions in our certificate of incorporation, bylaws and Delaware law could make a third party acquisition of us difficult.

Our certificate of incorporation and bylaws contain provisions that could make it more difficult for a third party to acquire us, even if doing so would be beneficial to our stockholders. We are also subject to certain provisions of Delaware law that could delay, deter or prevent a change in control of us. These provisions could limit the price that investors might be willing to pay in the future for shares of our common stock.

Risk Factors Relating to our Notes

We have incurred substantial indebtedness that may decrease our business flexibility, access to capital, and/or increase our borrowing costs, which may adversely affect our operations and financial results.

On May 13, 2020, we issued $260.0 million aggregate principal amount of 3.00% Notes due 2025. Holders of the Notes will have the right to require us to repurchase their Notes upon the occurrence of a fundamental change at a purchase price equal to 100% of the principal amount of the Notes to be purchased, plus accrued and unpaid interest, if any. In addition, the indenture for the Notes provides that we are required to repay amounts due under the indenture in the event that there is an event of default for the Notes that results in the principal, premium, if any, and interest, if any, becoming due prior to maturity date for the Notes. Our indebtedness may:

•limit our ability to borrow additional funds for working capital, capital expenditures, acquisitions or other general business purposes;

•limit our ability to use our cash flow or obtain additional financing for future working capital, capital expenditures, acquisitions or other general business purposes;
•require us to use a substantial portion of our cash flow from operations to make debt service payments;

•limit our flexibility to plan for, or react to, changes in our business and industry;

•place us at a competitive disadvantage compared to our less leveraged competitors; and

•increase our vulnerability to the impact of adverse economic and industry conditions.

Further, the indenture governing the Notes does not restrict our ability to incur additional indebtedness and we and our subsidiaries may incur substantial additional indebtedness in the future, subject to the restrictions contained in any future debt instruments existing at the time, some of which may be secured indebtedness.

We may not have the ability to raise the funds necessary for cash or combination settlement upon conversion of the Notes or to repurchase the Notes for cash upon a fundamental change, and our future debt may contain limitations on our ability to pay cash upon conversion of the Notes or to repurchase the Notes.

Holders of the Notes will have the right to require us to repurchase all or a portion of their notes upon the occurrence of a fundamental change at a fundamental change repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental change repurchase date. In addition, upon conversion of the Notes, unless we elect to deliver solely shares of our common stock to settle such conversion (other than paying cash in lieu of delivering any fractional share), we will be required to make cash payments in respect of the Notes being converted. However, we may not have enough available cash or be able to obtain financing at the time we are required to make repurchases of Notes surrendered therefor or Notes being converted. In addition, our ability to repurchase the Notes or to pay cash upon conversions of the Notes may be limited by law, by regulatory authority or by agreements governing our future indebtedness. Our failure to repurchase Notes at a time when the repurchase is required by the indenture governing the Notes or to pay any cash payable on future conversions of the Notes as required by such indenture would constitute a default under such indenture. A default under the indenture or the fundamental change itself could also lead to a default under agreements governing our future indebtedness. If the repayment of the related indebtedness were to be accelerated after any applicable notice or grace periods, we may not have sufficient funds to repay the indebtedness and repurchase the Notes or make cash payments upon conversions thereof.


45
The conditional conversion features of the Notes, if triggered, may adversely affect our financial condition and operating results.

In the event the conditional conversion features of the Notes is triggered, holders of Notes will be entitled to convert the Notes at any time during specified periods at their option. If one or more holders elect to convert their Notes, unless we elect to satisfy our conversion obligation by delivering solely shares of our common stock (other than paying cash in lieu of delivering any fractional share), we would be required to settle a portion or all of our conversion obligation through the payment of cash, which could adversely affect our liquidity. In addition, even if holders do not elect to convert their Notes, we could be required under applicable accounting rules to reclassify all or a portion of the outstanding principal of the Notes as a current rather than long-term liability, which would result in a material reduction of our net working capital.

The accounting method for convertible debt securities that may be settled in cash, such as the Notes, could have a material effect on our reported financial results.

Under ASC 470-20, Debt with Conversion and Other Options (ASC 470-20), an entity must separately account for the liability and equity components of the Notes that may be settled entirely or partially in cash upon conversion in a manner that reflects the issuer’s economic interest cost. The effect of ASC 470-20 on the accounting for the Notes is that the equity component is required to be included in the additional paid-in capital section of stockholders’ equity on our consolidated balance sheet at the issuance date, and the value of the equity component is treated as debt discount for purposes of accounting for the debt component of the Notes. As a result, we are required to record a greater amount of non-cash interest expense in current periods presented as a result of the amortization of the discounted carrying value of the Notes to their face amount over the respective terms of the Notes. We report lower net income in our financial results because ASC 470-20 requires interest to include both the current period’s amortization of the debt discount and the instrument’s coupon interest rate, which could adversely affect our future financial results, the trading price of our common stock or the Trading Price of the Notes. In addition, under certain circumstances, convertible debt instruments (such as the Notes) that may be settled entirely or partly in cash are currently accounted for utilizing the treasury stock method, the effect of which is that the shares issuable upon conversion of the Notes are not included in the calculation of diluted earnings per share except to the extent that the conversion value of the Notes exceeds their principal amount. Under the treasury stock method, for diluted earnings per share purposes, the transaction is accounted for as if the number of shares of common stock that would be necessary to settle such excess, if we elected to settle such excess in shares, are issued.

In August 2020, the FASB issued guidance that changes the accounting for the convertible debt instruments described above. Under the new guidance, an entity will no longer be required to separately account for the liability and equity components of convertible debt instruments. This is expected to reduce non-cash interest expense, thereby increasing net income after adoption of the new guidance. Additionally, the treasury stock method for calculating earnings per share will no longer be allowed for convertible debt instruments whose principal amount may be settled using shares. Rather, the if-converted method will be required. Application of the “if-converted” method may reduce our reported diluted earnings per share. The guidance is effective for interim and annual periods beginning after December 15, 2021. Early adoption is permitted, but no earlier than January 1, 2021. The Company will early adopt this guidance effective January 1, 2021 under the modified retrospective basis with the cumulative effect recognized through an adjustment to additional paid-in capital. Under this method, earnings per share amounts will not be restated in prior periods presented, but future earnings per share amounts will be impacted by the change to the if-converted method for calculating diluted earnings per share. The Company's adoption is expected to result in a decrease of approximately $42 million in additional paid in capital from the de-recognition of the bifurcated equity component and an increase of approximately $50 million in debt from the de-recognition of the discount associated with the bifurcated equity component. The Company expects to write-off the related deferred tax liabilities to additional paid in capital.

The Convertible Note Hedge and Warrant Transactions may affect the value of the Notes and our common stock.

In connection with the pricing of the Notes, we entered into Convertible Note Hedge Transactions with the option counterparties. We also entered into Warrant Transactions with the option counterparties pursuant to which we will sell Warrants for the purchase of our common stock. The Convertible Note Hedge Transactions are expected generally to reduce the potential equity dilution to our common stock upon any conversion of the Notes and/or offset any potential cash payments we are required to make in excess of the principal amount of converted Notes, as the case may be. However, the Warrant Transactions could separately have a dilutive effect on our common stock to the extent that the market price per share of our common stock exceeds the strike price of the Warrants unless, subject to the terms of the Warrant Transactions, we elect to cash settle instead of net share settle the Warrants.


46
In connection with establishing their initial hedges of the convertible note hedge and Warrant Transactions, the option counterparties or their respective affiliates expect to purchase shares of our common stock and/or enter into various derivative transactions with respect to our common stock concurrently with or shortly after the pricing of the Notes. These activities could increase (or reduce the size of any decrease in) the market price of our common stock or the Notes at that time.

In addition, the option counterparties and/or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to our common stock and/or purchasing or selling our common stock or other securities of ours in secondary market transactions following the pricing of the Notes and prior to the maturity of the Notes (and are likely to do so following any conversion of the Notes or during any observation period related to a conversion of notes). These activities could also cause a decrease, or avoid an increase, in the market price of our common stock or the Notes, which could affect the note holder’s ability to convert the Notes and, to the extent the activity occurs following conversion or during any observation period related to a conversion of Notes, it could affect the amount and value of the consideration that a note holder will receive upon conversion of such Notes.

In addition, if any such convertible note hedge and Warrant Transaction fails to become effective, the option counterparty thereto or its respective affiliate may unwind its hedge positions with respect to our common stock, which could adversely affect the value of our common stock and the value of the Notes.

The potential effect, if any, of these transactions and activities on the market price of our common stock or the Notes will depend in part on market conditions and cannot be ascertained at this time. Any of these activities could adversely affect the value of our common stock or the value of the Notes (and as a result, the value of the consideration, the amount of cash and/or the number of shares of common stock, if any, that a note holder would receive upon the conversion of any Notes) and, under certain circumstances, their ability to convert their Notes.

The Convertible Note Hedge Transactions and the Warrant Transactions are separate transactions (in each case that we entered into with the option counterparties), are not part of the terms of the Notes and will not change the holders’ rights under the Notes. A holder of the Notes will not have any rights with respect to the Convertible Note Hedge Transactions or the Warrant Transactions.

We do not make any representation or prediction as to the direction or magnitude of any potential effect that the transactions described above may have on the price of the Notes or our common stock. In addition, we do not make any representation that the option counterparties will engage in these transactions or that these transactions, once commenced, will not be discontinued without notice.

We are subject to counterparty risk with respect to the Convertible Note Hedge Transactions.

The option counterparties are financial institutions, and we will be subject to the risk that any or all of them might default under the Convertible Note Hedge Transactions. Our exposure to the credit risk of the option counterparties will not be secured by any collateral. Past global economic conditions from time to time have resulted in the actual or perceived failure or financial difficulties of many financial institutions, including the bankruptcy filing by Lehman Brothers Holdings Inc. and its various affiliates. If an option counterparty becomes subject to insolvency proceedings, we will become an unsecured creditor in those proceedings with a claim equal to our exposure at that time under the Convertible Note Hedge Transactions with such option counterparty. Our exposure will depend on many factors but, generally, an increase in our exposure will be correlated to an increase in the market price and in the volatility of our common stock. In addition, upon a default by an option counterparty, we may suffer adverse tax consequences and more dilution than we currently anticipate with respect to our common stock. We can provide no assurance as to the financial stability or viability of the option counterparties.

To the extent we choose to deliver shares upon conversion of the Notes, the ownership interests of existing stockholders will be diluted and our stock price may be adversely impacted.

Upon conversion of the Notes, we will pay or deliver, as the case may be, cash, shares of our common stock or a combination of cash and shares of our common stock, at our election. To the extent we choose to deliver shares upon conversion of some or all of the Notes, this will result in a dilution to the ownership interests of existing stockholders and may depress our stock price.


47
Certain provisions in the indentures governing the Notes may delay or prevent an otherwise beneficial takeover attempt of us.

Certain provisions in the indentures governing the Notes may make it more difficult or expensive for a third party to acquire us. For example, the indentures governing the Notes will require us to repurchase the Notes for cash upon the occurrence of a fundamental change (as defined in the relevant indenture governing the Notes) of us and, in certain circumstances, to increase the conversion rate for a holder that converts the Notes in connection with a make-whole fundamental change. A takeover of us may trigger the requirement that we repurchase the Notes, and/or increase the conversion rate, which could make it more costly for a potential acquirer to engage in such takeover. Such additional costs may have the effect of delaying or preventing a takeover of us that would otherwise be beneficial to investors.

General Risk Factors

Our success depends partly on our ability to operate without infringing on or misappropriating the proprietary rights of others.

We have been (and from time to time we may be) notified that third parties consider their patents or other intellectual property relevant to our products. We may be sued for infringing the intellectual property rights of others, including claims with respect to intellectual property of entities we may acquire. In addition, we may find it necessary, if threatened, to initiate a lawsuit seeking a declaration from a court that we do not infringe on the proprietary rights of others or that their rights are invalid or unenforceable. Intellectual property litigation is costly, and, even if we prevail, the cost of such litigation could affect our profitability. Furthermore, litigation is time-consuming and could divert management’s attention and resources away from our business. If we do not prevail in any litigation, we may have to pay damages and could be required to stop the infringing activity or obtain a license. Any required license may not be available to us on acceptable terms, if at all. Moreover, some licenses may be nonexclusive, and therefore our competitors may have access to the same technology licensed to us. If we fail to obtain a required license or are unable to design around a patent, we may be unable to sell some of our products, which could have a material adverse effect on our business, financial condition and results of operations.

We require collaboration with other organizations in obtaining relevant biomarkers, and access to oligonucleotides and enzymes that are patented or controlled by others. If we cannot continue to obtain these items or identify freedom to operate opportunities, our business, financial condition and results of operations could be negatively affected.

Security breaches, including with respect to cybersecurity, and other disruptions could compromise our information, products, and services and expose us to liability and harm our reputation and business.

In the ordinary course of our business, we collect and store sensitive data, including intellectual property, personal information, our proprietary business information and that of our customers, suppliers and business partners, and personally identifiable information of our customers and employees in our data centers and on our networks. The secure maintenance and transmission of this information is critical to our operations and business strategy. We rely on commercially available systems, software, tools and domestically available monitoring to provide security for processing, transmitting and storing this sensitive data. As a participant in the molecular diagnostic market, we may face cyber-attacks that attempt to penetrate our network security, including our data centers, sabotage or otherwise disable our research, products and services (including instruments at our customers’ sites, which may include personally identifiable information) or cause interruptions of our internal systems.

Furthermore, there are a variety of other state, national, foreign, and international laws and regulations that apply to the collection, use, retention, protection, security, disclosure, transfer, and other processing of personal data. California has passed the California Consumer Privacy Act of 2018 (CCPA), which took effect January 1, 2020. The CCPA applies broadly to information that identifies or is associated with any California household or individual, and compliance with the CCPA requires that we implement several operational changes, including processes to respond to individuals’ data access and deletion requests. In addition, many foreign data privacy regulations (including the General Data Protection Regulation (GDPR), which became effective in the European Union on May 25, 2018), can be more stringent than those in the United States. Each of the GDPR and the CCPA confer a private right of action on certain individuals and associations. These laws and regulations are rapidly evolving and changing, and could have an adverse effect on our operations. The costs of compliance with, and the other burdens imposed by, these and other laws and regulatory actions may increase our operational costs.


48
If successful, hackers may misappropriate personal or confidential business information. In addition, an associate, contractor or other third party with whom we do business may attempt to circumvent our security measures in order to obtain such information, and may purposefully or inadvertently cause a breach involving such information due to items such as business email compromise. We may be at increased risk if we outsource certain services or functions of our business or otherwise rely on third parties to store and use portions of sensitive data. A break or attack affecting any of these third parties could harm our business.

While we continue to implement additional protective measures to reduce the risk of, and to detect, cyber incidents, cyber-attacks are becoming more sophisticated and frequent, and the techniques used in such attacks change rapidly. Despite our cybersecurity measures (including employee and third-party training, monitoring of networks and systems and maintenance of backup and protective systems) which are continuously reviewed and upgraded, the Company’s information technology networks and infrastructure may still be vulnerable to damage, disruptions or shutdowns due to attack by hackers or breaches, employee error or malfeasance, power outages, computer viruses, telecommunication or utility failures, systems failures, natural disasters or other catastrophic events. Any such compromise of our, or our third-party IT service providers’, data security and any access, unauthorized use, public disclosure or loss of personal or confidential business information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, regulatory penalties, monetary losses, disruption of our operations, damage to our reputation or customers’ willingness to transact business with us and subject us to additional costs and liabilities, any of which could adversely affect our business.

Our success depends on building and sustaining our technology infrastructure.

We are increasingly dependent on information technology to enable us to improve the effectiveness of our operations and to maintain financial accuracy and efficiency. If we do not allocate and effectively manage the resources necessary to build, implement and sustain the proper technology infrastructure, we could be subject to transaction errors, the inability to properly support and service our customers, processing inefficiencies, loss of customers, business disruptions or loss of or damage to intellectual property through security breach or cyber-attack, each of which could materially and adversely affect our business.

Uncertain economic conditions and outlook may adversely impact our business, results of operations, financial condition, and liquidity.

Global economic conditions, including, but not limited to, effects resulting from the 2020 elections in the United States and from the COVID-19 pandemic, could adversely affect our results of operations. The credit markets and the financial services industry continue to experience volatility, both domestically and internationally. These conditions not only limit our access to capital but also make it extremely difficult for our customers, our vendors and us to accurately forecast and plan future business activities, and they could cause U.S. and foreign businesses and consumers to slow spending on our products and services, which would delay and lengthen sales cycles. Some of our customers rely on government research grants to fund technology purchases. If negative trends in the economy affect the government’s allocation of funds to research, there may be less grant funding available for certain of our customers to purchase technologies like those Luminex sells. Certain of our partners and their and our customers may face challenges gaining timely access to sufficient credit or may otherwise be faced with budget constraints, which could result in decreased purchases of, or development of products based on, our products or in an impairment of their ability to make timely payments to us. If our partners and our customers do not make timely payments to us, we may be required to assume greater credit risk relating to those customers, increase our allowance for doubtful accounts and our days sales outstanding would be negatively impacted. Although we maintain allowances for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments, and such losses have historically been within our expectations and the provisions established, we may not continue to experience the same loss rates that we have in the past given the current condition of the worldwide economy. Additionally, these economic conditions and market turbulence may also impact our suppliers, causing them to be unable to supply sufficient quantities of customized components in a timely manner, thereby impairing our ability to manufacture on schedule and at commercially reasonable costs.


49
Our operations in foreign countries expose us to certain risks inherent in doing business internationally, which may adversely affect our business, financial condition, and results of operations.

We expect that revenue from U.S. sales will continue to represent the majority of our total revenue, but our future profitability will depend in part on our ability to grow and ultimately maintain our product sales in foreign markets, particularly in Asia and Europe. In 2020, approximately 22% of our revenue was derived from sales to non-U.S. customers, with approximately 12% of revenue from sales to customers in Europe and approximately 7% of revenue from sales to customers in Asia. Continued concerns about the systemic impact of potential long-term and wide-spread recession and geopolitical issues have contributed to increased market volatility and diminished expectations for economic growth around the world. Uncertainty about global economic conditions, particularly in emerging markets and countries with government-sponsored healthcare systems, may cause decreased demand for our products and services and increased competition, which could result in lower sales volume and downward pressure on the prices for our products, longer sales cycles, and slower adoption of new technologies. As such, a significant slowdown in these foreign economies or lower investments in new infrastructure could have a negative impact on our sales. We also purchase a portion of the materials included in our products from overseas sources. A weakening of macroeconomic conditions may also adversely affect our suppliers, which could result in interruptions in supply. As a result of acquisitions and organic growth, we have operations and manufacturing facilities in foreign countries that expose us to certain risks. For example, fluctuations in exchange rates may affect our revenues, expenses and results of operations, as well as the value of our assets and liabilities as reflected in our financial statements. We are also subject to other types of risks, including the following:

•changes in or interpretations of foreign law that may adversely affect our ability to sell our products, perform services or repatriate profits to the United States;

•tariffs, customs and other barriers to importing/exporting materials and products in a cost-effective and timely manner;

•hyperinflation or economic or political instability in foreign countries;

•imposition of limitations on or increase of withholding and other taxes on remittances and other payments by foreign subsidiaries;

•conducting business in places where business practices and customs are unfamiliar and unknown;

•difficulties in staffing and managing international operations;

•the burden of complying with complex and changing foreign regulatory requirements;

•difficulties in accounts receivable collections;

•the imposition of restrictive trade policies, including export restrictions;

•worldwide political conditions;

•the imposition of inconsistent laws or regulations;

•reduced protection of intellectual property rights and trade secrets in some foreign countries;

•the imposition or increase of investment requirements and other restrictions by foreign governments;

•the interpretation of contractual provisions governed by foreign laws in the event of a contract dispute;

•uncertainties relating to foreign laws, including labor laws, and legal proceedings;

•the burden of complying with foreign and international laws and treaties;

•significant currency fluctuations;

•the burden of complying with and changes in international taxation policies;

•the burden of complying with a variety of U.S. laws, including the Foreign Corrupt Practices Act;

50
•the burden of complying with U.S. export control regulations and policies that restrict our ability to communicate with non-U.S. employees and to supply foreign affiliates, partners and customers; and

•the burden of complying with applicable international laws governing privacy and data security, such as the European Union General Data Protection Regulation.

Our international sales and purchases are subject to numerous U.S. and foreign laws and regulations, including, without limitation, tariffs, trade barriers, regulations relating to import-export control, technology transfer restrictions, the International Traffic in Arms Regulation promulgated under the Arms Export Control Act, the Foreign Corrupt Practices Act and the anti-boycott provisions of the U.S. Export Administration Act. If we fail to comply with these laws and regulations, we could be liable for administrative, civil or criminal liabilities, and in the extreme case, we could be suspended or debarred from government contracts or have our export privileges suspended, which could have a material adverse effect on our business.

Changes in policy in the U.S. and other countries regarding international trade, including import and export regulation and international trade agreements, could also negatively impact our business. In 2018, 2019 and 2020 the U.S. imposed tariffs on goods imported from China and certain other countries, which has resulted in retaliatory tariffs by China and other countries. Additional tariffs or further retaliatory trade measures taken by China or other countries in response, could affect the demand for our products and services, impact the competitive position of our products, prevent us from being able to sell products in certain countries or otherwise adversely impact our results of operations. The implementation of more restrictive trade policies, such as more detailed inspections, higher tariffs or new barriers to entry, could negatively impact our business, results of operations and financial condition.

International sales and purchases are also subject to a variety of other risks, including risks arising from currency fluctuations, collection issues and taxes. Our international sales are subject to variability as our selling prices become less competitive in countries with currencies that are declining in value against the U.S. dollar and more competitive in countries with currencies that are increasing in value against the U.S. dollar. In addition, our international purchases can become more expensive if the U.S. dollar weakens against the foreign currencies in which we are billed. We have not entered into any foreign currency derivative financial instruments; however, we may choose to do so in the future in an effort to manage or hedge our foreign exchange rate risk.

Our success depends on our ability to attract and retain our management and staff.

We depend on the principal members of our management and scientific staff, including our chief executive officer, Nachum Shamir, and our operations, marketing, research and development, technical support, technical service and sales staff. The loss of services of key members of management could delay or reduce our product development, marketing and sales and technical support efforts. In addition, recruiting and retaining qualified scientific and other personnel to perform research and development, technical support, technical service and marketing and sales work will be critical to our success. There is a shortage in our industry of qualified management and scientific personnel, and competition for these individuals is intense. There can be no assurance that we will be able to retain existing and attract additional personnel necessary to achieve our business objectives.

Our effective tax rate may fluctuate and we may incur obligations in tax jurisdictions in excess of amounts that have been accrued.

We are subject to income taxes in the United States and various foreign jurisdictions. Our effective tax rate may be lower or higher than experienced in the past due to numerous factors, including a change in the mix of our profitability from country to country, the establishment or release of valuation allowances against our deferred tax assets, and changes in tax laws. In addition, we have recorded gross unrecognized tax benefits in our financial statements that, if recognized, would impact our effective tax rate. We are subject to tax audits in various jurisdictions, including the United States, and tax authorities may disagree with certain positions we have taken and assess additional taxes. There can be no assurance that we will accurately predict the outcomes of these audits, and the actual outcomes could have a material impact on our net income or financial condition. Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations, which could have an adverse effect on our business and results of operations. The recognition of deferred tax assets is reduced by a valuation allowance if it is more likely than not that the tax benefits will not be realized. We regularly review our deferred tax assets for recoverability and establish a valuation allowance based on historical income, projected future income, the expected timing of the reversals of existing temporary differences, and the implementation of tax-planning strategies.


51
If we become subject to product liability claims, we may be required to pay damages that exceed our insurance coverage.

Our business exposes us to potential product liability claims that are inherent in the testing, production, marketing and sale of biotechnological, human diagnostic and therapeutic products. Although we believe that we are reasonably insured against these risks and we generally have limited indemnity protections in our supplier agreements, there can be no assurance that we will be able to obtain insurance in amounts or scope sufficient to provide us with adequate coverage against all potential liabilities. A product liability claim in excess of our insurance coverage or a claim that is outside of or exceeds our indemnity protections in our supplier agreements or a recall of one of our products would have to be paid out of our cash reserves.

If we become subject to claims relating to improper handling, storage or disposal of hazardous materials, we could incur significant cost and time to comply.

Our research and development processes involve the controlled storage, use and disposal of hazardous materials, including biological hazardous materials. We are subject to foreign, federal, state and local regulations governing the use, manufacture, storage, handling and disposal of materials and waste products. We may incur significant costs complying with both existing and future environmental laws and regulations. In particular, we are subject to regulation by the Occupational Safety and Health Administration (OSHA) and the Environmental Protection Agency (EPA), and to regulation under the Toxic Substances Control Act and the Resource Conservation and Recovery Act in the United States. OSHA or the EPA may adopt regulations that may affect our research and development programs. We are unable to predict whether any agency will adopt any regulations that would have a material adverse effect on our operations.

The risk of accidental contamination or injury from hazardous materials cannot be eliminated completely. In the event of an accident, we could be held liable for any damages that result, and any liability could exceed the limits or fall outside the coverage of our workers’ compensation insurance. We may not be able to maintain insurance on acceptable terms, if at all.

We may incur impairment charges on our goodwill and intangible assets which would reduce our earnings.

We are subject to Accounting Standards Codification (ASC) 350 “Goodwill and Other” (ASC 350) which requires that goodwill and other intangible assets that have an indefinite life be tested at least annually for impairment. Goodwill and other intangible assets with indefinite lives must also be tested for impairment between the annual tests if a triggering event occurs that would likely reduce the fair value of the asset below its carrying amount. As of December 31, 2020, goodwill and other intangible assets with indefinite lives represented approximately 25% of our total assets. In the future, if we determine that there has been impairment, our financial results for the relevant period would be reduced by the amount of the impairment, net of tax effects, if any.

We hold cash and cash equivalents at various foreign subsidiaries that may not be readily available to meet domestic
cash requirements.

Currently a majority of our cash and cash equivalents is held by our U.S. parent company, however, our various foreign subsidiaries have significant cash holdings, in particular our subsidiary in Canada. These cash balances held outside the United States may not be readily available, or may not be available without an additional tax burden, to meet our domestic cash requirements. We require a substantial amount of cash in the United States for operating requirements, purchases of property and equipment, and for potential future acquisitions. If we are unable to meet our domestic cash requirements using domestic cash flows from operations, domestic cash and cash equivalents, by settling loans receivable with our foreign subsidiaries, or by domestic borrowing, it may be necessary for us to consider repatriation of earnings. U.S. tax laws may allow for reductions to the potential tax burden on repatriation of foreign cash; however, such actions would require us to record additional income tax expense and remit additional taxes, which could have a material adverse effect on our results of operations, cash flows and financial condition.

We expect our operating results to continue to fluctuate from quarter to quarter.

The sale of our instruments and assays typically involves a significant technical evaluation and commitment of capital by us, our partners and end users. Accordingly, the sales cycle associated with our products is typically lengthy and subject to a number of significant risks, much of which is beyond our control, including partners’ budgetary constraints, inventory management practices, regulatory approval and internal acceptance reviews. As a result of this lengthy and unpredictable sales cycle, our operating results have historically fluctuated significantly from quarter to quarter. We expect this trend to continue for the foreseeable future.

52
The vast majority of our system sales are made to our strategic partners. Our partners typically purchase instruments in three phases during their commercialization cycle: first, instruments necessary to support internal assay development; second, instruments for sales force demonstrations; and finally, instruments for resale to their customers. As a result, most of our system placements are highly dependent on the continued commercial success of our strategic partners and can fluctuate from quarter to quarter as our strategic partners move from phase to phase. We expect this trend to continue for the foreseeable future.

Our assays are sometimes sold to large customers. The ordering and consumption patterns of these customers can fluctuate, affecting the timing of shipments and revenue recognition. In addition, certain products assist in the diagnosis of illnesses that are seasonal, and customer orders can fluctuate for this reason. The loss of any of these customers (including LabCorp’s decision to move to an alternative vendor for women’s health products in 2018) has had and is expected to continue to have a material adverse effect or our business, financial condition and results of operations.

    The seasonality of some of our assay offerings results in quarter to quarter fluctuations in the percentage of our quarterly revenues derived from our highest margin items (i.e., consumables, royalties and assays), as some customers make infrequent bulk purchases of $100,000 or more to address this demand. Our gross margin percentage is highly dependent upon the mix of revenue components each quarter. These fluctuations contribute to the variability and lack of predictability of both gross margin percentage and total gross profit from quarter to quarter. We expect this trend to continue for the foreseeable future.

    Due to the early stage of the market for molecular tests, projected growth scenarios for our assays are highly volatile and are based on a number of underlying assumptions that may or may not prove to be valid, including our ability to be successful with our direct assay sales strategy.

The “conflict minerals” rule of the SEC has caused us to incur additional expenses, could limit the supply and increase the cost of certain metals used in manufacturing our products, and could make us less competitive in our target markets.

On August 22, 2012, the SEC adopted a rule requiring disclosure of specified minerals, known as conflict minerals, that are necessary to the functionality or production of products manufactured or contracted to be manufactured by public companies. The rule requires companies to obtain sourcing data from suppliers, engage in supply chain due diligence, and file annually with the SEC a specialized disclosure report. The rule could limit our ability to source at competitive prices. Within our supply chain, we may not be able to sufficiently verify the origins of the relevant minerals used in our products through the data collection and due diligence procedures that we have implemented, which may harm our reputation. Furthermore, we may encounter challenges in satisfying those customers who require that all of the components of our products be certified as conflict free, and if we cannot satisfy these customers, they may choose a competitor’s products. We continue to investigate the presence of conflict materials within our supply chain.



ITEM 1B. UNRESOLVED STAFF COMMENTS

    None.

ITEM 2. PROPERTIES

    Our principal research and development, manufacturing and administrative facilities are located in Austin, Texas, and consist of approximately 249,000 square feet of leased space pursuant to lease agreements which expire between June 30, 2022 and August 1, 2030. We have options to renew these lease agreements in Austin, Texas. We maintain 20,000 square feet of leased office space in the Netherlands, approximately 34,700 square feet of leased office and manufacturing space in Toronto, Canada, approximately 35,000 square feet of leased office and manufacturing space in Madison, Wisconsin, approximately 64,000 square feet of leased office and manufacturing space in Northbrook, Illinois, approximately 28,000 square feet of leased office and manufacturing space in Seattle, Washington and approximately 8,000 square feet of leased office and research space in Hayward, California. In addition, we maintain approximately 7,500 square feet and approximately 2,100 square feet of leased office space in Shanghai and Beijing, respectively, People’s Republic of China, approximately 600 square feet of lease office space in Hong Kong and approximately 4,000 square feet of leased office space in Tokyo, Japan.

53
ITEM 3. LEGAL PROCEEDINGS

    When and if it appears probable in management’s judgment, and based upon consultation with outside counsel, that we will incur monetary damages or other costs in connection with any claims or proceedings, and such costs can be reasonably estimated, we record the estimated liability in the financial statements. If only a range of estimated losses can be estimated, we record an amount within the range that, in management’s judgment, reflects the most likely outcome; if none of the estimates within that range is a better estimate than any other amount, we record the liability at the low end of the range of estimates. Any such accrual would be charged to expense in the appropriate period. We disclose significant contingencies when the loss is not probable and/or the amount of the loss is not estimable, when we believe there is at least a reasonable possibility that a loss has been incurred. We recognize costs associated with legal proceedings in the period in which the services were provided. No material legal proceedings are known to be pending as of December 31, 2020.

ITEM 4. MINE SAFETY DISCLOSURES

    None.
54
PART II

ITEM 5. MARKET FOR THE REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Market Information

    Our common stock is traded on the Nasdaq Global Select Market under the symbol “LMNX.”

Holders

    As of February 25, 2021, we had 477 holders of record of our common stock. Because many of our shares are held by brokers and other institutions on behalf of stockholders, we are unable to estimate the total number of beneficial stockholders represented by these record holders.

Dividends

    In February 2017, the Board of Directors initiated a cash dividend program under which the Company anticipates paying a regular quarterly cash dividend. Future declarations of quarterly dividends and the establishment of future record and payment dates are subject to the final determination of the Company’s Board of Directors. Our ability to declare dividends may also from time to time be limited by the terms of any applicable credit facility. Luminex does not currently have a credit facility.

    During 2020, the Company paid dividends on common stock as follows:
2020Dividend per sharePayment Date
First Quarter$0.09April 9, 2020
Second Quarter$0.09July 9, 2020
Third Quarter$0.09October 15, 2020
Fourth Quarter$0.10January 14, 2021
    On February 8, 2021, we announced that our Board declared a quarterly cash dividend of $0.10 per share of common stock to be paid to shareholders of record as of the close of business on March 25, 2021 with a payment date of April 15, 2021.

Recent Sales of Unregistered Securities

    There were no sales of unregistered securities of Luminex during the twelve months ended December 31, 2020.

55
Performance Graph

    The following graph compares the change in Luminex’s cumulative total stockholder return on its common shares with the Nasdaq Composite Index and the Nasdaq Biotechnology Index.
lmnx-20201231_g2.jpg
 12/1512/1612/1712/1812/1912/20
Luminex Corporation100.00 94.58 93.23 110.39 112.13 113.51 
Nasdaq Composite100.00 108.87 141.13 137.12 187.44 271.64 
Nasdaq Biotechnology100.00 78.65 95.67 87.19 109.08 137.90 

56
Issuer Purchases of Equity Securities

    The stock repurchase activity for the fourth quarter of 2020 was as follows:
ISSUER PURCHASES OF EQUITY SECURITIES
Period
Total Number of Shares Purchased(1)
Average Price Paid per Share ($)Total Number of Shares Purchased as Part of Publicly Announced Plans or ProgramsApproximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs
10/1/2020 - 10/31/2020272 $22.67 — $— 
11/1/2020 - 11/30/2020— — — — 
12/1/2020 - 12/31/202091 23.48 — — 
Total Fourth Quarter363 $22.87 — $— 
(1) Total shares purchased includes shares attributable to the withholding of shares by Luminex to satisfy the payment of tax obligations related to the vesting of restricted shares.

ITEM 6. SELECTED FINANCIAL DATA

    The following selected consolidated financial data should be read in conjunction with the Consolidated Financial Statements and Notes thereto and with Item 7 “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and other financial data included elsewhere in this Annual Report on Form 10-K. The consolidated statement of comprehensive income data for the years ended December 31, 2020, 2019 and 2018 and the consolidated balance sheet data at December 31, 2020 and 2019 are derived from the audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K. The consolidated results of operations data for the years ended December 31, 2017 and 2016 and the consolidated balance sheet data at December 31, 2018, 2017 and 2016 are derived from audited consolidated financial statements not included in this Annual Report on Form 10-K.
 Year Ended December 31,
 20202019201820172016
Consolidated Results of Operations Data:(in thousands, except per share data)
Total revenue$417,396 $334,638 $315,818 $306,571 $270,639 
Gross profit247,852 182,739 195,491 199,046 179,655 
Income (loss) from operations42,443 (12,079)27,846 37,153 20,986 
Net income (loss)$15,170 $(3,838)$18,508 $29,423 $13,814 
Net income (loss) per common share, basic$0.33 $(0.09)$0.42 $0.67 $0.32 
Shares used in computing net income (loss) per common share (basic)45,102 44,148 43,727 43,173 42,584 
Net income (loss) per common share, diluted$0.32 $(0.09)$0.41 $0.67 $0.32 
Shares used in computing net income (loss) per common share (diluted)45,820 44,148 44,291 43,300 43,013 
 At December 31,
 20202019201820172016
Consolidated Balance Sheet Data:(in thousands)
Cash and cash equivalents$309,407 $59,173 $76,441 $127,112 $93,452 
Working capital421,570 144,401 151,369 179,393 133,537 
Total assets825,463 543,729 525,175 490,516 450,716 
Total long-term debt203,136 — — — — 
Total stockholders’ equity517,711 464,860 467,656 437,907 403,679 
Dividends declared per share$0.37 $0.30 $0.24 $0.24 $— 


57
ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This section of Form 10-K does not address certain items regarding the year ended December 31, 2018. Discussion and analysis of 2018 and year-to-year comparisons between 2019 and 2018 not included in this Form 10-K can be found in "Item 7. Management's Discussion and Analysis" of our Annual Report on Form 10-K for the year ended December 31, 2019. The following information should be read in conjunction with the Consolidated Financial Statements and the accompanying Notes included below in Item 8 and “Risk Factors” included above in Item 1A of this Annual Report on Form 10-K. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements.

Overview

    We develop, manufacture and sell proprietary biological testing technologies and products with applications throughout the life sciences industries, including diagnostics, pharmaceuticals and research. These industries depend on a broad range of tests, called assays, to perform diagnostic testing, conduct life science research and perform pharmaceutical testing.

    We primarily serve the life sciences industries by marketing products, including our specific testing equipment, called systems, and assays, to various types of testing laboratories. We have a large base of installed systems that has grown primarily from the following:

•placements made by customers within our Licensed Technologies Group, which customers either:

•license our xMAP technology and develop products that incorporate our xMAP technology into products that they then sell to end users, or

•purchase our proprietary xMAP laboratory instruments and our proprietary xMAP microspheres and sell xMAP-based assays and/or xMAP-based testing services, which run on the xMAP instruments, and pay a royalty to us; and

•in addition, we utilize a direct sales force that focuses on the sale of molecular diagnostic assays that run on our systems.

    As of December 31, 2020, Luminex had 82 strategic partners, of which 54 have released commercialized reagent-based products utilizing our technology. Our remaining LTG customers are in various stages of development and commercialization of products that incorporate our technology.

    Luminex has a number of forms of revenue that result from our business model:

•System revenue is generated from the sale of our xMAP multiplexing analyzers and peripherals, our VERIGENE readers and processors and our flow cytometers and cellular analysis instruments.

•Consumable revenue is generated from the sale of our dyed polystyrene microspheres, along with sheath and drive fluid. Our larger commercial and development partners often purchase these consumables in bulk to minimize the number of incoming qualification events and to allow for longer development and production runs.

•Royalty revenue is generated when a partner sells our proprietary microspheres to an end user, when a partner sells a kit incorporating our proprietary microspheres to an end user or when a partner utilizes a kit to provide a testing result to an end user. End users can be facilities such as testing labs, development facilities and research facilities that buy prepared kits and have specific testing needs or testing service companies that provide assay results to pharmaceutical research companies or physicians.

•Assay revenue is generated primarily from four sources: (i) sale of our branded kits, which are a combination of chemical and biological reagents and our proprietary xMAP bead technology used to perform diagnostic and research assays on samples, (ii) real-time Polymerase Chain Reaction (PCR) and multiplexed PCR assays using our proprietary MultiCode technology, (iii) ARIES cassettes designed to run a fully automated, sample-to-answer molecular assay on the ARIES System, and (iv) VERIGENE test cartridges, a sample-to-answer molecular assay designed to target infections in the bloodstream, respiratory tract, and gastrointestinal tract on the VERIGENE System.
58

•Service revenue is generated when a partner or other owner of a system purchases a service contract from us after the standard warranty has expired or pays us for our time and materials to service instruments. Service contract revenue is amortized over the life of the contract and the costs associated with those contracts are recognized as incurred.

•Other revenue consists of items such as training, shipping, parts sales, license revenue, grant revenue, contract research and development fees, milestone revenue, amounts paid to global purchasing organizations (which are accounted for as a reduction in revenue) and other items that individually amounted to less than 1.5% of total revenue in 2020.

2020 Highlights

•Consolidated revenue was $417.4 million for 2020, representing a 25% increase over revenue for 2019.

•Assay revenue of $211.9 million for 2020, representing an increase of 60% over 2019.

•Sample-to-answer assay revenue increased for 2020 by $33.2 million, or 49%, from 2019.

•Record placements of sample-to-answer systems, which consisted of 449 ARIES and VERIGENE systems sold or contracted through reagent rental agreements in 2020.

•Profitability increased to $15.2 million for 2020, an increase of more than 490% from 2019.

•Received two BARDA awards related to completing a 510(k) filing for Luminex’s NxTAG CoV Extended Panel and the ARIES SARS-CoV-2 assay for COVID-19 testing in March 2020.

•Received FDA EUA for the NxTAG CoV Extended Panel on March 27, 2020.

•Received FDA EUA for the xMAP SARS-CoV-2 Multi-Antigen IgG Assay on July 16, 2020, which was supported by a BARDA award received in March 2020.

•Received FDA EUA for the ARIES SARS-CoV-2 Assay on April 6, 2020.

•Received two additional BARDA awards related to completing a 510(k) filing for Luminex’s NxTAG RPP and SARS-CoV-2 panel; and support of the enhancement of our xMAP SARS-CoV-2 Multi-Antigen IgG Assay in September 2020.

•Issued $260.0 million principal amount of Notes in the second quarter 2020, due in May 2025.

COVID-19 Considerations

Since December 2019, COVID-19 has spread rapidly, with most countries and territories worldwide having confirmed cases, and a high concentration of cases in the U.S. and many other countries in which we operate. The rapid spread has resulted in authorities around the world implementing numerous measures to contain the virus, such as travel bans and restrictions, quarantines, shelter-in-place orders and business shutdowns. The pandemic and these containment measures have had, and are expected to continue to have, a substantial negative impact on businesses around the world and on global, regional and national economies.

Our priorities during the COVID-19 pandemic have been, among others, protecting the health and safety of our employees; providing multiple solutions to the marketplace, including our EUA SARS-CoV-2 tests; and ramping up manufacturing to help our customers meet and overcome their current challenges.

Our overall revenues were materially enhanced by COVID-19-related product sales. As of December 31, 2020, the COVID-19 pandemic was the primary driver behind our 25% increase in revenue over 2019. We experienced an overall 60% increase in assay revenue, with our combined respiratory-related products up more than 100% year-over-year as a result of the use of our products related to the pandemic. At the beginning of the pandemic, our customers initially used our products to rule out other respiratory illnesses. However, once we received EUAs for our COVID-19 molecular diagnostic tests, our volume shifted towards our COVID-19-specific products.
59

The increases in assay, system, and consumable sales revenue were partially offset by a decrease in royalty revenue as a result of pressures faced by some of our partners. System sales increased in 2020, primarily driven by higher placements of sample-to-answer systems, partially offset by lower sales of flow cytometry systems as compared to the prior year. Sample-to-answer sales continued to benefit in part from the COVID-19 pandemic, while flow cytometry instrument sales declined as compared to 2019. We sold 973 multiplexing analyzers in the year ended December 31, 2020, as compared to 990 multiplexing analyzers sold in the comparable period in 2019. In addition, royalty revenue from our partners declined in 2020, primarily driven by a reduction in non-bulk purchases from certain partners and the pressures faced by academic research and diagnostic institutions as a result of the pandemic in the U.S.

Given the increased demand for certain of our assay products in 2020, the pandemic has not negatively impacted the Company’s liquidity position to date. As of December 31, 2020, we believe that we have the cash necessary to meet our short-term liquidity needs. We also have not observed any material impairments of our assets or a significant change in the fair market value of our assets due to the COVID-19 pandemic.

Our additional research and development efforts related to our recent EUA SARS-CoV-2 tests were partially funded by two BARDA contracts awarded to the Company for the development, testing and submission of these tests. In September, 2020, we were awarded two additional BARDA contracts related to completing a 510(k) filing for Luminex’s expanded NxTAG Respiratory Pathogen Panel (RPP), which includes the SARS-CoV-2 virus for COVID-19 testing and to support the enhancement of the company’s xMAP SARS-CoV-2 Multi-Antigen IgG Assay. Please refer to “BARDA Contracts” below for further discussion.

During the year ended December 31, 2020, we focused our energies on increasing our manufacturing capacity (nearly doubling prior capability since the beginning of the year) while portions of our workforce worked remotely as their positions allowed. Our ability to continue to operate without any significant negative operational impact from the COVID-19 pandemic will, in part, depend on our ability to protect our employees and maintain our supply chain. Continued rapid expansion of capacity may be constrained by long lead-time purchased items and capital equipment needs. The Company continues to endeavor to follow the recommended actions of government and health authorities to protect our employees, with particular measures in place for employees who manufacture our products. For the year ended December 31, 2020, we maintained the consistency of our operations with minimal interruptions despite the impact of the COVID-19 pandemic. Although we intend to continue to take appropriate measures to ensure that any disruptions to our operations remain minimal during the pandemic, the complications resulting from the pandemic could result in unforeseen disruptions to our workforce and supply chain, including any potential interruptions in our ability to source, transport and supply materials to the Company that are necessary for continued operations, that could negatively impact our operations.

We believe the extent of the COVID-19 pandemic’s impact on our operating results and financial condition will be driven by many factors, most of which are beyond our control and ability to forecast. Such factors include, but are not limited to, the severity and duration of the pandemic, our ability to timely develop, commercialize and manufacture solutions related to the pandemic, the extent and the effectiveness of responsive actions taken by authorities of impacted countries, the impact of these and other factors on our employees, customers and suppliers, as well as any resulting impact of the economic uncertainty and volatility that could affect demand for our products. Because of these and other uncertainties, we cannot estimate the length or extent of the impact of the pandemic on our business.

BARDA Contracts

In March 2020, BARDA awarded the Company two milestone-based contracts, with a value of $642,450 each, funding approximately 36% of the overall cost of development, testing and submission for two EUAs to provide rapid answers to patients believed to have COVID-19. Luminex funded the remaining 64% of the total program costs, representing $1.1 million each. In March 2020, the Company received FDA EUA for its new NxTAG CoV Extended Panel, a high-throughput test for detecting SARS-CoV-2 that provides results for up to 96 samples in approximately four hours. The NxTAG CoV Extended Panel runs on Luminex’s easy-to-use, compact MAGPIX System. In April 2020, the Company received FDA EUA for its new ARIES SARS-CoV-2 Assay, which is designed to provide rapid answers to patients believed to have COVID-19, generating results in approximately two hours. The test can be run on both 6-unit and 12-unit ARIES Systems.


60
In September, BARDA awarded the Company two additional milestone-based contracts valued at $5,389,813 and $683,500, respectively, related to completing a 510(k) filing for Luminex’s expanded NxTAG RPP, which includes the SARS-CoV-2 virus for COVID-19 testing, and to support the enhancement of the company’s xMAP SARS-CoV-2 Multi-Antigen IgG Assay. The Company intends to submit this enhanced serology assay for an EUA when this project is completed. No government contract revenue has been recorded to date for either of these two new BARDA contracts.

FDA Matters

On June 26, 2020, the Company received a warning letter (the Warning Letter) from the FDA relating to the operations of the Company’s Austin, Texas and Northbrook, Illinois facilities (the Facilities) and the Company’s VERIGENE Processor SP System. The Warning Letter resulted from inspections held at the Facilities from February 10, 2020 to February 14, 2020. The company submitted a comprehensive response to each of those inspections. The subsequently issued Warning Letter primarily relates to the Company’s VERIGENE SP instrument and its hybridization heater in connection with certain FDA requirements under the Quality System Regulation (21 C.F.R. Part 820) and the regulation of Medical Device Corrections and Removals (21 C.F.R. Part 806).

The Company timely submitted a response and corrective action plan to the FDA regarding the issues raised in the Warning Letter, as requested by the FDA, and continues working diligently and expeditiously to resolve the issues raised by the FDA. The Warning Letter did not restrict the manufacture, production or shipment of any of the Company’s products, nor require the withdrawal of any product from the marketplace. The Company believes it has taken, and is continuing to take, appropriate measures to address the items identified by the FDA with respect to the VERIGENE SP instrument and its hybridization heater, and the Company included communication of these measures in its response to the Warning Letter. Specifically, we recalled affected product from the field and replaced them with new units. Additionally, we are executing a field action to re-calibrate all VERIGENE SP instruments deployed in the field with in-house built and verified temperature verification fixtures by March 18, 2021. In addition, the Company continues to evaluate what further corrective or preventive action may be required.

The Company has responded to the FDA’s concerns raised in the Warning Letter but cannot give assurances that the FDA will be satisfied with its response to the Warning Letter or that such actions will sufficiently resolve the issues identified in the Warning Letter. Failure to promptly and fully address the issues raised in the Warning Letter to the FDA’s satisfaction or to comply with U.S. medical device regulatory requirements in general could result in further regulatory and enforcement actions being initiated by the FDA. These actions could result in, among other things, product recalls, product seizures, injunctions, civil monetary penalties, further delays in obtaining marketing authorization for products, an impact on federal contracts, limitations on our ability to export products, and criminal enforcement action. Any such actions could disrupt our ongoing business and operations and potentially have a material adverse effect on our business, financial condition and results of operations.

Consumable Sales and Royalty Revenue Trends

    We have experienced significant fluctuations in consumable revenue in the past. Year-over-year changes in consumable revenue have been an increase of $0.4 million, a decrease of $1.6 million, and an increase of $0.8 million, in 2020, 2019, and 2018, respectively. While the changes over the past three years have not been significant, fluctuations can manifest through periodic changes in volume from our largest purchasing partners. These partners account for 60% of our total consumable sales volume. We expect these fluctuations to continue as the ordering patterns and inventory levels of our largest bulk purchasing partners remain variable. Additionally, even though we experience variability in consumable revenue, the key indicator of the success of our partners’ commercialization efforts is the rising level of royalties and reported royalty-bearing sales. However, during 2020, consumables were flat and royalties were lower than in 2019 as a result of the COVID-19 pandemic. We expect to return to growth in consumables and royalties as the COVID-19 pandemic subsides.

Growth in Inventory

Our inventory has increased from $77.1 million as of December 31, 2019 to $123.1 million as of December 31, 2020, primarily as a result of increases in COVID-19 assay finished goods and instrument inventory to support significant increases in demand. Inventory levels may increase in 2021, primarily as a result of stocking COVID-19-related products to further support current and anticipated demand and new product launches.

Future Operations

    We expect our areas of focus over the next twelve months to be:

•delivering on our revenue growth goals;
61

•development and commercialization of SARS-CoV-2-related diagnostic and serology tests, as well as support of partner activities focused on testing, treatment, and vaccines for SARS-CoV-2;

•maintenance and improvement of our existing products and the timely development, completion and successful commercial launch of our pipeline products;

•completing development and commercialization of the next generation sample-to-answer system, VERIGENE II, our next generation xMAP System and xMAP INTELLIFLEX;

•accelerating development and commercialization of the assays on our sample-to-answer diagnostic systems;

•monitoring and mitigating the effect of the ongoing uncertainty and volatility in global finance markets and changes in government funding on planned purchases by end users;

•improvement of ARIES and VERIGENE gross margins;

•placements of our VERIGENE and ARIES Systems, our sample-to-answer platforms and assays;

•increasing the growth of our LTG revenue through enrichment of our existing partner relationships and the addition of new partners;

•adoption and use of our platforms and consumables by our customers for their testing services; and

•expansion and enhancement of our installed base of systems and our market position within our identified target market segments.

    We anticipate continued revenue concentration in our higher margin items (assays, consumables and royalties). Additionally, we believe that a sustained investment in research and development is necessary in order to meet the needs of our marketplace and to provide a sustainable new product pipeline. We may experience volatility in research and development expenses as a percentage of revenue on a quarterly basis as a result of the timing of development expenses, clinical validation and clinical trials in advance of the commercial launch of our new products.

CRITICAL ACCOUNTING POLICIES

    The discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles (GAAP). The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. The following is a discussion of our most critical accounting policies used in the preparation of our financial statements, and the judgments and estimates involved under each. We also have other significant accounting policies that do not involve critical accounting estimates because they do not generally require us to make estimates and judgments that are difficult or subjective. These are described in Note 1 of our Consolidated Financial Statements provided herein in Item 8. Estimates and assumptions are reviewed periodically. Actual results may differ from these estimates under different assumptions or conditions.

    Revenue Recognition and Performance Obligations: Revenue is generated primarily from the sale of the Company’s products and related services, which are primarily support and maintenance services on the Company’s systems. The Company recognizes product revenue when the customer obtains control of the Company’s product, which typically occurs upon shipment or delivery to the customer depending upon the shipping terms. We treat shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost. Our customers do not typically have any contractual rights of return outside of our warranty provisions. The Company has allowed few returns to date and believes that returns of its products will be minimal.

62
    Royalties: For arrangements that include sales-based royalties, including minimum payments, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation, to which some or all of the royalty has been allocated, has been satisfied. This was a change in 2018 from how the Company has historically treated royalty payments, by recognizing royalty revenue when our strategic partners reported end-user sales to the Company, and is primarily the basis for our cumulative adjustment as of January 1, 2018 to retained earnings of $10.6 million before related tax impacts or $8.1 million net of related tax impacts. Royalty payments are typically received when our strategic partners report end-user sales to the Company.

    Reagent Rentals: The Company provides systems and certain other hardware to customers through reagent rental agreements, under which the customers commit to purchasing minimum quantities of disposable products at a stated price over a defined contract term, which is normally two to three years. Instead of rental payments, the Company recovers the cost of providing the system and other hardware in the amount charged for assays. Revenue is recognized over the defined contract term as assays are shipped. The depreciation costs associated with the system and other hardware are charged to cost of sales on a straight-line basis over the estimated life of the system. The costs to maintain these instruments in the field are charged to cost of sales as incurred. The Company began reclassifying the portion of reagent rental revenue associated with the recovery of the cost of providing the system and other hardware in reagent rental agreements from assay revenue to system revenue effective January 1, 2018. This change does not have any impact on top line revenue and the Company does not anticipate any material effects to its revenue categorization.

    Warranties: The Company provides a limited, assurance-type warranty, typically for twelve months from installation for the systems sold to end customers and fifteen months for the systems sold to partners. The Company accrues for the estimated cost of initial product warranties at the time revenue is recognized. While we engage in product quality programs and processes, our warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. While management believes that adequate reserve has been made in the consolidated financial statements for product warranties, should actual product failure rates, material usage or service delivery costs differ from our estimates, revisions to the estimated warranty liability would be required. However, we do not believe this estimate is subject to significant variability.

    License Revenues: The Company enters into out-licensing agreements, under which it licenses certain rights to its technology to third parties. These licenses are typically not distinct, as the customer cannot benefit from the license on its own, and do not have significant standalone functionality, but represent single performance obligations together with the sales of our consumables, systems and assays. The terms of these arrangements typically include payment to the Company of non-refundable, up-front license fees. Some of our current agreements range through 2027 and can be extended for up to twenty years. Each of these payments results in license revenues which are recognized ratably over time and are included in other revenues, except for revenues from royalties on net sales of licensed products, which are classified as royalty revenues. Deferred revenues related to these out-licensing agreements are shown in contract liabilities in the table included in Note 18, “Revenue Recognition,” in our Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K.

    Service Agreements: Revenue from extended service agreements is deferred when payment is received in advance of the performance obligation being satisfied or completed. Luminex provides an integrated service of maintenance and related activities for equipment sold to customers, where the nature of the overall promise is to provide a stand-ready service. As such, the performance obligation is recognized as a series of distinct service periods and the service revenue is recognized ratably over the term of the agreement. The extended service agreements typically range from one to four years and payment is typically received up-front.

    Reserves for Variable Consideration: Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from discounts and any other allowances that are offered within contracts between the Company and its customers relating to the Company’s sales of its products. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of revenue and accounts receivable. Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as the Company’s historical experience, current contractual requirements, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of each contract. The amount of variable consideration which is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company will adjust these estimates, which would affect net product revenue and earnings in the period when such variances become known.
63

    Inventory. Inventories are valued at the lower of cost and net realizable value. Cost is determined according to the standard cost method. Net realizable value is defined as the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. Inventories have been written down through an allowance for excess and obsolete inventories. The two major components of the allowance for excess and obsolete inventory are (i) a specific write-down for inventory items that we no longer use in the manufacture of our products or that no longer meet our specifications and (ii) a write-down against slow moving items for potential obsolescence. Inventory is reviewed on a regular basis and adjusted based on management’s review of inventories on hand compared to estimated future usage and sales. While management believes that adequate write-downs for inventory obsolescence have been made in the consolidated financial statements, scientific and technological advances will continue and we could experience additional inventory write-downs in the future. However, we do not believe this estimate is subject to significant variability.

    Purchase Price Allocation, Intangibles and Goodwill. The purchase price allocation for acquisitions requires extensive use of accounting estimates and judgments to allocate the purchase price to the identifiable tangible and intangible assets acquired, including in-process research and development, and liabilities assumed based on their respective fair values.  Intangible assets with definite lives are amortized over the assets’ estimated useful lives using the straight-line method.  We periodically review the estimated useful lives of our identifiable intangible assets, taking into consideration any events or circumstances that might result in a diminished fair value or revised useful life.

    Goodwill represents the excess of the cost over the fair value of the assets of the acquired business. We evaluate the carrying value of goodwill on a reporting unit level annually, on October 1st of each year, or more frequently if there is evidence that certain events or changes in circumstances indicate that the carrying amount of these assets may not be recoverable. In 2020 and 2019, the Company estimated the fair value of the reporting unit using a fair-value approach based on the market capitalization. This analysis requires a comparison of the carrying value of the reporting unit to the estimated fair value of the reporting unit. Determining the fair value of goodwill is subjective in nature and often involves the use of estimates and assumptions including, without limitation, use of estimates of future prices and volumes for the Company’s products, capital needs, economic trends and other factors which are inherently difficult to forecast. Our annual test, performed on the first day of the fourth quarter, did not result in an impairment charge for 2020 or 2019 as the estimated fair value of our reporting unit exceeded the carrying value by a significant enough amount that any reasonably likely change in the assumptions used in the analysis would not cause the carrying value to exceed the estimated fair value for the reporting unit as determined under our analysis.

    Accounting for Income Taxes. We calculate our provision for income taxes using the asset and liability method, under which deferred tax assets and liabilities are recognized by identifying the temporary differences arising from the different treatment of items for tax and accounting purposes. In determining the future tax consequences of events that have been recognized in our financial statements or tax returns, judgment is required. Differences between the anticipated and actual outcomes of these future tax consequences could have a material impact on our consolidated results of operations or financial position. The recognition of deferred tax assets is reduced by a valuation allowance if it is more likely than not that the tax benefits will not be realized. We regularly review our deferred tax assets for recoverability and establish a valuation allowance based on historical income, projected future income, the expected timing of the reversals of existing temporary differences and the implementation of tax-planning strategies. The excess of financial reporting basis over tax basis of our foreign subsidiaries are considered permanently reinvested, with the exception of the Canadian subsidiary. Accordingly, provision for withholding taxes on certain earnings has only been provided for this subsidiary.

    The GAAP guidance requires recognition of the impact of a tax position in our financial statements only if that position is more likely than not to be sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected in income tax expense. Determining the consolidated provision for income taxes involves judgments, estimates and the application of complex tax regulations. We are required to provide for income taxes in each of the jurisdictions where we operate, including estimated liabilities for uncertain tax positions. Although we believe that we have provided adequate liabilities for uncertain tax positions, the actual liability resulting from examinations by taxing authorities could differ from the recorded income tax liabilities and could result in additional income tax expense having a material impact on our consolidated results of operations. Changes of estimates in our income tax liabilities are reflected in our income tax provision in the period in which the factors resulting in the change to our estimate become known to us. We benefit from research tax credit incentives in the U.S. and Canada extended to taxpayers engaged in qualified research and experimental activities while carrying on a trade or business.

64
    Significant reform of the Internal Revenue Code was signed into legislation on December 22, 2017 pursuant to the U.S. Tax Cuts and Jobs Act of 2017 (the Tax Act). This legislation includes, among other things, changes to U.S. federal tax rates and the migration from a “worldwide” system of taxation to a territorial system. The U.S. tax reform modifications to the taxation of foreign profits and changes to deductibility of U.S operational expenses will have an ongoing impact to the tax estimates in our financial statements and may not be beneficial.

    Stock compensation. All stock-based compensation cost, including grants of stock options, restricted stock units and shares issued under the Company’s employee stock purchase plan, is measured at the grant date based on the fair value of the award and is recognized as an expense on a straight-line basis over the requisite service period, which is generally the vesting period. The fair value of our stock options is estimated using the Black-Scholes option pricing model. The Black-Scholes valuation calculation requires us to estimate key assumptions such as expected volatility, expected term and risk-free rate of return. Calculation of expected volatility is based on historical volatility. The expected term is calculated using the contractual term of the options as well as an analysis of our historical exercises of stock options. The estimate of the risk-free rate of return is based on the U.S. Treasury yield curve in effect at the time of grant. The dividend yield is based on our history and expectation of dividend payouts at the time of grant.

    The amount of stock-based compensation expense recognized during a period is based on the value of the portion of the awards that are ultimately expected to vest. As part of the requirements of ASC 718 “Stock Compensation”, the Company is required to estimate potential forfeitures of stock grants and adjust compensation cost recorded accordingly. The estimate of forfeitures is based on historical forfeiture performance and will be adjusted over the requisite service period to the extent that actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures will be recognized through a cumulative catch-up adjustment in the period of evaluation and will also impact the amount of stock compensation expense to be recognized in future periods. Ultimately, the actual expense recognized over the vesting period will only be for those awards that vest, except for the limited number of market based awards under long-term incentive plans.  If we use different assumptions for estimating stock-based compensation expense in future periods or if actual forfeitures differ materially from our estimated forfeitures, the change in our stock-based compensation expense could materially affect our operating income, net income and net income per share.

CONSOLIDATED RESULTS OF OPERATIONS

    The following table sets forth the percentage of total revenue of certain items in the Consolidated Results of Operations. The financial information and the discussion below should be read in conjunction with the Consolidated Financial Statements and Notes thereto.
 Year Ended December 31,
 202020192018
Revenue100 %100 %100 %
Cost of revenue41 %45 %38 %
Gross profit59 %55 %62 %
Operating expenses:
Research and development expense13 %17 %15 %
Selling, general and administrative expense34 %38 %35 %
Amortization of acquired intangible assets3 %3 %3 %
Total operating expenses49 %58 %53 %
Income from operations10 %(4)%9 %
Interest and other expense, net(3)%1 %— %
Loss from equity method investment— %— %— %
Income taxes(3)%2 %(3)%
Net income4 %(1)%6 %
65

Year Ended December 31, 2020 Compared to Year Ended December 31, 2019
 Year Ended December 31,  
 20202019VarianceVariance (%)
 (dollars in thousands)
Revenue$417,396 $334,638 $82,758 25 %
Gross profit$247,852 $182,739 $65,113 36 %
Gross margin percentage59 %55 %4 %N/A
Operating expenses$205,409 $194,818 $10,591 5 %
Income from operations$42,443 $(12,079)$54,522 451 %
Net income$15,170 $(3,838)$19,008 495 %
    Total revenue increased by 25% to $417.4 million for 2020 from $334.6 million in 2019. The Company experienced increases primarily in assay sales, partially offset by decreases in royalty revenue compared to the prior year period. Total assay revenue increased 60% as compared to the same period in 2019 and this increase was mainly attributable to increased demand for respiratory and related products stemming from the COVID-19 pandemic, with increases in both our non-automated and automated assay revenue. Non-automated assay revenue grew 77% to $109.1 million for 2020 from $61.7 million in 2019 and comprised 51% of total assay revenue for 2020 compared to 47% of total assay revenue for the comparable period in 2019. Automated assay revenue, which consists of ARIES and VERIGENE assays, grew 49% to $100.9 million for 2020 from $67.7 million in 2019.

    The following table presents our revenues disaggregated by revenue source for the years ended December 31, 2020 and 2019:
 Year Ended December 31,  
 20202019VarianceVariance (%)
(dollars in thousands)
System sales$70,764 $70,276 $488 1 %
Consumable sales48,936 48,542 394 1 %
Royalty revenue48,873 53,562 (4,689)(9)%
Assay revenue211,902 132,028 79,874 60 %
Service revenue23,341 22,413 928 4 %
Other revenue13,580 7,817 5,763 74 %
 $417,396 $334,638 $82,758 25 %
    We continue to have revenue concentration in a limited number of customers; however, revenue concentration has trended down significantly over the past several years. In 2020, the top five customers, by revenue, accounted for 22% of total revenue, down from 30% of total revenue in 2019 and 42% in 2018. In particular, our two largest customers by revenue accounted for 14% of 2020 total revenue (10% and 4%, respectively), a decrease from 17% of 2019 total revenue (12% and 5%, respectively). No other customer accounted for more than 6% of total revenue in 2020 or 2019. In 2020, approximately 22% of our revenue was derived from sales to non-U.S. customers, with approximately 12% of revenue from sales to customers in Europe and approximately 7% of revenue from sales to customers in Asia. This compares to approximately 25% of our 2019 revenue being derived from sales to non-U.S. customers, with approximately 11% of revenue from sales to customers in Europe and approximately 10% of revenue from sales to customers in Asia. This decline in the percentage of sales to non-U.S. customers has been driven primarily by a decrease in instruments sales as a result of the COVID-19 pandemic.

    Revenue from the sale of systems and peripheral components increased 1% to $70.8 million for 2020 from $70.3 million in 2019, and reflected a change in sales mix with higher sales of sample-to-answer systems, partially offset by lower sales of flow cytometry and multiplexing systems. Sample-to-answer sales benefited in part from the increased demand resulting from the COVID-19 pandemic, while both flow cytometry and multiplexing sales experienced pressures of reduced demand from the pandemic. We sold 973 multiplexing analyzers in 2020, as compared to 990 multiplexing analyzers sold in 2019. For 2020, our five highest selling partners accounted for 741 systems, or 76%, of total multiplexing analyzers sold, whereas our five highest selling partners in 2019 accounted for 787, or 79%, of total multiplexing analyzers sold.

66
    Consumable sales, comprised of microspheres and sheath fluid, increased 1% to $48.9 million in 2020 from $48.5 million in 2019, primarily driven by higher aggregate non-bulk purchases from several partners. During 2020, we had 74 bulk purchases of consumables totaling approximately $35.3 million, or 72% of total consumable revenue, ranging from $0.1 million to $3.9 million, as compared with 73 bulk purchases totaling approximately $36.2 million, or 74% of total consumable revenue, in 2019. We expect fluctuations in consumable sales on an ongoing basis. Partners who reported royalty-bearing sales accounted for $27.6 million, or 56%, of total consumable sales in 2020 compared to $34.0 million, or 70%, of the total consumable sales in 2019.

    Royalty revenue, which results when our partners sell products or testing services incorporating our technology, decreased 9% to $48.9 million for 2020 from $53.6 million for 2019, primarily attributable to an expectation of lower aggregate royalties to be reported by our partners. Some of our partners’ reports on end user sales indicated declines, which were primarily the result of the COVID-19 pandemic. Additionally, we expect modest fluctuations in the royalties submitted quarter to quarter based upon the varying contractual terms, differing reporting and payment requirements, and the addition of new partners. Our partners’ end user sales may reflect volatility from quarter to quarter and, therefore, that same volatility is reflected in our reported royalty revenues on a quarterly basis.

    Assay revenue increased 60% to $211.9 million for 2020 from $132.0 million for 2019, predominantly driven by increased demand for respiratory and related products stemming from the COVID-19 pandemic. Revenue for our non-automated testing assays increased by 77% to $109.1 million for 2020, from $61.7 million for 2019. Our sample-to-answer assay revenue, which consists of ARIES and VERIGENE assay sales, grew 49% to $100.9 million for 2020 from $67.7 million in 2019. No customer accounted for more than 4% of total assay revenue during 2020, down from 10% during the comparable period in 2019.

    Service revenue, comprised of extended warranty contracts earned ratably over the term of a contract and time and materials for billable service work not under an extended warranty contract, increased 4% to $23.3 million during 2020 from $22.4 million in 2019. This increase was primarily driven by an increase in the number of systems covered under extended service agreements. At December 31, 2020, we had approximately 3,500 Luminex systems covered under extended service agreements and $10.5 million in deferred revenue related to those contracts. At December 31, 2019, we had approximately 3,000 Luminex systems covered under extended service agreements and $8.7 million in deferred revenue related to those contracts.

    Other revenue, which includes training revenue, shipping revenue, miscellaneous part sales, amortized license fees, software revenue, custom service agreements and revenue from agreements with U.S. government agencies, increased to $13.6 million for 2020, compared to $7.8 million for 2019. This increase was primarily the result of two BARDA awards totaling approximately $1.3 million received in March 2020 for the development, testing and submission of our NxTAG and ARIES CoV assays, custom service revenue in the 2020, in addition to increases in shipping revenue in 2020, as compared to 2019.

    Gross Profit. Gross profit increased to $247.9 million for 2020, as compared to $182.7 million for 2019. Gross margin (gross profit as a percentage of total revenue) increased to 59% for 2020, from 55% for 2019. This increase in gross margin was primarily attributable to the economies of scale realized in manufacturing, in addition to (i) a favorable sales mix in 2020 and (ii) the absorption of the flow cytometry acquisition-related costs in 2019, primarily expenses of $1.1 million for the step-up in inventory to fair value, which did not repeat in 2020. The concentration of sales in our higher margin items (royalties, consumables, and non-automated assays), represented 50% of revenue for 2020, as compared to 49% in 2019. We anticipate fluctuation in gross margin and related gross profit in future periods primarily as a result of variability in consumable and system purchases and seasonality effects inherent in our assay revenue.

    Research and Development Expense. Research and development expense increased to $53.7 million, or 13% of total revenue, for 2020 from $56.2 million, or 17% of total revenue, in 2019. The decrease in research and development expense was primarily attributable to lower direct material expenses, reflecting development activities which were lower in 2020 or completed in 2019 for VERIGENE II assays, the xMAP INTELLIFLEX and Guava Next Gen systems. Research and development expenses in 2020 include expenses related to the development and testing of our NxTAG CoV Extended Panel and the ARIES SARS-CoV-2 Assay which were partially funded under the BARDA contracts awarded in March 2020 and our VERIGENE SP SARS-CoV-2 and VERIGENE II RSP Flex + CoV assays. Research and development headcount as of December 31, 2020 was 218, as compared to 216 as of December 31, 2019. The focus of our research and development activities is expanding the portfolio of COVID-19 solutions, in addition to our ongoing efforts around the development and commercialization of the VERIGENE II System and associated assays, and the development of the xMAP INTELLIFLEX System.

67
    Selling, General and Administrative Expense. Selling, general and administrative expenses, excluding the amortization of acquired intangible assets, increased to $140.2 million for 2020 from $127.2 million for 2019. The increase over the prior year period was primarily attributable to higher sales and marketing expenses, in particular, commission and personnel-related costs in 2020 related to the increase in revenue. Selling, general and administrative headcount at December 31, 2020 was 502, as compared to 495 at December 31, 2019. As a percentage of revenue, selling, general and administrative expense, excluding the amortization of acquired intangible assets, was 34% for 2020 and 38% for 2019.

    Interest and Other Expense, Net. Interest and other expense, net, consists primarily of interest expense and income. We earn interest income on our cash, cash equivalents and investments. Interest expense consists primarily of the interest from the amortization of debt discount, issuance costs, and coupon interest attributable to the Notes issued in May 2020, which was approximately $11.5 million in 2020.

    Income taxes. Our effective tax rate for 2020 was 47.6%, or a provision of $13.8 million, as compared to a benefit of 60.0%, or $5.7 million, for 2019. The tax expense for 2020 was primarily a result of U.S. federal tax under the global intangible low-tax income (GILTI) provisions of the Tax Act and tax expense of $2.1 million recorded related to valuation allowances which offset deferred tax assets of certain U.S. state net operating loss carryforwards. The tax benefit for 2019 reflects a reduction in unrecognized tax benefits related to the U.S. transition tax of $6.6 million as a result of a ruling for certain aspects of the earnings and profits (E&P) calculation of our Canadian subsidiary. Our rate is also impacted by our research tax credit benefit for our U.S. and Canadian entities.

We expect our worldwide mix of earnings will mainly be taxed in jurisdictions with a top statutory tax rate of 25% in the near-term. The Company also expects to generate annual research tax credit benefits. However, the Tax Act’s modifications to the taxation of foreign profits and changes to deductibility of U.S. operational expenses will have an ongoing impact to the tax estimates in our financial statements and may not be beneficial. As a result, unless the Tax Act is modified or repealed, we expect our consolidated effective tax rate to be in the 25% to 35% range over the next several years, absent any other significant discrete items. We continue to assess our business model and its impact in various tax jurisdictions.

LIQUIDITY AND CAPITAL RESOURCES
 December 31, 2020December 31, 2019
 (in thousands)
Cash and cash equivalents$309,407 $59,173 
    At December 31, 2020, we held cash and cash equivalents of $309.4 million and had working capital of $421.6 million. At December 31, 2019, we held cash and cash equivalents of $59.2 million and had working capital of $144.4 million. Cash, and cash equivalents increased by $250.2 million during 2020. The increase in cash and cash equivalents from the prior year is primarily attributable to the net proceeds of $217.6 million we received from the issuance of Notes in the second quarter 2020, net cash provided by operating activities of $49.9 million, and proceeds from the issuance of common stock of $20.4 million. These increases were partially offset by the purchases of property, plant and equipment of $17.9 million and dividend payments of $16.5 million.

    We have funded our operations to date primarily through cash generated from operations and the issuance of equity securities (in conjunction with an initial public offering in 2000, subsequent option exercises, and our follow-on public offering in 2008) and debt securities (in conjunction with the Notes offering). Our cash reserves are held directly or indirectly in a variety of short-term, interest-bearing instruments, including non-government sponsored debt securities. We do not have any investments in asset-backed commercial paper, auction rate securities, or mortgage backed or sub-prime style investments.

    Cash provided by operations was $49.9 million for 2020, as compared with cash provided by operations of $13.5 million for 2019. This increase was primarily attributable to higher net income generated in the year ended December 31, 2020 as compared to the year ended December 31, 2019. Cash used in investing activities was $17.9 million for 2020, a decrease from $20.6 million for 2019. Currently, exclusive of changes in available-for-sale securities, we expect cash used in investing activities to be primarily for purchases of property and equipment, and continued strategic investments or acquisitions.

    Cash provided by financing activities increased to $219.2 million for 2020, from cash used in financing activities of $10.5 million for 2019. This change in cash flows from financing activities was primarily attributable to the net proceeds of $217.6 million we received from the issuance of debt securities (in conjunction with the Notes offering).

68
    Our future capital requirements will depend on a number of factors, including our success in developing and expanding markets for our products, payments under possible future strategic arrangements, continued progress of our research and development of potential products, the timing and outcome of regulatory approvals, the need to acquire licenses to new technologies, costs associated with strategic acquisitions including acquisition and integration costs and assumed liabilities, the status of competitive products and potential costs associated with both protecting and defending our intellectual property. Additionally, actions taken as a result of the ongoing internal evaluation of our business could result in expenditures not currently contemplated in our estimates for 2021.

    Our short-term projects that are expected to require significant capital to complete include (i) our current in-process research and development of the next generation VERIGENE System, VERIGENE II, on which we began clinical trials in May 2018 and (ii) the next generation xMAP System, xMAP INTELLIFLEX. The Company is currently targeting the commercial launch of the VERIGENE II System in 2021 and believes the xMAP INTELLIFLEX will launch commercially in the first half of 2021. In addition, we closed on the purchase of the building in Northbrook, Illinois in the first quarter of 2021 for approximately $8.0 million. We believe that our existing cash and cash equivalents are sufficient to fund our operating expenses, capital equipment requirements and other expected liquidity requirements for the coming twelve months. Factors that could affect our capital requirements, in addition to those listed above, include, without limitation: (i) continued collections of accounts receivable consistent with our historical experience; (ii) our ability to manage our inventory levels consistent with past practices; (iii) volatility in our key partners’ consumable purchasing patterns; (iv) execution of partnership agreements that include significant up-front license fees; (v) execution of our stock repurchase and dividend programs from time to time and (vi) executing strategic investment or acquisition agreements requiring significant cash consideration. See also the “Safe Harbor Cautionary Statement” and risk factors of this report.

    In February 2017, the Board of Directors initiated a cash dividend program to pay a regular quarterly cash dividend. The timing and amount of future dividends and stock repurchases will vary based on a number of factors, including future capital requirements for strategic transactions, the availability of financing on acceptable terms, debt service requirements, changes to applicable tax laws or corporate laws, changes to our business model and periodic determination by our Board of Directors that cash dividends are in the best interests of stockholders and are in compliance with applicable laws and agreements of the Company. On February 8, 2021, we announced that our Board declared a quarterly cash dividend of $0.09 per share of common stock to be paid to shareholders of record as of the close of business on March 25, 2021 with a payment date of April 15, 2021.

    We hold cash and cash equivalents at various foreign subsidiaries. As a result of reductions to the U.S. taxation of dividends from foreign subsidiaries under the Tax Act and continued profitability of our Canadian subsidiary, in future years we may continue to repatriate earnings of our Canadian subsidiary. The cash and cash equivalents held by this subsidiary may be more readily available to meet domestic cash requirements in the next year, but will continue to be subject to foreign withholding tax that would be incurred upon repatriation. We anticipate that cash and cash equivalents held by all other foreign subsidiaries will continue to be permanently reinvested and may not be readily available to meet domestic cash requirements.

We believe that our cash provided by operations and our cash and cash equivalents will be sufficient to meet our anticipated capital needs for at least the next twelve months. However, any projections of future cash flows and capital requirements are subject to substantial uncertainty, including as a result of the risks, uncertainties and assumptions described in Item 1A “Risk Factors.” To the extent our capital resources are insufficient to meet future capital requirements, we will have to raise additional funds to continue the development and deployment of our technologies, or to supplement our position through strategic acquisitions. There can be no assurance that debt or equity funds will be available on favorable terms, if at all. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of those securities could result in dilution to our stockholders. Moreover, incurring debt financing could result in a substantial portion of our operating cash flow being dedicated to the payment of principal and interest on such indebtedness, could render us more vulnerable to competitive pressures and economic downturns and could impose restrictions on our operations. If adequate funds are not available, we may be required to curtail operations significantly or to obtain funds through entering into agreements on unattractive terms.
69
Contractual Obligations

    As of December 31, 2020, we had approximately $65.6 million in non-cancellable purchase obligations for the next 12 months. These obligations are included in our estimated cash usage during 2021. The following table reflects our total current non-cancellable obligations by period as of December 31, 2020 (in thousands):
 
Payment Due By Period
Contractual ObligationsTotalLess Than 1 Year1-3 Years3-5 YearsMore Than 5 Years
Long-term debt obligation, including interest$295,100 $7,800 $15,600 $271,700 $— 
Non-cancellable rental obligations21,376 7,206 10,047 4,123 — 
Non-cancellable purchase obligations (1)
68,103 65,560 2,353 190 — 
Minimum royalty commitments (2)
103 25 49 29 — 
Insurance premiums1,561 1,561 — — — 
Total (3)
$386,243 $82,152 $28,049 $276,042 $— 
(1) Purchase obligations predominantly relate to contractual arrangements in the form of purchase orders primarily as a result of normal inventory purchases or minimum payments due resulting when minimum purchase commitments are not met, as well as other operating commitments.
(2) Amounts represent minimum royalties payable on net sales of products incorporating licensed technology and subject to a minimum annual royalty payment.
(3) Due to the uncertainty with respect to the timing of future cash flows associated with Luminex’s unrecognized tax benefits at December 31, 2020, Luminex is unable to make reasonably reliable estimates of the timing of cash settlement with the respective taxing authority. Therefore,$3.7 million of unrecognized tax benefits have been excluded from the contractual obligations table above. See Note 11 to the Consolidated Financial Statements for a discussion on income taxes.

Inflation

    We do not believe that inflation has had a direct adverse effect on our operations to date. However, a substantial increase in product and manufacturing costs and personnel-related expenses could have an adverse impact on our results of operations in the event these expenses increase at a faster pace than we can increase our system, consumable and royalty revenue rates.

Recently Adopted Accounting Pronouncements

    See Note 18 to our Consolidated Financial Statements contained in Item 8 of this Annual Report.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

    Interest Rate Risk. Our interest income is sensitive to changes in the general level of domestic interest rates, particularly since our investments are in long-term instruments available-for-sale. A 50 basis point fluctuation from average investment returns at December 31, 2020 would yield a less than 0.5% variance in overall investment return, which would not have a material adverse effect on our financial condition.

    Foreign Currency Risk. Our international business is subject to risks, including, but not limited to: foreign exchange rate volatility, differing tax structures, unique economic conditions, other regulations and restrictions and changes in political climate. Accordingly, our future results could be materially and adversely impacted by changes in these and other factors.

70
    As of December 31, 2020, as a result of our foreign operations, we have costs, assets and liabilities that are denominated in foreign currencies, primarily Canadian dollars and to a lesser extent the Euro, Renminbi and Yen. For example, some fixed asset purchases and certain expenses are denominated in Canadian dollars while sales of products are primarily denominated in U.S. dollars. All transactions in our Netherlands and Japanese subsidiaries are denominated in Euros and Yen, respectively. All transactions, with the exception of our initial capital investment, in our Chinese subsidiary are denominated in Renminbi. As a consequence, movements in exchange rates could cause our foreign currency denominated expenses to fluctuate as a percentage of net revenue, affecting our profitability and cash flows. A significant majority of our revenues are denominated in U.S. dollars. The impact of foreign exchange on foreign denominated balances will vary in relation to changes between the U.S. dollar, Canadian dollar, Euro, Yen and Renminbi exchange rates. A 10% change in all of these exchange rates in relation to the U.S. dollar would result in a statement of comprehensive income impact of approximately $1.6 million on foreign currency denominated asset and liability balances as of December 31, 2020. As a result of our efforts to expand globally, in the future we will be exposed to additional foreign currency risk in multiple currencies. We regularly assess the market to determine if additional strategies are appropriate to mitigate future risks.

    In addition, the indirect effect of fluctuations in interest rates and foreign currency exchange rates could have a material adverse effect on our business financial condition and results of operations. For example, currency exchange rate fluctuations could affect international demand for our products. In addition, interest rate fluctuations could affect our customers’ buying patterns. Furthermore, interest rate and currency exchange rate fluctuations may broadly influence the United States and foreign economies resulting in a material adverse effect on our business, financial condition and results of operations. As a result, we cannot give any assurance as to the effect that future changes in foreign currency rates will have on our consolidated financial position, results of operations or cash flows. Our aggregate foreign currency transaction gain of $1,012,000 was included in determining our consolidated results for the year ended December 31, 2020.
71
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

Index to Consolidated Financial Statements
72
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

The Board of Directors and Stockholders of Luminex Corporation

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Luminex Corporation (the Company) as of December 31, 2020 and 2019, the related consolidated statement of comprehensive income, changes in stockholders’ equity and cash flows for each of the three years in the period ended December 31, 2020, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2020, in conformity with U.S. generally accepted accounting principles.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February 26, 2021 expressed an unqualified opinion thereon.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matters

The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

73
Revenues with variable considerations
Description of the matterAs described in Note 1 to the consolidated financial statements, revenues from product sales typically include variable consideration based on volume of sales during a designated time period. Revenue from customers is recorded based on a transaction price which includes estimates of variable consideration based on multiple data points including customer contractual tiered pricing, specific known market events and trends as well as historical and forecasted customer buying patterns which must be evaluated and updated as pricing terms and industry conditions change. For the year ended December 31, 2020, the Company recorded $417.4 million of product revenues which included such variable consideration.
Auditing the Company’s recognition of revenue related to variable consideration was complex due to the volume of transactions and incremental procedures performed to test the accuracy of the variable prices charged to customers and recorded as revenue. Each customer contract contains unique terms which must be evaluated to ensure the appropriate price is applied based on actual cumulative volume sales or forecasted sales levels to ensure the amount to be recognized in any given period is accurate.
How we addressed the matter in our auditWe obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the Company’s process to approve, review and execute pricing changes within the accounting system. For example, we tested controls over management’s monitoring and evaluation of the accuracy of pricing changes, including the appropriateness of the individuals authorizing and making the changes to pricing. We also tested the operating effectiveness of controls over the Company’s process to approve customer pricing and to ensure that the correct customer pricing based on contractual terms is utilized by the Company in determining variable consideration, including controls over management’s forecasting of sales volumes.
Our audit procedures over the Company’s estimates of variable consideration included, among others, reviewing contracts which included tiered pricing based on volume of sales and comparing such terms to historic sales and forecasted sales volumes to ensure pricing provided to the customer during the year was in line with the terms of the contract. We also analyzed credit memos to evaluate if there were any pricing adjustments and performed a look-back analysis to evaluate the historical accuracy of management’s sales volume forecasts. In addition, we performed correlation analyses between revenue, accounts receivable and cash to identify unusual or unexpected relationships.
Realizability of inventories
Description of the matterThe Company’s inventories totaled $123.1 million as of December 31, 2020, representing 15% of total assets. As explained in Note 1 of the consolidated financial statements, inventories are stated at the lower of cost or net realizable value, which includes considerations for inventory becoming obsolete or having quantities in inventory in excess of anticipated usage based upon the Company’s assumptions about future demand for products and other market conditions.
Auditing management’s estimate of inventory reserves involved subjective auditor judgment because management’s assessment of whether a write down is required and the measurement of any excess cost over net realizable value is judgmental and is sensitive to changes in assumptions, including management’s assumptions over future product demand and product expiration dates which may be impacted by, among other things, future market and economic conditions.
How we addressed the matter in our auditWe obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the Company’s inventory process and the related calculation of inventory reserves, including management’s assessment of the assumptions and data underlying the excess and obsolete inventory valuation such as forecasted usage of inventories.
Our audit procedures included, among others, evaluating the assumptions used by the Company to estimate future product demand, including assumptions surrounding forecasted sales or usage and testing the completeness and accuracy of the underlying data used in its calculations including product expiration or end of life dates, quantities on hand and inventory pricing. For example, we compared the estimated usage rates with the actual usage results of prior periods as well as management’s consideration of expected timing of estimated usage rates as compared to product expiration dates, and we performed a gross margin analysis by product type.
/s/ Ernst & Young LLP
We have served as the Company’s auditor since 1998.
Austin, Texas
February 26, 2021
74
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
 
The Board of Directors and Stockholders of Luminex Corporation

Opinion on Internal Control over Financial Reporting

We have audited Luminex Corporation’s internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control— Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Luminex Corporation (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2020, based on the COSO criteria.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2020 and 2019, the related consolidated statements of comprehensive income, changes in stockholders’ equity and cash flows for each of the three years in the period ended December 31, 2020, and the related notes and our report dated February 26, 2021 expressed an unqualified opinion thereon.

Basis for Opinion

The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.

Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

Definition and Limitations of Internal Control Over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ Ernst & Young LLP
Austin, Texas
February 26, 2021
75
LUMINEX CORPORATION
CONSOLIDATED BALANCE SHEETS
(in thousands, except share amounts)
As of December 31,
 20202019
ASSETS 
Current assets:  
Cash and cash equivalents$309,407 $59,173 
Accounts receivable, net66,963 55,815 
Inventories, net123,134 77,084 
Prepaids and other9,527 10,398 
Total current assets509,031 202,470 
Property and equipment, net64,146 65,515 
Intangible assets, net78,796 90,336 
Deferred income taxes21,077 27,702 
Goodwill118,145 118,145 
Right-of-use assets17,768 20,439 
Other16,500 19,122 
Total assets$825,463 $543,729 
LIABILITIES AND STOCKHOLDERS’ EQUITY
  
Current liabilities:  
Accounts payable$21,049 $17,983 
Accrued liabilities56,365 31,872 
Deferred revenue - current portion10,047 8,214 
Total current liabilities87,461 58,069 
Deferred revenue1,658 1,633 
Lease liabilities13,366 17,182 
Long-term debt203,136 — 
Other long-term liabilities2,131 1,985 
Total liabilities307,752 78,869 
Stockholders’ equity:  
Common stock, $.001 par value, 200,000,000 shares authorized; issued and outstanding: 45,682,687 shares at December 31, 2020; 44,325,369 shares at December 31, 201945 44 
Preferred stock, $.001 par value, 5,000,000 shares authorized; no shares issued and outstanding— — 
Additional paid-in capital434,021 380,304 
Accumulated other comprehensive loss(142)(1,380)
Retained earnings83,787 85,892 
Total stockholders’ equity517,711 464,860 
Total liabilities and stockholders’ equity$825,463 $543,729 
See the accompanying notes which are an integral part of these
Consolidated Financial Statements.
76
LUMINEX CORPORATION
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(in thousands, except per share amounts)
 Year Ended December 31,
 202020192018
 
Revenue$417,396 $334,638 $315,818 
Cost of revenue169,544 151,899 120,327 
Gross profit247,852 182,739 195,491 
Operating expenses:  
Research and development53,651 56,228 47,164 
Selling, general and administrative140,216 127,183 111,816 
Amortization of acquired intangible assets11,542 11,407 8,665 
Total operating expenses205,409 194,818 167,645 
Income (loss) from operations42,443 (12,079)27,846 
Interest and other expense, net(11,912)3,100 465 
Loss from equity method investment(1,591)(523)— 
Income (loss) before income taxes28,940 (9,502)28,311 
Income tax (expense) benefit(13,770)5,664 (9,803)
Net income (loss)$15,170 $(3,838)$18,508 
Net income (loss) attributable to common stockholders
Basic$14,873 $(3,773)$18,196 
Diluted14,872 (3,775)18,197 
Net income (loss) per share attributable to common stockholders
Basic$0.33 $(0.09)$0.42 
Diluted$0.32 $(0.09)$0.41 
Weighted-average shares used in computing net income (loss) per share
Basic45,102 44,148 43,727 
Diluted45,820 44,148 44,291 
Dividends declared per share$0.37 $0.30 $0.24 
Other comprehensive income (loss):
Foreign currency translation adjustments1,238 (253)(502)
Other comprehensive income (loss)1,238 (253)(502)
Comprehensive income (loss)$16,408 $(4,091)$18,006 
See the accompanying notes which are an integral part of these
Consolidated Financial Statements.
77
LUMINEX CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
Year Ended December 31,
202020192018
 
Cash flows from operating activities:  
Net income (loss)$15,170 $(3,838)$18,508 
Adjustments to reconcile net income (loss) to net cash provided by operating activities: 
Depreciation and amortization30,483 28,529 23,674 
Amortization of debt issuance costs6,533 — — 
Stock-based compensation14,852 13,198 12,226 
Deferred income tax (benefit) expense6,593 (7,444)8,159 
Loss on sale or disposal of assets851 641 730 
Loss (earnings) on equity method investment (1)
1,592 (2,719)— 
Other2,086 (329)(1,369)
Changes in operating assets and liabilities:
Accounts receivable, net(11,139)(2,440)(1,569)
Inventories, net(45,973)(13,559)(6,827)
Other assets4,125 4,789 (3,319)
Accounts payable3,184 3,370 4 
Accrued liabilities19,686 (5,630)103 
Deferred revenue1,888 (1,031)579 
Net cash provided by operating activities49,931 13,537 50,899 
Cash flows from investing activities:  
Purchase of property and equipment(17,910)(16,249)(21,292)
Business acquisition consideration, net of cash acquired— — (65,381)
Proceeds from net working capital adjustments related to business acquisition— 1,916 — 
Issuance of note receivable— — (1,000)
Purchase of equity affiliate— (6,980)— 
Proceeds from (payments to) cost method investment— 734 (1,782)
Proceeds from sale of assets and investments— — 2 
Acquired technology rights22 (40)(4,000)
Net cash used in investing activities(17,888)(20,619)(93,453)
Cash flows from financing activities:  
Proceeds from issuance of convertible note, net of issuance costs252,247 — — 
Purchase of convertible notes bond hedge(54,626)— — 
Proceeds from issuance of warrants19,968 — — 
Proceeds from issuance of common stock20,435 3,750 4,570 
Shares surrendered for tax withholding(2,373)(2,095)(2,312)
Dividends paid(16,485)(12,153)(10,654)
Net cash provided by (used in) financing activities219,166 (10,498)(8,396)
Effect of foreign currency exchange rate on cash(975)312 279 
Change in cash and cash equivalents250,234 (17,268)(50,671)
Cash and cash equivalents, beginning of period59,173 76,441 127,112 
Cash and cash equivalents, end of period$309,407 $59,173 $76,441 
(1) The (earnings) loss on equity method affiliate is shown net of the $3.2 million non-cash gain recognized in the fourth quarter 2019, resulting from the remeasurement of our equity method investment. See Note 2 - Investments and Other Assets for further details.
See the accompanying notes which are an integral part of these
Consolidated Financial Statements.
78
LUMINEX CORPORATION
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
(in thousands, except share data)
 Common Stock    
 Number of SharesAmountAdditional Paid-In CapitalAccumulated Other Comprehensive (Loss)Retained Earnings
Total Stockholders’ Equity
Balance at December 31, 201743,404,493 $43 $350,834 $(625)$87,655 $437,907 
Exercise of stock options157,754 — 2,814 — — 2,814 
Issuances of restricted stock, net of shares withheld for taxes253,152 1 (2,312)— — (2,311)
Stock compensation— — 12,187 — — 12,187 
Issuance of common shares under ESPP83,811 — 1,740 — — 1,740 
Net income— — — — 18,508 18,508 
Foreign currency translation adjustments— — — (502)— (502)
Dividends— — 86 — (10,796)(10,710)
Other— — — — 8,023 8,023 
Balance at December 31, 201843,899,210 $44 $365,349 $(1,127)$103,390 $467,656 
Exercise of stock options95,097 — 1,698 — — 1,698 
Issuances of restricted stock, net of shares withheld for taxes217,620 — (2,095)— — (2,095)
Stock compensation— — 13,198 — — 13,198 
Issuance of common shares under ESPP113,442 — 2,030 — — 2,030 
Net income— — — — (3,838)(3,838)
Foreign currency translation adjustments— — — (253)— (253)
Dividends— — 124 — (13,660)(13,536)
Balance at December 31, 201944,325,369 $44 $380,304 $(1,380)$85,892 $464,860 
Exercise of stock options990,071 1 17,988 — — 17,989 
Issuances of restricted stock, net of shares withheld for taxes240,100 — (2,373)— — (2,373)
Stock compensation— — 14,852 — — 14,852 
Issuance of common shares under ESPP127,147 — 2,391 — — 2,391 
Net income— — — — 15,170 15,170 
Foreign currency translation adjustments— — — 1,238 — 1,238 
Dividends— — 184 — (17,275)(17,091)
Equity component of convertible notes, net of issuance costs— — 41,950 — — 41,950 
Purchases of convertible note hedge— — (41,243)— — (41,243)
Issuance of warrants— — 19,968 — — 19,968 
Balance at December 31, 202045,682,687 $45 $434,021 $(142)$83,787 $517,711 
See the accompanying notes which are an integral part of these
Consolidated Financial Statements.
79
LUMINEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 — DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Description of Business

    Luminex Corporation, the “Company” or “Luminex,” develops, manufactures and sells proprietary biological testing technologies and products with applications throughout the life sciences industries, including diagnostics, pharmaceutical and research. These industries depend on a broad range of tests, called assays, to perform diagnostic testing and conduct life science research. The Company established a position in several segments of the life sciences industries by developing and delivering products that satisfy a variety of customer needs in specific market segments, including multiplexing, accuracy, precision, sensitivity, specificity, reduction of labor and ability to test for proteins and nucleic acids. These needs are addressed by the Company’s proprietary technologies.

    Multiplexing, the foundation of the Company, allows the end user in a laboratory to generate multiple laboratory results from a single sample with a single assay. This is important because the Company’s end user customers, which include laboratory professionals performing discovery and research and clinical laboratories performing tests on patients as ordered by physicians and other laboratories, have a fundamental need to perform high quality testing as efficiently as possible. Until the availability of multiplexing technology, the laboratory professional had to perform one assay at a time in a sequential manner, and if additional testing was required on a sample, a second assay would be performed to generate the second result, and so on until all the necessary tests were performed.

    The Company primarily serves the life sciences industries by marketing products, including our specific testing equipment and assays, to various types of testing laboratories. As of December 31, 2020, the Company had 82 strategic partners, 54 of which have released commercialized reagent-based products utilizing the Company’s technology. Luminex and these partners have sold approximately 17,900 xMAP-based instruments in laboratories worldwide as of December 31, 2020, some of which may be retired or otherwise not in use. The Company’s remaining partners are in various stages of development and commercialization of products incorporating the Company’s technology.

    A primary focus for the Company’s growth is the development and sale of molecular diagnostic assays utilizing the Company’s proprietary MultiCode and VERIGENE technologies for use on the Company’s installed base of systems. The Company utilizes a direct sales model for sales of these products, which is intended to take advantage of the Company’s increasing installed base of instruments. Luminex’s assays are primarily focused on multiplexed applications for the human molecular clinical diagnostics market. Luminex’s assays are currently focused on three segments of the molecular diagnostic testing market: infectious disease, personalized medicine and human genetics.

Principles of Consolidation

    The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany transactions and balances have been eliminated upon consolidation.

Use of Estimates

    The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual amounts and results could differ from those estimates, and such differences could be material to the financial statements.

Cash and Cash Equivalents

    Cash and cash equivalents consist of cash deposits and highly liquid investments with original maturities of three months or less when purchased.

Investments

    The Company determines the appropriate classification of its investments in equity securities at the time of purchase and reevaluates such determinations at each balance sheet date.

80
Fair Value of Financial Instruments

    The fair values of financial instruments are determined by obtaining non-binding market prices from the Company’s third-party portfolio managers on the last day of the quarter, whose sources may use quoted prices in active markets for identical assets or inputs other than quoted prices that are observable either directly or indirectly in determining fair value. The Company’s financial instruments include cash and cash equivalents, short-term investments, accounts receivable, equity-method investments, long-term investments, accounts payable and accrued liabilities. The fair values of these financial instruments were not materially different from their carrying or contract values at December 31, 2020 and 2019. See Note 6 for further details concerning fair value measurements.

Supplemental Cash Flow Statement Information (in thousands)
Year Ended December 31,
 202020192018
Cash paid during the period for taxes$2,141 $1,206 $2,214 
Cash paid during the period for interest and penalties3,969 29 17 
Effect of acquisitions:
Fair value of tangible assets acquired— 2,657 13,262 
Liabilities assumed— (1,915)(5,082)
Cost in excess of fair value of assets acquired— 18 32,647 
Acquired identifiable intangible assets— 609 26,797 
Deferred tax liabilities, net— 731 (4,433)
In-process research and development— (4,016)6,703 
Total purchase price — (1,916)69,894 
Less cash and cash equivalents acquired— — 4,513 
Net cash paid for business acquisition$— $(1,916)$65,381 

Concentration of Credit Risk

    Financial instruments which potentially subject the Company to concentrations of credit risk consist of short-term and long-term investments and trade receivables. The Company provides credit, in the normal course of business, to a number of its customers geographically dispersed primarily throughout the U.S. The Company attempts to limit its credit risk by performing ongoing credit evaluations of its customers and maintaining adequate allowances for potential credit losses, but the Company does not require collateral.

    One customer accounted for 10%, 12% and 14% of our total revenues in 2020, 2019 and 2018, respectively. Another customer accounted for 4%, 5% and 15% of our total revenues in 2020, 2019 and 2018, respectively. No other customer accounted for more than 10% of our total revenues in 2020, 2019 or 2018.

81
Inventories

    Inventories, consisting primarily of raw materials and purchased components, are stated at the lower of cost or net realizable value, with cost determined according to the standard cost method, which approximates the first-in, first-out method. Net realizable value is defined as the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. As a developer and manufacturer of high technology medical equipment, the Company may be exposed to a number of economic and industry factors that could result in portions of inventory becoming either obsolete or in excess of anticipated usage. These factors include, but are not limited to, technological changes in the Company’s markets, ability to meet changing customer requirements, competitive pressures on products and prices, and reliability and replacement of and the availability of key components from suppliers. The Company’s policy is to establish inventory reserves when conditions exist that suggest that inventory may be in excess of anticipated demand or is obsolete based upon the Company’s assumptions about future demand for products and market conditions. The Company regularly evaluates the ability to realize the value of inventory based on a combination of factors including the following: historical usage rates, forecasted sales or usage, product expiration or end of life dates, estimated current and future market values and new product introductions. Assumptions used in determining the Company’s estimates of future product demand may prove to be incorrect, in which case the provision required for excess and obsolete inventory would have to be adjusted. If inventory is determined to be above the lower of cost or net realizable value, excess or obsolete, the Company would be required to record impairment charges within cost of goods sold at the time of such determination. Although considerable effort is made to ensure the accuracy of forecasts of future product demand, any significant unanticipated changes in demand or expected usage could have a significant negative impact on the value of inventory and the Company’s operating results. When recorded, reserves are intended to reduce the carrying value of inventory to its net realizable value.

Property and Equipment

    Property and equipment are carried at cost less accumulated amounts for amortization and depreciation. Property and equipment are typically amortized or depreciated on a straight-line basis over the useful lives of the assets, which typically range from two to seven years. Leasehold improvements and equipment under capital leases are amortized on a straight-line basis over the shorter of the remaining term of the lease or the estimated useful life of the improvements and equipment. The Company classifies the carrying value of Luminex’s xMAP, ARIES and VERIGENE Systems placed within the reagent rental program and the instruments on loan to customers in property and equipment as “Assets on loan/rental.”

Leases

With the adoption of the new lease guidance effective January 1, 2019, the Company determines whether an agreement represents a lease and at commencement we evaluate each lease agreement to determine whether the lease is an operating or financing lease. The Company recorded an operating lease right-of-use asset and an operating lease liability on its balance sheet. Right-of-use lease assets represent the Company’s right to use the underlying asset for the lease term and the lease obligation represents the Company’s commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. The right-of-use lease asset includes any lease payments made prior to commencement and excludes any lease incentives. The lease term may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or expectations regarding the terms. Variable lease costs such as common area costs and property taxes are expensed as incurred. For all lease agreements we combine lease and non-lease components. Leases with an initial term of twelve months or less are not recorded on the balance sheet.

82
Goodwill and Other Intangible Assets

    Goodwill represents the excess of the cost over the fair value of the assets of the acquired business. In accordance with Accounting Standards Codification (ASC) 350 “Goodwill and Other” (ASC 350), goodwill is reviewed for impairment at least annually at the beginning of the fourth quarter, or more frequently if impairment indicators arise, tested at our sole reporting unit level. Events or circumstances that could trigger an impairment test include, but are not limited to, a significant adverse change in the business climate, significant changes in our use of the acquired assets, significant negative industry or economic trends, significant under-performance relative to operating performance indicators and significant changes in competition. The Company determined that no triggering events occurred during the year ended December 31, 2020. In 2020 and 2019, the Company estimated the fair value of the reporting unit using a fair-value-based approach based on the market capitalization. Determining the fair value of goodwill is subjective in nature and often involves the use of estimates and assumptions including, without limitation, use of estimates of future prices and volumes for the Company’s products, capital needs, economic trends and other factors which are inherently difficult to forecast. The Company’s annual test did not result in an impairment charge in 2020, as the estimated fair value of the reporting unit continued to exceed the carrying value by a significant enough amount such that any reasonably likely change in the assumptions used in the analysis would not cause the carrying value to exceed the estimated fair value for the reporting unit. No goodwill impairments were recorded in 2020, 2019 or 2018.

    Intangible assets are amortized on a straight-line basis over their respective estimated useful lives ranging from 9 to 15 years. Any in-process research and development will be an indefinite-lived intangible asset until completion or abandonment, at which point it will be accounted for as a finite-lived intangible asset or written off if abandoned.

Impairment of Long-Lived Assets

    Long-lived assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that their net book value may not be recoverable. When such factors and circumstances exist, the Company compares the projected undiscounted future cash flows associated with the related asset or group of assets over their estimated useful lives against their respective carrying amounts. Impairment, if any, is based on the excess of the carrying amount over the fair value of those assets and is recorded in the period in which the determination was made.

Revenue Recognition, Receivables and Allowance for Doubtful Accounts

    Performance Obligations: Revenue is generated primarily from the sale of the Company’s products and related services, which are primarily support and maintenance services on the Company’s systems. The Company recognizes revenue when the customer obtains control of promised products or services, in an amount that reflects the consideration which the Company expects to receive in exchange for these products or services. To determine revenue recognition for arrangements, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract, identifies the performance obligations and assesses whether each promised good or service is distinct. The Company allocates the total transaction price to each performance obligation in an amount based on the estimated relative standalone selling prices of the promised goods or service underlying each performance obligation and recognizes as revenue when such performance obligation is satisfied. Revenue recognition typically occurs upon shipment or delivery to the customer depending upon the shipping terms. We treat shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost. Our customers do not typically have any contractual rights of return outside of our warranty provisions. The Company has allowed few returns to date and believes that returns of its products will be minimal in the future.

    Royalties:  For arrangements that include sales-based royalties, including minimum payments, the Company recognizes revenue at the later of: (i) when the related sales occur, or (ii) when the performance obligation, to which some or all of the royalty has been allocated, has been satisfied. Royalty payments are typically received when our strategic partners report the end-user sales to the Company.

83
    Reagent Rentals: The Company provides systems and certain other hardware to customers through reagent rental agreements, under which the customers commit to purchasing minimum quantities of assays at a stated price over a defined contract term, which is normally two to three years. Instead of rental payments, the Company recovers the cost of providing the system and other hardware in the amount charged for assays. Revenue is recognized over the defined contract term as assays are shipped. The depreciation costs associated with the system and other hardware are charged to cost of sales on a straight-line basis over the estimated life of the system. The costs to maintain these instruments in the field are charged to cost of sales as incurred. Under the guidance, the Company reclassified the portion of reagent rental revenue associated with the recovery of the cost of providing the system and other hardware in reagent rental agreements from assay revenue to system revenue.

    Warranties: The Company provides a limited, assurance-type warranty, typically for twelve months from installation for the systems sold to end customers and fifteen months for the systems sold to partners. The Company accrues for the estimated cost of initial product warranties at the time revenue is recognized. While the Company engages in product quality programs and processes, the Company’s warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. While the Company believes that adequate reserve has been made in the consolidated financial statements for product warranties, should actual product failure rates, material usage or service delivery costs differ from the Company’s estimates, revisions to the estimated warranty liability would be required. Warranty expenses are evaluated and adjusted periodically.

    License Revenues: The Company enters into out-licensing agreements, under which it licenses certain rights to its technology to third parties. These licenses are typically not distinct, as the customer cannot benefit from the license on its own, and do not have significant standalone functionality, but represent single performance obligations together with the sales of our consumables, systems and assays. The terms of these arrangements typically include payment to the Company of non-refundable, up-front license fees and can extend up to twenty years. Each of these payments results in license revenues which are recognized ratably over time and are included in other revenues, except for revenues from royalties on net sales of licensed products, which are classified as royalty revenues. Deferred revenues related to these out-licensing agreements are shown in contract liabilities in Note 18, “Revenue Recognition”.

    Service Agreements: Revenue from extended service agreements is deferred when payment is received in advance of the performance obligation being satisfied or completed. Luminex provides an integrated service of maintenance and related activities for equipment sold to customers, where the nature of the overall promise is to provide a stand-ready service. As such, the performance obligation is recognized as a series of distinct service periods and the service revenue is recognized ratably over the term of each agreement. The extended service agreements typically range from one to four years and payment is typically received up-front.

    Reserves for Variable Consideration: Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from discounts and any other allowances that are offered within contracts between the Company and its customers relating to the Company’s sales of its products. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable. Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as the Company’s historical experience, current contractual requirements, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of each contract. The amount of variable consideration which is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company will adjust these estimates, which would affect net product revenue and earnings in the period when such variances become known.

84
    Receivables and Allowance for Doubtful Accounts: We recognize receivables when we have an unconditional right to payment, which represents the amount we expect to collect in a transaction and is most often equal to the transaction price in the contract. The Company adopted the new credit loss standard effective January 1, 2020. The primary impact for the Company was the timing of recording expected credit losses on its trade receivables. The Company’s allowance for doubtful accounts is based upon its expected credit losses, which is based upon its historical loss experience. Management prepared an analysis of partner versus non-partner credit loss experience and noted that its loss experience between partners and non-partners was very comparable. These receivables have been pooled together, as similar risk characteristics exist between them. On the rare occasion that interest is charged on trade receivables, it is recognized when received and there are no related fees and costs. Receivable balances are written off to the allowance for doubtful accounts when, in the judgment of management, they are considered uncollectible. The Company's credit losses have historically been within the Company’s expectations, but there can be no assurance that the Company will continue to experience the same level of credit losses that it has in the past. A significant change in the liquidity or financial position of any one of the Company’s significant customers, or a deterioration in the economic environment in general, could have a material adverse impact on the collectability of the Company’s accounts receivable and its future operating results, including a reduction in future revenues and additional allowances for doubtful accounts.

Product-Related Expenses

    The Company provides for the estimated cost of initial product warranties at the time revenue is recognized. While the Company engages in product quality programs and processes, the Company’s warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. Should actual product failure rates, material usage or service delivery costs differ from the Company’s estimates, revisions to the estimated warranty liability would be required. Shipping and handling costs associated with product sales are included in cost of sales. Advertising costs are charged to operations as incurred. The Company does not have any direct-response advertising.  Advertising expenses, which include trade shows and conventions, were approximately $1.4 million, $3.5 million and $2.8 million for 2020, 2019 and 2018, respectively, and were included in selling, general and administrative expense in the Consolidated Statements of Comprehensive Income.

Research and Development Costs

    Research and development costs are expensed in the period incurred. Nonrefundable advance payments for research and development activities for materials, equipment, facilities and purchased intangible assets that have an alternative future use are deferred and capitalized. In addition, the Company capitalizes certain internally developed products used for evaluation during development projects that also have alternative future uses. These internally developed assets are generally depreciated on a straight-line basis over the useful life of the assets, which range from one to five years.

Foreign Currency Translation

    The financial statements of the Company’s foreign subsidiaries are translated in accordance with ASC 830, “Foreign Currency Matters.” The reporting currency for the Company is the U.S. dollar. With the exception of its Canadian subsidiary, whose functional currency is the U.S. dollar, the functional currency of the Company’s foreign subsidiaries is their local currency. Accordingly, assets and liabilities of these subsidiaries are translated at the exchange rate in effect at each balance sheet date. Before translation, the Company re-measures foreign currency denominated assets and liabilities, including inter-company accounts receivable and payable, into the functional currency of the respective entity, resulting in unrealized gains or losses recorded in selling, general and administrative expenses in the Consolidated Statement of Comprehensive Income. Revenues and expenses are translated using average exchange rates during the respective period. Foreign currency translation adjustments are accumulated as a component of other comprehensive income as a separate component of stockholders’ equity. Gains and losses arising from transactions denominated in foreign currencies are included in selling, general and administrative expenses in the Consolidated Statement of Comprehensive Income and to date have not been material.

Incentive Compensation

    Management incentive plans are tied to various financial and non-financial performance metrics. Bonus accruals made throughout the year related to the various incentive plans are based on management’s best estimate of the achievement of the specific metrics. Adjustments to the accruals are made on a quarterly basis as forecasts of performance are updated. At year-end, the accruals are adjusted to reflect the actual results achieved.

85
Income Taxes

    The Company accounts for income taxes under the asset and liability method.  Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.  Deferred tax balances are adjusted to reflect tax rates based on currently enacted tax laws, which will be in effect in the years in which the temporary differences are expected to reverse.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period of the enactment date.  A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets unless it is more likely than not that those assets will be realized.

    The Company accounts for uncertain tax positions in accordance with ASC 740, “Income Taxes”, which clarifies the accounting for uncertainty in tax positions. These provisions require recognition of the impact of a tax position in the Company’s financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense.

Earnings Per Share

    Basic net income per share is computed by dividing the net income for the period by the weighted average number of common shares outstanding during the period. Diluted net income per share is computed by dividing the net income for the period by the weighted average number of common shares and potential common shares from outstanding stock options, restricted stock units (RSUs) and contingently issuable shares resulting from an award subject to performance or market conditions determined by applying the treasury stock method. In periods with a net loss, potentially dilutive securities composed of incremental common shares issuable upon the exercise of stock options and warrants, and common shares issuable on conversion of preferred stock, would be excluded from historical diluted loss per share because of their anti-dilutive effect.

Stock-Based Compensation

    The Company accounts for stock-based employee compensation plans under the fair value recognition and measurement provisions of ASC 718 “Stock Compensation” (ASC 718). ASC 718 requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based payments including stock options, restricted stock units and shares issued under the Company’s employee stock purchase plan. Pursuant to ASC 718, stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as expense over the requisite service period.

NOTE 2 — INVESTMENTS AND OTHER ASSETS

    Marketable Securities

    The Company determines the appropriate classification of any investments in debt and equity securities at the time of purchase and re-evaluates such determinations at each balance sheet date.

    Available-for-sale securities consisted of the following as of December 31, 2020 (in thousands):
 Amortized CostGains in Accumulated Other Comprehensive IncomeLosses in Accumulated Other Comprehensive IncomeEstimated Fair Value
Current:    
Money Market funds$707 $— $— $707 
Total current securities707 — — 707 
Noncurrent:    
Total noncurrent securities— — — — 
Total available-for-sale securities$707 $— $— $707 
86
    Available-for-sale securities consisted of the following as of December 31, 2019 (in thousands):
 Amortized CostGains in Accumulated Other Comprehensive IncomeLosses in Accumulated Other Comprehensive IncomeEstimated Fair Value
Current:    
Money Market funds$707 $— $— $707 
Total current securities707 — — 707 
Noncurrent:    
Total noncurrent securities— — — — 
Total available-for-sale securities$707 $— $— $707 

    There were no proceeds from the sales of available-for-sale securities for the years ended December 31, 2020 and December 31, 2019. Realized gains and losses on sales of investments are determined using the specific identification method and are included in other income (expense) in the Consolidated Statement of Comprehensive Income. There were no available-for-sale debt securities as of December 31, 2020 or December 31, 2019.

    Non-Marketable Securities and Other-Than-Temporary Impairment

    During the year ended December 31, 2018, the Company made a $1.8 million investment in Combinati, a private company. Subsequently, on October 1, 2019, the Company made an additional $7.0 million investment in Combinati, bringing the Company's ownership to approximately 28.4% of the voting interest of Combinati. The Company does not have majority control of the entity in which the investment was made, but has the ability to exercise significant influence over operating and financial policies due to its larger ownership percentage and its seat on the Board of Directors. The Company does not have unilateral decision making power, and therefore will not consolidate the investee; therefore, the Company accounts for this investment using the equity method. In the fourth quarter of 2019, we remeasured the existing, minority interest investment based on the fair value prior to the additional investment and recorded a gain of approximately $3.2 million in Other income, net in the Consolidated Statements of Comprehensive Income. The minority interest investment in Combinati is classified in equity method investments to distinguish it from other minority interest investments that take the fair value alternative. The Company's proportionate share of income or loss of approximately 28.4% is recorded in other income (expense), net in the Consolidated Statement of Comprehensive Income. This non-marketable equity investment is recorded at cost minus impairment, if any, plus or minus changes resulting from qualifying observable price changes. The Company periodically reviews this equity investment for other-than-temporary declines in fair value based on the specific identification method and writes down the investment to its fair value when it determines that an other-than-temporary decline has occurred.

    As of December 31, 2020, the carrying value of the Company’s total investment in Combinati was $9.9 million, which exceeded the Company’s share of Combinati’s net assets by $8.1 million and is not amortized. For the year ended December 31, 2020, the Company recorded the allocable share of Combinati’s net income in its Consolidated Statement of Comprehensive Income and as an adjustment to the invested balance.

    In August 2018, the Company exercised its purchase option on a second private company and acquired 100% of its capital stock in a non-cash transaction involving (i) a prior investment of $2.0 million being applied to the purchase option, (ii) the forgiveness and application of a $2.4 million note and related interest receivable to the purchase option and (iii) a tax impact of $0.1 million. This acquisition was accounted for as an asset acquisition rather than a business combination, as substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset, a next generation technology. The Company recorded the $4.3 million asset acquisition as a defensive, in-process research and development (IP R&D) intangible asset. There were no gains or losses recognized as part of this transaction.

    The Company owned a minority interest in another private company based in the U.S. through its initial investment of $1.0 million in the third quarter of 2012. We were informed that this private company will be dissolving and ceasing operations in the first quarter of 2020. We received cash representing the majority of our investment in the fourth quarter of 2019 and recorded an impairment of $205,000 in Other income, net in the Consolidated Statements of Comprehensive Income during 2019 based upon these circumstances. We received the final cash payment for the remainder of this minority interest in the first quarter of 2020, recorded in cash flows from investing activities in the Consolidated Statements of Cash Flows.

87
    These minority interest investments do not have readily determinable fair values. Therefore, the Company has elected the measurement alternative for its minority interests and the investments are recorded at cost, less any impairment, including changes resulting from observable price changes. The Company regularly evaluates the carrying value of its investment for impairment and whether any events or circumstances are identified that would significantly harm the fair value of the investment. The primary indicators the Company utilizes to identify these events and circumstances are the investee’s ability to remain in business, such as the investee’s liquidity and rate of cash use, and the investee’s ability to secure additional funding and the value of that additional funding. In the event a decline in fair value is less than the investment’s carrying value, the Company will record an impairment charge in Other income, net in the Consolidated Statements of Comprehensive Income. Other than the $205,000 impairment in 2019 discussed above, the Company has not recorded any impairment charges related to these non-marketable investments.

    As the inputs utilized for the Company’s periodic impairment assessment are not based on observable market data, the determination of fair value of its investments is classified within Level 3 of the fair value hierarchy. See Note 6 - Fair Value Measurement to our Condensed Consolidated Financial Statements for further information on the fair value hierarchy and the three classification levels. To determine the fair value of these investments, the Company uses all available financial information related to the entities, including information based on recent or pending third-party equity investments in these entities. In certain instances, an investment’s fair value is not estimated as there are no identified events or changes in the circumstances. There have been no unrealized gains or losses related to these Level 3 minority interest investments.

    Other long-term assets consisted of the following at December 31 (in thousands):
 20202019
Purchased technology rights (net of accumulated amortization of $8,872 and $8,300 in 2020 and 2019, respectively)$5,454 $6,027 
Minority interest and equity method investments9,909 11,501 
Other1,137 1,594 
 $16,500 $19,122 

    For the years ended December 31, 2020 and 2019, the Company recognized amortization expense related to the amortization of purchased technology rights of approximately $572,000 and $667,000, respectively. Future amortization expense is estimated to be $542,000 in 2021, $543,000 in 2022, $537,000 in 2023, $532,000 in 2024, $532,000 in 2025 and $2,768,000 thereafter.

NOTE 3 — ACCOUNTS RECEIVABLE AND RESERVES

    Accounts receivable consisted of the following (in thousands):
 20202019
Accounts receivable$68,629 $56,956 
Less: Allowance for doubtful accounts(1,666)(1,141)
 $66,963 $55,815 

    The following table summarizes the changes in the allowance for doubtful accounts (in thousands):
Balance at December 31, 2017$1,345 
Net increases charged to costs and expenses(437)
Write-offs of uncollectible accounts(65)
Balance at December 31, 2018$843 
Net recoveries charged to costs and expenses400 
Write-offs of uncollectible accounts(102)
Balance at December 31, 20191,141 
Net recoveries charged to costs and expenses546 
Write-offs of uncollectible accounts(21)
Balance at December 31, 20201,666 

88
NOTE 4 — INVENTORIES, NET

    Inventories consisted of the following at December 31 (in thousands):
 20202019
Parts and supplies$86,380 $45,459 
Work-in-progress18,858 15,532 
Finished goods17,896 16,093 
 $123,134 $77,084 

    The Company has non-cancellable purchase commitments with certain of its component suppliers in the amount of approximately $68.1 million at December 31, 2020. Should production requirements fall below the level of the Company’s commitments, the Company could be required to take delivery of inventory for which it has no immediate need or incur an increased cost per unit going forward.

NOTE 5 — FAIR VALUE MEASUREMENT

    ASC 820 “Fair Value Measurement” (ASC 820) defines fair value, establishes a framework for measuring fair value under U.S. GAAP and enhances disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. ASC 820 describes a fair value hierarchy based on the following three levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last unobservable:

    Level 1—Quoted prices in active markets for identical assets or liabilities.

    Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

    Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

    The Company determines the fair value of its investment portfolio assets by obtaining non-binding market prices from its third-party portfolio managers on the last day of the quarter, whose sources may use quoted prices in active markets for identical assets (Level 1 inputs) or inputs other than quoted prices that are observable either directly or indirectly (Level 2 inputs) in determining fair value. There were no transfers between Level 1, Level 2 or Level 3 measurements for the year ended December 31, 2020.

    The following table represents the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2020 and 2019 (in thousands):
 Fair Value Measurements as of December 31, 2020 Using
 Level 1Level 2Level 3Total
Assets:    
Money Market funds$707 $— $— $707 
 Equity investment$— $— $9,909 $9,909 
 Fair Value Measurements as of December 31, 2019 Using
 Level 1Level 2Level 3Total
Assets:    
Money Market funds$707 $— $— $707 
Minority interest investments - long-term$— $— $22 $22 
Equity investment$— $— $11,501 $11,501 

89
NOTE 6 — PROPERTY AND EQUIPMENT

    Property and equipment consisted of the following at December 31 (in thousands):
 20202019
Laboratory equipment$70,189 $60,486 
Leasehold improvements45,784 43,471 
Computer equipment4,034 3,916 
Purchased software22,981 22,621 
Furniture and fixtures6,081 5,924 
Assets on loan/rental32,544 28,946 
181,613 165,364 
Less: Accumulated depreciation(117,467)(99,849)
 $64,146 $65,515 

    Depreciation expense was $18.4 million and $16.5 million for the years ended December 31, 2020 and 2019, respectively.

NOTE 7 — GOODWILL AND OTHER INTANGIBLE ASSETS

    The changes in the carrying amount of goodwill during the period are as follows (in thousands):
 December 31, 2020December 31, 2019
Balance at beginning of period$118,145 $118,127 
Flow cytometry acquisition $— $18 
Balance at end of period$118,145 $118,145 
90
    A portion of the Company’s goodwill is not expected to be deductible for tax purposes. The Company’s intangible assets are reflected in the table below (in thousands, except weighted average lives):
 Finite-livedIndefinite-lived 
 Technology, trade secrets and know-howCustomer lists and contractsOther identifiable intangible assetsIP R&DTotal
2019     
Balance as of December 31, 2018$98,469 $23,819 $10,655 $24,013 $156,956 
Flow cytometry acquisition purchase price allocation adjustments(116)(428)1,154 (4,016)(3,406)
Balance as of December 31, 201998,353 23,391 11,809 19,997 153,550 
Less: accumulated amortization:     
Accumulated amortization balance as of December 31, 2018(40,501)(9,036)(2,271)— (51,808)
Amortization expense(7,784)(2,428)(1,194)— (11,406)
Accumulated amortization balance as of December 31, 2019(48,285)(11,464)(3,465)— (63,214)
Net balance as of December 31, 2019$50,068 $11,927 $8,344 $19,997 $90,336 
Weighted average life (in years)111010  
2020     
Balance as of December 31, 2019$98,353 $23,391 $11,809 $19,997 $153,550 
Completion of IPR&D projects2,687 (2,687)— 
Balance as of December 31, 2020101,040 23,391 11,809 17,310 153,550 
Less: accumulated amortization:     
Accumulated amortization balance as of December 31, 2019(48,285)(11,464)(3,465)— (63,214)
Amortization expense(7,919)(2,427)(1,194)— (11,540)
Accumulated amortization balance as of December 31, 2020(56,204)(13,891)(4,659)— (74,754)
Net balance as of December 31, 2020$44,836 $9,500 $7,150 $17,310 $78,796 
Weighted average life (in years)111010  

    The Company currently has two IP R&D projects. The first relates to the development of the next generation VERIGENE System, VERIGENE II. The Company is targeting the commercial launch of the VERIGENE II System in 2021. The second is a defensive IP R&D project related to the Company’s next generation xMAP System, xMAP INTELLIFLEX, which the Company currently believes will launch commercially in the first half of 2021. The next generation Guava System (Guava Next Gen System), acquired as part of the Company’s acquisition of EMD Millipore Corporation’s flow cytometry portfolio, was launched commercially in the second quarter of 2020 and transferred from IP R&D to finite-lived technology, trade secrets and know-how and is being amortized.

    The estimated aggregate amortization expense for the next five fiscal years and thereafter is as follows (in thousands):
2020$11,316 
202110,070 
20229,721 
20239,721 
20248,188 
Thereafter12,470 
 $61,486 

91
NOTE 8 — OTHER COMPREHENSIVE (LOSS) INCOME

    Comprehensive loss represents a measure of all changes in equity that result from recognized transactions and other economic events other than those resulting from investments by and distributions to shareholders. Other comprehensive loss for the Company includes foreign currency translation adjustments and net unrealized holding gains and losses on available-for-sale investments.

    The following table presents the changes in each component of accumulated other comprehensive loss, net of tax (in thousands):
Accumulated Other Comprehensive Loss Items - Foreign Currency
Balance as of December 31, 2019$(1,380)
Other comprehensive loss
1,238 
Net current-period other comprehensive loss1,238 
Balance as of December 31, 2020$(142)

    There are no tax benefits or expenses related to the other comprehensive loss for the twelve months ended December 31, 2020.

NOTE 9 — ACCRUED LIABILITIES

    Accrued liabilities consisted of the following as of December 31 (in thousands):
20202019
Compensation and employee benefits$33,992 $17,011 
Dividends payable4,711 4,104 
Income and other taxes7,058 1,538 
Warranty costs1,849 1,641 
Royalties payable782 1,335 
Current operating lease liabilities5,942 5,053 
Convertible notes interest payable996 — 
Other1,035 1,190 
$56,365 $31,872 

    Sales of certain of the Company’s systems are subject to a warranty. System warranties typically extend for a period of twelve months from the date of installation or no more than 15 months from the date of shipment. The Company estimates the amount of warranty claims on sold products that may be incurred based on current and historical data. The actual warranty expense could differ from the estimates made by the Company based on product performance. Warranty expenses are evaluated and adjusted periodically.

    The following table summarizes the changes in the warranty accrual (in thousands):
Accrued warranty costs at December 31, 2017$1,308 
Warranty services provided(2,159)
Accrual for warranty costs2,752 
Accrued warranty costs at December 31, 20181,901 
Warranty services provided(2,868)
Accrual for warranty costs2,608 
Accrued warranty costs at December 31, 20191,641 
Warranty services provided(2,362)
Accrual for warranty costs2,570 
Accrued warranty costs at December 31, 2020$1,849 

92
NOTE 10 — CONVERTIBLE SENIOR NOTES

In May 2020, the Company issued $260.0 million principal amount of Convertible Senior Notes due in May 2025 (Notes). The interest rates for the Notes is fixed at 3.00% per annum with interest payable semi-annually on May 15 and November 15 of each year, commencing on November 15, 2020. The Notes mature on May 15, 2025, unless earlier converted or repurchased in accordance with their terms prior to such date. Each $1,000 of principal amount of the Notes will initially be convertible into 22.8918 shares of the Company's common stock, which is equivalent to an initial conversion price of approximately $43.68 per share. The initial conversion price for each of the Notes is subject to adjustment upon the occurrence of certain specified events. On December 3, 2020, we announced that our Board declared an increased quarterly cash dividend of $0.10 per share of common stock to be paid to shareholders of record as of the close of business on December 23, 2020 with a payment date of January 14, 2021. This increase in the dividend adjusted the conversion price to $43.67 per share, or 22.9009 shares of the Company's common stock for each $1,000 of principal amount of the Notes.

Holders may convert their Notes at their option at any time prior to the close of business on the business day immediately preceding November 15, 2024 only under the following circumstances:

•during any calendar quarter commencing after the calendar quarter ending on June 30, 2020 (and only during such calendar quarter), if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day;

•during the five business day period after any five consecutive trading day period (Measurement Period) in which the trading price (as defined in the relevant indenture governing the Notes) per $1,000 principal amount of Notes for each trading day of the Measurement Period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day; or

•upon the occurrence of specified corporate events as set forth in the indenture governing the Notes.

On or after November 15, 2024 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or any portion of their Notes at any time, regardless of the foregoing circumstances. Upon conversion, the Company will pay or deliver cash, shares of its common stock or a combination of cash and shares of its common stock, at the Company’s election. The Company currently intends to settle the principal amount of the Notes in cash, and settle any excess amount with shares of the Company’s common stock, upon conversion. As of December 31, 2020, the Notes were not yet convertible.

If a fundamental change (as defined in the relevant indenture governing the Notes) occurs prior to the maturity date, holders of each of the Notes may require the Company to repurchase all or a portion of their Notes for cash at a repurchase price equal to 100% of the principal amount of the Notes, plus any accrued and unpaid interest up to, but excluding, the fundamental change repurchase date.

In accounting for the issuance of the Notes, the Company separated each of the Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value, as of the date of issuance, of a similar debt without the conversion feature. The effective interest rate used for the liability component was 8.50%. The liability component of the Notes is recorded in long-term debt, and the interest payable within the next twelve months is recorded in accrued liabilities on the Condensed Consolidated Balance Sheets as of December 31, 2020. The carrying amount of the equity component representing the conversion feature was determined by deducting the fair value of the liability components from the total initial proceeds. The difference between the par amount of the Notes and the carrying amount of the liability component represents debt discounts that are amortized to interest expense over the respective terms of the Notes using the effective interest rate method. The equity components are not remeasured as long as they continue to meet the conditions for equity classification.

In accounting for the $7.7 million of issuance costs related to the Notes, the Company allocated the total amount of issuance costs incurred to the liability and equity components in proportion to the allocation of the proceeds from issuance to the liability and equity components. Issuance costs attributable to the liability components are amortized to interest expense over the respective terms of the Notes using the effective interest rate method. The issuance costs attributable to the equity components were netted against the respective equity components in additional paid-in capital.

93
Issuance costs attributable to the liability component, totaling $6.0 million, are being amortized to expense over the expected life of the Notes using the effective interest method. Issuance costs attributable to the equity component related to the conversion feature, totaling $1.7 million, were netted with the equity component.

The Notes consist of the following:
As of December 31, 2020
Liability component:
Principal$260,000 
Unamortized debt discount(51,352)
Unamortized debt issuance costs(5,512)
Net carrying amount$203,136 
Equity component:
Net carrying amount$41,950 

The following table sets forth total interest expense recognized related to the Notes for the years ended December 31 (in thousands):
20202019
Contractual interest expense$4,940 $— 
Amortization of debt issuance costs531 — 
Amortization of debt discount 6,002 — 
Total$11,473 $— 

As of December 31, 2020, the remaining period over which the debt discount and debt issuance costs will be amortized was 4.4 years.

Convertible Note Hedge and Warrant Transactions

Concurrent with the offering of the Notes, the Company entered into privately negotiated convertible note hedge transactions (Convertible Note Hedge Transactions) with certain financial institutions (Option Counterparties) related to the issuance of the Notes. The Convertible Note Hedge Transactions are generally expected to reduce the potential dilution to the Company’s common stock upon any conversion of Notes or offset any cash payments the Company is required to make in excess of the principal amount of converted Notes.

The Company also entered into separate privately negotiated warrant transactions (Warrant Transactions) with each of the Option Counterparties pursuant to which the Company issued Warrants that will be exercisable into a number of shares of the Company’s common stock at a price per share equal to $69.89, subject to certain adjustments under the terms of the Warrant Transactions. The Warrant Transactions could separately have a dilutive effect on the Company’s common stock if the market value per share of the Company’s common stock exceeds the applicable strike price of the Warrants. However, subject to certain conditions, the Company may elect to settle the Warrants in cash.

The Convertible Note Hedge Transactions and the Warrant Transactions are separate transactions, in each case, entered into by the Company with the same Option Counterparties and are not part of the terms of the Notes and will not affect any holder’s rights under the Notes. The holders of the Notes will not have any rights with respect to the Convertible Note Hedge Transactions or Warrant Transactions. The Company used approximately $34.7 million of the net proceeds of the issuance of the Notes to pay the costs of the Convertible Note Hedge Transactions, after such cost was partially offset by the proceeds to the Company from the sale of the Warrants in the Warrant Transactions. The Convertible Note Hedge Transactions and Warrant Transactions do not meet the criteria for derivative accounting as they are indexed to the Company's stock. The amounts paid for the Convertible Note Hedge Transactions and the proceeds received from the Warrant Transactions have been included as a net reduction to additional paid-in capital.


94
NOTE 11 — INCOME TAXES
 
    The components of income before income taxes for the years ended December 31 are as follows (in thousands):
 202020192018
Domestic$(33,631)$(31,314)$7,242 
Foreign62,571 21,812 21,069 
Total$28,940 $(9,502)$28,311 
    
The components of the provision (benefit) for income taxes attributable to continuing operations for the years ended December 31 are as follows (in thousands):
 202020192018
Current:   
Federal$(7)$821 $(3,318)
Foreign6,689 951 515 
State179 (163)600 
Total current expense (benefit)$6,861 $1,609 $(2,203)
Deferred:   
Federal(2,913)(10,179)6,351 
Foreign8,886 4,597 5,271 
State936 (1,691)384 
Total deferred expense (benefit)6,909 (7,273)12,006 
Total provision (benefit) for income taxes$13,770 $(5,664)$9,803 
    
The provision (benefit) for income taxes differs from the amount computed by applying the statutory federal rate to pretax income as follows (in percentages):
 Year Ended December 31,
 202020192018
Statutory tax rate21.0 %21.0 %21.0 %
State taxes, net of federal benefit(3.5)%9.6 %3.0 %
Permanent items(2.4)%(1.6)%2.6 %
Effect of foreign operations10.2 %(11.7)%3.4 %
Research and incentive tax credit generated(7.7)%18.9 %(8.7)%
Valuation allowance9.1 %0.8 %0.4 %
Income tax reserves1.0 %67.3 %24.7 %
Remeasurement U.S. deferreds0.0 %0.0 %(0.3)%
Transition tax0.0 %(5.3)%(16.6)%
Foreign earnings withholding tax0.1 %6.6 %(7.9)%
Global intangible low-taxed income18.6 %(44.4)%5.7 %
Other measurement period Tax Act adjustments0.0 %0.0 %2.6 %
Canadian income tax audit0.0 %0.0 %4.8 %
Other1.2 %(1.0)%(0.1)%
 47.6 %60.2 %34.6 %

    The Company accounts for income taxes using the asset and liability method in accordance with ASC 740 “Income Taxes” (ASC 740). Under this method, deferred income taxes are recognized for the future tax consequences of differences between the tax and financial accounting bases of assets and liabilities at the end of each reporting period. Deferred income taxes are based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized.
95

    Significant components of the Company’s deferred tax assets and liabilities as of December 31 are as follows (in thousands):
 20202019
Deferred tax assets: 
Accrued liabilities and other$7,479 $4,577 
Net operating loss and credit carryforwards40,966 52,141 
Deferred revenue2,119 1,023 
Operating lease liability4,060 5,023 
Stock compensation and other7,542 7,791 
Bond hedge12,103 — 
Gross deferred tax assets74,269 70,555 
Valuation allowance(16,882)(17,906)
Total deferred tax assets$57,387 $52,649 
Deferred tax liabilities:  
Accrued liabilities and other$(4,230)$(1,287)
Depreciation and amortization(15,710)(18,443)
Operating lease right-of-use assets(3,649)(4,550)
Equity method investment(279)(667)
Convertible debt(12,442)
Total deferred tax liabilities(36,310)(24,947)
Net deferred tax assets$21,077 $27,702 
    
The Company has established a valuation allowance against a portion of its remaining deferred tax assets because it is more likely than not that certain deferred tax assets will not be realized. In determining whether deferred tax assets are realizable, the Company considered numerous factors including historical profitability, the amount of future taxable income and the existence of taxable temporary differences that can be used to realize deferred tax assets. The valuation allowance decreased approximately $1.0 million in 2020 from 2019 primarily due to releasing valuation allowance of $3.6 million against deferred tax assets of certain state net operating loss carryforwards, state research credit carryforwards, and deferred tax assets for stock compensation, and recording additional valuation allowance on the deferred tax assets of certain state net operating loss carryforwards of $2.6 million. The Company’s valuation allowance is primarily offsetting certain state net operating loss and state tax credit carryforwards, and certain stock based compensation. We anticipate portions of our deferred tax assets will not be realized under the provisions of Section 162(m) of the Tax Act which limits the deductibility of executive compensation.

    At December 31, 2020, the Company had gross federal, state and foreign net operating loss carryforwards of approximately $41.9 million, $283.8 million, and $6.1 million, respectively. These losses expire beginning in 2021. Federal and state net operating losses of approximately $41.9 million and $268.9 million, respectively, were acquired as part of the acquisitions of U.S. companies. These acquired net operating losses are subject to annual limitations due to the “change of ownership” provisions of Section 382 of the Internal Revenue Code of 1986, as amended, and similar state provisions. The Company has federal, state and foreign credit carryforwards of approximately $8.6 million, $3.4 million, and $2.6 million, respectively. These credits begin to expire in 2023, except for approximately $1.1 million of state research credits which have an indefinite carryforward period. Certain of these credits are subject to annual limitations under the change in ownership provisions.

96
    The excess of financial reporting basis over tax basis of the Company’s foreign subsidiaries is considered permanently reinvested with the exception of certain earnings of the Canadian subsidiary. The cumulative amount of excess financial reporting basis of the Company’s non-U.S. subsidiaries was approximately $14.3 million at December 31, 2020, $22.5 million at December 31, 2019 and $3.8 million at December 31, 2018. Since the Company does not intend to permanently reinvest portions of its previously taxed Canadian earnings, it has recorded a deferred tax liability of approximately $30 thousand related to state income taxes associated with the ultimate repatriation from Canada to the U.S. of these previously taxed earnings. Beginning January 1, 2018, the Tax Act implemented a territorial tax system in the U.S. such that the income earned by the Company’s non-U.S. subsidiaries will be subject to a 100% dividend received deduction, with certain exceptions. We have not recognized a deferred tax liability related to withholding taxes or state income taxes on the excess financial reporting basis of our other foreign subsidiaries because the Company currently intends to reinvest earnings of these subsidiaries in operations outside the U.S. Determination of the amount of the unrecognized deferred tax liability on these unremitted earnings is not practicable.

    As of December 31, 2020 and December 31, 2019, the Company had recorded gross unrecognized tax benefits of approximately $3.7 million and $3.4 million, respectively. All of the unrecognized tax benefits as of December 31, 2020, if recognized, would impact the effective tax rate. The Company recognizes interest expense and penalties associated with uncertain tax positions as a component of income tax expense. During the years ended December 31, 2020 and 2019, the Company recognized approximately $26 thousand and $1 thousand in tax related interest and penalties, respectively. Reserves for interest and penalties as of December 31, 2020 and 2019 are not significant as the Company has net operating loss carryovers and tax credit carryforwards.

    A reconciliation of the beginning and ending balance of unrecognized tax benefits is as follows (in thousands):
20202019
Balance at beginning of year$3,423 $9,721 
Additions based on tax positions related to the current year311 342 
Additions for tax positions of prior years— 398 
Reductions for tax positions of prior years(30)(7,038)
Balance at end of year$3,704 $3,423 
    
As of December 31, 2020, there were no unrecognized tax benefits that we expect would change significantly over the next 12 months.

    The Company files U.S., state, and foreign income tax returns in jurisdictions with varying statutes of limitations. In the United States and Canada, the statute of limitations with respect to the federal income tax returns for tax years after 2015 are open to audit; however, since the Company has net operating losses, the taxing authority has the ability to review tax returns prior to the 2015 tax year and make adjustments to these net operating loss carryforwards. In the fourth quarter of 2020, the IRS completed its audit of the Company's 2016 tax return with no material adjustments. In addition, during 2020 the IRS began auditing the Company's 2017 tax return with respect to certain limited issues. The IRS completed its audit of the Company's 2017 tax return in the fourth quarter of 2020 with no tax adjustments. We are not under audit in any major taxing jurisdictions at this time.

97
NOTE 12 — EARNINGS PER SHARE

    A reconciliation of the denominators used in computing per share net income (EPS) is as follows (in thousands, except per share amounts):
 Year Ended December 31,
 202020192018
Basic:   
Net income (loss)$15,170 $(3,838)$18,508 
Less: allocation to participating securities(297)65 (312)
Net income (loss) attributable to common stockholders$14,873 $(3,773)$18,196 
Weighted average common stock outstanding45,102 44,148 43,727 
Net income (loss) per share attributable to common stockholders$0.33 $(0.09)$0.42 
Diluted:   
Net income (loss)$15,170 $(3,838)$18,508 
Less: allocation to participating securities(298)63 (311)
Net income (loss) attributable to common stockholders$14,872 $(3,775)$18,197 
Weighted average common stock outstanding45,102 44,148 43,727 
Effect of dilutive securities: stock options and awards718 — 564 
Weighted-average shares used in computing net income (loss) per share45,820 44,148 44,291 
Net income (loss) per share attributable to common stockholders$0.32 $(0.09)$0.41 

    Basic net income (loss) per share is computed by dividing the net income (loss) for the period by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share is computed by dividing the net income (loss) for the period by the weighted average number of common and common equivalent shares outstanding during the period. Restricted stock awards (RSAs) and stock options to acquire 1,620,252 shares, 1,271,248 shares, and 619,113 shares for the years ended December 31, 2020, 2019 and 2018, respectively, were excluded from the computations of diluted earnings per share because the effect of including the RSAs and stock options would have been anti-dilutive.

    We apply the two-class method of computing earnings per share, which requires the calculation of separate earnings per share amounts for our non-vested, time-based restricted stock awards with non-forfeitable dividends and for our common stock. Our non-vested, time-based restricted stock awards with non-forfeitable dividends are considered securities which participate in undistributed earnings with common stock. Under the two-class computation method, net losses are not allocated to participating securities unless the holder of the security has a contractual obligation to share in the losses. Our non-vested, time-based restricted stock awards with non-forfeitable dividends do not have such an obligation so they are not allocated losses.

NOTE 13 — STOCKHOLDERS’ EQUITY, EMPLOYEE BENEFIT PLANS AND STOCK-BASED COMPENSATION

Preferred Stock

    The Company’s Board of Directors has the authority to issue up to 5,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof, including dividend rights, dividend rates, conversion rights, voting rights, terms of redemption, redemption prices, liquidation preferences and the number of shares constituting any series or the designation of such series, without further vote or action by the Company’s stockholders. At December 31, 2020 and 2019, there was no preferred stock issued and outstanding.

Dividends

    In February 2017, the Board of Directors initiated a cash dividend program under which the Company began paying a regular quarterly cash dividend. The following table shows cash dividends declared, recorded, and paid (or to be paid) in the periods shown:
98
Date Paid or
To Be Paid		Dividends Declared per Share
Twelve Months EndingDate DeclaredDate Payable
December 31, 2018
January 24, 2018March 23, 2018April 13, 2018$0.06 
May 18, 2018June 22, 2018July 13, 2018$0.06 
September 11, 2018September 21, 2018October 12, 2018$0.06 
December 11, 2018December 22, 2018January 10, 2019$0.06 
December 31, 2019
February 8, 2019March 21, 2019April 11, 2019$0.06 
May 21, 2019June 20, 2019July 11, 2019$0.06 
July 31, 2019September 26, 2019October 17, 2019$0.09 
December 6, 2019December 19, 2019January 15, 2020$0.09 
December 31, 2020
February 18, 2020March 19, 2020April 9, 2020$0.09 
May 22, 2020June 18, 2020July 9, 2020$0.09 
September 10, 2020September 24, 2020October 15, 2020$0.09 
December 3, 2020December 23, 2020January 14, 2021$0.10 
    
The Company’s current intent is to pay a continuing dividend on a quarterly basis. However, future declaration of dividends is subject to the final determination of the Company’s Board of Directors.

Stock-Based Compensation

    At December 31, 2020, the Company has one stock-based employee compensation plan pursuant to which grants may be made: the Luminex Corporation 2018 Equity Incentive Plan (Equity Incentive Plan) which was approved at the Company’s Annual Meeting on May 17, 2018. No further grants shall be made pursuant to the 2000 Long-Term Incentive Plan (2000 Plan), the 2001 Broad-Based Stock Option Plan (2001 Plan) or the 2006 Equity Incentive Plan (2006 Plan). In addition, at December 31, 2020, the Company has one plan pursuant to which discount purchases may be made by the participants in such plan: the Luminex Corporation Employee Stock Purchase Plan (ESPP), which was approved at the Company’s Annual Meeting on May 17, 2012 and amended at the Company’s Annual Meeting on May 18, 2017.

Equity Incentive Plans

    Under the Company’s Equity Incentive Plan and, the 2006 Plan, certain employees, consultants and non-employee directors have been granted RSAs, restricted stock units (RSUs) and options to purchase shares of common stock. The options, RSAs, and RSUs generally vest in installments over a three to five year period, and the options expire either seven or ten years after the date of grant.

    The ESPP provides for the granting of rights to certain employees of the Company to defer an elected percentage, up to 15%, of their base salary through the purchase of the Company’s common stock, discounted by 15%. As of December 31, 2020, there were approximately 2,400,000 shares authorized for future issuance under the Company’s Equity Incentive Plan and 83,044 shares eligible for purchase pursuant to the terms and conditions of the ESPP as more fully described below.

    The Equity Incentive Plan, the 2006 Plan and the ESPP are administered by the Compensation Committee of the Board of Directors. The Compensation Committee has the authority to determine the terms and conditions under which awards will be granted from the Equity Incentive Plan, including the number of shares, vesting schedule and term, as applicable. Any option exercise prices, as set forth in the Equity Incentive Plan, will be equal to the fair market value on the date of grant. Under certain circumstances, the Company may repurchase previously granted RSAs and RSUs.

99
    On February 27, 2020 and February 21, 2019, the Compensation Committee approved awards of stock options (the Performance Options) to the Company’s named executive officers and certain other executives that vest over four years based on achievement of certain operating profit and revenue targets for each of 2020 and 2019, respectively. The Performance Options have an exercise price equal to the closing market price for the Company’s common stock on the Nasdaq Global Select Market on the date of grant (March 12, 2020 and 2019, respectively) and expire seven years from the date of grant. The Performance Options were measured over a one-year performance period ending on December 31, 2020 and 2019, respectively. Following the end of the applicable fiscal year, the Committee determined the number of Performance Options which were eligible to vest based upon the level of achievement of an established Company performance goal (the Company Financial Goal). If the Company failed to meet the threshold performance for the performance period, no Performance Options would be eligible to vest. Minimum vesting for minimum threshold performance started at 30% of the target value for the Company Financial Goal. If the Company’s performance exceeded the target performance, the recipient may receive additional Performance Options above the target number, subject to a maximum of 200% of the target award. The Company’s financial performance resulted in delivery of 200% and 83% of the number of target Performance Options granted for 2020 and 2019, respectively. The Performance Options that are eligible to vest after the determination date will vest 25% on each of the first four anniversaries of the grant date. In the event of a change of control of the Company before the end of the performance period, the Performance Options will automatically vest based on the greater of actual achievement of the pro-rated Company Financial Goal as of the date of the change of control or 100% of target performance, as determined by the Committee in its sole discretion. The Performance Options are exercisable into shares of the Company’s common stock.

Accounting for Stock Compensation

    Stock-based compensation costs are generally based on the fair value calculated from the Black-Scholes option-pricing model on the date of grant for stock options, performance options and market value on the date of grant for RSAs. The fair values of stock and stock options are amortized as compensation expense on a straight-line basis over the vesting period of the grants.

    In accordance with ASC 718, the Company evaluates the assumptions used in the Black-Scholes model at each grant date using a consistent methodology for computing expected volatility, expected term and risk-free rate of return. Calculation of expected volatility is based on historical volatility. The expected life is calculated using the contractual term of the options as well as an analysis of the Company’s historical exercises of stock options and performance options. The estimate of the risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant. The dividend yield is based on our history and expectation of dividend payouts at the time of grant. The assumptions used are summarized in the following table:
 202020192018
Dividend yield1.5 %0.9 %1.2 %
Expected volatility0.3 0.4 0.4 
Risk-free rate of return0.9 %2.6 %2.7 %
Expected life of a 10 year contractual term option7 years7 years7 years
Expected life of a 7 year contractual term option4.75 years4.88 years4.88 years
Weighted average fair value at grant date$6.17 $7.69 $8.23 

    As part of the requirements of ASC 718, the Company is required to estimate potential forfeitures of stock grants and adjust compensation cost recorded accordingly. The estimate of forfeitures is based on historical forfeiture performance and will be adjusted over the requisite service period to the extent that actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures will be recognized through a cumulative catch-up adjustment in the period of evaluation and will also impact the amount of stock compensation expense to be recognized in future periods.

100
    The Company’s stock option activity for the year ended December 31, 2020 is as follows:
Stock OptionsShares
(in thousands)		Weighted Average Exercise PriceWeighted Average Remaining Contractual Life (in years)Aggregate Intrinsic Value (in thousands)
Outstanding at December 31, 20193,793 $20.17   
Granted1,508 23.09   
Exercised(998)18.18   
Canceled or expired(550)24.43   
Outstanding at December 31, 20203,753 $21.25 4.48$7,633 
Vested at December 31, 2020 and expected to vest3,687 $21.22 4.45$7,623 
Exercisable at December 31, 20201,519 $19.12 3.00$6,248 

    During the years ended December 31, 2020, 2019 and 2018, the total exercise intrinsic value of stock options exercised was $16.2 million, $0.4 million and $1.3 million, respectively, and the total fair value of stock options that vested was $10.6 million, $11.9 million and $12.7 million, respectively. Exercise intrinsic value represents the difference between the market value of the Company’s common stock at the time of exercise and the price paid by the employee to exercise the options. The Company had $10.5 million of total unrecognized compensation costs related to stock options at December 31, 2020 that are expected to be recognized over a weighted-average period of 2.57 years.

    The Company’s restricted share activity for the year ended December 31, 2020 is as follows:
Restricted Stock AwardsShares
(in thousands)		Weighted Average Grant Price
Non-vested at December 31, 2019810 $22.28 
Granted416 23.26 
Vested(295)21.49 
Cancelled or expired(38)22.65 
Non-vested at December 31, 2020893 $22.98 
Restricted Stock UnitsShares
(in thousands)		Weighted Average Remaining Contractual Life (in years)Aggregate Intrinsic Value (in thousands)
Non-vested at December 31, 2019522 
Granted100 
Vested(45)
Cancelled or expired(7)
Non-vested at December 31, 2020570 1.09$13 
Vested at December 31, 2020 and expected to vest563 1.05$13 
Exercisable at December 31, 2020403 0.00$9 

    As of December 31, 2020, there was $18.7 million of unrecognized compensation cost related to RSAs and RSUs. That cost is expected to be recognized over a weighted average-period of 2.17 years. The total fair value of restricted shares vested during the year ended December 31, 2020, 2019 and 2018 was $7.3 million, $6.0 million and $6.7 million, respectively.

101
    RSAs and RSUs may be granted at the discretion of the Compensation Committee of the Board of Directors under the Equity Incentive Plan in connection with the hiring or retention of key employees and are subject to certain conditions. Restrictions expire at certain dates after the grant date in accordance with specific provisions in the applicable agreement. During the year ended December 31, 2020, the Company awarded 416,142 shares of RSAs, which had a fair value at the date of grant ranging from $23.05–$31.65. During the year ended December 31, 2019, the Company awarded 413,967 shares of RSAs, which had a fair value at the date of grant ranging from $20.04–$24.43. During the year ended December 31, 2018, the Company awarded 387,436 shares of RSAs, which had a fair value at the date of grant ranging from $20.33–$29.33. During the year ended December 31, 2020, the Company awarded 99,584 shares of RSUs and dividend equivalents, which had a fair value at the date of grant ranging from $23.09–$31.65. During the year ended December 31, 2019, the Company awarded 120,498 shares of RSUs and dividend equivalents, which had a fair value at the date of grant ranging from $21.01–$24.43. During the year ended December 31, 2018, the Company awarded 95,127 shares of RSUs, which had a fair value at the date of grant ranging from $21.98–$26.39. Compensation under these RSAs and RSUs was charged to expense over the restriction period and amounted to $9.2 million, $8.2 million, and $6.2 million in 2020, 2019 and 2018, respectively. There were no significant stock compensation costs capitalized into assets as of December 31, 2020, 2019 or 2018.

    The Company received $18.0 million, $1.7 million and $2.8 million for the exercise of stock options during the years ended December 31, 2020, 2019 and 2018, respectively. Cash was not used to settle any equity instruments previously granted. The Company issued shares pursuant to grants relating to each of the Equity Incentive Plan, the 2006 Plan and 2000 Plan from reserves upon the exercise of stock options and vesting of RSAs.

    The following are the stock-based compensation costs recognized in the Company’s consolidated statements of comprehensive income (in thousands):
 Year Ended December 31,
 202020192018
Cost of revenue$2,332 $2,028 $1,715 
Research and development2,027 1,635 1,409 
Selling, general and administrative10,493 9,535 9,102 
Stock-based compensation costs reflected in net income (loss) $14,852 $13,198 $12,226 

Employee Stock Purchase Plan

    In May 2012, the Company’s stockholders approved the ESPP, which provides for the purchase of up to 500,000 shares of the Company’s common stock by eligible employees. In May 2017, the Company’s stockholders approved an amendment to the ESPP Plan, which increased the shares available under the ESPP by 341,744 shares. The ESPP period is semi-annual and allows participants to purchase the Company’s common stock at 85% of the lesser of (i) the closing market value per share of the common stock on the first trading date of the option period or (ii) the closing market value per share of the common stock on the last trading date of the option period. As of December 31, 2020, 2019 and 2018, 758,700 shares, 631,553 shares and 518,111 shares, respectively had been issued out of the ESPP. The related stock-based compensation expense was $0.7 million, $0.6 million and $0.5 million for 2020, 2019 and 2018, respectively.

    The Company uses the Black-Scholes model to estimate the fair value of shares to be issued under the ESPP as of the grant date using the following weighted average assumptions:
 202020192018
Assumptions:
Risk-free interest rates0.18 %2.55 %2.1 %
Expected life0.5 years0.5 years0.5 years
Expected volatility0.34710.350.44
Dividend yield1.454 %0.942 %1.2 %
102
Reserved Shares of Common Stock

    At December 31, 2020 and 2019, the Company had reserved 6,808,668 and 8,349,808 shares of common stock, respectively, for the issuance of common stock upon the exercise of options, issuance of RSAs, RSUs, purchase of common stock pursuant to the ESPP or other awards issued pursuant to the Company’s equity plans and arrangements. The following table summarizes the reserved shares by plan as of December 31, 2020:
 Options and RSUs OutstandingShares Available for Future IssuanceTotal Shares Reserved
Equity Incentive Plan4,339,804 2,385,820 6,725,624 
ESPP— 83,044 83,044 
 4,339,804 2,468,864 6,808,668 

Employee Savings Plans and Other Benefit Plans

    Effective January 1, 2001, the Company began sponsoring a retirement plan authorized by section 401(k) of the Internal Revenue Code for the Company’s employees in the United States. In accordance with the 401(k) plan, all employees are eligible to participate in the plan on the first day of the month following the commencement of full time employment. For 2020, 2019 and 2018, each employee could contribute a percentage of compensation up to a maximum of $19,500, $19,000, and $18,500 per year, respectively, with the Company matching 50% of each employee’s contributions. Effective January 1, 2010, the Company began contributing to a deferred profit sharing plan for its Canadian employees. All Canadian employees are eligible to participate in the plan. The Company’s contributions to these plans for 2020, 2019 and 2018 were $5.4 million, $5.1 million and $4.0 million, respectively.

    Several of the Company’s Netherlands employees are covered by a defined benefit plan. The cost and total liability to the Company is not material. Effective January 1, 2011, all of the Company’s new hires in the Netherlands are eligible to participate in a defined contribution plan.

NOTE 14 — REVENUE RECOGNITION

    Contract assets are included within Accounts receivables, net and contract liabilities are included in Deferred revenue on the Company’s Balance Sheet. The following table presents the opening and closing balances of the Company’s contract assets and liabilities for the twelve months ended December 31, 2020 (in thousands):
 Balance at
December 31, 2020		 Balance at December 31, 2019
Contract assets:
Unbilled receivables - Royalties$12,054 $12,257 
Contract liabilities - short-term:
Deferred revenue - Service $9,346 $7,771 
Deferred revenue - Licenses197 207 
Deferred revenue - Instruments78 2 
Deferred revenue - Other426 234 
Total Contract liabilities - short-term$10,047 $8,214 
Contract liabilities - long-term:  
Deferred revenue - Service$1,190 $968 
Deferred revenue - Licenses468 665 
Total Contract liabilities - long-term$1,658 $1,633 


103
    During the twelve months ended December 31, 2020, the Company recognized the following revenues as a result of changes in the contract asset and contract liability balances in the period (in thousands):
 Year Ended December 31, 2020
Revenue recognized in the period:
Amounts included as contract liabilities at the beginning of the period$9,387 
Performance obligations satisfied in previous periods -

NOTE 15 — COMMITMENTS AND CONTINGENCIES

Leases

    We have leased all of our research, manufacturing and office space and have entered into various other leases in conducting our business. Our leases have remaining lease terms of one year to six years, and some of our leases include options to extend the leases for up to ten years, tenant improvement allowances, rent holidays and rent escalation clauses. As the Company’s leases do not provide an implicit rate, we have used an estimated incremental borrowing rate of 5.75%, based on the information available at the commencement date in determining the present value of lease payments.

    The components of the lease expense were as follows (in thousands):
Twelve Months Ended December 31,
202020192018
Operating lease cost(a)
$9,792 $9,434 $7,032 
(a) Includes short-term lease expense costs, which were immaterial in the years ended December 31, 2020, 2019 and 2018

    Supplemental cash flow information related to leases was as follows (in thousands):
Twelve Months EndedTwelve Months Ended
December 31, 2020December 31, 2019
Cash paid for amounts included in the measurement of lease liabilities$7,072 $6,553 
    
Supplemental balance sheet information related to leases was as follows (in thousands):
December 31, 2020December 31, 2019
Operating leases:
Operating lease right-of-use assets$17,768 $20,439 
Operating lease liabilities$19,308 $22,235 
Weighted average remaining lease term3.52 years4.36 years
Weighted average discount rate5.75 %5.75 %

    Minimum annual lease commitments as of December 31, 2020 under non-cancellable leases for each of the next five years and in the aggregate were as follows (in thousands):
Operating Leases
2021$7,206 
20225,540 
20234,507 
20243,177 
2025945 
Thereafter— 
Total lease payments21,375 
Less: imputed interest(2,067)
Lease liabilities at December 31, 2020$19,308 
104
    These non-cancellable lease commitments related to facilities include certain rent escalation provisions which have been included in the minimum annual rental commitments shown above. These amounts are recorded to expense on a straight-line basis over the life of the lease. In addition, some of the Company’s leases contain options to renew the lease for five to ten years at the then prevailing market rental rate, right of first refusal to lease additional space that becomes available, or leasehold improvement incentives.

Non-Cancellable Purchase Commitments

    As of December 31, 2020 the Company had approximately $68.1 million in purchase commitments primarily with several of its inventory suppliers as well as other operating commitments. Certain of our supply agreements require purchase and delivery of minimum amounts of components through 2020, and purchases under these arrangements were $0.5 million, $0.8 million and $2.2 million for the years ended December 31, 2020, 2019 and 2018, respectively.

Employment Contracts

    The Company has entered into employment contracts with certain of its key executives. Generally, certain amounts may become payable in the event the Company terminates the executives’ employment without cause or the executive resigns for good reason.

Legal Proceedings

    In the normal course of business, the Company is subject to claims, lawsuits and legal proceedings. When and if it appears probable in management’s judgment, and based upon consultation with outside counsel, that we will incur monetary damages or other costs in connection with any claims or proceedings, and such costs can be reasonably estimated, we record the estimated liability in the financial statements.  If only a range of estimated losses can be estimated, we record an amount within the range that, in management’s judgment, reflects the most likely outcome; if none of the estimates within that range is a better estimate than any other amount, we record the liability at the low end of the range of estimates. Any such accrual would be charged to expense in the appropriate period. We disclose significant contingencies when the loss is not probable and/or the amount of the loss is not estimable, when we believe there is at least a reasonable possibility that a loss has been incurred. We recognize costs associated with legal proceedings in the period in which the services were provided.

NOTE 16 — GUARANTEES

    The terms and conditions of the Company’s development and supply and license agreements with its strategic partners generally provide for a limited indemnification of such partners, arising from the sale of Luminex systems and consumables, against losses, expenses and liabilities resulting from third-party claims based on an alleged infringement on an intellectual property right of such third party. The terms of such indemnification provisions generally limit the scope of and remedies for such indemnification obligations to a multiple of amounts paid by such strategic partner to Luminex during the previous annual period(s). To date, the Company has not had to reimburse any of its strategic partners for any losses arising from such indemnification obligations.

105
NOTE 17 — GEOGRAPHIC INFORMATION

    The table below provides information regarding product revenues and property and equipment, net from the Company’s sales to customers within the United States and in foreign countries for the years ended December 31 (in thousands):
 Sales to CustomersProperty and Equipment, net
 202020192018202020192018
Domestic$325,781 $252,381 $261,726 $61,755 $63,180 $63,382 
Foreign:      
Europe48,635 36,625 21,672 89 178 394 
Asia30,018 32,220 21,603 577 442 519 
Canada5,293 4,775 1,725 1,715 1,993 
Other12,962 8,119 6,042 — — — 
 $417,396 $334,638 $315,818 $64,146 $65,515 $66,288 
    The Company’s aggregate foreign currency transaction gain of $1,012,000, and losses of $432,000 and $487,000 were included in determining the consolidated results for the years ended December 31, 2020, 2019 and 2018, respectively.

NOTE 18 — RECENT ACCOUNTING PRONOUNCEMENTS

    Recently adopted accounting guidance

    In June 2016, the FASB issued guidance on financial instruments and related credit losses. The guidance requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis. The statement of comprehensive income reflects the measurement of credit losses for newly recognized financial assets, as well as the expected credit losses during the period. The measurement of expected credit losses is based upon historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. Credit losses relating to available-for-sale debt securities will be recorded through an allowance for credit losses rather than as a direct write-down to the security. The updated guidance is effective for annual periods beginning after December 15, 2019, and is applicable to the Company in fiscal 2020. The Company adopted the new standard effective January 1, 2020. The primary impact for the Company was the timing of recording expected credit losses on its trade receivables. The Company does not have a history of significant credit losses and this guidance did not have a material impact on its consolidated financial statements.

    Recent accounting guidance not yet adopted

    In December 2019, the FASB issued final guidance that simplifies the accounting for income taxes by eliminating some exceptions to the general approach in ASC 740, Income Taxes. The guidance amended certain disclosure requirements that had become redundant, outdated or superseded. Additionally, this guidance includes provisions for investment company reporting modernization, amends accounting for the interim period effects of changes in tax laws or rates, and simplifies aspects of the accounting for franchise taxes. The guidance is effective for annual periods beginning after December 15, 2020, and is applicable for the Company in fiscal 2021. Early adoption is permitted. The Company does not anticipate that this guidance will have a material impact on its consolidated financial statements.

106
In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies accounting for convertible instruments by removing major separation models required under U.S. GAAP. This update also amends the guidance for the derivatives scope exception for contracts in an entity's own equity to reduce form-over-substance-based accounting conclusions and requires the application of the if-converted method for calculating diluted earnings per share. The update also requires entities to provide expanded disclosures about the terms and features of convertible instruments and how the instruments have been reported in the entity’s financial statements. The guidance is effective for interim and annual periods beginning after December 15, 2021. Early adoption is permitted, but no earlier than January 1, 2021. The Company will early adopt this guidance effective January 1, 2021 under the modified retrospective basis with the cumulative effect recognized through an adjustment to additional paid-in capital. Under this method, earnings per share amounts will not be restated in prior periods presented, but future earnings per share amounts will be impacted by the change to the if-converted method for calculating diluted earnings per share. The Company's adoption is expected to result in a decrease of approximately $42 million in additional paid in capital from the de-recognition of the bifurcated equity component and an increase of approximately $50 million in debt from the de-recognition of the discount associated with the bifurcated equity component. The Company expects to write-off the related deferred tax liabilities to additional paid in capital.

NOTE 19 — SELECTED QUARTERLY RESULTS (UNAUDITED)

    The following table sets forth certain quarterly financial data for the periods indicated (in thousands, except per share data):
 Quarter Ended
 March 31,
2020		June 30,
2020		September 30,
2020		December 31,
2020
Revenue$90,424 $109,519 $106,060 $111,393 
Gross profit50,346 69,681 63,381 64,444 
Income (loss) from operations1,641 18,776 11,526 10,500 
Net income (loss)654 12,510 1,767 239 
Basic income (loss) per common share0.01 0.27 0.04 0.01 
Diluted income (loss) per common share0.01 0.27 0.04 0.01 
Cash dividends per common share0.09 0.09 0.09 0.10 
 Quarter Ended
 March 31,
2019		June 30,
2019		September 30,
2019		December 31,
2019
Revenue$82,408 $83,056 $78,673 $90,501 
Gross profit45,807 45,227 41,840 49,865 
Income from operations(3,584)(5,756)(5,722)2,983 
Net income (loss)2,960 (4,931)(5,250)3,383 
Basic income (loss) per common share0.07 (0.11)(0.12)0.08 
Diluted income (loss) per common share0.07 (0.11)(0.12)0.07 
Cash dividends per common share0.06 0.06 0.09 0.09 
See Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations for further discussion.


107
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

    None.

ITEM 9A. CONTROLS AND PROCEDURES
 
Evaluation of Disclosure Controls and Procedures

    We maintain disclosure controls and procedures, as defined in Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934 (Exchange Act), which are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and that such information is accumulated and communicated to the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. We carried out an evaluation, under the supervision and with the participation of the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of the Company’s disclosure controls and procedures as of the end of the period covered by this report. Based on the evaluation and criteria of these disclosure controls and procedures, the Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures were effective at a reasonable assurance level and designed to ensure that material information relating to the Company and its subsidiaries would be made known to such officers on a timely basis.
Management’s Report on Internal Control Over Financial Reporting

    Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f) and 15 d-15(f). Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2020 based on the 2013 framework in Internal Control - Integrated Framework, issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

    Based on that evaluation, our management concluded that our internal control over financial reporting was effective as of December 31, 2020. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risks that controls may become inadequate because of change in conditions, or that the degree of the compliance with the policies or procedures may deteriorate.

    Our independent registered public accounting firm, Ernst & Young LLP, has issued a report on their assessment of the effectiveness of our internal control over financial reporting, which is provided in Item 8 “Financial Statements and Supplementary Data,” page 75.

Changes in Internal Control Over Financial Reporting

    There have been no changes in our internal control over financial reporting identified in connection with the evaluation required by Exchange Act Rule 13a-15(d) during the fourth quarter of 2020 that have materially affected or are reasonably likely to materially affect, our internal control over financial reporting.

ITEM 9B. OTHER INFORMATION

    None.

108
PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

    The information required by this Item, including information concerning our directors and executive officers, audit committee, and audit committee financial experts, code of ethics and compliance with Section 16(a) of the Exchange Act is incorporated by reference to information under the captions “Proposal 1 - Election of Class I Directors”, “Corporate Governance” and “Delinquent Section 16(a) Reports” in our definitive proxy statement for our 2021 Annual Meeting of Stockholders to be held on or about May 20, 2021 (Proxy Statement). It is anticipated that our Proxy Statement will be filed with the Securities and Exchange Commission on or about April 1, 2021.

    Pursuant to General Instruction G(3), certain information with respect to our executive officers is set forth under the caption “Information about our Executive Officers” in Item 1 of this Annual Report on Form 10-K.

ITEM 11. EXECUTIVE COMPENSATION

    Information required by this Item is incorporated by reference to the section of the Proxy Statement entitled “Corporate Governance” and “Executive and Director Compensation.”

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

    Information required by this Item is incorporated by reference to the section of the Proxy Statement entitled “Security Ownership of Certain Beneficial Owners and Management.”

Securities Authorized for Issuance Under Equity Compensation Plans

    The following table sets forth, as of December 31, 2020, certain information with respect to shares of our common stock authorized for issuance under our equity compensation plans.
Plan CategoryNumber of Securities to be Issued Upon Exercise of Outstanding Options and Restricted Stock UnitsWeighted-Average Exercise Price of Outstanding OptionsNumber of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column (A))
 (A)
(B)(2)
(C)
Equity compensation plans approved by security holders(1)
4,339,804 $21.25 2,468,864 
Equity compensation plans not approved by security holders— $— — 
Total4,339,804  2,468,864 
(1) Includes approximately 570,000 shares that are issuable upon vesting of outstanding restricted stock units. The remaining balance consists of outstanding stock option grants.
(2) The weighted average exercise price does not take into account the shares issuable upon vesting of outstanding restricted stock units, which have no exercise price.

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

    Information required by this Item is incorporated by reference to the sections of the Proxy Statement entitled “Certain Relationships and Related Party Transactions” and “Corporate Governance.”

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES

    Information required by this Item is incorporated by reference to the section of the Proxy Statement entitled “Ratification of Appointment of Independent Registered Public Accounting Firm.”

109
PART IV

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES

(a)The following documents are filed as a part of this Annual Report on Form 10-K:

(1)Financial Statements:

The Financial Statements required by this item are submitted in Part II, Item 8 of this report.

(2)Financial Statement Schedules:

All schedules are omitted because they are not applicable or the required information is shown in the Financial Statements or in the notes thereto.

(3)Exhibits:
EXHIBIT
NUMBER		DESCRIPTION OF DOCUMENT
110
EXHIBIT
NUMBER		DESCRIPTION OF DOCUMENT
111
EXHIBIT
NUMBER		DESCRIPTION OF DOCUMENT
112
EXHIBIT
NUMBER		DESCRIPTION OF DOCUMENT
101The following materials from Luminex Corporation's Annual Report on Form 10-K for the year ended December 31, 2020, formatted in XBRL: (i) Condensed Consolidated Balance Sheets; (ii) Condensed Consolidated Statements of Comprehensive Income; (iii) Condensed Consolidated Statements of Cash Flows; (iv) Condensed Consolidated Statements of Changes in Stockholders’ Equity and (iv) Notes to Condensed Consolidated Financial Statements.
104The cover page from the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, formatted in Inline XBRL (included in Exhibit 101).
#    Management contract or compensatory plan or arrangement.
*    Schedules, annexes and exhibits omitted pursuant to Item 601(b)(2) of Regulation S-K. Luminex agrees to furnish a supplemental copy of omitted schedules to the Securities and Exchange Commission upon request.

113
ITEM 16. FORM 10-K SUMMARY

    None.

SIGNATURES

    Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

LUMINEX CORPORATION
    By: /s/ Nachum Shamir
    Nachum Shamir
Chairman, President and Chief Executive Officer
Date: February 26, 2021

POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Nachum Shamir and Harriss T. Currie, each his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments to this Report, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
SIGNATURESTITLEDATE
/s/ Nachum ShamirChairman, President and Chief Executive Officer, DirectorFebruary 26, 2021
Nachum Shamir(Principal Executive Officer) 
/s/ Harriss T. CurrieChief Financial Officer, Senior Vice President of Finance (Principal Financial Officer and Principal Accounting Officer)February 26, 2021
Harriss T. Currie 
/s/ Stephen L. EckDirectorFebruary 26, 2021
Stephen L. Eck  
/s/ Thomas W. EricksonDirectorFebruary 26, 2021
Thomas W. Erickson  
/s/ Jim D. KeverDirectorFebruary 26, 2021
Jim D. Kever  
/s/ Dijuana K. LewisDirectorFebruary 26, 2021
Dijuana K. Lewis  
/s/ Kevin M. McNamaraDirectorFebruary 26, 2021
Kevin M. McNamara  
/s/ Edward A. OgunroDirectorFebruary 26, 2021
Edward A. Ogunro  
/s/ Kenneth A. SametDirectorFebruary 26, 2021
Kenneth A. Samet
114
 EX-10.53 2 lmnx-12312020xexhibit1053.htm EX-10.53 Document

Exhibit 10.53
PURCHASE AND SALE AGREEMENT


    This Purchase and Sale Agreement (the “Agreement”) is entered into this _____ day of ______________, 2020 (“Final Execution Date”) by and between Northbrook Commercial Properties, LLC, an Illinois limited liability company having its principal place of business at 1818 Skokie Blvd., Northbrook IL 60062 (“Seller”) and Luminex Corporation, a Delaware corporation having its principal place of business at 12212 Technology Blvd, Austin TX 78727 (“Purchaser”).

WITNESSETH

In consideration of the mutual covenants hereinafter contained and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Purchaser hereby agrees to purchase from Seller and Seller hereby agrees to sell to Purchaser the following:

(a) that certain parcel of land containing approximately 5.76 acres of land area and the building thereon containing approximately 83,173 square feet of floor area, which property is commonly known as 4080-4100 Commercial Blvd., Northbrook IL 60062 (Tax Parcel ID# 04-06-107-004-0000:) and as legally described in Exhibit A attached hereto, together with all building improvements including all fixtures, hereditaments and appurtenances located thereon and used in connection with the Property, and all appurtenant rights thereto including any water or mineral rights (collectively, the “Real Estate”);

(b) all of Seller’s right title and interest in and to the commercial leases (the “Leases”) of the Real Estate, which Leases are described in Exhibit B attached hereto;

(c) all of Seller’s right, title and interest in and to any appliances, equipment or other personal property (the “Personalty”) currently located within and/or used in connection with the operation of the Real Estate; and

(d) all of all of Seller’s right, title and interest in and to warranties, licenses, permits, goodwill and other intangible property (the “Intangibles”) arising or used in connection with the Real Estate or the use, ownership or operation thereof. The Real Estate, together with the Leases, the Personalty and the Intangibles, are hereinafter referred to collectively as the “Property.”

Such purchase and sale shall be upon and subject to the following terms and conditions:

1.    Purchase Price.    The purchase price for the Property (the “Purchase Price”) shall be Eight Million and 00/100 Dollars ($8,000,000.00) and shall be payable as follows:

    (a)    Eighty Thousand and 00/100 Dollars ($80,000.00) by cashier’s check or by wire transfer of funds within three (3) business days after the full execution of this Agreement, as earnest money (the “Earnest Money”), to be deposited with and held in escrow by the Title Company (as defined in Paragraph 4 hereof). At Purchaser’s option, said Earnest Money may be deposited in an interest-bearing account with all interest thereon to be added to and applied in the same manner as the Earnest Money. Notwithstanding anything in this Agreement to the contrary, One Hundred Dollars ($100.00) of the Earnest Money is delivered to the Title Company for delivery by the Title Company to Seller as “Independent Consideration” (herein so called), and the Earnest Money is reduced by the amount of the Independent Consideration, which amount has been bargained for and agreed to as consideration for Seller’s execution and delivery of this Agreement. The Independent Consideration is in addition to and
1 | Page


independent of all other consideration provided for in this Agreement and is non-refundable in all events. If the sale is consummated in accordance with the terms hereof all Earnest Money shall be applied to the Purchase Price to be paid by Purchaser at the Closing (hereinafter defined). If the sale is consummated in accordance with the terms hereof all Earnest Money shall be applied to the Purchase Price to be paid by Purchaser at the Closing (hereinafter defined). In the event this Agreement is terminated by Purchaser in accordance with the terms hereof the Earnest Money shall be returned to Purchaser; and

    (b)    The balance, plus or minus prorations as herein provided, shall be paid by wire transfer of funds at Closing (as defined in Paragraph 8 hereof).

2.    Survey.     Within thirty five (35) days after the Final Execution Date, Seller shall obtain, at Seller’s expense, a currently dated 2016 ALTA/NSPS Land Survey (the “Survey”) prepared by a surveyor licensed in the state wherein the Property is located and containing the following Table A Matters 1, 2, 3, 4, 6(b), 7(a), 7(b)(1), 7(c), 8, 9, 10, 11(a), 13, 14, 16, 17, and 18, and is certified to Seller, Purchaser, and Title Insurer. In the event the Survey shows any easement, right of way, encroachment, conflict or condition (“Defects”) materially affecting the Property that is unacceptable to Purchaser, in Purchaser’s sole discretion, Purchaser shall, within thirty (30) days after receipt of the Survey, the Title Commitment and the Underlying Documents (hereinafter defined), notify Seller in writing of such Defects. Upon the expiration of such thirty (30) day period, Purchaser shall be deemed to have accepted the Survey and all matters shown thereon (other than the Defects which are the subject of a notification permitted under the preceding sentence) and such matters (except for the Defects) shall be included in the term “Permitted Exception” as used herein. The approved Survey shall be attached to this Agreement as Exhibit A, replacing the description of the Property, if any, previously attached as Exhibit A. In the event Seller notifies Purchaser that Seller is unable or unwilling to correct such unacceptable Defects, or if Seller fails to correct such unacceptable Defects to the reasonable satisfaction of Purchaser prior to the Closing Date, Purchaser may terminate this Agreement by notice in writing to Seller. In the event of any termination pursuant to this paragraph, the parties shall have no further right or obligation hereunder (except for any liabilities accruing prior to termination and covenants expressly intended to survive hereunder) and the Earnest Money shall be returned to Purchaser.

3.    Title.    Within ten (10) days after the Final Execution Date, Seller shall procure, at Seller’s expense, and shall deliver to Purchaser a commitment for an ALTA 2006 policy of title insurance or equivalent (the “Title Commitment”) issued by Chicago Title Insurance Company (the “Title Company”). Such Title Commitment must show title to the Property in Seller and commit to the issuance of an owner’s policy of title insurance in the amount of the Purchase Price, including an extended coverage endorsement over general exceptions usually contained in such title policies. The Title Commitment shall identify the Property by the legal description set forth in the Survey, specify all easements, liens, encumbrances, restrictions, conditions and covenants affecting the Property and shall be accompanied by copies of all documents referred to therein as exceptions to title (“Underlying Documents”). In the event any exceptions (title defects) appear in the Title Commitment that are unacceptable to Purchaser, in Purchaser’s sole discretion, Purchaser shall, within thirty (30) days after receipt of the Survey, the Title Commitment and the Underlying Documents, notify Seller in writing thereof. Upon the expiration of such thirty (30) day period, Purchaser shall be deemed to have accepted all exceptions to title shown on the Title Commitment (other than those which are the subject of a notification permitted under the preceding sentence) and such exceptions (except title defects) shall be included in the term “Permitted Exceptions” as used herein. Subject to Paragraph 4 below, any exceptions to liens or other encumbrances that can be removed by the payment of a definite or ascertainable amount of money will be removed at Closing by application of the Purchase Price thereto. Seller shall cause the Title Company to furnish an updated Title Commitment to Purchaser prior to
2 | Page


Closing indicating the exceptions that have been removed or will be removed at Closing by application of the Purchase Price or otherwise. If any exception that is unacceptable to Purchaser cannot be removed at or prior to Closing, Purchaser may either (i) accept the Title Commitment in its updated form, (ii) terminate this Agreement, or (iii) extend the Closing Date for a period that Purchaser deems reasonable for curing such objections, but not to exceed thirty (30) days. If cure is not affected within such extended period, Purchaser may again elect (i) or (ii) above. Upon any such termination, each party shall be released from all duties or obligations contained herein (except for any liabilities accruing prior to termination and covenants expressly intended to survive hereunder) and the Earnest Money shall be returned to Purchaser.

If Purchaser elects not to terminate this Agreement in accordance with this subsection, Purchaser may cause the Title Company to reissue from time to time the Title Commitment prior to Closing. Purchaser shall have the right to object to any newly discovered exceptions appearing on any subsequently issued Title Commitment, other than the Permitted Exceptions, and shown on any updated Title Commitment. If Seller fails to cure such items, Purchaser shall again have the right to terminate this Agreement and be reimbursed the Earnest Money or waive the objection(s). The time periods for objecting to and curing the additional exceptions and for terminating this Agreement shall be the same as those set forth in this subsection, commencing with the date Purchaser receives the updated Title Commitment, and, if necessary, the Closing Date shall be extended for such purposes.

4.    Nanosphere Lease.

A. Intentionally omitted.

B. Seller and Purchaser further acknowledge that (x) a portion of the Property is currently leased by Seller to an affiliate of Purchaser, Nanosphere, Inc. (“Nanosphere”); and (y) Seller has asserted that under such Lease with Nanosphere, Seller is entitled to reimbursement of fuel costs and other amounts alleged by TempAir in the TempAir Claim to be due and payable. Effective as of the Final Execution Date, Seller shall be deemed to have released, discharged and remised Purchaser, Nanosphere and their respective employees, officers, successors and assigns from and against any (i) claim for reimbursement for such fuel costs, or (ii) other cost or liability arising out of or in connection with the TempAir Claim; provided, however that nothing contained herein shall be deemed to affect, impair or release any obligation of Nanosphere under its Lease which accrues up to and including the Closing Date.

5.    Seller’s Representations and Warranties. Seller represents and warrants to Purchaser as follows, which representations and warranties shall be deemed made by Seller to Purchaser as of the Closing Date, shall survive the Closing and but for such representations and warranties Purchaser would not execute this Agreement:

(a)    As of the Closing Date, except for the tenants under the Leases, there shall be no parties in possession of any portion of the Property as lessees, tenants at sufferance, or trespassers;

(b)    There are no pending condemnation or similar proceedings affecting the Property, or any part thereof, and Seller has received no written notice that any such proceeding is threatened or contemplated by any governmental authority;

(c)    Seller has the present full authority and power to execute this Agreement and to close the sale of the Property and the signatory below on behalf of Seller has full authority and power to execute this Agreement and to close the sale of the Property;

3 | Page


(d)    Seller has no actual knowledge of any deposit, storage, disposal, removal, burial, discharge, spillage, uncontrolled loss, seepage or filtration of oil, petroleum or chemical liquids or solids, liquid or gaseous products or any hazardous wastes or hazardous substances (collectively “Hazardous Substances”), as those terms are used in any appropriate and applicable law, code or ordinance including, but not limited to, the Comprehensive Environmental Response, Compensation and Liability Act of 1980, as amended, at, upon, under or within the Property.

(e)    Seller has not received any notice of any uncured violation on the Property of any applicable federal, state or local statute, law or regulation pertaining to environmental matters or any other matters which would adversely affect Purchaser’s proposed use of the Property as contemplated herein;

(f)    (i) There is no suit, claim, action, arbitration, investigation or legal, administrative or other proceeding pending against or affecting Seller with respect to environmental or any other matters which would adversely affect Purchaser’s proposed use of the Property as contemplated herein and, to the actual knowledge of Seller, (ii) to Seller’s actual knowledge, there is no litigation or governmental investigation threatened against Seller or the Property before any federal, state or local court, board or other governmental or administrative agency which would adversely affect Purchaser’s proposed use of the Property, and (iii) there are no outstanding judgments, consents, decrees or injunctions involving environmental or any other matters which would adversely affect Purchaser’s proposed development of the Property to which Seller is a party or by which it is bound.

(h)     There is no agreement to which Seller is a party or, to Seller's actual knowledge, binding on Seller which is in conflict with this Agreement or which challenges or impairs Seller's ability to execute or perform its obligations under this Agreement.

(i)As of Closing, all contractors, subcontractors, suppliers, architects, engineers, and others hired by or on behalf of Seller and who have performed services or labor or have supplied materials in connection with Seller's repair, development, ownership, or management of the Property have been paid in full and all liens arising therefrom (or claims which with the passage of time or the giving of notice, or both, could mature into liens) have been satisfied and released.

    (j)    Seller has no actual knowledge that the Seller Deliveries pursuant to Paragraph 16 do not constitute true, correct and complete copies of all of the material documents and information in Seller's possession or control relating to the Property, its development, and its condition, as of the date of delivery.

    (k)    Neither Seller nor any of its affiliates (i) has been determined by competent authority to be subject to the prohibitions contained in Presidential Executive Order No. 13224 (September 23, 2001) or in any enabling or implementing legislation or other Presidential Executive Orders in respect thereof, (ii) is a person or entity who has been previously indicted for or convicted of any felony involving a crime or crimes of moral turpitude or for any violation of the Patriot Act, or (iii) is currently under investigation by any governmental authority for alleged criminal activity. Seller has no reason to believe that this transaction, including, without limitation, the source of its funds, would result in a violation by Purchaser or Seller of the Patriot Act, OFAC Laws and Regulations, or any other anti-terrorism or anti-money laundering laws or regulations, including, without limitation, the Bank Secrecy Act, as amended, or the Money Laundering Control Act of 1986, as amended.

    (l) The Leases are the only leases, licenses, occupancy agreements, and/or other possessory agreements that affect the Property. The only documents that comprise the Leases are listed in Schedule
4 | Page


1, and (ii) Seller has delivered to Purchaser a true, correct and complete copy of the Leases. Seller has neither delivered, nor received a written notice that a default, breach, or inaccurate or incomplete reconciliation of operating expense or tax reimbursements exists under the Leases that remains uncured. The tenants under the Leases (a) have not prepaid any sums more than one month in advance, (b) are not delinquent in paying rent or operating expense payments, or (c) have not exercised self-help or offset costs, expenses, or losses it has incurred against any payments due under the Leases. No leasing commissions or unpaid tenant improvement allowances are now or hereafter due or payable with respect to the Leases for any current term or any exercised or exercisable options. Seller has not entered into (or permitted or suffered the entry into) any leasing commission agreements with respect to the Property (x) under which any commission or fee has been earned but not fully paid or (y) that will be binding on Purchaser or the Property after the Closing.

Anything contained herein to the contrary notwithstanding:

I.For purposes of Paragraph 5, the terms “knowledge of” or “actual knowledge” of Seller shall mean the actual knowledge of Jamal Alwattar, managing member of Seller;

II.Subject to the express covenants, obligations and warranties of Seller hereunder, (i) Purchaser shall make and rely solely upon its own investigations regarding the condition and suitability of the Property and upon Closing shall be deemed to have accepted the Property in “AS IS, WHERE IS” condition, (ii) SELLER MAKES NO WARRANTIES, EXPRESSED OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, IMPLIED WARRANTIES OF MERCHANTABILITY, HABITABILITY AND/OR FITNESS FOR A PARTICULAR PURPOSE, IN CONNECTION WITH THE INCLUDED ASSETS OR THE USE THEREOF. WITHOUT LIMITING THE FOREGOING, SELLER HEREBY EXPRESSLY DISCLAIMS ANY WARRANTIES OR REPRESENTATIONS WITH RESPECT TO THE PROFITABILITY OF THE BUSINESS, THE TRANSFERABILITY OF ANY LICENSE, PERMIT OR APPROVAL RELATING TO THE INCLUDED ASSETS OR THE BUSINESS OR BUYER’S ABILITY TO OBTAIN OR MAINTAIN ANY LICENSES, PERMITS OR APPROVALS WHICH MAY BE REQUIRED IN CONNECTION WITH THE INCLUDED ASSETS OR THE BUSINESS; and

III.If, prior to the Closing Purchaser acquires actual, provable knowledge that any of Seller's representations and warranties is not correct in all material respects (such inaccuracy being hereinafter called a "Known Inaccuracy" and the date as of which Purchaser acquires actual knowledge of same being hereinafter called the "Inaccuracy Date"), Purchaser shall give written notice of such Known Inaccuracy to Seller within ten (10) days of such Inaccuracy Date and Seller shall have a period of up to 30 days to correct and mitigate such Known Inaccuracy such that Purchaser will not sustain any material damage or prejudice thereby (and if the such 30-day period extends beyond the date scheduled for Closing, the date of Closing shall be extended for a corresponding number of days). In the event Seller fully corrects such Known Inaccuracy within such 30-day period, the parties shall proceed to Closing and Purchaser shall have no further recourse therefor. If Seller does not fully correct such Known Inaccuracy within such 30-day period, Purchaser shall have the right to terminate this Agreement by giving written notice to Seller, in which event the Earnest Money shall be refunded to Purchaser.

6.    Purchaser’s Representations and Warranties. Purchaser represents and warrants to Seller as follows, which representations and warranties shall be deemed made by Purchaser to Seller as of the
5 | Page


Closing Date, shall survive the Closing and but for such representations and warranties Seller would not execute this Agreement:

(a)    Purchaser has the present full authority and power to execute this Agreement and to close the purchase of the Property.

7.    Suitability. Purchaser shall have one hundred twenty (120) days from the Final Execution Date (the “Study Period”) to satisfy itself in its sole discretion of the acceptability of the Property including, without limitation:

(a)    Purchaser’s satisfaction with the physical, environmental and overall condition of the Property for the ownership, use, development and operation of the Property contemplated by Purchaser.

(b)    Purchaser may, at its sole risk, cost and expense, conduct or cause to be conducted environmental, soil and engineering tests and studies of the Property (provided, however that Purchaser shall not cause to be performed any core drilling or invasive testing, including without limitation, any so-called Phase II environmental studies, without the prior written consent of Seller, which consent shall not be unreasonably withheld), and, in this connection, Purchaser or its designated agents may, upon reasonable prior notice, enter upon the Property for purposes of inspection, soil analysis, core drilling or other tests that may be deemed necessary to Purchaser or its consultant or engineer. Purchaser shall restore or repair any damage caused, related to or arising out of Purchaser’s conducting of such tests. Purchaser shall indemnify, hold harmless and, at Seller’s option, defend Seller against any and all claims, actions, causes of action, expenses, costs, penalties and liability arising out of Purchaser’s work or that of its employees, agents or contractors on the Property, which indemnity shall also include the payment of reasonable attorneys’ fees and other costs. Without limiting the foregoing, it shall be a condition to entry upon the Premises by Purchaser, its employees, agents or contractors that Purchaser shall have furnished Seller with a certificate of general liability insurance in an amount of not less than $1,000,000.00, single limit, which insurance shall insure against claims and demands for damage to property or injury to persons or loss of life arising out of or related to such entry upon the Premises, shall name Seller as an additional insured thereunder and shall otherwise be in commercially reasonable form.

(c)    Purchaser shall determine whether the improvements and the use contemplated by Purchaser for the Property are prohibited by any governmental or quasi-governmental authority (local, state or federal), including, but not limited to, zoning, subdivision and special use authorities.

(d)    Purchaser shall verify that all utilities necessary for the development and operation of Purchaser’s business are currently available to the Property and the capacities and cost thereof are satisfactory.

(e)    Purchaser’s review of all Leases or other agreements affecting the Property.

(f)    Purchaser shall determine whether the general real estate taxes and special assessments applicable to the Property are reasonable and satisfactory.

    Upon written notice by Purchaser given to Seller not later than the expiration of the then-existing (120-day) Study Period, the Study Period will be deemed automatically extended for one additional period of thirty (30) days; provided that, Purchaser shall simultaneously deliver $10,000.00 (“Additional Earnest Money”) for such 30-day extension to the Title Company, which Additional Earnest Money shall be non-refundable to Purchaser and paid to Seller (except in the event of a Seller default or the failure of a condition to Closing) but shall, in all instances, be applicable to the Purchase Price. If the sale
6 | Page


is consummated in accordance with the terms hereof all Earnest Money, including any Additional Earnest Money, shall be applied to the Purchase Price to be paid by Purchaser at the Closing.

If Purchaser in its sole judgment determines that it is not feasible to acquire or develop the Property for reasons gathered in its investigations, Purchaser may, by giving written notice in accordance with Paragraph 8 hereof to Seller, terminate this Agreement (hereinafter “Termination Notice”). In such event the Earnest Money shall be returned to Purchaser. Said Termination Notice must be received on or the expiration of the Study Period (as may be extended hereunder) or Purchaser shall be conclusively presumed to have irrevocably waived the right to terminate under this Paragraph 8.

8.    Closing.    

    (a)    The closing hereunder (herein referred to as the “Closing “) shall take place at the office of the Title Company on the business day which is within ten (10) business days after the end of the Study Period, or on such other date as shall be mutually agreed upon (the “Closing Date”) unless this Agreement shall have been terminated by Purchaser in accordance with this Agreement.

    On or before the Closing Date, Seller shall deposit with the Title Company, in commercially reasonable form: (i) a special warranty deed for the Real Estate to Purchaser, subject only to the Leases and the other Permitted Exceptions and the lien of non-delinquent real estate taxes; (ii) bill of sale conveying all Personalty which is included with the sale of the Property, except those items, if any, specifically excluded on Exhibit C attached hereto; (iii) closing statement; (iv) assignment to Purchaser of Seller’s right, title and interest under the Leases (which assignment shall provide that Seller shall be responsible for all obligations of landlord which accrue under the Leases up to and including the Closing Date and Purchaser shall be responsible for all obligations of landlord which accrue under the Leases after the Closing Date); (v) assignment of the Intangibles; and (vi) written releases of any lien, security interest, mortgage, deed of trust, mechanic’s lien or other encumbrance affecting the Property not assumed by Purchaser; (vii) limited liability company certificates of good standing and a certified copy of resolutions of the board of directors, members, managers or partners of Seller approving this sale and authorizing signatories of Seller hereto to execute this Agreement and execute and deliver any and all closing documents; (viii) notification to the tenants under the Leases that the Property has been sold to Purchaser in form reasonably acceptable to Purchaser; and (ix) customary lien, owner’s and FIRPTA non-foreign affidavits reasonably acceptable to Purchaser and the Title Company. Seller and Purchaser shall jointly deposit such other documents as may be reasonably required to complete the purchase and sale of the Property on or before the Closing Date. Seller shall also use commercially reasonable efforts to obtain and deliver at Closing (x) estoppel certificates (“Estoppel Certificates”) from each of the tenants under the Leases, which certificates shall certify as to each such Leases: (i) that such Leases are in full force and effect; (ii) the amount of rent and security deposit thereunder and the date to which rent has been paid; (iii) the term of such Leases, including any applicable renewals; (iv) that such Leases are in full force and effect and that no defaults, offsets or claims exist thereunder; and (v) such other matters as may be reasonably requested by Purchaser; and (y) subordination, non-disturbance and attornment agreements (“SNDAs”) reasonably acceptable to Purchaser.

At the Closing:

(1)    at Seller’s expense, Seller shall deliver or cause to be delivered to Purchaser an ALTA 2006 owner’s title insurance policy or equivalent issued by the Title Company in the amount of the Purchase Price insuring that Purchaser owns fee simple title to the Property, subject
7 | Page


only to the standard printed exceptions (other than general exceptions which shall be waived by the Title Company by extended coverage endorsement) and the Permitted Exceptions.

(2)    Purchaser shall pay the Purchase Price to Seller, adjusted as provided herein, , by wire transfer in immediately available funds to a bank account of Seller’s choice. The escrow agent, upon receipt of the funds required from Purchaser, shall record Seller’s deed (affixing necessary real estate transfer tax stamps after recording, the cost thereof to be paid by Seller) and any other documents deposited by the parties into the escrow to be recorded, later date the Title Commitment and do such other acts as shall be necessary to carry out the provisions of this Agreement.

    (b)     All costs and expenses of Closing the purchase and sale of the Property shall be borne and paid at Closing unless otherwise stated herein, as follows:

By Seller:        Title Insurance Premiums (relating to Purchase Price) with extended coverage over general exceptions
            Seller’s Attorneys’ Fees
            Escrow/Closing Fees (50%)
            Recording Fees for releases, if any.
State, County and Local Transfer Taxes
            Survey Costs

By Purchaser:        Purchaser’s Attorneys’ Fees
            Escrow/Closing Fees (50%)
Recording Fees for Deed
Title Insurance Premiums (relating solely to endorsements requested by Purchaser, and any additional coverage above the Purchase Price)

    (c)    The parties agree that the escrow agent at the Title Company shall receive the following instructions. The Title Company shall accept the Earnest Money. Said Earnest Money deposit shall be held in escrow by the Title Company and shall be released and delivered to Seller in cash, by cashier’s check or wired funds in accordance with the provisions of this Agreement on the Closing Date. Title Company assumes no liability under this Agreement other than that of a stakeholder. If there is any dispute as to whether Title Company is obligated to deliver the funds or as to whom that sum is to be delivered, Title Company shall not be obligated to make any delivery of the sum, but in such event may hold the sum until receipt by Title Company of an authorization in writing signed by all parties to such dispute, directing the disposition of the sum, or in the absence of such authorization, Title Company may hold the sum until the final determination of the rights of the parties in an appropriate proceeding. No provision of this Agreement shall be construed to relieve Title Company of any obligations or liabilities which may now exist or hereafter accrue by virtue of any writing other than this Paragraph 9.

    (d)    Each party warrants to the other that neither of them nor their agents or representatives have engaged or contracted any broker with respect to the transaction contemplated herein, and each party agrees to indemnify and hold the other party harmless from any and all claims for brokerage fees arising out of its actions.

    (e)    Notwithstanding anything to the contrary contained in this Agreement ,each of Seller and Purchaser acknowledges and agrees that Purchaser’s receipt of the Estoppel Certificates and SNDAs is an express condition to Closing. In the event Purchaser does not receive such Estoppel Certificates and
8 | Page


SNDAs in form and substance satisfactory to Purchaser, Purchaser shall have the right, in its sole discretion, to terminate this Agreement at any time prior to Closing, and, upon such termination, Purchaser shall receive the Earnest Money.

9.Real Estate Taxes, Rent, Insurance, Possession; Risk of Loss, Condemnation and New Encumbrances.

A.Prior to or at Closing, Seller shall pay all general real estate taxes and installments of any and all special assessments which are due and payable as of the Closing Date. Taxes on the Property which accrue in the current year and installments of any and all special assessments due and payable in the current year shall be prorated on the basis of 105% of the most recently ascertainable full year’s taxes to the Closing Date, or the revised Closing Date if the Closing is extended as herein provided, so that Seller bears that portion of the accrued taxes and those installments of any and all special assessments which accrue for the period up to and including the Closing Date and Purchaser bears that portion of the accrued taxes and those installments of any and all special assessments which accrue for all periods subsequent to the Closing Date. The parties agree that such proration shall be re-prorated between the parties, upon issuance of actual tax bills for the year in which the Closing occurs, with any adjustment between the parties to be made in cash within 15 business days of demand therefor. Prior to or at Closing, Seller shall also pay all personal property taxes, if any, and special taxing district taxes, if any which are due and payable as of the Closing Date. Subdivision assessments, common area charges, fees and charges for utilities shall be prorated to the Closing Date.

B.Rents and other charges paid under the Leases shall be prorated as of midnight of the day before Closing; provided that any rents or other charges which are payable under the Leases but not yet received as of the Closing Date (collectively, “Tenant Receivables”) shall be apportioned on the basis of the period for which same is payable and if as and when collected as follows: (1) first, Tenant Receivables due for the month in which the Closing shall be prorated as of the Closing Date; (2) second, to Tenant Receivables due Purchaser for periods following the month in which the Closing occurred; (3) third, to Tenant Receivables due Seller for the month prior to Closing,
and (4) thereafter, to delinquent Tenant Receivables which were due and payable to Seller as of Closing but not collected by Seller as of Closing. Any rent or other income received by Purchaser after the Closing which is owed to Seller, or any rent or other income received by Seller after the Closing which is owed by Seller to Purchaser shall be remitted to the party entitled thereto within ten (10) business days of receipt thereof.

C.All Security Deposits (to the extent they exist) not applied by Seller shall be transferred or credited to Purchaser at Closing, together with any interest accrued thereon; provided, however, Purchaser acknowledges and agrees that Seller shall be entitled to retain the $75,000 Security Deposit in connection with the Nanosphere Lease. As of the Closing, Purchaser shall assume Seller's obligations related to the Security Deposits (except for the Nanosphere Lease Security Deposit) to the extent they are credited or transferred to Purchaser.

D.All such expenses shall be prorated and adjusted on the basis of a 365 day year with the Closing Date charged to the Seller, provided however, with respect to those fees and charges which may be read or computed by the party rendering services so that such fee or charge may be billed directly to the Seller with respect to charges incurred up to and including the Closing Date and to Purchaser with respect to any charges incurred after the Closing Date, then either party hereto may cause such fee or charge to be read and billed directly to the appropriate party and such
9 | Page


charge shall not be subject to proration under this Agreement. Seller shall deliver possession of the Property to Purchaser at Closing (including all keys therefor) free and clear of tenants and other occupants, subject to the rights of the tenants under the Leases, and otherwise in the same condition as on the Final Execution Date, ordinary wear and tear excepted.

E.Seller shall bear the risk of loss until Closing. Insurance, if any, shall be canceled as of the Closing Date. Purchaser has the right to walk through the Property prior to Closing to verify that the physical condition of the Property, fixtures and any personal property included in the sale complies with this Agreement.

F.In the event of any condemnation of the Property or any part thereof prior to Closing which, in the opinion of Purchaser, would have an adverse impact upon Purchaser’s intended use of the Property, Purchaser may elect to terminate this Agreement upon written notice to Seller, and upon Seller’s receipt of such notice, Purchaser shall have no further duties or obligations hereunder (except for any liabilities accruing prior to such termination) and the Earnest Money shall be refunded to Purchaser.

G.During the term of this Agreement, Seller shall not, without in each instance first obtaining Purchaser’s written consent, which may not be unreasonably withheld, consent to or permit (i) any modification to existing easements, covenants, conditions, restrictions or rights-of-way affecting the Property; (ii) any new easements, covenants, conditions, restrictions or rights-of-way affecting the Property; (iii) any zoning changes or other changes of governmental approvals; (iv) any modifications to or amendments of the Leases; or (v) enter into any new leases.

10.    Remedies.

(a)    In the event Purchaser fails to comply with any or all of the obligations, covenants, warranties or agreements to be performed, honored or observed by Purchaser under and pursuant to the terms and provisions of this Agreement and such default is not cured within ten (10) days after Purchaser’s receipt of written notice thereof (other than Purchaser’s failure to tender the Purchase Price on the date of Closing, a default for which no notice is required), then Seller may terminate this Agreement and retain the Earnest Money as liquidated damages and both parties shall be released from any further liability hereunder except for the indemnification provisions of Paragraph 7 herein. The remedies set forth in this subparagraph (a) shall be the sole and exclusive remedies of Seller in the event Purchaser shall be in default hereunder.

(b)    In the event Seller fails to comply with any or all of the obligations, covenants, warranties or agreements to be performed, honored or observed by Seller under and pursuant to the terms and provisions of this Agreement, and such default is not cured within ten (10) days after Seller’s receipt of written notice thereof, then Purchaser may: (i) terminate this Agreement, in which event the Earnest Money shall be refunded to Purchaser, except for the sum of $100.00 which shall be retained by Seller as consideration for Purchaser investigating the Property, and both parties shall be released from any further liability hereunder, and (ii) bring an action for specific performance against Seller to enforce the terms of this Agreement, and (iii) be entitled to all remedies available at law or in equity, including without limitation, damages. The remedies set forth in this subparagraph (b) shall be the sole and exclusive remedies of Purchaser in the event Seller shall be in default hereunder.

10 | Page


(c)    The failure of either party to act upon a default of the other in any of the terms, conditions or obligations under this Agreement shall not be deemed a waiver of any subsequent breach or default under the terms, conditions or obligations hereof by such defaulting party.

11.    Notices.    All notices or communications herein required or which either party desires to give to the other shall be in writing, shall be deemed given when received and shall be personally delivered or sent by or by overnight delivery service, to the respective addresses as provided above or to such other addresses as the parties may from time to designate by written notice to the other party.

12.    Assignment.

    (a)    Purchaser shall not consent to or permit any Prohibited Transfer (as defined in subparagraph (b) below) of its rights under this Agreement without obtaining, in each and every instance, the prior written consent of Seller which consent shall not be unreasonably withheld, conditioned or delayed.

    (b)    For purposes of this Paragraph 13, any conveyance, sale, assignment, transfer, lien, pledge, mortgage, security interest or other encumbrance or alienation (or agreement to do any of the foregoing) of any of Purchaser’s rights in, to or pursuant to this Agreement, which occurs or is granted, accomplished, attempted, or effectuated without the prior written consent of Seller shall constitute a “Prohibited Transfer”.

    Notwithstanding the foregoing, Purchaser shall be permitted to assign its rights in this Agreement without Seller’s consent to any subsidiary, successor or affiliated company of Purchaser or to Purchaser’s parent company or to Purchaser’s designated holding company and the same shall not be considered a Prohibited Transfer.

13.    Miscellaneous Provisions.

    (a)    The representations, warranties, covenants and agreements of the parties, as well as any rights and benefits of the parties, pertaining to a period of time following the Closing, shall survive the Closing and shall not be merged therein.

(b)    This Agreement shall be construed under and in accordance with the laws of the state wherein the Property is located and according to its fair meaning, and not in favor of or against any party.

    (c)    This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective legal representatives, successors and permitted assigns.

    (d)    In case any one or more of the provisions contained in this Agreement shall for any reason be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions hereof, and this Agreement shall be construed as if such invalid, illegal or unenforceable provision had never been contained herein.

    (e)    This Agreement constitutes the sole and only agreement of the parties hereto and supersedes any prior understandings or written or oral agreements between the parties respecting the within subject matter. This Agreement cannot be amended or modified except by written agreement signed by Purchaser and Seller and no email communications between Purchaser and Seller shall be deemed to amend this Agreement.

11 | Page


    (f)    All parties hereto pledge their good faith efforts to act in a timely and reasonable manner to consummate the transaction herein contemplated.

    (g)    Words of any gender used in this Agreement shall be held and construed to include any other gender, and words in the singular number shall be held to include the plural, and vice versa, unless the context requires otherwise.

    (h)    The paragraph headings herein are for reference purposes only and are not intended in any way to describe, interpret, define or limit the scope, extent or intent of this Agreement or any part hereof. The failure by either party to enforce against the other any term or provision of this Agreement shall not be deemed a waiver of such party’s right to enforce against the other party the same or any other such term or provision.

    (i)    If either party files any action or brings any proceeding against the other arising out of this Agreement or is made a party to any action or proceeding brought by a third party arising out of this Agreement, then as between Purchaser and Seller, the prevailing party shall be entitled to recover, as an element of its costs of suit and not as damages, reasonable attorneys’ fees to be fixed by the court. The “prevailing party” shall be the party who is entitled to recover its costs of suit, whether or not the suit proceeds to final judgment. A party not entitled to recover its costs shall not recover attorneys’ fees.

    (j)    Except for the payment of monies, if either party hereto shall be delayed or hindered in or prevented from the performance of any act required hereunder by reason of strikes, lockouts, labor troubles, fines, acts of God, natural disasters, inability to procure material, failure of power, pandemic, restrictive governmental laws or regulation, riots, insurrection, war, or any other cause beyond the reasonable control of the party delayed in performing work or doing acts required under this Agreement, the period for the performance of any such act shall be extended for a period equivalent to the period of such delay.

    (k)    If the time for performance of any obligation under this Agreement expires on a Saturday, Sunday or a legal holiday, then the time for such performance shall be extended to the next succeeding day that is not a Saturday, Sunday or a legal holiday.

    (l)    This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original, and all of which, taken together, shall be deemed to constitute one agreement.

    (m)    Time is of the essence with respect to each provision of this Agreement.

    (n)    SELLER AND PURCHASER MUTUALLY AGREE THAT THEY WAIVE ALL RIGHTS TO A TRIAL BY JURY IN THE EVENT OF ANY DISPUTE OR COURT ACTION ARISING FROM, GROWING OUT OF, OR RELATED TO THIS AGREEMENT. THE PARTIES ACKNOWLEDGE THAT THIS WAIVER IS A SIGNIFICANT CONSIDERATION TO, AND A MATERIAL INDUCEMENT FOR, PURCHASER TO ENTER INTO THIS AGREEMENT.

    (o)    The parties agree that the venue of any litigation shall be in the Circuit Court of Cook County, Illinois or in the Federal courts situated in Cook County, Illinois.

14.    Purchaser’s Indemnification. In the event that this Agreement is terminated by either Purchaser or Seller prior to Closing, and notwithstanding the fact that such termination shall release Purchaser from its obligation to buy the Property, nothing herein shall be deemed to release Purchaser from any liability arising out of or connected with Purchaser’s activities (or those of its employees, agents, or contractors)
12 | Page


on the Property, including, but not limited to, its actions on the Property while exercising its rights pursuant to Paragraph 8 hereof. This provision shall survive Closing of the transaction herein contemplated and the delivery of the Deed.

15.    Seller’s Deliveries. Within five (5) business days after the Final Execution Date, Seller shall cause to be delivered to Purchaser the following to the extent same are in Seller’s possession and control (or shall certify to Purchaser that it is not in possession of such document(s)):

(a)    Most recent real estate property tax and/or assessment notice;
(b)    Copy of all existing Leases, if any, affecting the Property;
(c)    Copies of all warranties that may exist with respect to the Property including any warranties on equipment servicing the Property and warranties on any personal property used in connection with the Property and which is being conveyed to Purchaser;
(d)    Copy of the latest appraisal of the Property;
(e)    Any property surveys;
(f)    Copies of any prior title abstracts, title policies, title commitments or title work;
(g)    Copies of any prior environmental studies (Phase I or II), reports or inspections or correspondence including but not limited to asbestos, PCB or other toxic or hazardous substance, underground or above ground storage tanks and/or radon gas ;
(h)    Construction plans, drawings or renderings of the Property;
(i)    As-built construction plans to the Property including architectural, electrical, mechanical, and structural systems, landscaping, engineering reports and certificates of occupancy;
(j)    Copies of all contracts relating to the operation, maintenance and management of the Property;
(k)    Copies of all insurance policies or certificates pertaining to the Property and copies of any claims which have been made in the past 2 years; and
(l)    all other written information and documentation reasonably requested by Purchaser concerning the ownership, operation, leasing, use or maintenance of the Property.

16.    1031 Exchange. Seller shall have the option to have the Property treated as part of a tax deferred exchange pursuant to Section 1031 of the Internal Revenue Code. Purchaser agrees to cooperate in the exchange provided: (i) that any additional cost incurred by Purchaser by reason of the involvement of the Property in such a tax deferred exchange, including reasonable attorneys’ fees incurred by Purchaser shall be paid by Seller, (ii) that Purchaser shall not be required to incur or assume any liability as a result of the involvement of the Property in such a tax deferred exchange; (iii) that Seller hereby indemnifies, defends and holds Purchaser harmless from any liability, loss, cost, damage or expense, including but not limited to reasonable attorneys’ fees and court costs incurred or claimed as a result of including the Property in such tax deferred exchange; (iv) Purchaser shall in no way be liable in any manner for any tax consequence that may be attributable to the Seller; (v) the Closing Date will not be delayed to accommodate such tax deferred exchange; and (vi) subject to the above, Purchaser agrees to execute any documents reasonably approved by Purchaser and which may be reasonably requested by the Seller to effectuate the Section 1031 exchange.

[SIGNATURE PAGE TO FOLLOW]
IN WITNESS THEREOF, the parties have executed this Agreement as of the day and year first above written.
13 | Page




SELLER:                Northbrook Commercial Properties, LLC,
                    an Illinois limited liability company



Date of Seller’s Execution        By:        /s/ Jamal Alwattar
December 4, 2020
                    Print Name:    Jamal Alwattar
        
                    Its:        Principal




PURCHASER:                Luminex Corporation,
                    a Delaware corporation



Date of Purchaser’s Execution        By:        /s/ Harriss T. Currie
December 4, 2020
                    Print Name:     Harriss T. Currie    
    
                    Its:        Sr. Vice President of Finance & CFO




Exhibits:
A—Legal Description of Real Estate
B---The Leases
C---Excluded Personalty
Schedule 1---Leases
14 | Page

 EX-10.54 3 lmnx-12312020xexhibit1054.htm EX-10.54 Document

Exhibit 10.54

LEASE AGREEMENT


BETWEEN


SUNDANCE CONSOLIDATED, L.L.C.


as LANDLORD,


and

LUMINEX CORPORATION


as Tenant,




12306 Technology Blvd.,
Austin, Texas 78727





TABLE OF CONTENTS






















The mailing, delivery or negotiation of this Lease shall not be deemed an offer to enter into any transaction or to enter into any relationship, whether on the terms contained herein or on any other terms. This Lease shall not be binding, nor shall either party have any obligations or liabilities or any rights with respect thereto, or with respect to the premises, unless and until both parties have executed and delivered this Lease. Until such execution and delivery of this Lease, either party may terminate all negotiation and discussion of the subject matter hereof, without cause and for any reason, without recourse or liability.
LIST OF DEFINED TERMS



Defined Term    Page


affiliate    14
Alterations    4
Arbitration Notice    1
Base Rent    1
Base Rent Abatement Period    2
Binding Notice    1
Brokers    15
Building    1
Building Structure    3
Claimant    12
Commencement Date    1
Construction Allowance    1
Environmental Law    17
Estimates    2
Event of Default    10
Fair Market Rental    1
Hazardous Substances    17
HVAC System    4
including    14
Initial Improvements    1
Initial Renewal Notice    1
Land    1
Landlord    1
Landlord's Mortgagee    13
Law    14
Laws    14
Lease    1
Loss    7
Mortgage    13
MSDS    18
Operating Expenses    2
Permitted Activities    17
Permitted Alterations    4
Permitted Materials    17
Permitted Transfer    8
Premises    1
Primary Lease    13
Proportionate Share    1
Record Drawings    2
Rejection Notice    1
Renewal Amendment    1
Renewal Term    1
rent    3
Repair Period    6
Review Period    2
Rooftop Equipment    16
SNDA    13
Taking    9
Taxes    3
Tenant    1
Tenant Affiliate    8
Tenant Party    14
Term    1
Transfer    8
Vacation Date    8



LEASE AGREEMENT


This Lease Agreement (this "Lease") is entered into by SUNDANCE CONSOLIDATED, L.L.C., a Texas limited liability company ("Landlord") and LUMINEX CORPORATION, a Delaware corporation ("Tenant").

1.PREMISES, TERM AND INITIAL IMPROVEMENTS

(a)    Landlord leases to Tenant and Tenant leases from Landlord, the approximately 50,332 square foot building (the "Building") located on, and together with, the real property described on Exhibit A (the "Land") and any other improvements located on the Land (collectively, the "Premises"), subject to the terms and conditions in this Lease. Landlord and Tenant stipulate that, as of the date of this Lease, the size of the Building is 50,332 square feet and Tenant's "Proportionate Share" is 100%. Tenant will be sole tenant of the Building on the Commencement Date.

(b)    The Lease term shall be one hundred twenty three (123) months, beginning on the earlier to occur of: (i) thirty (30) days after issuance of the certificate of occupancy for the Initial Improvements (as defined in Exhibit B), or (ii) May 1, 2020 (such earlier date being the "Commencement Date") and ending one hundred twenty three (123) months after the Commencement Date (or, if the Commencement Date is not the first day of a calendar month, ending one hundred twenty three (123) months after the first day of the first full calendar month after the Commencement Date) (the "Term") which defined term shall include all renewals and extensions of the Term, if any. Upon the Commencement Date, Landlord and Tenant shall execute a Notice of Commencement in the form attached hereto as Exhibit C acknowledging the Commencement Date and the date the Lease will expire.

(c)    Landlord will deliver possession of the Premises to Tenant on December 16, 2020 for purposes of commencement of Tenant’s construction of the Initial Tenant Improvements (the date of such delivery being the “Delivery Date”). Within thirty (30) days after the Delivery Date, Landlord will cause the following work to be completed in the Premises (the “Delivery Obligations”): (i) performance, at Landlord’s expense, of the roof repairs described in the work proposal attached hereto as Exhibit B-1, (ii) performance of any work necessary to deliver the dock doors in good working order so long as the cost of such work does not exceed $5,000; provided, however, if the cost of such dock door work exceeds $5,000, Tenant shall be responsible for such excess costs, and (iii) performance of any work necessary to deliver the HVAC unit serving the office portion of the Building (“Office HVAC”) in good working order. The dock doors and Office HVAC will be deemed to have been delivered in good working order unless Tenant notifies Landlord in writing within thirty (30) days after the Delivery Date of any material deficiencies in the dock doors or Office HVAC, which deficiencies shall be promptly remedied by Landlord at its expense (subject to Tenant’s obligation to pay for any dock door work in excess of $5,000). Other than the Delivery Obligations, Landlord has no obligation to construct any improvements or perform any repairs to prepare the Premises for Tenant’s occupancy.

2.BASE RENT, ADDITIONAL RENT AND SECURITY DEPOSIT

(a)    Tenant shall pay to Landlord "Base Rent" in advance, without demand, deduction or set off (except as expressly stated otherwise in Section 20 of this Lease) equal to the following amounts for the following periods of time:




Period
Monthly Base Rent
Per Square Foot of Building

Monthly Base Rent
Commencement Date – Month 3*$0.00$0.00
Months 4 – 15$0.70$35,232.40
Months 16 – 27$0.72$36,113.21
Months 28 – 39$0.74$37,016.04
Months 40 – 51$0.75$37,941.44
Months 52 – 63$0.77$38,889.98
Months 64 – 75$0.79$39,862.23
Months 76 – 87$0.81$40,858.78
Months 88 – 99$0.83$41,880.25
Months 100 – 111$0.85$42,927.26
Months 112 – 123$0.87$44,000.44

*Tenant’s obligation to pay Base Rent for the Premises shall be abated for the initial three (3) months of the Term of the Lease (the “Base Rent Abatement Period ”). However, only Base Rent shall be abated during the Base Rent Abatement Period, and Tenant shall remain responsible for Tenant’s Proportionate Share of Operating Expenses and all other sums due under the Lease during the Base Rent Abatement Period.

The first monthly installment (after the expiration of any periods for which no Base Rent is due), plus the other monthly charges set forth in Section 2(b), shall be due on the date hereof; thereafter, monthly installments of Base Rent shall be due on the first day of each calendar month following the Commencement Date. If the Term begins on a day other than the first day of a month or ends on a day other than the last day of a month, the Base Rent and additional rent for such partial month shall be prorated.

(b)    Tenant shall pay, as additional rent (including for any period during which no Base Rent is due under Section 2(a) above), its Proportionate Share of the following items: (1) Taxes (defined below) and the cost of any tax consultant employed to assist Landlord in determining the fair tax valuation of the Building and Land; and (2) the cost of any insurance maintained by Landlord, and (3) a management fee not to exceed 3% of gross rents from the Premises (collectively, "Operating Expenses"). On the same day that Base Rent is due, Tenant shall pay to Landlord an amount equal to 1/12 of Landlord's estimate of Tenant's Proportionate Share of annual Operating Expenses. The initial monthly payments are based upon Landlord's estimate of the Operating Expenses for the year in question, and shall be increased or decreased annually to reflect the projected actual Operating Expenses for that year. Within 90 days after each calendar year or as soon thereafter as is reasonably practicable, Landlord shall deliver to Tenant a statement setting forth the actual Operating Expenses for such year. Within ninety (90) days after Tenant’s receipt of such annual statement (“Review Period”), Tenant may elect to inspect, at reasonable times, in a reasonable manner and with at least thirty (30) days prior written notice to Landlord, such of Landlord’s books of account and records as pertain to and contain information concerning such costs and expenses in order to verify the amounts thereof; and if Tenant does not so elect to review Landlord’s books during such ninety (90) day period, Tenant will be deemed to have approved Landlord’s calculation of Operating Expenses as for the calendar year covered by the statement. If Tenant's total payments in respect of Operating Expenses for any year are less than Tenant's Proportionate Share of Operating Expenses for that year, Tenant shall pay the difference to Landlord within ten days after Landlord's request therefor; if such payments are more than Tenant's Proportionate Share of Operating Expenses, Landlord shall retain such excess and credit it against Tenant's future monthly payments, except that any credit remaining at the expiration or earlier termination of this Lease shall be paid to Tenant within thirty (30) days after such expiration or termination. If Tenant determines during the Review Period that Operating Expenses for the year in question are less than reported in the annual statement by more than five percent (5%), Landlord shall reimburse Tenant’s expenses incurred as a result of Tenant’s inspection not to exceed $2,000. The amounts of the initial monthly Base Rent and Tenant's Proportionate Share of Operating Expenses (and the part thereof attributable to Taxes) are as follows:



Base Rent (Section 2(a))    $35,232.40
Estimated Operating Expenses (Taxes and insurance only) (Section 2(b))     $8,556.44
Total initial monthly payment    $43,788.84

(c)    If any payment required of Tenant under this Lease is not paid within five (5) days after due, Landlord may charge Tenant a fee equal to 5% of the delinquent payment to reimburse Landlord for its cost and inconvenience incurred as a consequence of Tenant's delinquency. Notwithstanding the forgoing, Tenant shall be entitled to one written notice with a ten (10) day opportunity to cure a delinquent payment within any consecutive twelve month period before Tenant is obligated to pay the late charge set forth in this paragraph.

(d)    All payments and reimbursements required to be made by Tenant under this Lease shall constitute "rent" (herein so called).

3.TAXES

(a)    Landlord shall pay all taxes, assessments and governmental charges whether federal, state, county, or municipal and whether they are imposed by taxing or management districts or authorities presently existing or hereafter created, including any assessments or charges from a property owner’s association or other encumbrances (collectively, "Taxes") that accrue against the Premises, the Land and the Building. As used herein, Taxes include the franchise tax, also known as a margin tax, codified in Chapter 71, Texas Tax Code. If at any time the present method of taxation shall be changed so that in lieu of the whole or any part of any Taxes levied, assessed or imposed on the Premises and leasehold improvements, there shall be levied, assessed or imposed on Landlord a substitute tax therefor directly on the rents received therefrom and/or a franchise tax, assessment, levy or charge measured by or based, in whole or in part, upon rents or income from the Premises (a “Substitute Tax”), then the Substitute Tax, or the part thereof so measured or based, shall be deemed Taxes for the purposes of this Section.

(b)    Tenant shall (1) before delinquency pay all taxes levied or assessed against any personal property, fixtures or alterations placed in the Premises and (2) upon the request of Landlord, deliver to Landlord receipts from the applicable taxing authority or other evidence acceptable to Landlord to verify that such taxes have been paid. If any such taxes are levied or assessed against Landlord or Landlord's property and (A) Landlord pays them or (B) the assessed value of Landlord's property is increased thereby and Landlord pays the increased taxes, then Tenant shall pay to Landlord such taxes within ten days after Landlord's request therefor.

(c)    TENANT HEREBY WAIVES ALL RIGHTS TO PROTEST THE APPRAISED VALUE OF THE PREMISES OR TO APPEAL THE SAME AND ALL RIGHTS TO RECEIVE NOTICES OF REAPPRAISALS AS SET FORTH IN SECTIONS 41.413 AND 42.015 OF THE TEXAS TAX CODE. However, Landlord, in its reasonable business judgment, will endeavor to challenge the appraised value of the Premises for ad valorem taxes so as to minimize, to the extent practicable and possible, the amount of Taxes applicable to the Premises.
4.LANDLORD'S MAINTENANCE

This Lease is intended to be a net lease; accordingly, Landlord's maintenance obligations are limited to maintenance, repair, and replacement at Landlord’s cost of the Building's roof, the slab, structural columns and structural walls (collectively, the "Building Structure"); however, Landlord shall not be responsible (1) for any such work until Tenant delivers to Landlord written notice of the need therefor or (2) for alterations to the Building Structure required by Law because of Tenant's use of the Premises (which alterations shall be performed by Tenant) or (3) any damage to the Building Structure caused by Tenant. The Building Structure does not include skylights, windows, glass or plate glass, doors, special storefronts or office entries, all of which shall be maintained by Tenant. Tenant acknowledges and agrees that Landlord has no maintenance or repair obligations with respect to the Premises, other than those expressly set forth in this Section 4.



5.TENANT'S MAINTENANCE AND REPAIR OBLIGATIONS

(a)    Tenant shall maintain all parts of the Premises [except only for maintenance work which Landlord is expressly responsible for under Section 4 above] including without limitation, truck court, exterior areas, dock and loading areas, man doors, truck doors, dock levelers, shelters, seals and bumpers (if any), lighting, plumbing, restrooms, water, sewer and electrical lines up to the meter, fire sprinklers and fire protection systems, entries, doors, ceilings, windows, interior walls, and the interior side of demising walls, electrical systems, and air rotation equipment in good condition and promptly make all necessary repairs and replacements to the Premises, normal wear and tear and damage by casualty excepted. Tenant shall keep the Premises, including all exterior areas, in a clean and sanitary condition at all times. Tenant shall repair and pay for any damage caused by a Tenant Party (defined below) or caused by Tenant's default hereunder.

(b)    Tenant shall maintain the hot water equipment and the heating, air condition, and ventilation equipment and systems (the "HVAC System") in good repair and condition and in accordance with Law and with such equipment manufacturers' suggested operation/maintenance service program; such obligation shall include replacement of all equipment necessary to maintain such equipment and system in good working order. Within ten days after the Commencement Date, Tenant shall enter into regularly scheduled preventive maintenance/service contracts for such equipment, each in compliance with Landlord's specifications and otherwise in form and substance and with a contractor reasonably acceptable to Landlord, and deliver copies thereof to Landlord. Tenant shall also provide Landlord with (i) a copy of all renewal or substitute maintenance/service contracts within 30 days prior to the expiration of the existing service contract, and (ii) upon Landlord's request, a copy of all maintenance or service reports with respect to such contract. At least 14 days before the end of the Term and upon written request from Landlord within ninety (90) days before the end of the Term, Tenant shall deliver to Landlord a certificate from an engineer reasonably acceptable to Landlord certifying that the hot water equipment and the HVAC System are then in good repair and working order, normal wear and tear excepted.

6.ALTERATIONS

The Initial Improvements to the Building shall be governed by the Work Letter attached to this Lease as Exhibit B. Otherwise, Tenant shall not make any alterations, additions or improvements (collectively, "Alterations"), to the Premises without the prior written consent of Landlord; provided, however, Tenant may make non-structural alterations to the Building without Landlord’s prior written consent (“Permitted Alterations”) so long as (i) such Permitted Alterations do not cost more than $50,000 in any instance or series of related instances, (ii) no governmental permit or approval is required for such Permitted Alterations, and (iii) Tenant provides Landlord with prior written notice of its intended Permitted Alterations. Landlord shall not be required to notify Tenant of whether it consents to any Alterations until it (a) has received plans and specifications therefor which are sufficiently detailed to allow construction of the work depicted thereon to be performed in a good and workmanlike manner, and (b) has had a reasonable opportunity to review them. If the Alterations will affect the Building Structure, HVAC System, or mechanical, electrical, or plumbing systems, then the plans and specifications therefor must be prepared by a licensed engineer reasonably acceptable to Landlord. Landlord's approval of any plans and specifications shall not be a representation that the plans or the work depicted thereon will comply with law or be adequate for any purpose, but shall merely be Landlord's consent to performance of the work. Upon completion of any Alterations, Tenant shall deliver to Landlord accurate, reproducible as-built plans therefor. Tenant may erect shelves, bins, machinery and trade fixtures provided that such items (1) do not alter the basic character of the Premises; (2) do not overload or damage the same; and (3) may be removed without damage to the Premises. Unless Landlord specifies in writing otherwise, all Alterations shall be Landlord's property when installed in the Premises. All work performed by a Tenant Party in the Premises (including that relating to the installations, repair, replacement, or removal of any item) shall be performed in accordance with Laws and with Landlord's specifications and requirements, in a good and workmanlike manner, and so as not to damage or alter the Building Structure or the Premises. Any contractors used by Tenant must carry liability insurance reasonably acceptable to Landlord, and


Tenant shall deliver evidence of such insurance to Landlord before any construction is commenced. In connection with any such alteration, addition, or improvement costing in excess of $10,000.00, Tenant shall pay to Landlord an administration fee of 5% of all costs incurred for such work. Tenant shall be responsible for compliance with American With Disabilities Act of 1990 for the interior, non-structural portions of the Premises, Landlord shall be responsible for compliance with the American With Disabilities Act of 1990 relative to the Building Structure, and all Building common areas including, but not limited to, parking areas, sidewalks, entrances, and access ways, unless such compliance is required solely in connection with Tenant's specific use of the Premises or a Tenant alteration of the Building, in which case such compliance shall be Tenant's responsibility.

7.SIGNS

Tenant shall not place, install or attach any signage, decorations, advertising media, blinds, draperies, window treatments, bars, or security installations to the Premises or the Building without Landlord's prior written approval, which shall not be unreasonably withheld, delayed or conditioned. Landlord hereby agrees that Tenant may install a sign on the exterior of the Building, subject to compliance with all applicable Laws, and the provisions of this Section 7. Upon the expiration or earlier termination of this Lease, Tenant shall remove all Tenant's signage, and Tenant shall repair, paint, and/or replace any portion of the Premises or the Building damaged or altered as a result of its signage when it is removed (including, without limitation, any discoloration of the Building). Tenant shall not (a) make any changes to the exterior of the Premises or the Building, (b) install any exterior lights, decorations, balloons, flags, pennants, banners or paintings, or (c) erect or install any signs, windows or door lettering, decals, window or storefront stickers, placards, decorations or advertising media of any type that is visible from the exterior of the Premises or the Building without Landlord's prior written consent. Landlord shall not be required to notify Tenant of whether it consents to any sign until it (1) has received detailed, to-scale drawings thereof specifying design, material composition, color scheme, and method of installation, and (2) has had a reasonable opportunity to review them.

8.UTILITIES

Tenant shall be solely responsible for arranging for utility service to the premises, including all electricity, water, sewer, gas (if any) and telecommunications services used at the Premises. Tenant shall pay all utility charges directly to the utility provider, together with any taxes, penalties, surcharges, maintenance charges, and the like pertaining thereto.

9.INSURANCE

Tenant shall maintain (a) workers' compensation insurance providing coverage for statutory benefits in the state in which the Premises is located and employer's liability coverage with minimum limits of not less than $1,000,000 for (i) each accident, (ii) each employee, and (iii) policy limit for disease (with a waiver of subrogation endorsement reasonably acceptable to Landlord); (b) commercial general liability insurance on the most current ISO Form CG 00 01 or coverage at least as broad as coverage provided under such form, to cover liability arising from occurrences on or about the Premises and acts of Tenant Parties on or about the Premises, without modification to the separation of insureds provision, with limits of not less than $1,000,000 per occurrence, $2,000,000 general aggregate; (c) business automobile liability insurance covering owned, hired and non-owned vehicle, with limits of not less than $1,000,000 combined single limit per occurrence for bodily injury and property damage liability; (d) umbrella/excess liability insurance, on an occurrence basis, that applies in excess of the required commercial general liability, business automobile liability, and employer’s liability policies with a minimum limit of $2,000,000 per occurrence and $2,000,000 in the annual aggregate; (e) property insurance – special form covering the replacement cost (without deduction for depreciation and containing ordinance or law coverage) of all Alterations and Tenant's property in the Premises (including without limitation removable trade fixtures and leasehold improvements), naming Landlord and Landlord's Mortgagee (defined below) as loss payee as their interests may appear with respect


to Alterations and leasehold improvements; (f) business income and extra expense insurance covering failure of Tenant's equipment and covering all periods of interruption, with limits not less than one hundred percent (100%) of all charges payable by Tenant under this Lease for a period of twelve (12) months; and (g) such other insurance as Landlord may reasonably require, including Pollution or Environmental Liability insurance. The foregoing commercial general liability and umbrella liability policies are subject to increases in coverage amounts, as reasonably determined by Landlord in the event Tenant is permitted in writing by Landlord to use the Premises for light manufacturing. Such liability policies shall (A) name Landlord, Landlord's Mortgagee, Landlord's agents, and their respective Affiliates (defined below), as additional insureds on a form that does not limit the coverage provided under such policy to any additional insured (i) by reason of other insurance available to such additional insured, or (ii) to claims for which a primary insured has agreed to indemnify the additional insured, and (B) provide primary and non-contributory coverage to Landlord, Landlord's Mortgagee, Landlord's agents, and their respective Affiliates when any policy issued to such parties (collectively or individually) is similar or duplicate in coverage, in which case such policy shall be excess over Tenant's policies. All policies required to be maintained by Tenant hereunder shall (1) be issued by an insurance company with a rating of at least "A: VII" or better as set forth in the most current issue of AM Best's Insurance Reports, unless otherwise approved by Landlord in writing, (2) provide that such insurance may not be cancelled unless 30 days' prior written notice is first given to Landlord, and (3) be delivered to Landlord by Tenant before the earlier of the Commencement Date or the date Tenant occupies the Premises and at least 15 days before each renewal thereof. Landlord must give its prior written approval to all deductibles and self-insured retentions under Tenant's policies. No insurance policy will contain endorsements that restrict, limit, or exclude coverage in a manner that is inconsistent with the foregoing requirements. In the event Landlord engages a third party servicer for collection and review of insurance certificates from tenants of the Premises/Building on Landlord's behalf, upon receipt of written notice from Landlord of the identity of such third party servicer, Tenant agrees to register with such servicer for such servicer's receipt of Tenant's certificates of insurance, provide such servicer with Tenant's certificates of insurance and communicate with such servicer regarding Tenant's insurance required hereunder and compliance therewith.

Landlord shall maintain “AllRisk” property insurance at replacement cost on the Building at all times during the Term of the Lease. The cost for such insurance and other insurance maintained by Landlord shall be included in Operating Expenses.
10.CASUALTY DAMAGE

(a)    Tenant shall give written notice to Landlord of any damage to the Premises or the Building promptly on discovery of the same. If the Premises or the Building is totally destroyed by an insured peril, or so damaged by an insured peril that, in Landlord's reasonable estimation, rebuilding or repairs cannot be substantially completed within 270 days after the date of Landlord's actual knowledge of such damage, then either Landlord or (if a Tenant Party did not cause such damage) Tenant may terminate this Lease by delivering to the other written notice thereof within 30 days after such damage, in which case, the rent shall be abated from the date of occurrence through the unexpired portion of this Lease, effective upon the date such damage occurred. Time is of the essence with respect to the delivery of such notices.

(b)    Subject to Section 10(c), if this Lease is not terminated under Section 10(a), then Landlord shall restore the Premises to substantially its previous condition, except that Landlord shall not be required to rebuild, repair or replace any part of the contents required to be covered by Tenant's insurance under Section 9 and Tenant shall use the proceeds from such insurance for the replacement of trade fixtures, furniture, inventory and other personal property and for the restoration of Tenant's Alterations, improvements and additions to the Premises. If the Premises are untenantable, in whole or in part, during the period beginning on the date such damage occurred and ending on the date of substantial completion of Landlord's repair or restoration work (the "Repair Period") then the rent for such period shall be reduced to such extent as may be fair and reasonable under the circumstances.

(c)    If the Premises are destroyed or substantially damaged by any peril not covered by the insurance maintained by Landlord or any Landlord's Mortgagee (defined below) requires that insurance proceeds be applied to the indebtedness secured by its Mortgage (defined below) or to the Primary Lease (defined below) obligations,


Landlord may terminate this Lease by delivering written notice of termination to Tenant within 30 days after such destruction or damage or such requirement is made known by any such Landlord's Mortgagee, as applicable, whereupon all rights and obligations hereunder shall cease and terminate, except for any liabilities of Landlord orTenant which accrued before this Lease is terminated, provided that all Base Rent and any additional rent accruing after the date of the casualty shall be abated, and any rent or other monies paid in advance by Tenant under the terms of this Lease for the period from and after the casualty shall be repaid to Tenant. If Landlord does not terminate this Lease under this provision, then Landlord shall restore the Premises and rent shall be abated in accordance with paragraph 10(b) above.

11.LIABILITY, INDEMNIFICATION, WAIVER OF SUBROGATION AND NEGLIGENCE

(a)    Landlord shall not be liable to Tenant or Tenant's agents, employees or contractors, or those claiming by, through, or under any of them for any injury to or death of any person or persons or any damage to or loss, or loss of use of any real or personal property caused by casualty, theft, or any criminal or tortuous acts or omissions of any third party. In addition, Landlord and Tenant each waives any claims it might have against the other for any damage to or theft, destruction, loss or loss of use of any property, to the extent the same is insured against under any insurance policy that covers the Premises, Landlord's or Tenant's fixtures, personal property, leasehold improvements, or business, or is required to be insured against by the party which might have such claim under the terms of this Lease, REGARDLESS OF WHETHER THE NEGLIGENCE (OF WHATEVER TYPE OR NATURE) OR FAULT OF THE OTHER PARTY CAUSED SUCH LOSS. EACH PARTY SHALL CAUSE ITS INSURANCE CARRIER TO ENDORSE ALL APPLICABLE POLICIES WAIVING THE CARRIER'S RIGHT OF RECOVERY UNDER SUBROGATION OR OTHERWISE AGAINST THE OTHER PARTY. For the purpose of the foregoing waiver, the amount of any deductible applicable to any loss or damage shall be deemed covered by, and recoverable by the insured under the insurance policy to which such deductible relates.

(b)    Subject to Section 11(a), Tenant shall defend, indemnify, and hold harmless Landlord and its agents and employees from and against all claims, demands, liabilities, causes of action, suits, judgments, attorneys' fees and expenses for any Loss arising from any occurrence within, on or about the Premises or arising from Tenant's failure to perform its obligations under this Lease or arising from any act or omission (whether negligent, intentional or otherwise) of Tenant or Tenant's agents, employees, invitees or contractors, except to the extent that a Loss is caused by the negligence, gross negligence or intentional misconduct of Landlord. The term "Loss" means any injury to or death of any person or persons or any damage to or theft, destruction, loss, or loss of use of any real or personal property caused by casualty, theft, fire, or any acts or omissions of any person or party, and any injury or damage or inconvenience which may arise through repair or alteration of any part of the Premises, or failure to make repairs, or from any other cause.

(c)    Subject to Section 11(a), Landlord shall defend, indemnify, and hold harmless Tenant and its agents and employees from and against any and all claims, demands, liabilities, causes of action, suits, judgments, attorneys’ fees and expenses for a Loss only to the extent caused by the negligence, gross negligence, or willful misconduct on the part of Landlord or its agents, employees or contractors.

THE PROVISIONS OF THIS SECTION 11 SHALL SURVIVE TERMINATION OR EXPIRATION OF THIS LEASE.

12.USE

The Premises shall be used only for offices, manufacturing, receiving, storing, shipping and selling products, materials and merchandise made or distributed by Tenant and for such other lawful purposes as may be incidental thereto, provided that such uses are in compliance with all applicable Laws; however, no retail sales may be made from the Premises. Tenant shall be solely responsible for complying with all Laws applicable to the use,


occupancy, and condition of the Premises. Tenant shall not permit any objectionable or unpleasant odors, smoke, dust, gas, light, noise or vibrations to emanate from the Premises; nor take any other action that would constitute a nuisance or would disturb, unreasonably interfere with, or endanger Landlord or any other person; nor permit the Premises to be used for any purpose or in any manner that would (1) void the insurance thereon, (2) increase the insurance risk, or (3) cause the disallowance of any sprinkler credits. Tenant shall pay to Landlord on demand any increase in the cost of any insurance on the Premises incurred by Landlord, which is caused by Tenant's use of the Premises or because Tenant vacates the Premises. Tenant and its invitees shall be allowed access to the Premises and parking facilities 24 hours per day, seven days per week.
13.INSPECTION

Upon twenty four (24) hours notice, Landlord and Landlord's agents and representatives may enter the Premises during business hours to inspect the Premises; to make such repairs as may be required or permitted under this Lease; to perform any unperformed obligations of Tenant hereunder; and to show the Premises to prospective purchasers, mortgagees, ground lessors, and (during the last 6 months of the Term) tenants. During the last 6 months of the Term, Landlord may erect a sign on the Premises indicating that the Premises are available. Tenant shall notify Landlord in writing of its intention to vacate the Premises at least 60 days before Tenant will vacate the Premises; such notice shall specify the date on which Tenant intends to vacate the Premises (the "Vacation Date"). At least 30 days before the Vacation Date, Tenant shall arrange to meet with Landlord for a joint inspection of the Premises. After such inspection, Landlord shall prepare a list of items that Tenant must perform before the Vacation Date, which shall not include repairs due to normal wear and tear or casualty. If Tenant fails to arrange for such inspection, then Landlord may conduct such inspection and Landlord's determination of the work Tenant is required to perform before the Vacation Date shall be conclusive. If Tenant fails to perform such work before the Vacation Date, then Landlord may perform such work at Tenant's cost. Tenant shall pay all costs incurred by Landlord in performing such work within ten days after Landlord's request therefor.

14.ASSIGNMENT AND SUBLETTING

(a)Tenant shall not, without the prior written consent of Landlord, which will not be unreasonably withheld, delayed or conditioned (except that Landlord may, in its sole discretion, withhold its consent to any proposed collateral assignment of this Lease), (1) advertise that any portion of the Premises is available for lease or cause or allow any such advertisement, (2) assign, transfer, or encumber this Lease or any estate or interest herein, whether directly or by operation of law, (3) permit any other entity to become Tenant hereunder by merger, consolidation, or other reorganization, (4) if Tenant is an entity other than a corporation whose stock is publicly traded (or a corporation whose stock is in the process of being publicly traded), permit the transfer of an ownership interest in Tenant so as to result in a change in the current control of Tenant, (5) sublet any portion of the Premises, (6) grant any license, concession, or other right of occupancy of any portion of the Premises, or (7) permit the use of the Premises by any parties other than Tenant (any of the events listed in items (1) through (7) being a "Transfer"). If Tenant requests Landlord's consent to a Transfer, then Tenant shall provide Landlord with a written description of all terms and conditions of the proposed Transfer, copies of the proposed documentation, and the following information about the proposed transferee: name and address; reasonably satisfactory information about its business and business history; its proposed use of the Premises; banking, financial, and other credit information; and general references sufficient to enable Landlord to determine the proposed transferee's creditworthiness and character. Tenant shall reimburse Landlord for its reasonable attorneys' fees and other expenses incurred in connection with considering any request for its consent to a Transfer up to but not exceeding $1,500.00. If Landlord consents to a proposed Transfer, then the proposed transferee shall deliver to Landlord a written agreement whereby it expressly assumes the Tenant's obligations hereunder (however, any transferee of less than all of the space in the Premises shall be liable only for obligations under this Lease that are properly allocable to the space subject to the Transfer, and only to the extent of the rent it has agreed to pay Tenant therefor). Landlord's consent to a Transfer shall not release Tenant from performing its obligations under this Lease, but rather Tenant and its transferee shall be jointly and severally liable therefor. Landlord's consent to any Transfer shall not waive Landlord's rights as to any subsequent Transfers. If an Event of Default occurs while the Premises or any part thereof are subject to a Transfer,


then Landlord, in addition to its other remedies, may collect directly from such transferee all rents becoming due to Tenant and apply such rents against Tenant's rent obligations under this Lease. Tenant authorizes its transferees to make payments of rent directly to Landlord upon receipt of notice from Landlord to do so.

(b)Notwithstanding anything to the contrary in this Lease, Tenant may (i) assign or sublet the Premises, or any part thereof, to any entity controlling, controlled by, or under common control with the original Tenant named herein (a “Tenant Affiliate”) having a net worth not less than the net worth of Tenant as of the date hereof, and/or (ii) transfer the ownership interests controlling Tenant to a person or entity having a net worth not less than the net worth of Tenant as of the date hereof, without the prior written consent of Landlord; provided, however, Tenant shall provide at least ten (10) days written notice prior to assigning this Lease to, or entering into any sublease with, any Tenant Affiliate, or transferring the ownership interests, and shall include all documentation establishing the Tenant Affiliate’s or transferee’s net worth in such notice. Further notwithstanding the above, Tenant may assign or sublet the Premises, or any part thereof, to any successor to Tenant by purchase, merger, consolidation or reorganization (hereinafter, collectively, referred to as “Permitted Transfer”, and such transferee, a “Permitted Transferee”) without the consent of Landlord, provided: (1) no Event of Default exists; (2) if such proposed transferee is a successor to Tenant by purchase, said proposed transferee shall acquire all or substantially all of the stock or assets of Tenant’s business or, if such proposed transferee is a successor to Tenant by merger, consolidation or reorganization, the continuing or surviving entity shall own all or substantially all of the assets of Tenant; (3) such proposed transferee shall have a net worth not less than the net worth of Tenant as of the date hereof; and (4) Tenant shall provide at least ten (10) days written notice prior to any Permitted Transfer and shall include reasonable documentation establishing the transferee’s net worth in such notice.

(c)Landlord may, within 30 days after submission of Tenant's written request for Landlord's consent to a Transfer, cancel this Lease (or, as to a subletting, cancel as to the portion of the Premises proposed to be sublet) as of the date the proposed Transfer was to be effective; provided, however, Tenant may elect by written notice to landlord within twenty (20) days after receipt of Landlord’s cancellation notice to rescind in Transfer Request in which case this Lease shall not be cancelled but shall remain in full force and effect. If Landlord cancels this Lease as to any portion of the Premises, then this Lease shall cease for such portion of the Premises and Tenant shall pay to Landlord all rent accrued through the cancellation date relating to the portion of the Premises covered by the proposed Transfer. Thereafter, Landlord may lease such portion of the Premises to the prospective transferee (or to any other person) without liability to Tenant.

(d)Tenant shall pay to Landlord one-half of all rents received by Tenant under any Transfer, which are in excess of the rents payable by Tenant under this Lease and the reasonable costs incurred by Tenant in connection with such reletting. Tenant shall hold such amounts in trust for Landlord and pay them to Landlord within ten (10) days after receipt.

15.CONDEMNATION

If any portion of the Building is taken for any public or quasi-public use by right of eminent domain or private purchase in lieu thereof (a "Taking"), and the Taking prevents or materially interferes with the use of the Premises for the purpose for which they were leased to Tenant, either party may terminate this Lease by delivering to the other written notice thereof within 30 days after the Taking, in which case rent shall be abated during the unexpired portion of the Term, effective on the date of such Taking. If a portion of the Land (but not any portion of the Building) is subject to a Taking, but the Taking does not prevent or materially interfere with the use of the Premises for the purpose for which they were leased to Tenant, then neither party may terminate this Lease, but the rent payable during the unexpired portion of the Term shall be reduced to such extent as may be fair and reasonable under the circumstances. All compensation awarded for any Taking shall be the property of Landlord, and Tenant assigns any interest it may have in any such award to Landlord; however, Landlord shall have no interest in any award made to Tenant for loss of business or goodwill or for the taking of Tenant's trade fixtures, the cost of relocating Tenant and/or disruption of Tenant's business, if a separate award for such items is made to Tenant.



16.SURRENDER OF PREMISES, HOLDING OVER

(a)    No act by Landlord shall be an acceptance of a surrender of the Premises, and no agreement to accept a surrender of the Premises shall be valid unless it is in writing and signed by Landlord. At the end of the Term or the termination of Tenant's right to possess the Premises, Tenant shall (1) deliver to Landlord the Premises with all improvements located thereon in good repair and condition, reasonable wear and tear (subject however to Tenant's maintenance obligations) excepted, and with the HVAC System and hot water equipment, light and light fixtures (including ballasts), and overhead doors and related equipment in good working order, (2) deliver to Landlord all keys to the Premises, and (3) remove all signage placed on the Premises, the Building, or the Land by or at Tenant's request. All Building fixtures, alterations, additions, and improvements (whether temporary or permanent) shall be Landlord's property and shall remain on the Premises except as provided in the next two sentences. Provided that Tenant has performed all of its obligations hereunder, Tenant may remove all equipment, trade fixtures, furniture, and personal property placed in the Premises by Tenant (but Tenant shall not remove any such item which was paid for, in whole or in part, by Landlord). For purposes of clarification of the foregoing, Landlord agrees that Tenant may remove any equipment used in Tenant’s business operations from the Premises. Additionally, Tenant shall remove such alterations, additions, improvements, fixtures, equipment, wiring, furniture, and other property as Landlord may request, provided such request is made within thirty (30) days after the end of the Term and provided that the installation or construction of the applicable alteration, improvement, additions, fixture or wiring was not consented to by Landlord in writing (unless at the time of consent, Landlord informed Tenant that such item would need to be removed upon expiration of the Lease). All items not so removed shall, at the option of Landlord, be deemed abandoned by Tenant and may be appropriated, sold, stored, destroyed, or otherwise disposed of by Landlord without notice to Tenant and without any obligation to account for such items and Tenant shall pay for the costs incurred by Landlord in connection therewith. Any such disposition shall not be considered a strict foreclosure or other exercise of Landlord's rights in respect of the security interest granted under Section 26. All work required of Tenant under this Section 16 shall be coordinated with Landlord and be done in a good and workmanlike manner, in accordance with all Laws, and so as not to damage the Building or unreasonably interfere with other tenants' use of their premises. Tenant shall, at its expense, repair all damage caused by any work performed by Tenant under this Section 16.

(b)    If Tenant fails to vacate the Premises at the end of the Term or otherwise remains in possession of any portion of the Premises, then such holdover shall be an incurable default, and Tenant shall be a Tenant at will and Tenant shall pay, in addition to the other rent due hereunder, a monthly rental (without reduction for partial months) equal to 150% of all rental payable during the last month of the Term. Notwithstanding the foregoing, nothing under Texas law shall require Landlord to give Tenant more than thirty (30) days prior written notice to terminate Tenant’s tenancy-at-will. Additionally, Tenant shall defend, indemnify, and hold harmless Landlord from any damage, liability and expense incurred because of such holding over, including, without limitation, attorneys’ fees and expenses, and loss of future tenants or rentals. No payments of money by Tenant to Landlord after the Term shall reinstate, continue or extend the Term, and no extension of this Term shall be valid unless it is in writing and signed by Landlord and Tenant.

17.QUIET ENJOYMENT

Provided Tenant has fully performed its obligations under this Lease, and subject to the terms and provisions of this Lease, Tenant shall peaceably and quietly hold and enjoy the Premises for the Term, without hindrance from Landlord or any party claiming by, through, or under Landlord.

18.EVENT OF DEFAULT

Each of the following events shall constitute an "Event of Default" under this Lease:



(a)    Tenant fails to pay any rent when due or any payment or reimbursement required hereunder when due, and in either case such failure continues for a period of five days from the date such payment was due, however, that only for one such failure in any consecutive 12-month period, such failure shall not constitute an Event of Default if the failure in question is remedied within ten (10) days after Tenant’s receipt of written notice from Landlord.

(b)    The filing of a petition by or against Tenant or any guarantor of Tenant's obligations hereunder (1) in any bankruptcy or other insolvency proceeding; (2) seeking any relief under any debtor relief Law; (3) for the appointment of a liquidator, receiver, trustee, custodian, or similar official for all or substantially all of Tenant's property or for Tenant's interest in this Lease; or (4) for reorganization or modification of Tenant's capital structure (however, if any such petition is filed against Tenant, then the filing of such petition shall not constitute an Event of Default, unless it is not dismissed within sixty (60) days after the filing thereof).

(c)    Tenant fails to discharge any lien placed upon the Premises in violation of Section 22 within thirty (30) days after any such lien or encumbrance is filed against the Premises.

(d)    Tenant fails to comply with any term, provision or covenant of this Lease (other than those listed in this Section 18), and such failure continues for thirty (30) days, or immediately if the failure involves a hazardous condition, after written notice thereof to Tenant. If it will reasonably take more than thirty (30) days to cure such default, then Tenant will have a reasonable time to cure so long as Tenant promptly commences its effort to cure and diligently pursues such cure to completion. In addition, if Landlord provides Tenant with notice of Tenant's failure to comply with the same specific term, provision or covenant of this Lease on more than two (2) occasions during any 12 month period, Tenant's subsequent violation of the same term, provision or covenant shall, at Landlord's option, be deemed an incurable Event of Default by Tenant.

(e)    In the event Tenant vacates all or substantially all of the Premises for five (5) or more days no Event of Default shall occur so long as (i) Tenant provides Landlord prior written notice of Tenant's intent to vacate, (ii) Tenant pays any additional insurance premiums which may result from such vacation, (iii) Tenant takes such action as Landlord may reasonably request to protect the Premises (including the Building) from vandalism and trespass, and (iv) Tenant otherwise continues to observe and perform all of Tenant's obligations and covenants contained in this Lease, including keeping all Building systems in the Premises operating at levels necessary to prevent damage to the Building or the Building systems, as reasonably determined by Landlord, and if such vacation continues for any period of ninety (90) or more consecutive days (other than a vacancy due to a casualty, condemnation, or a vacancy for which Tenant is expressly entitled to abatement of rent under this Lease) Landlord shall have the right, but not the obligation, to terminate this Lease by delivering written notice of termination to Tenant prior to the date that Tenant occupies or re-occupies all or substantially all of the Premises. For purposes of this section, Tenant shall be considered to have “vacated” the Premises if Tenant shuts down or “mothballs” its business operations in the Premises, or removes all or substantially all of its equipment and property in the Premises in connection with a cessation of business operations in the Premises, but Tenant shall not be considered to have “vacated” the Premises during any period in which a governmental order requires or recommends that employees refrain from entering the work place, such as a “work stoppage” or “shelter in place” order.

19.REMEDIES

(a)    Upon any Event of Default, Landlord may, in addition to all other rights and remedies afforded Landlord hereunder or by Law, take any of the following actions:

(1)    Terminate this Lease by giving Tenant written notice thereof; in which event, Tenant shall pay to Landlord the sum of (A) all rent accrued hereunder through the date of termination, (B) all amounts due under Section 19(b), and (C) an amount equal to (i) the total rent that Tenant would have been required to pay for the remainder of the Term discounted to present value at a per annum rate equal to the rate of interest set forth for 26-


week U.S. governmental bills sold at a discount from face value in units of $10,000 to $1,000,000 as published on the date this Lease is terminated by The Wall Street Journal, Southwest Edition, in its listing of "Money Rates" under the heading "Treasury Bills" (or, if no such rate is published, the "Discount Rate" as published on such date under the "Money Rates" listing), minus (ii) the then present fair rental value of the Premises for such period, similarly discounted; or

(2)    Terminate Tenant's right to possess the Premises without terminating this Lease by giving written notice thereof to Tenant, in which event Tenant shall pay to Landlord (A) all rent and other amounts accrued hereunder to the date of termination of possession, (B) all amounts due from time to time under Section 19(b), and (C) all rent and other sums required hereunder to be paid by Tenant during the remainder of the Term, diminished by any net sums thereafter received by Landlord through reletting the Premises during such period. Landlord shall use commercially reasonable efforts to mitigate damages; provided, however, Landlord shall not be liable for, nor shall Tenant's obligations hereunder be diminished because of, Landlord's failure upon commercially reasonable effort to relet the Premises or to collect rent due for a reletting and Landlord shall be deemed to have complied with this mitigation requirement so long as Landlord places signage on the Premises and lists the Premises in substantially the same way it does for other similar space in its inventory. Tenant shall not be entitled to the excess of any consideration obtained by reletting over the rent due hereunder. Reentry by Landlord in the Premises shall not affect Tenant's obligations hereunder for the unexpired Term; rather, Landlord may, from time to time, bring action against Tenant to collect amounts due by Tenant, without the necessity of Landlord's waiting until the expiration of the Term. Unless Landlord delivers written notice to Tenant expressly stating that it has elected to terminate this Lease, all actions taken by Landlord to exclude or dispossess Tenant of the Premises shall be deemed to be taken under this Section 19(a)(2). If Landlord elects to proceed under this Section 19(a)(2), it may at any time elect to terminate this Lease under Section 19(a).

Additionally, without notice, Landlord may alter locks or other security devices at the Premises to deprive Tenant of access thereto, and Landlord shall not be required to provide a new key or right of access to Tenant.

(b)    Tenant shall pay to Landlord all costs incurred by Landlord (including court costs and reasonable attorneys' fees and expenses) in (1) obtaining possession of the Premises, (2) removing and storing Tenant's or any other occupant's property, (3) repairing, restoring, altering, remodeling, or otherwise putting the Premises into condition acceptable to a new tenant, (4) if Tenant is dispossessed of the Premises and this Lease is not terminated, reletting all or any part of the Premises (including brokerage commissions, cost of tenant finish work, and other costs incidental to such reletting), (5) performing Tenant's obligations which Tenant failed to perform, and (6) enforcing, or advising Landlord of; its rights, remedies, and recourses. Landlord's acceptance of rent following an Event of Default shall not waive Landlord's rights regarding such Event of Default. Landlord's receipt of rent with knowledge of any default by Tenant hereunder shall not be a waiver of such default, and no waiver by Landlord of any provision of this Lease shall be deemed to have been made unless set forth in writing and signed by Landlord. No waiver by Landlord of any violation or breach of any of the terms contained herein shall waive Landlord's rights regarding any future violation of such term or violation of any other term. If Landlord repossesses the Premises pursuant to the authority herein granted, then Landlord shall have the right to (A) keep in place and use or (B) remove and store, at Tenant's expense, all of the furniture, fixtures, equipment and other property in the Premises, including that which is owned by or leased to Tenant at all times before any foreclosure thereon by Landlord or repossession thereof by any lessor thereof or third party having a lien thereon. Landlord may relinquish possession of all or any portion of such furniture, fixtures, equipment and other property to any person (a "Claimant") who presents to Landlord a copy of any instrument represented by Claimant to have been executed by Tenant (or any predecessor of Tenant) granting Claimant the right under various circumstances to take possession of such furniture, fixtures, equipment or other property, without the necessity on the part of Landlord to inquire into the authenticity or legality of the instrument. Landlord may, at its option and without prejudice to or waiver of any rights it may have, (i) escort Tenant to the Premises to retrieve any personal belongings of Tenant and/or its employees not covered by the Landlord's statutory lien or the security interest described in Section 26 or (ii) obtain a list from Tenant of the personal property of Tenant and/or its employees that is not covered by the Landlord's statutory lien or the security interest described in Section 26, and make such property available to Tenant and/or Tenant's employees; however, Tenant first shall pay in cash all costs and estimated expenses to be incurred in connection with the removal of such property and making it available. The rights of Landlord herein stated are in addition to any and all other rights that


Landlord has or may hereafter have at law or in equity, and Tenant agrees that the rights herein granted Landlord are commercially reasonable.

(c)    TENANT AND LANDLORD HEREBY KNOWINGLY AND VOLUNTARILY WAIVE TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTER CLAIM, BROUGHT BY ONE PARTY AGAINST THE OTHER OR ANY MATTER WHATSOEVER ARISING OUT OF OR IN ANY WAY CONNECTED WITH THIS LEASE, THE RELATIONSHIP OF LANDLORD AND TENANT CREATED HEREBY, TENANT'S USE OR OCCUPANCY OF THE PREMISES AND/OR ANY CLAIM FOR INJURY OR DAMAGE. THE PARTIES ARE HEREBY AUTHORIZED TO FILE A COPY OF THIS PARAGRAPH IN ANY PROCEEDING AS CONCLUSIVE EVIDENCE OF THE FOREGOING WAIVER.

20.LANDLORD'S DEFAULT

If Landlord fails to perform any of its obligations hereunder within thirty (30) days after written notice from Tenant specifying such failure (provided that Landlord shall be allowed such additional time as may be reasonably necessary so long as Landlord commences performance within such thirty (30) day period and thereafter diligently pursues such failure to completion) (a “Landlord’s Default”), Tenant's exclusive remedy shall be an action for damages, except as expressly provided otherwise in this paragraph. Unless Landlord fails to so cure such Landlord’s Default after such notice, Tenant shall not have any remedy or cause of action by reason thereof. If Landlord’s Default renders the Premises untenantable, Tenant shall so advise Landlord in Tenant’s written notice and Tenant shall be entitled to an abatement of Base Rent based on the portion of the Premises which is untenantable until Landlord cures Landlord’s Default. In the event of a Landlord’s Default, Tenant shall have the right to cure Landlord’s Default when necessary to address an emergency situation or to prevent waste and Tenant shall have the right to offset amounts reasonably and actually incurred by Tenant to cure Landlord’s Default against Base Rent next coming due and payable to Landlord. If Landlord fails to pay the Construction Allowance when due following Tenant’s compliance with the terms and conditions of Exhibit B (including Section 3 thereof) and such failure constitutes a Landlord’s Default (provided that Landlord’s cure period after notice of default shall be limited to 30 days), Tenant shall have the right to offset the unpaid balance of the Construction Allowance against Base Rent next coming due under the Lease. Liability of Landlord to Tenant for any default by Landlord, shall be limited to actual, direct, but not consequential, damages therefor and, subject to the provisions in this paragraph, shall be recoverable only from the interest of Landlord in the Building and the Land; provided, however, if Landlord does not maintain an equity interest in the Building and the Land of at least 20% of the actual value of the Building and Land, then in such case the Landlord shall be liable for Tenant’s actual and direct damages from a Landlord’s Default to the extent such damages are not recoverable from Landlord’s interest in the Building and the Land.  However, Tenant agrees that none of Landlord’s owners, partners, members, investors, employees or officers shall be personally liable for any claim against Landlord. TENANT HEREBY WAIVES ITS STATUTORY LIEN UNDER SECTION 91.004 OF THE TEXAS PROPERTY CODE.

21.MORTGAGES

(a)    This Lease shall be subordinate to any deed of trust, mortgage or other security instrument (a "Mortgage") and any ground lease, master lease, or primary lease (a "Primary Lease") that now or hereafter covers any portion of the Premises (the mortgagee under any Mortgage or the lessor under any Primary Lease is referred to herein as "Landlord's Mortgagee") and to increases, renewals, modifications, consolidations, replacements, and extensions thereof; provided, however; so long as Tenant is the sole tenant of the Building the foregoing automatic subordination shall be conditioned on Tenant’s receipt of a subordination non-disturbance and attornment agreement (“SNDA”) on terms and conditions reasonably acceptable to Tenant and any Landlord’s Mortgagee. Tenant agrees to execute and return any such SNDA with ten (10) days after written request provided the terms and conditions thereof are reasonably acceptable to Tenant. However, any Landlord's Mortgagee may elect to subordinate its Mortgage or Primary Lease (as the case may be) to this Lease by delivering written notice thereof to Tenant.



(b)    Tenant shall attorn to any party succeeding to Landlord's interest in the Premises, whether by purchase, foreclosure, deed in lieu of foreclosure, power of sale, termination of lease, or otherwise, upon such party's request, and shall execute such agreements confirming such attornment as such party may reasonably request. Tenant shall not seek to enforce any remedy it may have for any default on the part of Landlord without first giving written notice by certified mail, return receipt requested, specifying the default in reasonable detail to any Landlord's Mortgagee whose address has been given to Tenant, and affording such Landlord's Mortgagee the same opportunity to perform Landlord's obligations hereunder.

(c)    Notwithstanding any such attornment or subordination of a Mortgage or Primary Lease to this Lease, the Landlord's Mortgagee shall not be liable for any acts of any previous landlord, shall not be obligated to furnish the Construction Allowance (as defined in Exhibit B) and shall not be bound by any amendment to which it did not consent in writing nor any payment of rent made more than one month in advance.

22.ENCUMBRANCES

Tenant has no authority, express or implied, to create or place any lien or encumbrance of any kind or nature whatsoever upon, or in any manner to bind Landlord's property or the interest of Landlord or Tenant in the Premises or to charge the rent for any claim in favor of any person dealing with Tenant, including those who may furnish materials or perform labor for any construction or repairs. Landlord shall promptly deliver to Tenant copies of any notices of mechanics liens received by Landlord. Tenant shall pay or cause to be paid all sums due for any labor performed or materials furnished in connection with any work performed on the Premises by or at the request of Tenant within thirty (30) days after the filing of any such lien, unless Tenant is validly contesting the lien in good faith and provides to Landlord a bond in the amount of 150% of the claim or provides other security reasonably acceptable to Landlord. Tenant shall give Landlord immediate written notice of the placing of any lien or encumbrance against the Premises.

23.MISCELLANEOUS

(a)    Words of any gender used in this Lease shall include any other gender, and words in the singular shall include the plural, unless the context otherwise requires. The captions inserted in this Lease are for convenience only and in no way affect the interpretation of this Lease. The following terms shall have the following meanings: "Laws" shall mean all federal, state, and local laws, rules, and regulations; all court orders, governmental directives, and governmental orders; and all restrictive covenants affecting the Premises, and "Law" shall mean any of the foregoing; "affiliate" shall mean any person or entity which, directly or indirectly, controls, is controlled by, or is under common control with the party in question; "Tenant Party" shall include Tenant, any assignees claiming by, through, or under Tenant, any subtenants claiming by, through, or under Tenant, and any of their respective agents, contractors, employees, and invitees; and "including" shall mean including, without limitation. The normal rule of construction that any ambiguities be resolved against the drafting party shall not apply to the interpretation of this Lease or any exhibits or amendments hereto.

(b)    Landlord may transfer and assign, in whole or in part, its rights and obligations in the Building and property that are the subject to this Lease, in which case Landlord shall have no further liability hereunder. Each party shall furnish to the other, promptly upon demand, a corporate resolution, proof of due authorization by partners, or other appropriate documentation evidencing the due authorization of such party to enter into this Lease.

(c)    Whenever a period of time is herein prescribed for action to be taken by a party (other than the payment of rent), the party shall not be liable or responsible for, and there shall be excluded from the computation for any such period of time, any delays due to strikes, riots, acts of God, shortages of labor or materials, war, governmental laws, regulations, or restrictions, or any other causes of any kind whatsoever which are beyond the control of the party in question.



(d)    Tenant shall, from time to time, but no more than twice per 12-month period, within ten days after request of Landlord, deliver to Landlord, or Landlord's designee, a certificate of occupancy for the Premises, financial statements for itself and any guarantor of its obligations hereunder, evidence reasonably satisfactory to Landlord that Tenant has performed its obligations under this Lease (including evidence of the payment of the Security Deposit), and an estoppel certificate stating that this Lease is in full effect, the date to which rent has been paid, the unexpired Term and such other factual matters pertaining to this Lease as may be requested by Landlord. Tenant's obligation to furnish the above-described items in a timely fashion is a material inducement for Landlord's execution of this Lease. Landlord agrees to provide, for Tenant, an estoppel certificate for any loan transactions or other transactions where confirmation of the validity of this Lease would be deemed reasonably necessary.

(e)    This Lease constitutes the entire agreement of the Landlord and Tenant with respect to the subject matter of this Lease, and contains all of the covenants and agreements of Landlord and Tenant with respect thereto. Landlord and Tenant each acknowledge that no representations, inducements, promises or agreements, oral or written, have been made by Landlord or Tenant, or anyone acting on behalf of Landlord or Tenant, which are not contained herein, and any prior agreements, promises, negotiations, or representations not expressly set forth in this Lease are of no effect. This Lease may not be altered, changed or amended except by an instrument in writing signed by both parties hereto. This Lease shall not be effective until an original of this Lease executed by both Landlord and Tenant is delivered to and accepted by Landlord.

(f)    All obligations of Tenant hereunder not fully performed by the end of the Term shall survive, including, without limitation, all payment obligations with respect to Operating Expenses and utilities and all obligations concerning the condition and repair of the Premises. Upon the end of the Term and before Tenant vacates the Premises, Tenant shall pay to Landlord any amount reasonably estimated by Landlord as necessary to put the Premises in good condition and repair, reasonable wear and tear excluded. Tenant shall also, prior to vacating the Premises, pay to Landlord the amount, as estimated by Landlord, of Tenant's obligation hereunder for underpayment of Operating Expenses for the year in which the Term ends. All such amounts shall be used and held by Landlord for payment of such obligations of Tenant hereunder, with Tenant being liable for any additional costs therefor upon demand by Landlord or with any excess to be returned to Tenant after all such obligations have been determined and satisfied as the case may be. Any Security Deposit held by Landlord may be credited against the amount due by Tenant under this Section 23(f).

(g)    If any provision of this Lease is illegal, invalid or unenforceable, then the remainder of this Lease shall not be affected thereby, and in lieu of each such provision, there shall be added, as a part of this Lease, a provision as similar in terms to such illegal, invalid or unenforceable clause or provision as may be possible and be legal, valid and enforceable

(h)    Whenever Tenant requests Landlord to take any action not required of it hereunder or give any consent required or permitted under this Lease, Tenant will reimburse Landlord for Landlord's reasonable, out-of-pocket costs payable to third parties and incurred by Landlord in reviewing the proposed action or consent, including reasonable attorneys', engineers’ or architects’ fees, within 30 days after Landlord's delivery to Tenant of a statement of such costs. Tenant will be obligated to make such reimbursement without regard to whether Landlord consents to any such proposed action.

(i)    All references in this Lease to "the date hereof" or similar references shall be deemed to refer to the last date, in point of time, on which all parties hereto have executed this Lease.

(j)    Landlord and Tenant each warrant to the other that it has not dealt with any broker or agent in connection with this Lease, other than HPI Real Estate, Inc. and Endeavor Real Estate Group (collectively, the "Brokers"). Pursuant to separate commission agreements, Landlord shall be solely responsible for the payment of the total commission owed pursuant to the commission agreement between Landlord and HPI Real Estate, Inc. Endeavor Real Estate Group shall then be paid its commission pursuant to its commission agreement with HPI Real Estate, Inc. Tenant and Landlord shall each indemnify the other against all costs, attorneys' fees, and other liabilities for commissions or other compensation claimed by any broker or agent (other than the Brokers) claiming the same by, through, or under the indemnifying party.



(k)    If and when included within the term "Tenant," as used in this instrument, there is more than one person, firm or corporation, all shall jointly arrange among themselves for their joint execution of a notice specifying an individual at a specific address within the continental United States for the receipt of notices and payments to Tenant. If and when included within the term "Landlord," as used in this instrument, there is more than one person, firm or corporation, all shall jointly arrange among themselves for their joint execution of a notice specifying an individual at a specific address within the continental United States for the receipt of notices and payments to Landlord. All parties included within the terms "Landlord" and "Tenant," respectively, shall be bound by notices given in accordance with the provisions of Section 24 to the same effect as if each had received such notice.

(l)    The terms and conditions of this Lease are confidential and Tenant shall not disclose the terms of this Lease to any third party other than Tenant’s attorneys, brokers, accountants and other consultants and except as may be required by law or to enforce its rights hereunder.

(m)    Tenant shall pay interest on all past-due rent from the date due until paid at the maximum lawful rate. In no event, however, shall the charges permitted under this Section 23(m) or elsewhere in this Lease, to the extent they are considered to be interest under applicable Law, exceed the maximum lawful rate of interest.

(n)    Intentionally deleted.

(o)    THIS LEASE WILL BE GOVERNED IN ACCORDANCE WITH THE LAWS OF THE STATE OF TEXAS.

(p)    Landlord and Tenant agree that each provision of this Lease for determining charges, amounts and additional rent payments by Tenant (including without limitation, Sections 2 and 3 of this Lease) is commercially reasonable, and as to each such charge or amount, constitutes a "method by which the charge is to be computed" for purposes of Section 93.012 (Assessment of Charges) of the Texas Property Code, as such section now exists or as it may be hereafter amended or succeeded.

(q)    WAIVER OF CONSUMER RIGHTS. TENANT HEREBY WAIVES ALL ITS RIGHTS UNDER THE TEXAS DECEPTIVE TRADE PRACTICES - CONSUMER PROTECTION ACT, SECTION 17.41 ET. SEQ. OF THE TEXAS BUSINESS AND COMMERCE CODE, A LAW THAT GIVES CONSUMERS SPECIAL RIGHTS AND PROTECTIONS. AFTER CONSULTATION WITH AN ATTORNEY OF TENANT'S OWN SELECTION, TENANT VOLUNTARILY CONSENTS TO THIS WAIVER.

(r)    Landlord and Tenant acknowledge and agree that this Lease, including all exhibits a part hereof, is not a construction contract or an agreement collateral to or affecting a construction contract.

(s)    Any legal proceeding that is brought to enforce this Lease or any guaranty of this Lease (if any), or that arises out of a dispute in connection with this Lease or any guaranty of this Lease (if any), shall be conducted in the county in which the Premises are located. If either party should prevail in any litigation instituted by or against the other related to this Lease, the prevailing party, as determined by the court, shall receive from the non-prevailing party all costs and reasonable attorneys’ fees through all levels of proceedings incurred in such litigation, including costs on appeal, as determined by the court.

(t)    Tenant shall have access to, and may place equipment on, the roof of the Building at Tenant’s sole cost and expense (“Rooftop Equipment”). Tenant’s access to the roof shall be limited to placing, operating, maintaining, repairing, and removing said Rooftop Equipment, which includes telecommunications equipment. Tenant’s access and Rooftop Equipment shall not interfere with Landlord’s use of the roof. In addition, Tenant’s rights to any Roof Equipment shall be subject to and conditioned on the following:



(i)    If installation of the Rooftop Equipment requires any roof penetrations, Tenant must use the contractor designated by Landlord and shall cause such work to be done in a manner that will preserve any roof warranty held by Landlord.

(ii)    Tenant will ensure that the Rooftop Equipment complies at all times with all applicable laws, codes, ordinances, rules, regulations, and encumbrances. In addition, Tenant must ensure that neither the Rooftop Equipment nor any appurtenant wiring or cabling interfere with or otherwise adversely affect the mechanical systems of the Building. Tenant will keep in full force and effect and renew, as applicable, all required permits, approvals, and licenses required for the Rooftop Equipment (and will provide copies of such renewals to Landlord).

(iii)    Tenant will ensure that the Rooftop Equipment (i) is properly secured and installed so as not to be affected by high winds or other weather elements; (ii) is properly grounded; (iii) does not exceed the load limits of the Building; and (iv) does not damage the Building. Tenant will indemnify and defend Landlord from and against Losses arising from any overburden or damage to the roof or Building to the extent arising from or resulting from the installation, use, operation, maintenance, repair or removal of the Rooftop Equipment

(iv)    Upon the expiration or earlier termination of the Lease, unless otherwise instructed by Landlord in writing, Tenant, at its sole cost and expense, shall remove the Rooftop Equipment and restore the any areas affected by the Rooftop Equipment to the condition which existed prior to the installation of the Rooftop Equipment, normal wear and tear, casualty and condemnation excepted.


(u)    Tenant shall have the right to keep and maintain on the Premises, at Tenant’s sole cost and expense, generators to provide electricity whenever the regularly provided electrical current is disrupted for any reason.

24.NOTICES

Each provision of this instrument or of any applicable Laws and other requirements with reference to the sending, mailing or delivering of notice or the making of any payment hereunder shall be deemed to be complied with when and if the following steps are taken.

(a)    All rent shall be payable to Landlord at the address for Landlord set forth in Section 2(d) above or at such other address as Landlord may specify from time to time by written notice delivered in accordance herewith, or by wire transfer of immediately available funds to an account or accounts designated from time to time by Landlord to Tenant with remittance detail from Tenant to Landlord to identify the components of each payment. Tenant's obligation to pay rent shall not be deemed satisfied until such rent has been actually received by Landlord.

(b)    All payments required to be made by Landlord to Tenant hereunder shall be payable to Tenant at the address set forth below, or at such other address within the continental United States as Tenant may specify from time to time by written notice delivered in accordance herewith.

(c)    Any written notice or document required or permitted to be delivered hereunder shall be deemed to be delivered upon the earlier to occur of (1) tender of delivery (in the case of a hand-delivered notice), (2) deposit in the United States Mail, postage prepaid, Certified Mail, or (3) receipt by facsimile transmission, in each case, addressed to the parties hereto at the respective addresses set out below, or at such other address as they have theretofore specified by written notice delivered in accordance herewith. If Landlord has attempted to deliver notice to Tenant at Tenant's address reflected on Landlord's books but such notice was returned or acceptance thereof was refused, then Landlord may post such notice in or on the Premises, which notice shall be deemed delivered to Tenant upon the posting thereof. Additionally, electronic mail may be used, but only to distribute routine communications,


such as financial statements and other information, and may not be used for providing notice of default of a party hereto or for requesting the consent of the other party when obtaining such consent is required under this Lease.

Landlord:

Tenant:

Sundance Consolidated LLC
c/o Scott Rempe
12909 Dessau Rd
Austin, Texas 78754
512-801-0408 - Telephone
scott@packsaddlepartners.com - Email

Prior to Commencement Date:
Luminex Corporation
Attn: General Counsel            
12212 Technology Blvd., Austin, TX 78727
             - Telephone
             - Email


From and after Commencement Date:
The Premises


25.HAZARDOUS WASTE

The term "Hazardous Substances," as used in this Lease shall mean pollutants, contaminants, toxic or hazardous wastes, or any other substances, the removal of which is required or the use of which is restricted, prohibited or penalized by any "Environmental Law," which term shall mean any Law relating to health, pollution, or protection of the environment. Tenant hereby agrees that (a) no activity will be conducted on the Premises that will produce any Hazardous Substances, except for such activities that are part of the ordinary course of Tenant's business activities (the "Permitted Activities") provided such Permitted Activities are conducted in accordance with all Environmental Laws and have been approved in advance in writing by Landlord; (b) the Premises will not be used in any manner for the storage of any Hazardous Substances except for any temporary storage of such materials that are used in the ordinary course of Tenant's business (the "Permitted Materials") provided such Permitted Materials are properly stored in a manner and location satisfying all Environmental Laws and approved in advance in writing by Landlord (Landlord has approved use of the Permitted Materials described in Exhibit G so long as such Permitted Materials are used in the ordinary course of Tenant’s business and in accordance with all Environmental Laws); (c) no portion of the Premises will be used as a landfill or a dump; (d) Tenant will not install any underground tanks of any type; (e) Tenant will not allow any surface or subsurface conditions to exist or come into existence that constitute, or with the passage of time may constitute a public or private nuisance; (f) Tenant will not permit any Hazardous Substances to be brought onto the Premises, except for the Permitted Materials, and if so brought or found located thereon, the same shall be immediately removed by Tenant, with proper disposal, and all required cleanup procedures shall be diligently undertaken pursuant to all Environmental Laws; (g) Tenant will maintain on the Premises a list of all materials stored at the Premises for which a material safety data sheet (an "MSDS") was issued by the producers or manufacturers thereof, together with copies of the MSDS's for such materials, and shall deliver such list and MSDS copies to Landlord upon Landlord's request therefor; and (h) Tenant shall remove all Permitted Materials from the Premises in a manner reasonably acceptable to Landlord before Tenant's right to possess the Premises is terminated. If at any time during or after the Term, the Premises are found to be so contaminated or subject to such conditions due to the introduction of Hazardous Substances by Tenant or Tenant’s use of the Premises, Tenant shall defend, indemnify and hold Landlord harmless from all claims, demands, actions, liabilities, costs, expenses, damages and obligations of any nature arising from or as a result of the use of the Premises by Tenant, except for any conditions or contamination caused by Landlord. The foregoing indemnity shall survive termination or expiration of this Lease. However, Landlord agrees that Tenant shall not be responsible for Hazardous Substances, if any, existing on the Premises prior to the Delivery Date (“Pre-Existing Hazardous Substance Conditions”) except to the extent such Pre-Existing Substance Conditions are made worse by Tenant, and any claims, demands, actions, liabilities, costs, expenses, damages and obligations arising from any Pre-Existing Hazardous Substance Conditions shall be excluded from the foregoing indemnity except to the extent such Pre-Existing Substance Conditions are made worse by Tenant. In the event any remediation or removal of Hazardous Substances is required at the Premises by any governmental authority, Landlord will be responsible only for the cost of remediation or removal of Pre-Existing Hazardous Substance Conditions, if any, except to the extent such Pre-Existing Hazardous Substances Conditions are made worse by Tenant. Landlord is not responsible for the costs of remediating or removing any Hazardous Substances introduced to the Premises on or after the Delivery Date. Unless expressly identified on an addendum to this Lease, as of the date hereof there are no "Permitted Activities" or "Permitted Materials" for purposes of the foregoing provision and none shall exist unless and until approved in writing by the Landlord. Landlord may enter the Premises and conduct environmental inspections and tests therein as it may reasonably require from time to time, provided that Landlord shall use reasonable efforts to minimize the interference with Tenant's business. Such inspections and tests shall be conducted at Landlord's expense, unless they reveal the presence of Hazardous Substances (other than Permitted Materials or those placed in the Premises by


Landlord) or that Tenant has not complied with the requirements set forth in this Section 25, in which case Tenant shall reimburse Landlord for the cost thereof within ten days after Landlord's request therefor.

TENANT ACKNOWLEDGES THAT (1) IT HAS INSPECTED AND ACCEPTS THE PREMISES IN AN "AS IS, WHERE IS" CONDITION, SUBJECT ONLY TO LANDLORD'S DELIVER OBLIGATIONS UNDER SECTION 1(C) OF THE LEASE, (2) THE BUILDING'S IMPROVEMENTS ARE SUITABLE FOR THE PURPOSE FOR WHICH THE PREMISES ARE LEASED AND LANDLORD HAS MADE NO WARRANTY, REPRESENTATION, COVENANT, OR AGREEMENT WITH RESPECT TO THE MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OF THE PREMISES, (3) THE PREMISES ARE IN GOOD AND SATISFACTORY CONDITION, (4) NO REPRESENTATIONS AS TO THE REPAIR OF THE PREMISES, NOR PROMISES TO ALTER, REMODEL OR IMPROVE THE PREMISES HAVE BEEN MADE BY LANDLORD (EXCEPT FOR LANDLORD’S DELIVER OBLIGATIONS SET FORTH IN SECTION 1(C) OF THIS LEASE), AND (5) NO WARRANTIES, EXPRESS OR IMPLIED, ARE MADE REGARDING THE CONDITION OR SUITABILITY OF THE PREMISES ON THE COMMENCEMENT DATE. FURTHER, TO THE EXTENT PERMITTED BY LAW, TENANT WAIVES ANY IMPLIED WARRANTY OF SUITABILITY OR OTHER IMPLIED WARRANTIES THAT LANDLORD WILL MAINTAIN OR REPAIR THE PREMISES OR ITS APPURTENANCES EXCEPT AS MAY BE CLEARLY AND EXPRESSLY PROVIDED IN THIS LEASE.

[Remainder of page intentionally left blank; signatures follow.]





Executed by Landlord on the 21st day of December, 2020.

LANDLORD:

                        SUNDANCE CONSOLIDATED, L.L.C.,
                        a Texas limited liability company


                        By:        /s/ Scott Rempe
                        Name:        Scott Rempe
                        Title:        Member






    Executed by Tenant on the 21st day of December, 2020.

TENANT:

                        LUMINEX CORPORATION,
                        a Delaware corporation


                        By:        /s/ Harriss T. Currie
                        Name:        Harriss T. Currie    
                        Title:        Sr. Vice President of Finance & CFO


                        Taxpayer ID #     74-2747608



EXHIBIT A    Description of Premises
EXHIBIT B    Work Letter
EXHIBIT B-1     Roof Repair Work Proposal
EXHIBIT B-2    Preliminary Space Plan for Initial Improvements
EXHIBIT C    Notice of Commencement
EXHIBIT D    Intentionally Deleted
EXHIBIT E    Renewal Option
EXHIBIT F    Right of First Offer
EXHIBIT G    Approved Permitted Materials



 EX-23.1 4 lmnx-12312020xexhibit231.htm EX-23.1 Document

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the following Registration Statements:

(1)Registration Statement (Form S-8 No. 333-225117) pertaining to the Luminex Corporation 2018 Equity Incentive Plan;

(2)Registration Statement (Form S-8 No. 333-218176) pertaining to the Luminex Corporation Amended and Restated Employee Stock Purchase Plan;

(3)Registration Statement (Form S-8 No. 333-204170) pertaining to the Luminex Corporation Third Amended and Restated 2006 Equity Incentive Plan;

(4)Registration Statement (Form S-8 No. 333-181485) pertaining to the Luminex Corporation Employee Stock Purchase Plan;

(5)Registration Statement (Form S-8 No. 333-181484) pertaining to the Luminex Corporation Second Amended and Restated 2006 Equity Incentive Plan;

(6)Registration Statement (Form S-8 No. 333-159382) pertaining to the Amended and Restated 2006 Equity Incentive Plan;

(7)Registration Statement (Form S-8 No. 333-141042) pertaining to the Tm Bioscience Corporation Share Option Plan;

(8)Registration Statement (Form S-8 No. 333-134450) pertaining to the Luminex Corporation 2006 Equity Incentive Plan and the Luminex Corporation 2006 Management Stock Purchase Plan;

(9)Registration Statement (Form S-8 No. 333-118772) pertaining to the Balthrop Non-Qualified Stock Option Agreement of Luminex Corporation;

(10)Registration Statement (Form S-8 No. 333-87918) pertaining to the 2001 Broad-Based Stock Option Plan of Luminex Corporation;

(11)Registration Statement (Form S-8 No. 333-46686) pertaining to the 2000 Long-Term Incentive Plan of Luminex Corporation;

(12)Registration Statement (Form S-3 No. 333-151691) pertaining to the Automatic Shelf Registration of Securities of Luminex Corporation

of our reports dated February 26, 2021, with respect to the consolidated financial statements of Luminex Corporation, and the effectiveness of internal control over financial reporting of Luminex Corporation, included in this Annual Report (Form 10-K) for the year ended December 31, 2020.


/s/ Ernst & Young LLP
Austin, Texas
February 26, 2021


 EX-31.1 5 lmnx-12312020xexhibit311.htm EX-31.1 Document

Exhibit 31.1
 
CERTIFICATION

I, Nachum Shamir, certify that:

1. I have reviewed this report on Form 10-K of Luminex Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date: February 26, 2021
 By:/s/ Nachum Shamir
Nachum Shamir
Chairman, President and CEO


 EX-31.2 6 lmnx-12312020xexhibit312.htm EX-31.2 Document

Exhibit 31.2
 
CERTIFICATION

I, Harriss T. Currie, certify that:

1. I have reviewed this report on Form 10-K of Luminex Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: February 26, 2021
 By:/s/ Harriss T. Currie
Harriss T. Currie
Chief Financial Officer, Senior Vice President of Finance

 EX-32.1 7 lmnx-12312020xexhibit321.htm EX-32.1 Document

Exhibit 32.1
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

    In connection with the Annual Report of Luminex Corporation (the “Company”) on Form 10-K for the period ended December 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Nachum Shamir, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

    (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

    (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Nachum Shamir   
Nachum Shamir
Chairman, President and CEO
February 26, 2021

    A SIGNED ORIGINAL OF THIS WRITTEN STATEMENT REQUIRED BY SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 HAS BEEN PROVIDED TO LUMINEX CORPORATION AND WILL BE RETAINED BY LUMINEX CORPORATION AND FURNISHED TO THE SECURITIES AND EXCHANGE COMMISSION OR ITS STAFF UPON REQUEST.

 EX-32.2 8 lmnx-12312020xexhibit322.htm EX-32.2 Document

Exhibit 32.2
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

    In connection with the Annual Report of Luminex Corporation (the “Company”) on Form 10-K for the period ended December 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Harriss T. Currie, Senior Vice President – Finance, Chief Financial Officer and Treasurer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

    (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

    (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Harriss T. Currie   
Harriss T. Currie
Chief Financial Officer, Senior Vice President of Finance
February 26, 2021

    A SIGNED ORIGINAL OF THIS WRITTEN STATEMENT REQUIRED BY SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 HAS BEEN PROVIDED TO LUMINEX CORPORATION AND WILL BE RETAINED BY LUMINEX CORPORATION AND FURNISHED TO THE SECURITIES AND EXCHANGE COMMISSION OR ITS STAFF UPON REQUEST.

 EX-101.SCH 9 lmnx-20201231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - COVER PAGE Document link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - INCOME STATEMENTS link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - INCOME STATEMENTS INCOME STATEMENTS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - CASH FLOWS STATEMENTS link:presentationLink link:calculationLink link:definitionLink 1006007 - Statement - STOCKHOLDERS' EQUITY STATEMENTS link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 2102101 - Disclosure - BUSINESS COMBINATIONS link:presentationLink link:calculationLink link:definitionLink 2203202 - Disclosure - BUSINESS COMBINATIONS Business Combinations - Pro Forma (Policies) link:presentationLink link:calculationLink link:definitionLink 2404401 - Disclosure - Business Combinations - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - INVESTMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 1407402 - Statement - INVESTMENTS Details (Details) link:presentationLink link:calculationLink link:definitionLink 2106102 - Disclosure - Investments, Equity Method and Joint Ventures link:presentationLink link:calculationLink link:definitionLink 2107103 - Disclosure - ACCOUNTS RECEIVABLE (Notes) link:presentationLink link:calculationLink link:definitionLink 2308302 - Disclosure - ACCOUNTS RECEIVABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - ACCOUNTS RECEIVABLE (Details) link:presentationLink link:calculationLink link:definitionLink 2110104 - Disclosure - INVENTORIES link:presentationLink link:calculationLink link:definitionLink 2311303 - Disclosure - INVENTORIES (Tables) link:presentationLink link:calculationLink link:definitionLink 2412404 - Disclosure - INVENTORIES (Details) link:presentationLink link:calculationLink link:definitionLink 2113105 - Disclosure - FAIR VALUE (Notes) link:presentationLink link:calculationLink link:definitionLink 2314304 - Disclosure - FAIR VALUE (Tables) link:presentationLink link:calculationLink link:definitionLink 2415405 - Disclosure - FAIR VALUE (Details) link:presentationLink link:calculationLink link:definitionLink 2116106 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Notes) link:presentationLink link:calculationLink link:definitionLink 2317305 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 2418406 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 2119107 - Disclosure - GOODWILL link:presentationLink link:calculationLink link:definitionLink 2420407 - Disclosure - GOODWILL (Details) link:presentationLink link:calculationLink link:definitionLink 2121108 - Disclosure - INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 2322306 - Disclosure - INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 2423408 - Disclosure - INTANGIBLE ASSETS (Detail) link:presentationLink link:calculationLink link:definitionLink 1108109 - Statement - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) link:presentationLink link:calculationLink link:definitionLink 1409409 - Statement - ACCUMULATED OTHER COMPREHENSIVE INCOME Details (Details) link:presentationLink link:calculationLink link:definitionLink 2124110 - Disclosure - ACCRUED LIABILITIES (Notes) link:presentationLink link:calculationLink link:definitionLink 2325307 - Disclosure - ACCRUED LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 2426410 - Disclosure - ACCRUED LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 2127111 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 2328308 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 2429411 - Disclosure - Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2130112 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 2331309 - Disclosure - INCOME TAXES Tables (Tables) link:presentationLink link:calculationLink link:definitionLink 2432412 - Disclosure - Income Taxes - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2133113 - Disclosure - EARNINGS PER SHARE link:presentationLink link:calculationLink link:definitionLink 2334310 - Disclosure - EARNINGS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 2435413 - Disclosure - EARNINGS PER SHARE Details (Details) link:presentationLink link:calculationLink link:definitionLink 2136114 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 2337311 - Disclosure - STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 2438414 - Disclosure - STOCKHOLDERS' EQUITY Details (Details) link:presentationLink link:calculationLink link:definitionLink 2139115 - Disclosure - CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 2340312 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) link:presentationLink link:calculationLink link:definitionLink 2441415 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 2142116 - Disclosure - GUARANTEES (Notes) link:presentationLink link:calculationLink link:definitionLink 2343313 - Disclosure - GUARANTEES (Tables) link:presentationLink link:calculationLink link:definitionLink 2444416 - Disclosure - GUARANTEES (Details) link:presentationLink link:calculationLink link:definitionLink 2145117 - Disclosure - GEOGRAPHIC INFORMATION (Notes) link:presentationLink link:calculationLink link:definitionLink 2346314 - Disclosure - GEOGRAPHIC INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 2447417 - Disclosure - GEOGRAPHIC INFORMATION (Details) link:presentationLink link:calculationLink link:definitionLink 2148118 - Disclosure - RECENT ACCOUNTING (Notes) link:presentationLink link:calculationLink link:definitionLink 2349315 - Disclosure - RECENT ACCOUNTING (Tables) link:presentationLink link:calculationLink link:definitionLink 2450418 - Disclosure - RECENT ACCOUNTING (Details) link:presentationLink link:calculationLink link:definitionLink 2151119 - Disclosure - REVENUE RECOGNITION (Notes) link:presentationLink link:calculationLink link:definitionLink 2352316 - Disclosure - REVENUE RECOGNITION (Tables) link:presentationLink link:calculationLink link:definitionLink 2453419 - Disclosure - REVENUE RECOGNITION (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 10 lmnx-20201231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 11 lmnx-20201231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 12 lmnx-20201231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Schedule of Product Warranty Liability [Table Text Block] Schedule of Product Warranty Liability [Table Text Block] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Disclosure [Text Block] Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Payables and Accruals [Abstract] Payables and Accruals [Abstract] Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Fair Value, Inputs, Level 3 [Member] Fair Value, Inputs, Level 3 [Member] Licensing Agreements [Member] Licensing Agreements [Member] Liabilities and stockholders’ equity Liabilities and Equity [Abstract] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Effective Income Tax Rate Reconciliation, Tax Exempt Income, Percent Effective Income Tax Rate Reconciliation, Tax Exempt Income, Percent Indefinite-lived Intangible Assets, Period Increase (Decrease) Indefinite-lived Intangible Assets, Period Increase (Decrease) Product Warranty Accrual, Current Product Warranty Accrual, Current Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt Current Fiscal Year End Date Current Fiscal Year End Date Intangible Assets, Net (Excluding Goodwill) Intangible Assets, Net (Excluding Goodwill) Proceeds from Convertible Debt Proceeds from Convertible Debt Effective Income Tax Rate Reconciliation, Tax Settlement, Foreign, Percent Effective Income Tax Rate Reconciliation, Tax Settlement, Foreign, Percent Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date Operating income Operating Income (Loss) Operating Income (Loss) Defined Contribution Plan, Administrative Expense Defined Contribution Plan, Administrative Expense Entity Address, Postal Zip Code Entity Address, Postal Zip Code Total current liabilities Liabilities, Current Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Assets Assets [Abstract] Accounting Policies [Abstract] Accounting Policies [Abstract] Taxes Payable, Current Taxes Payable, Current Entity Shell Company Entity Shell Company Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Accounts payable Accounts Payable, Current Document Type Document Type Comprehensive Income (Loss) Note [Text Block] Comprehensive Income (Loss) Note [Text Block] Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accounts Payable and Accrued Liabilities Disclosure [Text Block] Retained earnings Retained Earnings (Accumulated Deficit) Operating Lease, Right-of-Use Asset Operating Lease, Right-of-Use Asset Debt Instrument, Unamortized Discount Debt Instrument, Unamortized Discount Cost-method Investments, Description [Text Block] Cost-method Investments, Description [Text Block] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Current State and Local Tax Expense (Benefit) Current State and Local Tax Expense (Benefit) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit Income Taxes Income Tax, Policy [Policy Text Block] Lease, Cost Lease, Cost Payments to Acquire Equity Method Investments Payments to Acquire Equity Method Investments Operating Expenses Operating Expenses Operating Expenses Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Common Stock, Par or Stated Value Per Share Common Stock, Par or Stated Value Per Share Other long-term liabilities Other Liabilities, Noncurrent Deferred Income Tax Assets, Net Deferred Income Tax Assets, Net Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value Inventory, Work in Process, Net of Reserves Inventory, Work in Process, Net of Reserves Stock-based compensation expense APIC, Share-based Payment Arrangement, Increase for Cost Recognition Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Inventory, Net Inventory, Net Fair Value, Measurement Frequency [Domain] Measurement Frequency [Domain] Investments Investment, Policy [Policy Text Block] Entity File Number Entity File Number Statement [Line Items] Statement [Line Items] Deferred Foreign Income Tax Expense (Benefit) Deferred Foreign Income Tax Expense (Benefit) Increase (Decrease) in Deferred Income Taxes Increase (Decrease) in Deferred Income Taxes Loans, Notes, Trade and Other Receivables Disclosure [Text Block] Loans, Notes, Trade and Other Receivables Disclosure [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Interest Payable, Current Interest Payable, Current Payments to Acquire Notes Receivable Payments to Acquire Notes Receivable Statement [Table] Statement [Table] Finite-Lived Intangible Assets, Amortization Expense, after Year Five Finite-Lived Intangible Asset, Expected Amortization, after Year Five Allowance for Doubtful Accounts Receivable, Write-offs Accounts Receivable, Allowance for Credit Loss, Writeoff Preferred Stock, Shares Issued Preferred Stock, Shares Issued Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent Business Combinations [Abstract] Business Combinations [Abstract] Principles of Consolidation Consolidation, Policy [Policy Text Block] Unamortized Debt Issuance Expense Unamortized Debt Issuance Expense Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Common stock issued Proceeds from Issuance of Common Stock Basic and Diluted Earnings Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Operating Leases, Future Minimum Payments Due Operating Leases, Future Minimum Payments Due Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Research and Development Expense, Policy [Policy Text Block] Research and Development Expense, Policy [Policy Text Block] Disclosure Text Block [Abstract] Disclosure Text Block [Abstract] Amendment Flag Amendment Flag Other Accrued Liabilities, Current Other Accrued Liabilities, Current Net cash from operations Net Cash Provided by (Used in) Operating Activities Measurement Frequency [Axis] Measurement Frequency [Axis] Compensation Related Costs, Policy [Policy Text Block] Compensation Related Costs, Policy [Policy Text Block] Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block] Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Effective Income Tax Rate Reconciliation, Deduction, Other, Percent Effective Income Tax Rate Reconciliation, Deduction, Other, Percent Local Phone Number Local Phone Number Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Income (Loss) Attributable to Parent, before Tax Income (Loss) Attributable to Parent, before Tax Income (Loss) Attributable to Parent, before Tax Effect of foreign exchange rates on cash and cash equivalents Effect of Exchange Rate on Cash and Cash Equivalents Accounts receivable, allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Net Cash Provided by (Used in) Financing Activities [Abstract] Net Cash Provided by (Used in) Financing Activities [Abstract] Selling, General and Administrative Expense Selling, General and Administrative Expense Preferred Stock [Text Block] Preferred Stock [Text Block] Current Federal Tax Expense (Benefit) Current Federal Tax Expense (Benefit) Amortization of Intangible Assets Amortization of Intangible Assets Amortization of Intangible Assets Deferred Tax Liabilities, Tax Deferred Income Deferred Tax Liabilities, Tax Deferred Income Deferred Tax Assets, Deferred Income Deferred Tax Assets, Deferred Income Entity Current Reporting Status Entity Current Reporting Status Summary of Positions for which Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Table Text Block] Summary of Positions for which Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Table Text Block] Customer-Related Intangible Assets [Member] Customer-Related Intangible Assets [Member] Business Description and Accounting Policies [Text Block] Business Description and Accounting Policies [Text Block] Other Assets, Noncurrent Other Assets, Noncurrent Equity Method Investments and Joint Ventures Disclosure Equity Method Investments and Joint Ventures Disclosure [Text Block] Cash and Cash Equivalents, Fair Value Disclosure Cash and Cash Equivalents, Fair Value Disclosure Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Total assets Assets Interest Expense, Debt Interest Expense, Debt Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Schedule of Accrued Liabilities [Table Text Block] Schedule of Accrued Liabilities [Table Text Block] Finite-Lived Intangible Assets, Net Finite-Lived Intangible Assets, Net Finite-Lived Intangible Assets, Net Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Business Description and Basis of Presentation [Text Block] Business Description and Basis of Presentation [Text Block] Entity Small Business Entity Small Business Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentration Risk, Credit Risk, Policy [Policy Text Block] Other, net Stockholders' Equity, Other Depreciation, Depletion and Amortization Depreciation, Depletion and Amortization Entity Filer Category Entity Filer Category Deferred Tax Assets, Tax Deferred Expense, Other Deferred Tax Assets, Tax Deferred Expense, Other Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Other Intangible Assets [Member] Other Intangible Assets [Member] Proceeds from Sale of Productive Assets Proceeds from Sale of Productive Assets Total liabilities Liabilities Entity Address, City or Town Entity Address, City or Town Document Annual Report Document Annual Report Investments and Other Noncurrent Assets [Text Block] Investments and Other Noncurrent Assets [Text Block] Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Other Comprehensive Income Location [Domain] Other Comprehensive Income Location [Domain] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Other Investments Not Readily Marketable [Table Text Block] Other Investments Not Readily Marketable [Table Text Block] Net Income (Loss) Available to Common Stockholders, Basic Net Income (Loss) Available to Common Stockholders, Basic Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 1 [Member] Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Inventories Increase (Decrease) in Inventories Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Document Fiscal Year Focus Document Fiscal Year Focus Accounts payable Increase (Decrease) in Accounts Payable Additional Paid-in Capital Additional Paid-in Capital [Member] Other Operating Activities, Cash Flow Statement Other Operating Activities, Cash Flow Statement Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Accounts Receivable, Gross, Current Accounts Receivable, before Allowance for Credit Loss, Current Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other Fair Value Measurements Fair Value of Financial Instruments, Policy [Policy Text Block] Common Stock, Shares, Outstanding Common Stock, Shares, Outstanding Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Allowance for Doubtful Accounts Receivable, Period Increase (Decrease) Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease) Research and development Research and Development Expense Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Accounting Changes and Error Corrections [Abstract] Accounting Changes and Error Corrections [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Payments to Acquire Businesses, Net of Cash Acquired Payments to Acquire Businesses, Net of Cash Acquired Common stock, shares authorized Common Stock, Shares Authorized Proceeds from Stock Options Exercised Proceeds from Stock Options Exercised Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Property, Plant and Equipment, Gross Property, Plant and Equipment, Gross Deferred Federal Income Tax Expense (Benefit) Deferred Federal Income Tax Expense (Benefit) Revenue Recognition, Policy [Policy Text Block] Revenue [Policy Text Block] COVER PAGE [Abstract] COVER PAGE [Abstract] COVER PAGE [Abstract] Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Income Statement [Abstract] Income Statement [Abstract] Accumulated other comprehensive Income (loss) AOCI Attributable to Parent [Member] Operating Lease, Liability, Noncurrent Operating Lease, Liability, Noncurrent Finite-Lived Intangible Assets, Amortization Expense, Year Four Finite-Lived Intangible Asset, Expected Amortization, Year Four Accrued Royalties, Current Accrued Royalties, Current Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments Estimates and Assumptions Use of Estimates, Policy [Policy Text Block] Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent Current assets: Assets, Current [Abstract] Finite-Lived Intangible Assets, Period Increase (Decrease) Finite-Lived Intangible Assets, Period Increase (Decrease) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive Income (Loss), Net of Tax, Attributable to Parent Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Preferred Stock, Par or Stated Value Per Share Preferred Stock, Par or Stated Value Per Share Entity Public Float Entity Public Float Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Additions to property and equipment Payments to Acquire Property, Plant, and Equipment Entity Tax Identification Number Entity Tax Identification Number Long-term Debt Long-term Debt [Text Block] Deferred Tax Liabilities, Deferred Expense Deferred Tax Liabilities, Deferred Expense Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Common Stock, Capital Shares Reserved for Future Issuance Common Stock, Capital Shares Reserved for Future Issuance Income (Loss) from Equity Method Investments Income (Loss) from Equity Method Investments Trading Symbol Trading Symbol Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block] Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block] Components of Inventories Schedule of Inventory, Current [Table Text Block] Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount Share-based Payment Arrangement, Amount Capitalized Stock-based compensation expense Share-based Payment Arrangement, Noncash Expense Payments Related to Tax Withholding for Share-based Compensation Payment, Tax Withholding, Share-based Payment Arrangement Goodwill, Acquired During Period Goodwill, Acquired During Period Intangible Assets Disclosure [Text Block] Intangible Assets Disclosure [Text Block] Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Debt Instrument, Convertible, Remaining Discount Amortization Period Debt Instrument, Convertible, Remaining Discount Amortization Period Long-term Debt Long-term Debt Operating Leases, Future Minimum Payments, Due Thereafter Operating Leases, Future Minimum Payments, Due Thereafter Unearned revenue Increase (Decrease) in Contract with Customer, Liability Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Operating Leases, Future Minimum Payments Due, Next Twelve Months Operating Leases, Future Minimum Payments Due, Next Twelve Months City Area Code City Area Code Deferred Tax Assets, Net Deferred Tax Assets, Net Cost of Goods and Services Sold Cost of Goods and Services Sold Equity Components [Axis] Equity Components [Axis] Title of 12(b) Security Title of 12(b) Security Restricted Stock [Member] Restricted Stock [Member] Standard and Extended Product Warranty Accrual, Decrease for Payments Standard and Extended Product Warranty Accrual, Decrease for Payments Inventory, Finished Goods, Net of Reserves Inventory, Finished Goods, Net of Reserves Deferred Tax Assets, Gross Deferred Tax Assets, Gross Receivables [Abstract] Receivables [Abstract] Operating Lease, Liability, Current Operating Lease, Liability, Current Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Equity Method Investments and Joint Ventures [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Defined Contribution Plan, Employer Matching Contribution, Percent of Match Defined Contribution Plan, Employer Matching Contribution, Percent of Match Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Fair Value Disclosures [Text Block] Fair Value Disclosures [Text Block] Net Cash Provided by (Used in) Operating Activities [Abstract] Net Cash Provided by (Used in) Operating Activities [Abstract] Purchase Obligation Purchase Obligation Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Share-based Payment Arrangement [Policy Text Block] Current Foreign Tax Expense (Benefit) Current Foreign Tax Expense (Benefit) Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Operating Lease, Weighted Average Discount Rate, Percent Operating Lease, Weighted Average Discount Rate, Percent Operating Liabilities Increase (Decrease) in Other Operating Liabilities Deferred Tax Liabilities, Gross Deferred Tax Liabilities, Gross Proceeds from Issuance of Warrants Proceeds from Issuance of Warrants Intangible Assets, Gross (Excluding Goodwill) Intangible Assets, Gross (Excluding Goodwill) Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Standard and Extended Product Warranty Accrual, Increase for Warranties Issued Standard and Extended Product Warranty Accrual, Increase for Warranties Issued Common stock cash dividends paid Payments of Ordinary Dividends, Common Stock Accounts Receivable, Net, Current Accounts Receivable, after Allowance for Credit Loss, Current Other Comprehensive Income Location [Axis] Other Comprehensive Income Location [Axis] Cost of Sales, Policy [Policy Text Block] Cost of Goods and Service [Policy Text Block] Income (Loss) from Equity Method Investments, Net of Dividends or Distributions Income (Loss) from Equity Method Investments, Net of Dividends or Distributions Foreign Currency Transactions and Translations Policy [Policy Text Block] Foreign Currency Transactions and Translations Policy [Policy Text Block] Deferred Tax Assets, Net of Valuation Allowance Deferred Tax Assets, Net of Valuation Allowance Goodwill Goodwill Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block] Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block] Deferred Tax Assets, Operating Loss Carryforwards Deferred Tax Assets, Operating Loss Carryforwards Payments for Hedge, Financing Activities Payments for Hedge, Financing Activities Common Stock, Dividends, Per Share, Declared Common Stock, Dividends, Per Share, Declared Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 2 [Member] Other Other Assets, Current Equity [Abstract] Equity [Abstract] Entity Central Index Key Entity Central Index Key Schedule of Intangible Assets and Goodwill [Table Text Block] Schedule of Intangible Assets and Goodwill [Table Text Block] Indefinite-lived Intangible Assets Acquired Indefinite-lived Intangible Assets Acquired Short-term unearned revenue Contract with Customer, Liability, Current Entity Emerging Growth Company Entity Emerging Growth Company Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price New Accounting Pronouncements and Changes in Accounting Principles [Text Block] Accounting Standards Update and Change in Accounting Principle [Text Block] Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Debt Instrument, Convertible, Conversion Price Debt Instrument, Convertible, Conversion Price Estimated Future Amortization Expense Related to Intangible Assets Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Weighted Average Number of Shares Outstanding, Diluted Weighted Average Number of Shares Outstanding, Diluted Earnings Per Share, Basic Earnings Per Share, Basic Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Debt Disclosure [Abstract] Operating Lease, Weighted Average Remaining Lease Term Operating Lease, Weighted Average Remaining Lease Term Finite-lived Intangible Assets Acquired Finite-lived Intangible Assets Acquired Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities Common Stock, Value, Outstanding Common Stock, Value, Outstanding Net cash used in financing Net Cash Provided by (Used in) Financing Activities ESPP APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition Adjustments to Additional Paid in Capital, Warrant Issued Adjustments to Additional Paid in Capital, Warrant Issued Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Allocated Share-based Compensation Expense Share-based Payment Arrangement, Expense Unrecognized Tax Benefits Unrecognized Tax Benefits Unrecognized Tax Benefits Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Other Long-term Investments Other Long-term Investments Finite-Lived Intangible Assets, Amortization Expense, Year Two Finite-Lived Intangible Asset, Expected Amortization, Year Two Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Earnings Per Share Earnings Per Share, Policy [Policy Text Block] Entity Voluntary Filers Entity Voluntary Filers Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Deferred Tax Liabilities, Investment in Noncontrolled Affiliates Deferred Tax Liabilities, Investment in Noncontrolled Affiliates Net Cash Provided by (Used in) Investing Activities [Abstract] Net Cash Provided by (Used in) Investing Activities [Abstract] Common Stock, Shares, Issued Common Stock, Shares, Issued Cash and cash equivalents Cash and cash equivalents, end of period Cash and Cash Equivalents, at Carrying Value Deferred Tax Liabilities, Other Deferred Tax Liabilities, Other Segment Reporting [Abstract] Segment Reporting [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Stockholders' Equity Attributable to Parent Stockholders' Equity Attributable to Parent Stockholders' Equity Attributable to Parent Liabilities and Equity Liabilities and Equity Revenue Recognition, Deferred Revenue [Policy Text Block] Revenue Recognition, Deferred Revenue [Policy Text Block] Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated Other Comprehensive Income (Loss), Net of Tax Income Tax Disclosure [Text Block] Income Tax Disclosure [Text Block] Employee-related Liabilities, Current Employee-related Liabilities, Current Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Payments to Acquire Intangible Assets Payments to Acquire Intangible Assets Restricted Stock Units (RSUs) [Member] Restricted Stock Units (RSUs) [Member] Operating Leases, Future Minimum Payments, Due in Four Years Operating Leases, Future Minimum Payments, Due in Four Years Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Participating Securities, Distributed and Undistributed Earnings (Loss), Basic Participating Securities, Distributed and Undistributed Earnings (Loss), Basic Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent Current Income Tax Expense (Benefit) Current Income Tax Expense (Benefit) Marketable Securities [Table Text Block] Marketable Securities [Table Text Block] Gain (Loss) on Disposition of Property Plant Equipment Gain (Loss) on Disposition of Property Plant Equipment Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Finite-Lived Intangible Asset, Useful Life Finite-Lived Intangible Asset, Useful Life Equity Component [Domain] Equity Component [Domain] Deferred Tax Liabilities, Leasing Arrangements Deferred Tax Liabilities, Leasing Arrangements Deferred Tax Assets, Valuation Allowance Deferred Tax Assets, Valuation Allowance Entity Address, Address Line One Entity Address, Address Line One Gross margin Gross Profit Property, Plant and Equipment, Net Property, Plant and Equipment, Net Finite-Lived Intangible Assets, Amortization Expense, Year Three Finite-Lived Intangible Asset, Expected Amortization, Year Three Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Share-based Payment Arrangement [Text Block] Net Income (Loss) Attributable to Parent Net Income (Loss) Attributable to Parent Net Income (Loss) Attributable to Parent Entity Address, State or Province Entity Address, State or Province Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] INVENTORIES Inventory Disclosure [Text Block] Other Comprehensive Income (Loss), Net of Tax Other Comprehensive Income (Loss), Net of Tax Other Comprehensive Income (Loss), Net of Tax Total current assets Assets, Current Description of New Accounting Pronouncements Not yet Adopted [Text Block] Description of New Accounting Pronouncements Not yet Adopted [Text Block] Goodwill Disclosure [Text Block] Goodwill Disclosure [Text Block] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Stockholders' Equity Attributable to Parent [Abstract] Stockholders' Equity Attributable to Parent [Abstract] Guarantees [Text Block] Guarantees [Text Block] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Entity Interactive Data Current Entity Interactive Data Current Finite-Lived Intangible Assets, Amortization Expense, Year Five Finite-Lived Intangible Asset, Expected Amortization, Year Five Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate Revenue Recognition and Deferred Revenue [Abstract] Revenue Recognition and Deferred Revenue [Abstract] Long-term unearned revenue Contract with Customer, Liability, Noncurrent Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Net Income (Loss) Available to Common Stockholders, Diluted Net Income (Loss) Available to Common Stockholders, Diluted Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent Stock Issued During Period, Shares, Employee Stock Purchase Plans Stock Issued During Period, Shares, Employee Stock Purchase Plans Common Stock Common Stock [Member] Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent Debt Instrument, Convertible, Stock Price Trigger Debt Instrument, Convertible, Stock Price Trigger Technology-Based Intangible Assets [Member] Technology-Based Intangible Assets [Member] Property, Plant and Equipment [Table Text Block] Property, Plant and Equipment [Table Text Block] Proceeds from (Payments to) Noncontrolling Interests Proceeds from (Payments to) Noncontrolling Interests Finite-Lived Intangible Assets, Gross Finite-Lived Intangible Assets, Gross Dividends Payable, Current Dividends Payable, Current Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Preferred Stock, Value, Outstanding Preferred Stock, Value, Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Other income, net Nonoperating Income (Expense) Employee Stock Option [Member] Share-based Payment Arrangement, Option [Member] Net change in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Weighted Average Number of Shares Outstanding, Basic Weighted Average Number of Shares Outstanding, Basic Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Deferred State and Local Income Tax Expense (Benefit) Deferred State and Local Income Tax Expense (Benefit) Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Income (Loss) from Continuing Operations before Income Taxes, Domestic Income (Loss) from Continuing Operations before Income Taxes, Domestic Payments for (Proceeds from) Previous Acquisition Payments for (Proceeds from) Previous Acquisition Additional Paid in Capital Additional Paid in Capital Shareholders' Equity and Share-based Payments [Text Block] Shareholders' Equity and Share-based Payments [Text Block] Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months Finite-Lived Intangible Asset, Expected Amortization, Year One Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents, Policy [Policy Text Block] Revenues Revenues Operating Leases, Future Minimum Payments, Due in Three Years Operating Leases, Future Minimum Payments, Due in Three Years Inventory, Policy [Policy Text Block] Inventory, Policy [Policy Text Block] Provision for income taxes Provision for income taxes Income Tax Expense (Benefit) Operating Leases, Future Minimum Payments, Due in Five Years Operating Leases, Future Minimum Payments, Due in Five Years Participating Securities, Distributed and Undistributed Earnings (Loss), Diluted Participating Securities, Distributed and Undistributed Earnings (Loss), Diluted Property, Plant and Equipment, Policy [Policy Text Block] Property, Plant and Equipment, Policy [Policy Text Block] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Accrued Liabilities, Current Accrued Liabilities, Current Earnings Per Share, Diluted Earnings Per Share, Diluted Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] Operating Leases, Future Minimum Payments, Due in Two Years Operating Leases, Future Minimum Payments, Due in Two Years Recorded Unconditional Purchase Obligation Recorded Unconditional Purchase Obligation Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit Long-term Debt, Gross Long-term Debt, Gross Depreciation Depreciation Inventory, Raw Materials and Purchased Parts, Net of Reserves Inventory, Raw Materials and Purchased Parts, Net of Reserves Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Stock Issued During Period, Value, Employee Stock Ownership Plan Stock Issued During Period, Value, Employee Stock Ownership Plan Operating Assets Increase (Decrease) in Other Operating Assets Stock Issued During Period, Value, Stock Options Exercised Stock Issued During Period, Value, Stock Options Exercised Indefinite-lived Intangible Assets (Excluding Goodwill) Indefinite-lived Intangible Assets (Excluding Goodwill) Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Deferred Income Tax Expense (Benefit) Deferred Income Tax Expense (Benefit) Award Type [Axis] Award Type [Axis] Finite-Lived Intangible Assets, Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Amortization of Debt Issuance Costs Amortization of Debt Issuance Costs Security Exchange Name Security Exchange Name Preferred Stock, Shares Authorized Preferred Stock, Shares Authorized Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Other Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Other Common stock cash dividends Dividends, Common Stock, Cash Retained earnings Retained Earnings [Member] Preferred Stock, Shares Outstanding Preferred Stock, Shares Outstanding Unrecorded Unconditional Purchase Obligation, Imputed Interest Unrecorded Unconditional Purchase Obligation, Imputed Interest Effective tax rate Effective Income Tax Rate Reconciliation, Percent Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Net cash used in investing Net Cash Provided by (Used in) Investing Activities Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Allowance for Doubtful Accounts Receivable Accounts Receivable, Allowance for Credit Loss Equity Award [Domain] Award Type [Domain] Document Transition Report Document Transition Report Prepaid Expense and Other Assets, Noncurrent Prepaid Expense and Other Assets, Noncurrent Allowance for Credit Losses on Financing Receivables [Table Text Block] Financing Receivable, Allowance for Credit Loss [Table Text Block] Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Cost Method Investments, Fair Value Disclosure Cost Method Investments, Fair Value Disclosure Property, Plant and Equipment Disclosure [Text Block] Property, Plant and Equipment Disclosure [Text Block] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms EARNINGS PER SHARE Earnings Per Share [Text Block] Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent Current liabilities: Liabilities, Current [Abstract] Income (Loss) from Continuing Operations before Income Taxes, Foreign Income (Loss) from Continuing Operations before Income Taxes, Foreign U.S. federal statutory tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Guarantees and Product Warranties [Abstract] Guarantees and Product Warranties [Abstract] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] EX-101.PRE 13 lmnx-20201231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 14 lmnx-20201231_g1.jpg GRAPHIC begin 644 lmnx-20201231_g1.jpg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end GRAPHIC 15 lmnx-20201231_g2.jpg GRAPHIC begin 644 lmnx-20201231_g2.jpg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end XML 16 lmnx-20201231_htm.xml IDEA: XBRL DOCUMENT 0001033905 2020-01-01 2020-12-31 0001033905 2020-06-30 0001033905 2021-02-26 0001033905 2020-12-31 0001033905 2019-12-31 0001033905 2019-01-01 2019-12-31 0001033905 2018-01-01 2018-12-31 0001033905 2020-01-01 2020-03-31 0001033905 2020-04-01 2020-06-30 0001033905 2020-07-01 2020-09-30 0001033905 2020-10-01 2020-12-31 0001033905 2019-01-01 2019-03-31 0001033905 2019-04-01 2019-06-30 0001033905 2019-07-01 2019-09-30 0001033905 2019-10-01 2019-12-31 0001033905 2018-12-31 0001033905 2017-12-31 0001033905 us-gaap:CommonStockMember 2017-12-31 0001033905 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001033905 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001033905 us-gaap:RetainedEarningsMember 2017-12-31 0001033905 us-gaap:CommonStockMember 2018-01-01 2018-12-31 0001033905 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0001033905 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0001033905 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0001033905 us-gaap:CommonStockMember 2018-12-31 0001033905 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001033905 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001033905 us-gaap:RetainedEarningsMember 2018-12-31 0001033905 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001033905 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001033905 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0001033905 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001033905 us-gaap:CommonStockMember 2019-12-31 0001033905 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001033905 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001033905 us-gaap:RetainedEarningsMember 2019-12-31 0001033905 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001033905 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001033905 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0001033905 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001033905 us-gaap:CommonStockMember 2020-12-31 0001033905 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001033905 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001033905 us-gaap:RetainedEarningsMember 2020-12-31 0001033905 us-gaap:LicensingAgreementsMember 2020-12-31 0001033905 us-gaap:LicensingAgreementsMember 2019-12-31 0001033905 us-gaap:FairValueInputsLevel1Member 2020-12-31 0001033905 us-gaap:FairValueInputsLevel2Member 2020-12-31 0001033905 us-gaap:FairValueInputsLevel3Member 2020-12-31 0001033905 us-gaap:FairValueInputsLevel1Member 2019-12-31 0001033905 us-gaap:FairValueInputsLevel2Member 2019-12-31 0001033905 us-gaap:FairValueInputsLevel3Member 2019-12-31 0001033905 us-gaap:TechnologyBasedIntangibleAssetsMember 2018-12-31 0001033905 us-gaap:CustomerRelatedIntangibleAssetsMember 2018-12-31 0001033905 us-gaap:OtherIntangibleAssetsMember 2018-12-31 0001033905 us-gaap:TechnologyBasedIntangibleAssetsMember 2019-01-01 2019-12-31 0001033905 us-gaap:CustomerRelatedIntangibleAssetsMember 2019-01-01 2019-12-31 0001033905 us-gaap:OtherIntangibleAssetsMember 2019-01-01 2019-12-31 0001033905 us-gaap:TechnologyBasedIntangibleAssetsMember 2019-12-31 0001033905 us-gaap:CustomerRelatedIntangibleAssetsMember 2019-12-31 0001033905 us-gaap:OtherIntangibleAssetsMember 2019-12-31 0001033905 us-gaap:TechnologyBasedIntangibleAssetsMember 2020-01-01 2020-12-31 0001033905 us-gaap:CustomerRelatedIntangibleAssetsMember 2020-01-01 2020-12-31 0001033905 us-gaap:OtherIntangibleAssetsMember 2020-01-01 2020-12-31 0001033905 us-gaap:TechnologyBasedIntangibleAssetsMember 2020-12-31 0001033905 us-gaap:CustomerRelatedIntangibleAssetsMember 2020-12-31 0001033905 us-gaap:OtherIntangibleAssetsMember 2020-12-31 0001033905 us-gaap:EmployeeStockOptionMember 2019-12-31 0001033905 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001033905 us-gaap:EmployeeStockOptionMember 2020-12-31 0001033905 us-gaap:RestrictedStockMember 2020-01-01 2020-12-31 0001033905 us-gaap:RestrictedStockMember 2019-01-01 2019-12-31 0001033905 us-gaap:RestrictedStockMember 2018-01-01 2018-12-31 0001033905 us-gaap:RestrictedStockMember 2019-12-31 0001033905 us-gaap:RestrictedStockMember 2020-12-31 0001033905 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0001033905 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-12-31 0001033905 us-gaap:RestrictedStockUnitsRSUMember 2020-12-31 0001033905 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0001033905 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-12-31 0001033905 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001033905 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 iso4217:USD shares iso4217:USD shares pure utr:Rate 2020-12-31 0001033905 --12-31 2020 FY false 46688309 1344295984 2020-12-31 0.001 0.001 200000000 200000000 45682687 44325369 45682687 44325369 0.001 0.001 5000000 5000000 0 0 0 0 1140000 843000 117467000 99849000 90424000 109519000 106060000 111393000 40078000 39838000 42679000 46949000 50346000 69681000 63381000 64444000 48705000 50905000 51855000 53944000 1641000 18776000 11526000 10500000 654000 12510000 1767000 239000 0.01 0.27 0.04 0.01 0.01 0.27 0.04 0.01 0.09 0.09 0.09 0.10 82408000 83056000 78673000 90501000 36601000 37829000 36833000 40636000 45807000 45227000 41840000 49865000 49391000 50983000 47562000 46882000 -3584000 -5756000 -5722000 2983000 2960000 -4931000 -5250000 3383000 0.07 -0.11 -0.12 0.08 0.07 -0.11 -0.12 0.07 0.06 0.06 0.09 0.09 10-K true 2020-12-31 false LUMINEX CORPORATION DE 000-30109 74-2747608 12212 Technology Blvd., Austin, TX 78727 (512) 219-8020 Common Stock, $0.001 par value LMNX NASDAQ Yes No Yes Yes Large Accelerated Filer false false false 1344295984 46688309 309407000 59173000 66963000 55815000 123134000 77084000 9527000 10398000 509031000 202470000 64146000 65515000 78796000 90336000 21077000 27702000 118145000 118145000 17768000 20439000 16500000 19122000 825463000 543729000 21049000 17983000 56365000 31872000 10047000 8214000 87461000 58069000 1658000 1633000 13366000 17182000 203136000 0 2131000 1985000 307752000 78869000 45000 44000 0 0 434021000 380304000 -142000 -1380000 83787000 85892000 517711000 464860000 825463000 543729000 417396000 334638000 315818000 169544000 151899000 120327000 247852000 182739000 195491000 53651000 56228000 47164000 140216000 127183000 111816000 11542000 11407000 8665000 205409000 194818000 167645000 42443000 -12079000 27846000 -11912000 3100000 465000 -1591000 -523000 0 28940000 -9502000 28311000 13770000 -5664000 9803000 15170000 -3838000 18508000 14873000 -3773000 18196000 14872000 -3775000 18197000 0.33 -0.09 0.42 0.32 -0.09 0.41 45102000 44148000 43727000 45820000 44148000 44291000 0.37 0.30 0.24 1238000 -253000 -502000 1238000 -253000 -502000 16408000 -4091000 18006000 15170000 -3838000 18508000 30483000 28529000 23674000 6533000 14852000 13198000 12226000 -6593000 7444000 -8159000 -851000 -641000 -730000 -1592000 2719000 0 2086000 -329000 -1369000 11139000 2440000 1569000 45973000 13559000 6827000 -4125000 -4789000 3319000 3184000 3370000 4000 19686000 -5630000 103000 1888000 -1031000 579000 49931000 13537000 50899000 17910000 16249000 21292000 0 0 65381000 0 -1916000 0 0 0 1000000 0 6980000 0 0 734000 -1782000 0 0 2000 -22000 40000 4000000 -17888000 -20619000 -93453000 252247000 0 0 54626000 0 0 19968000 0 0 20435000 3750000 4570000 2373000 2095000 2312000 16485000 12153000 10654000 219166000 -10498000 -8396000 -975000 312000 279000 250234000 -17268000 -50671000 59173000 76441000 127112000 309407000 59173000 76441000 43404493 43000 350834000 -625000 87655000 437907000 157754 0 2814000 0 0 2814000 253152 1000 -2312000 0 0 -2311000 0 12187000 0 0 12187000 83811 0 1740000 0 0 1740000 0 0 0 18508000 18508000 0 0 -502000 0 -502000 0 -86000 0 10796000 10710000 0 0 0 8023000 8023000 43899210 44000 365349000 -1127000 103390000 467656000 95097 0 1698000 0 0 1698000 217620 0 -2095000 0 0 -2095000 0 13198000 0 0 13198000 113442 0 2030000 0 0 2030000 0 0 0 -3838000 -3838000 0 0 -253000 0 -253000 0 -124000 0 13660000 13536000 44325369 44000 380304000 -1380000 85892000 464860000 990071 1000 17988000 0 0 17989000 240100 0 -2373000 0 0 -2373000 0 14852000 0 0 14852000 127147 0 2391000 0 0 2391000 0 0 0 15170000 15170000 0 0 1238000 0 1238000 0 -184000 0 17275000 17091000 41950000 41950000 -41243000 -41243000 19968000 19968000 45682687 45000 434021000 -142000 83787000 517711000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NOTE 1 — DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of Business</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Luminex Corporation, the “Company” or “Luminex,” develops, manufactures and sells proprietary biological testing technologies and products with applications throughout the life sciences industries, including diagnostics, pharmaceutical and research. These industries depend on a broad range of tests, called assays, to perform diagnostic testing and conduct life science research. The Company established a position in several segments of the life sciences industries by developing and delivering products that satisfy a variety of customer needs in specific market segments, including multiplexing, accuracy, precision, sensitivity, specificity, reduction of labor and ability to test for proteins and nucleic acids. These needs are addressed by the Company’s proprietary technologies. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Multiplexing, the foundation of the Company, allows the end user in a laboratory to generate multiple laboratory results from a single sample with a single assay. This is important because the Company’s end user customers, which include laboratory professionals performing discovery and research and clinical laboratories performing tests on patients as ordered by physicians and other laboratories, have a fundamental need to perform high quality testing as efficiently as possible. Until the availability of multiplexing technology, the laboratory professional had to perform one assay at a time in a sequential manner, and if additional testing was required on a sample, a second assay would be performed to generate the second result, and so on until all the necessary tests were performed. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company primarily serves the life sciences industries by marketing products, including our specific testing equipment and assays, to various types of testing laboratories. As of December 31, 2020, the Company had 82 strategic partners, 54 of which have released commercialized reagent-based products utilizing the Company’s technology. Luminex and these partners have sold approximately 17,900 xMAP-based instruments in laboratories worldwide as of December 31, 2020, some of which may be retired or otherwise not in use. The Company’s remaining partners are in various stages of development and commercialization of products incorporating the Company’s technology. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    A primary focus for the Company’s growth is the development and sale of molecular diagnostic assays utilizing the Company’s proprietary MultiCode and VERIGENE technologies for use on the Company’s installed base of systems. The Company utilizes a direct sales model for sales of these products, which is intended to take advantage of the Company’s increasing installed base of instruments. Luminex’s assays are primarily focused on multiplexed applications for the human molecular clinical diagnostics market. Luminex’s assays are currently focused on three segments of the molecular diagnostic testing market: infectious disease, personalized medicine and human genetics. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany transactions and balances have been eliminated upon consolidation.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual amounts and results could differ from those estimates, and such differences could be material to the financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Cash and cash equivalents consist of cash deposits and highly liquid investments with original maturities of three months or less when purchased.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company determines the appropriate classification of its investments in equity securities at the time of purchase and reevaluates such determinations at each balance sheet date. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The fair values of financial instruments are determined by obtaining non-binding market prices from the Company’s third-party portfolio managers on the last day of the quarter, whose sources may use quoted prices in active markets for identical assets or inputs other than quoted prices that are observable either directly or indirectly in determining fair value. The Company’s financial instruments include cash and cash equivalents, short-term investments, accounts receivable, equity-method investments, long-term investments, accounts payable and accrued liabilities. The fair values of these financial instruments were not materially different from their carrying or contract values at December 31, 2020 and 2019. See Note 6 for further details concerning fair value measurements.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Supplemental Cash Flow Statement Information (in thousands)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:64.735%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.897%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.899%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid during the period for taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,141 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,206 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,214 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid during the period for interest and penalties</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,969 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of acquisitions:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of tangible assets acquired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,657 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,262 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,915)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,082)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost in excess of fair value of assets acquired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,647 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired identifiable intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,797 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">731 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,433)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,016)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,703 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchase price </span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,916)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,894 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less cash and cash equivalents acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,513 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid for business acquisition</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,916)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,381 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Financial instruments which potentially subject the Company to concentrations of credit risk consist of short-term and long-term investments and trade receivables. The Company provides credit, in the normal course of business, to a number of its customers geographically dispersed primarily throughout the U.S. The Company attempts to limit its credit risk by performing ongoing credit evaluations of its customers and maintaining adequate allowances for potential credit losses, but the Company does not require collateral.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    One customer accounted for 10%, 12% and 14% of our total revenues in 2020, 2019 and 2018, respectively. Another customer accounted for 4%, 5% and 15% of our total revenues in 2020, 2019 and 2018, respectively. No other customer accounted for more than 10% of our total revenues in 2020, 2019 or 2018. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Inventories, consisting primarily of raw materials and purchased components, are stated at the lower of cost or net realizable value, with cost determined according to the standard cost method, which approximates the first-in, first-out method. Net realizable value is defined as the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. As a developer and manufacturer of high technology medical equipment, the Company may be exposed to a number of economic and industry factors that could result in portions of inventory becoming either obsolete or in excess of anticipated usage. These factors include, but are not limited to, technological changes in the Company’s markets, ability to meet changing customer requirements, competitive pressures on products and prices, and reliability and replacement of and the availability of key components from suppliers. The Company’s policy is to establish inventory reserves when conditions exist that suggest that inventory may be in excess of anticipated demand or is obsolete based upon the Company’s assumptions about future demand for products and market conditions. The Company regularly evaluates the ability to realize the value of inventory based on a combination of factors including the following: historical usage rates, forecasted sales or usage, product expiration or end of life dates, estimated current and future market values and new product introductions. Assumptions used in determining the Company’s estimates of future product demand may prove to be incorrect, in which case the provision required for excess and obsolete inventory would have to be adjusted. If inventory is determined to be above the lower of cost or net realizable value, excess or obsolete, the Company would be required to record impairment charges within cost of goods sold at the time of such determination. Although considerable effort is made to ensure the accuracy of forecasts of future product demand, any significant unanticipated changes in demand or expected usage could have a significant negative impact on the value of inventory and the Company’s operating results. When recorded, reserves are intended to reduce the carrying value of inventory to its net realizable value. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Property and equipment are carried at cost less accumulated amounts for amortization and depreciation. Property and equipment are typically amortized or depreciated on a straight-line basis over the useful lives of the assets, which typically range from two to seven years. Leasehold improvements and equipment under capital leases are amortized on a straight-line basis over the shorter of the remaining term of the lease or the estimated useful life of the improvements and equipment. The Company classifies the carrying value of Luminex’s xMAP, ARIES and VERIGENE Systems placed within the reagent rental program and the instruments on loan to customers in property and equipment as “Assets on loan/rental.”</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the adoption of the new lease guidance effective January 1, 2019, the Company determines whether an agreement represents a lease and at commencement we evaluate each lease agreement to determine whether the lease is an operating or financing lease. The Company recorded an operating lease right-of-use asset and an operating lease liability on its balance sheet. Right-of-use lease assets represent the Company’s right to use the underlying asset for the lease term and the lease obligation represents the Company’s commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. The right-of-use lease asset includes any lease payments made prior to commencement and excludes any lease incentives. The lease term may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or expectations regarding the terms. Variable lease costs such as common area costs and property taxes are expensed as incurred. For all lease agreements we combine lease and non-lease components. Leases with an initial term of twelve months or less are not recorded on the balance sheet.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill and Other Intangible Assets</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Goodwill represents the excess of the cost over the fair value of the assets of the acquired business. In accordance with Accounting Standards Codification (ASC) 350 “Goodwill and Other” (ASC 350), goodwill is reviewed for impairment at least annually at the beginning of the fourth quarter, or more frequently if impairment indicators arise, tested at our sole reporting unit level. Events or circumstances that could trigger an impairment test include, but are not limited to, a significant adverse change in the business climate, significant changes in our use of the acquired assets, significant negative industry or economic trends, significant under-performance relative to operating performance indicators and significant changes in competition. The Company determined that no triggering events occurred during the year ended December 31, 2020. In 2020 and 2019, the Company estimated the fair value of the reporting unit using a fair-value-based approach based on the market capitalization. Determining the fair value of goodwill is subjective in nature and often involves the use of estimates and assumptions including, without limitation, use of estimates of future prices and volumes for the Company’s products, capital needs, economic trends and other factors which are inherently difficult to forecast. The Company’s annual test did not result in an impairment charge in 2020, as the estimated fair value of the reporting unit continued to exceed the carrying value by a significant enough amount such that any reasonably likely change in the assumptions used in the analysis would not cause the carrying value to exceed the estimated fair value for the reporting unit. No goodwill impairments were recorded in 2020, 2019 or 2018. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Intangible assets are amortized on a straight-line basis over their respective estimated useful lives ranging from 9 to 15 years. Any in-process research and development will be an indefinite-lived intangible asset until completion or abandonment, at which point it will be accounted for as a finite-lived intangible asset or written off if abandoned.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Long-lived assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that their net book value may not be recoverable. When such factors and circumstances exist, the Company compares the projected undiscounted future cash flows associated with the related asset or group of assets over their estimated useful lives against their respective carrying amounts. Impairment, if any, is based on the excess of the carrying amount over the fair value of those assets and is recorded in the period in which the determination was made.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition, Receivables and Allowance for Doubtful Accounts</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance Obligations: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is generated primarily from the sale of the Company’s products and related services, which are primarily support and maintenance services on the Company’s systems. The Company recognizes revenue when the customer obtains control of promised products or services, in an amount that reflects the consideration which the Company expects to receive in exchange for these products or services. To determine revenue recognition for arrangements, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract, identifies the performance obligations and assesses whether each promised good or service is distinct. The Company allocates the total transaction price to each performance obligation in an amount based on the estimated relative standalone selling prices of the promised goods or service underlying each performance obligation and recognizes as revenue when such performance obligation is satisfied. Revenue recognition typically occurs upon shipment or delivery to the customer depending upon the shipping terms. We treat shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost. Our customers do not typically have any contractual rights of return outside of our warranty provisions. The Company has allowed few returns to date and believes that returns of its products will be minimal in the future. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">    Royalties:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  For arrangements that include sales-based royalties, including minimum payments, the Company recognizes revenue at the later of: (i) when the related sales occur, or (ii) when the performance obligation, to which some or all of the royalty has been allocated, has been satisfied. Royalty payments are typically received when our strategic partners report the end-user sales to the Company.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">    Reagent Rentals: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides systems and certain other hardware to customers through reagent rental agreements, under which the customers commit to purchasing minimum quantities of assays at a stated price over a defined contract term, which is normally two to three years. Instead of rental payments, the Company recovers the cost of providing the system and other hardware in the amount charged for assays. Revenue is recognized over the defined contract term as assays are shipped. The depreciation costs associated with the system and other hardware are charged to cost of sales on a straight-line basis over the estimated life of the system. The costs to maintain these instruments in the field are charged to cost of sales as incurred. Under the guidance, the Company reclassified the portion of reagent rental revenue associated with the recovery of the cost of providing the system and other hardware in reagent rental agreements from assay revenue to system revenue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">    Warranties: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides a limited, assurance-type warranty, typically for twelve months from installation for the systems sold to end customers and fifteen months for the systems sold to partners. The Company accrues for the estimated cost of initial product warranties at the time revenue is recognized. While the Company engages in product quality programs and processes, the Company’s warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. While the Company believes that adequate reserve has been made in the consolidated financial statements for product warranties, should actual product failure rates, material usage or service delivery costs differ from the Company’s estimates, revisions to the estimated warranty liability would be required. Warranty expenses are evaluated and adjusted periodically.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">    License Revenues: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into out-licensing agreements, under which it licenses certain rights to its technology to third parties. These licenses are typically not distinct, as the customer cannot benefit from the license on its own, and do not have significant standalone functionality, but represent single performance obligations together with the sales of our consumables, systems and assays. The terms of these arrangements typically include payment to the Company of non-refundable, up-front license fees and can extend up to twenty years. Each of these payments results in license revenues which are recognized ratably over time and are included in other revenues, except for revenues from royalties on net sales of licensed products, which are classified as royalty revenues. Deferred revenues related to these out-licensing agreements are shown in contract liabilities in Note 18, “Revenue Recognition”.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">    Service Agreements: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from extended service agreements is deferred when payment is received in advance of the performance obligation being satisfied or completed. Luminex provides an integrated service of maintenance and related activities for equipment sold to customers, where the nature of the overall promise is to provide a stand-ready service. As such, the performance obligation is recognized as a series of distinct service periods and the service revenue is recognized ratably over the term of each agreement. The extended service agreements typically range from one to four years and payment is typically received up-front. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">    Reserves for Variable Consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from discounts and any other allowances that are offered within contracts between the Company and its customers relating to the Company’s sales of its products. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable. Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as the Company’s historical experience, current contractual requirements, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of each contract. The amount of variable consideration which is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company will adjust these estimates, which would affect net product revenue and earnings in the period when such variances become known.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">    Receivables and Allowance for Doubtful Accounts:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We recognize receivables when we have an unconditional right to payment, which represents the amount we expect to collect in a transaction and is most often equal to the transaction price in the contract. The Company adopted the new credit loss standard effective January 1, 2020. The primary impact for the Company was the timing of recording expected credit losses on its trade receivables. The Company’s allowance for doubtful accounts is based upon its expected credit losses, which is based upon its historical loss experience. Management prepared an analysis of partner versus non-partner credit loss experience and noted that its loss experience between partners and non-partners was very comparable. These receivables have been pooled together, as similar risk characteristics exist between them. On the rare occasion that interest is charged on trade receivables, it is recognized when received and there are no related fees and costs. Receivable balances are written off to the allowance for doubtful accounts when, in the judgment of management, they are considered uncollectible. The Company's credit losses have historically been within the Company’s expectations, but there can be no assurance that the Company will continue to experience the same level of credit losses that it has in the past. A significant change in the liquidity or financial position of any one of the Company’s significant customers, or a deterioration in the economic environment in general, could have a material adverse impact on the collectability of the Company’s accounts receivable and its future operating results, including a reduction in future revenues and additional allowances for doubtful accounts. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product-Related Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company provides for the estimated cost of initial product warranties at the time revenue is recognized. While the Company engages in product quality programs and processes, the Company’s warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. Should actual product failure rates, material usage or service delivery costs differ from the Company’s estimates, revisions to the estimated warranty liability would be required. Shipping and handling costs associated with product sales are included in cost of sales. Advertising costs are charged to operations as incurred. The Company does not have any direct-response advertising.  Advertising expenses, which include trade shows and conventions, were approximately $1.4 million, $3.5 million and $2.8 million for 2020, 2019 and 2018, respectively, and were included in selling, general and administrative expense in the Consolidated Statements of Comprehensive Income.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Costs</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Research and development costs are expensed in the period incurred. Nonrefundable advance payments for research and development activities for materials, equipment, facilities and purchased intangible assets that have an alternative future use are deferred and capitalized. In addition, the Company capitalizes certain internally developed products used for evaluation during development projects that also have alternative future uses. These internally developed assets are generally depreciated on a straight-line basis over the useful life of the assets, which range from one to five years.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The financial statements of the Company’s foreign subsidiaries are translated in accordance with ASC 830, “Foreign Currency Matters.” The reporting currency for the Company is the U.S. dollar. With the exception of its Canadian subsidiary, whose functional currency is the U.S. dollar, the functional currency of the Company’s foreign subsidiaries is their local currency. Accordingly, assets and liabilities of these subsidiaries are translated at the exchange rate in effect at each balance sheet date. Before translation, the Company re-measures foreign currency denominated assets and liabilities, including inter-company accounts receivable and payable, into the functional currency of the respective entity, resulting in unrealized gains or losses recorded in selling, general and administrative expenses in the Consolidated Statement of Comprehensive Income. Revenues and expenses are translated using average exchange rates during the respective period. Foreign currency translation adjustments are accumulated as a component of other comprehensive income as a separate component of stockholders’ equity. Gains and losses arising from transactions denominated in foreign currencies are included in selling, general and administrative expenses in the Consolidated Statement of Comprehensive Income and to date have not been material.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Incentive Compensation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Management incentive plans are tied to various financial and non-financial performance metrics. Bonus accruals made throughout the year related to the various incentive plans are based on management’s best estimate of the achievement of the specific metrics. Adjustments to the accruals are made on a quarterly basis as forecasts of performance are updated. At year-end, the accruals are adjusted to reflect the actual results achieved.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company accounts for income taxes under the asset and liability method.  Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.  Deferred tax balances are adjusted to reflect tax rates based on currently enacted tax laws, which will be in effect in the years in which the temporary differences are expected to reverse.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period of the enactment date.  A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets unless it is more likely than not that those assets will be realized.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company accounts for uncertain tax positions in accordance with ASC 740, “Income Taxes”, which clarifies the accounting for uncertainty in tax positions. These provisions require recognition of the impact of a tax position in the Company’s financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Earnings Per Share</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Basic net income per share is computed by dividing the net income for the period by the weighted average number of common shares outstanding during the period. Diluted net income per share is computed by dividing the net income for the period by the weighted average number of common shares and potential common shares from outstanding stock options, restricted stock units (RSUs) and contingently issuable shares resulting from an award subject to performance or market conditions determined by applying the treasury stock method. In periods with a net loss, potentially dilutive securities composed of incremental common shares issuable upon the exercise of stock options and warrants, and common shares issuable on conversion of preferred stock, would be excluded from historical diluted loss per share because of their anti-dilutive effect.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company accounts for stock-based employee compensation plans under the fair value recognition and measurement provisions of ASC 718 “Stock Compensation” (ASC 718). ASC 718 requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based payments including stock options, restricted stock units and shares issued under the Company’s employee stock purchase plan. Pursuant to ASC 718, stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as expense over the requisite service period.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of Business</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Luminex Corporation, the “Company” or “Luminex,” develops, manufactures and sells proprietary biological testing technologies and products with applications throughout the life sciences industries, including diagnostics, pharmaceutical and research. These industries depend on a broad range of tests, called assays, to perform diagnostic testing and conduct life science research. The Company established a position in several segments of the life sciences industries by developing and delivering products that satisfy a variety of customer needs in specific market segments, including multiplexing, accuracy, precision, sensitivity, specificity, reduction of labor and ability to test for proteins and nucleic acids. These needs are addressed by the Company’s proprietary technologies. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Multiplexing, the foundation of the Company, allows the end user in a laboratory to generate multiple laboratory results from a single sample with a single assay. This is important because the Company’s end user customers, which include laboratory professionals performing discovery and research and clinical laboratories performing tests on patients as ordered by physicians and other laboratories, have a fundamental need to perform high quality testing as efficiently as possible. Until the availability of multiplexing technology, the laboratory professional had to perform one assay at a time in a sequential manner, and if additional testing was required on a sample, a second assay would be performed to generate the second result, and so on until all the necessary tests were performed. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company primarily serves the life sciences industries by marketing products, including our specific testing equipment and assays, to various types of testing laboratories. As of December 31, 2020, the Company had 82 strategic partners, 54 of which have released commercialized reagent-based products utilizing the Company’s technology. Luminex and these partners have sold approximately 17,900 xMAP-based instruments in laboratories worldwide as of December 31, 2020, some of which may be retired or otherwise not in use. The Company’s remaining partners are in various stages of development and commercialization of products incorporating the Company’s technology. </span></div>    A primary focus for the Company’s growth is the development and sale of molecular diagnostic assays utilizing the Company’s proprietary MultiCode and VERIGENE technologies for use on the Company’s installed base of systems. The Company utilizes a direct sales model for sales of these products, which is intended to take advantage of the Company’s increasing installed base of instruments. Luminex’s assays are primarily focused on multiplexed applications for the human molecular clinical diagnostics market. Luminex’s assays are currently focused on three segments of the molecular diagnostic testing market: infectious disease, personalized medicine and human genetics. 2020-12-31 2020-12-31 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany transactions and balances have been eliminated upon consolidation.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual amounts and results could differ from those estimates, and such differences could be material to the financial statements.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Cash and cash equivalents consist of cash deposits and highly liquid investments with original maturities of three months or less when purchased.</span></div> Investments    The Company determines the appropriate classification of its investments in equity securities at the time of purchase and reevaluates such determinations at each balance sheet date. <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The fair values of financial instruments are determined by obtaining non-binding market prices from the Company’s third-party portfolio managers on the last day of the quarter, whose sources may use quoted prices in active markets for identical assets or inputs other than quoted prices that are observable either directly or indirectly in determining fair value. The Company’s financial instruments include cash and cash equivalents, short-term investments, accounts receivable, equity-method investments, long-term investments, accounts payable and accrued liabilities. The fair values of these financial instruments were not materially different from their carrying or contract values at December 31, 2020 and 2019. See Note 6 for further details concerning fair value measurements.</span></div> 2020-12-31 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Financial instruments which potentially subject the Company to concentrations of credit risk consist of short-term and long-term investments and trade receivables. The Company provides credit, in the normal course of business, to a number of its customers geographically dispersed primarily throughout the U.S. The Company attempts to limit its credit risk by performing ongoing credit evaluations of its customers and maintaining adequate allowances for potential credit losses, but the Company does not require collateral.</span></div>    One customer accounted for 10%, 12% and 14% of our total revenues in 2020, 2019 and 2018, respectively. Another customer accounted for 4%, 5% and 15% of our total revenues in 2020, 2019 and 2018, respectively. No other customer accounted for more than 10% of our total revenues in 2020, 2019 or 2018. Inventories    Inventories, consisting primarily of raw materials and purchased components, are stated at the lower of cost or net realizable value, with cost determined according to the standard cost method, which approximates the first-in, first-out method. Net realizable value is defined as the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. As a developer and manufacturer of high technology medical equipment, the Company may be exposed to a number of economic and industry factors that could result in portions of inventory becoming either obsolete or in excess of anticipated usage. These factors include, but are not limited to, technological changes in the Company’s markets, ability to meet changing customer requirements, competitive pressures on products and prices, and reliability and replacement of and the availability of key components from suppliers. The Company’s policy is to establish inventory reserves when conditions exist that suggest that inventory may be in excess of anticipated demand or is obsolete based upon the Company’s assumptions about future demand for products and market conditions. The Company regularly evaluates the ability to realize the value of inventory based on a combination of factors including the following: historical usage rates, forecasted sales or usage, product expiration or end of life dates, estimated current and future market values and new product introductions. Assumptions used in determining the Company’s estimates of future product demand may prove to be incorrect, in which case the provision required for excess and obsolete inventory would have to be adjusted. If inventory is determined to be above the lower of cost or net realizable value, excess or obsolete, the Company would be required to record impairment charges within cost of goods sold at the time of such determination. Although considerable effort is made to ensure the accuracy of forecasts of future product demand, any significant unanticipated changes in demand or expected usage could have a significant negative impact on the value of inventory and the Company’s operating results. When recorded, reserves are intended to reduce the carrying value of inventory to its net realizable value. <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Property and equipment are carried at cost less accumulated amounts for amortization and depreciation. Property and equipment are typically amortized or depreciated on a straight-line basis over the useful lives of the assets, which typically range from two to seven years. Leasehold improvements and equipment under capital leases are amortized on a straight-line basis over the shorter of the remaining term of the lease or the estimated useful life of the improvements and equipment. The Company classifies the carrying value of Luminex’s xMAP, ARIES and VERIGENE Systems placed within the reagent rental program and the instruments on loan to customers in property and equipment as “Assets on loan/rental.”</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill and Other Intangible Assets</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Goodwill represents the excess of the cost over the fair value of the assets of the acquired business. In accordance with Accounting Standards Codification (ASC) 350 “Goodwill and Other” (ASC 350), goodwill is reviewed for impairment at least annually at the beginning of the fourth quarter, or more frequently if impairment indicators arise, tested at our sole reporting unit level. Events or circumstances that could trigger an impairment test include, but are not limited to, a significant adverse change in the business climate, significant changes in our use of the acquired assets, significant negative industry or economic trends, significant under-performance relative to operating performance indicators and significant changes in competition. The Company determined that no triggering events occurred during the year ended December 31, 2020. In 2020 and 2019, the Company estimated the fair value of the reporting unit using a fair-value-based approach based on the market capitalization. Determining the fair value of goodwill is subjective in nature and often involves the use of estimates and assumptions including, without limitation, use of estimates of future prices and volumes for the Company’s products, capital needs, economic trends and other factors which are inherently difficult to forecast. The Company’s annual test did not result in an impairment charge in 2020, as the estimated fair value of the reporting unit continued to exceed the carrying value by a significant enough amount such that any reasonably likely change in the assumptions used in the analysis would not cause the carrying value to exceed the estimated fair value for the reporting unit. No goodwill impairments were recorded in 2020, 2019 or 2018. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Intangible assets are amortized on a straight-line basis over their respective estimated useful lives ranging from 9 to 15 years. Any in-process research and development will be an indefinite-lived intangible asset until completion or abandonment, at which point it will be accounted for as a finite-lived intangible asset or written off if abandoned.</span></div> 2020-12-31 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Long-lived assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that their net book value may not be recoverable. When such factors and circumstances exist, the Company compares the projected undiscounted future cash flows associated with the related asset or group of assets over their estimated useful lives against their respective carrying amounts. Impairment, if any, is based on the excess of the carrying amount over the fair value of those assets and is recorded in the period in which the determination was made.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance Obligations: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is generated primarily from the sale of the Company’s products and related services, which are primarily support and maintenance services on the Company’s systems. The Company recognizes revenue when the customer obtains control of promised products or services, in an amount that reflects the consideration which the Company expects to receive in exchange for these products or services. To determine revenue recognition for arrangements, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract, identifies the performance obligations and assesses whether each promised good or service is distinct. The Company allocates the total transaction price to each performance obligation in an amount based on the estimated relative standalone selling prices of the promised goods or service underlying each performance obligation and recognizes as revenue when such performance obligation is satisfied. Revenue recognition typically occurs upon shipment or delivery to the customer depending upon the shipping terms. We treat shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost. Our customers do not typically have any contractual rights of return outside of our warranty provisions. The Company has allowed few returns to date and believes that returns of its products will be minimal in the future. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">    Royalties:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  For arrangements that include sales-based royalties, including minimum payments, the Company recognizes revenue at the later of: (i) when the related sales occur, or (ii) when the performance obligation, to which some or all of the royalty has been allocated, has been satisfied. Royalty payments are typically received when our strategic partners report the end-user sales to the Company.</span><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">    Reagent Rentals: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides systems and certain other hardware to customers through reagent rental agreements, under which the customers commit to purchasing minimum quantities of assays at a stated price over a defined contract term, which is normally two to three years. Instead of rental payments, the Company recovers the cost of providing the system and other hardware in the amount charged for assays. Revenue is recognized over the defined contract term as assays are shipped. The depreciation costs associated with the system and other hardware are charged to cost of sales on a straight-line basis over the estimated life of the system. The costs to maintain these instruments in the field are charged to cost of sales as incurred. Under the guidance, the Company reclassified the portion of reagent rental revenue associated with the recovery of the cost of providing the system and other hardware in reagent rental agreements from assay revenue to system revenue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">    Warranties: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides a limited, assurance-type warranty, typically for twelve months from installation for the systems sold to end customers and fifteen months for the systems sold to partners. The Company accrues for the estimated cost of initial product warranties at the time revenue is recognized. While the Company engages in product quality programs and processes, the Company’s warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. While the Company believes that adequate reserve has been made in the consolidated financial statements for product warranties, should actual product failure rates, material usage or service delivery costs differ from the Company’s estimates, revisions to the estimated warranty liability would be required. Warranty expenses are evaluated and adjusted periodically.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">    License Revenues: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into out-licensing agreements, under which it licenses certain rights to its technology to third parties. These licenses are typically not distinct, as the customer cannot benefit from the license on its own, and do not have significant standalone functionality, but represent single performance obligations together with the sales of our consumables, systems and assays. The terms of these arrangements typically include payment to the Company of non-refundable, up-front license fees and can extend up to twenty years. Each of these payments results in license revenues which are recognized ratably over time and are included in other revenues, except for revenues from royalties on net sales of licensed products, which are classified as royalty revenues. Deferred revenues related to these out-licensing agreements are shown in contract liabilities in Note 18, “Revenue Recognition”.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">    Service Agreements: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from extended service agreements is deferred when payment is received in advance of the performance obligation being satisfied or completed. Luminex provides an integrated service of maintenance and related activities for equipment sold to customers, where the nature of the overall promise is to provide a stand-ready service. As such, the performance obligation is recognized as a series of distinct service periods and the service revenue is recognized ratably over the term of each agreement. The extended service agreements typically range from one to four years and payment is typically received up-front. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">    Reserves for Variable Consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from discounts and any other allowances that are offered within contracts between the Company and its customers relating to the Company’s sales of its products. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable. Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as the Company’s historical experience, current contractual requirements, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of each contract. The amount of variable consideration which is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company will adjust these estimates, which would affect net product revenue and earnings in the period when such variances become known.</span></div> Receivables and Allowance for Doubtful Accounts: We recognize receivables when we have an unconditional right to payment, which represents the amount we expect to collect in a transaction and is most often equal to the transaction price in the contract. The Company adopted the new credit loss standard effective January 1, 2020. The primary impact for the Company was the timing of recording expected credit losses on its trade receivables. The Company’s allowance for doubtful accounts is based upon its expected credit losses, which is based upon its historical loss experience. Management prepared an analysis of partner versus non-partner credit loss experience and noted that its loss experience between partners and non-partners was very comparable. These receivables have been pooled together, as similar risk characteristics exist between them. On the rare occasion that interest is charged on trade receivables, it is recognized when received and there are no related fees and costs. Receivable balances are written off to the allowance for doubtful accounts when, in the judgment of management, they are considered uncollectible. The Company's credit losses have historically been within the Company’s expectations, but there can be no assurance that the Company will continue to experience the same level of credit losses that it has in the past. A significant change in the liquidity or financial position of any one of the Company’s significant customers, or a deterioration in the economic environment in general, could have a material adverse impact on the collectability of the Company’s accounts receivable and its future operating results, including a reduction in future revenues and additional allowances for doubtful accounts. <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product-Related Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company provides for the estimated cost of initial product warranties at the time revenue is recognized. While the Company engages in product quality programs and processes, the Company’s warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. Should actual product failure rates, material usage or service delivery costs differ from the Company’s estimates, revisions to the estimated warranty liability would be required. Shipping and handling costs associated with product sales are included in cost of sales. Advertising costs are charged to operations as incurred. The Company does not have any direct-response advertising.  Advertising expenses, which include trade shows and conventions, were approximately $1.4 million, $3.5 million and $2.8 million for 2020, 2019 and 2018, respectively, and were included in selling, general and administrative expense in the Consolidated Statements of Comprehensive Income.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Costs</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Research and development costs are expensed in the period incurred. Nonrefundable advance payments for research and development activities for materials, equipment, facilities and purchased intangible assets that have an alternative future use are deferred and capitalized. In addition, the Company capitalizes certain internally developed products used for evaluation during development projects that also have alternative future uses. These internally developed assets are generally depreciated on a straight-line basis over the useful life of the assets, which range from one to five years.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The financial statements of the Company’s foreign subsidiaries are translated in accordance with ASC 830, “Foreign Currency Matters.” The reporting currency for the Company is the U.S. dollar. With the exception of its Canadian subsidiary, whose functional currency is the U.S. dollar, the functional currency of the Company’s foreign subsidiaries is their local currency. Accordingly, assets and liabilities of these subsidiaries are translated at the exchange rate in effect at each balance sheet date. Before translation, the Company re-measures foreign currency denominated assets and liabilities, including inter-company accounts receivable and payable, into the functional currency of the respective entity, resulting in unrealized gains or losses recorded in selling, general and administrative expenses in the Consolidated Statement of Comprehensive Income. Revenues and expenses are translated using average exchange rates during the respective period. Foreign currency translation adjustments are accumulated as a component of other comprehensive income as a separate component of stockholders’ equity. Gains and losses arising from transactions denominated in foreign currencies are included in selling, general and administrative expenses in the Consolidated Statement of Comprehensive Income and to date have not been material.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Incentive Compensation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Management incentive plans are tied to various financial and non-financial performance metrics. Bonus accruals made throughout the year related to the various incentive plans are based on management’s best estimate of the achievement of the specific metrics. Adjustments to the accruals are made on a quarterly basis as forecasts of performance are updated. At year-end, the accruals are adjusted to reflect the actual results achieved.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company accounts for income taxes under the asset and liability method.  Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.  Deferred tax balances are adjusted to reflect tax rates based on currently enacted tax laws, which will be in effect in the years in which the temporary differences are expected to reverse.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period of the enactment date.  A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets unless it is more likely than not that those assets will be realized.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company accounts for uncertain tax positions in accordance with ASC 740, “Income Taxes”, which clarifies the accounting for uncertainty in tax positions. These provisions require recognition of the impact of a tax position in the Company’s financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Earnings Per Share</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Basic net income per share is computed by dividing the net income for the period by the weighted average number of common shares outstanding during the period. Diluted net income per share is computed by dividing the net income for the period by the weighted average number of common shares and potential common shares from outstanding stock options, restricted stock units (RSUs) and contingently issuable shares resulting from an award subject to performance or market conditions determined by applying the treasury stock method. In periods with a net loss, potentially dilutive securities composed of incremental common shares issuable upon the exercise of stock options and warrants, and common shares issuable on conversion of preferred stock, would be excluded from historical diluted loss per share because of their anti-dilutive effect.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company accounts for stock-based employee compensation plans under the fair value recognition and measurement provisions of ASC 718 “Stock Compensation” (ASC 718). ASC 718 requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based payments including stock options, restricted stock units and shares issued under the Company’s employee stock purchase plan. Pursuant to ASC 718, stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as expense over the requisite service period.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NOTE 2 — INVESTMENTS AND OTHER ASSETS</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">    Marketable Securities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company determines the appropriate classification of any investments in debt and equity securities at the time of purchase and re-evaluates such determinations at each balance sheet date. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Available-for-sale securities consisted of the following as of December 31, 2020 (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:40.811%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gains in Accumulated Other Comprehensive Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Losses in Accumulated Other Comprehensive Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money Market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total noncurrent securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Available-for-sale securities consisted of the following as of December 31, 2019 (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:40.811%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gains in Accumulated Other Comprehensive Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Losses in Accumulated Other Comprehensive Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money Market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total noncurrent securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    There were no proceeds from the sales of available-for-sale securities for the years ended December 31, 2020 and December 31, 2019.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span>Realized gains and losses on sales of investments are determined using the specific identification method and are included in other income (expense) in the Consolidated Statement of Comprehensive Income. There were no available-for-sale debt securities as of December 31, 2020 or December 31, 2019. Marketable Securities<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company determines the appropriate classification of any investments in debt and equity securities at the time of purchase and re-evaluates such determinations at each balance sheet date. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Available-for-sale securities consisted of the following as of December 31, 2020 (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:40.811%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gains in Accumulated Other Comprehensive Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Losses in Accumulated Other Comprehensive Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money Market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total noncurrent securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Available-for-sale securities consisted of the following as of December 31, 2019 (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:40.811%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gains in Accumulated Other Comprehensive Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Losses in Accumulated Other Comprehensive Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money Market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total noncurrent securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    There were no proceeds from the sales of available-for-sale securities for the years ended December 31, 2020 and December 31, 2019.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span>Realized gains and losses on sales of investments are determined using the specific identification method and are included in other income (expense) in the Consolidated Statement of Comprehensive Income. There were no available-for-sale debt securities as of December 31, 2020 or December 31, 2019. 2020-12-31 <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:40.811%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gains in Accumulated Other Comprehensive Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Losses in Accumulated Other Comprehensive Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money Market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total noncurrent securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:40.811%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gains in Accumulated Other Comprehensive Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Losses in Accumulated Other Comprehensive Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money Market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total noncurrent securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 2020-12-31 2020-12-31 Non-Marketable Securities and Other-Than-Temporary Impairment<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    During the year ended December 31, 2018, the Company made a $1.8 million investment in Combinati, a private company. Subsequently, on October 1, 2019, the Company made an additional $7.0 million investment in Combinati, bringing the Company's ownership to approximately 28.4% of the voting interest of Combinati. The Company does not have majority control of the entity in which the investment was made, but has the ability to exercise significant influence over operating and financial policies due to its larger ownership percentage and its seat on the Board of Directors. The Company does not have unilateral decision making power, and therefore will not consolidate the investee; therefore, the Company accounts for this investment using the equity method. In the fourth quarter of 2019, we remeasured the existing, minority interest investment based on the fair value prior to the additional investment and recorded a gain of approximately $3.2 million in Other income, net in the Consolidated Statements of Comprehensive Income. The minority interest investment in Combinati is classified in equity method investments to distinguish it from other minority interest investments that take the fair value alternative. The Company's proportionate share of income or loss of approximately 28.4% is recorded in other income (expense), net in the Consolidated Statement of Comprehensive Income. This non-marketable equity investment is recorded at cost minus impairment, if any, plus or minus changes resulting from qualifying observable price changes. The Company periodically reviews this equity investment for other-than-temporary declines in fair value based on the specific identification method and writes down the investment to its fair value when it determines that an other-than-temporary decline has occurred. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    As of December 31, 2020, the carrying value of the Company’s total investment in Combinati was $9.9 million, which exceeded the Company’s share of Combinati’s net assets by $8.1 million and is not amortized. For the year ended December 31, 2020, the Company recorded the allocable share of Combinati’s net income in its Consolidated Statement of Compre</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hensive Income and as an adjustment to the invested balance.</span></div> 2020-12-31 In August 2018, the Company exercised its purchase option on a second private company and acquired 100% of its capital stock in a non-cash transaction involving (i) a prior investment of $2.0 million being applied to the purchase option, (ii) the forgiveness and application of a $2.4 million note and related interest receivable to the purchase option and (iii) a tax impact of $0.1 million. This acquisition was accounted for as an asset acquisition rather than a business combination, as substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset, a next generation technology. The Company recorded the $4.3 million asset acquisition as a defensive, in-process research and development (IP R&amp;D) intangible asset. There were no gains or losses recognized as part of this transaction.    The Company owned a minority interest in another private company based in the U.S. through its initial investment of $1.0 million in the third quarter of 2012. We were informed that this private company will be dissolving and ceasing operations in the first quarter of 2020. We received cash representing the majority of our investment in the fourth quarter of 2019 and recorded an impairment of $205,000 in Other income, net in the Consolidated Statements of Comprehensive Income during 2019 based upon these circumstances. We received the final cash payment for the remainder of this minority interest in the first quarter of 2020, recorded in cash flows from investing activities in the Consolidated Statements of Cash Flows.    These minority interest investments do not have readily determinable fair values. Therefore, the Company has elected the measurement alternative for its minority interests and the investments are recorded at cost, less any impairment, including changes resulting from observable price changes. The Company regularly evaluates the carrying value of its investment for impairment and whether any events or circumstances are identified that would significantly harm the fair value of the investment. The primary indicators the Company utilizes to identify these events and circumstances are the investee’s ability to remain in business, such as the investee’s liquidity and rate of cash use, and the investee’s ability to secure additional funding and the value of that additional funding. In the event a decline in fair value is less than the investment’s carrying value, the Company will record an impairment charge in Other income, net in the Consolidated Statements of Comprehensive Income. Other than the $205,000 impairment in 2019 discussed above, the Company has not recorded any impairment charges related to these non-marketable investments. <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:76.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.899%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased technology rights (net of accumulated amortization of $8,872 and $8,300 in 2020 and 2019, respectively)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,454 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,027 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minority interest and equity method investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,909 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,501 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,137 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,594 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,500 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,122 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 5454000 6027000 9909000 11501000 1137000 1594000 16500000 19122000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NOTE 3 — ACCOUNTS RECEIVABLE AND RESERVES</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Accounts receivable consisted of the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:76.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.899%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,629 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,956 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Allowance for doubtful accounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,666)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,141)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,963 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,815 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The following table summarizes the changes in the allowance for doubtful accounts (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:87.919%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.881%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2017</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,345 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increases charged to costs and expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(437)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs of uncollectible accounts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2018</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">843 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net recoveries charged to costs and expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs of uncollectible accounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,141 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net recoveries charged to costs and expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs of uncollectible accounts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,666 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:76.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.899%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,629 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,956 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Allowance for doubtful accounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,666)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,141)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,963 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,815 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 68629000 56956000 1666000 1141000 66963000 55815000 <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:87.919%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.881%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2017</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,345 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increases charged to costs and expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(437)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs of uncollectible accounts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2018</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">843 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net recoveries charged to costs and expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs of uncollectible accounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,141 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net recoveries charged to costs and expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs of uncollectible accounts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,666 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 1345000 -437000 65000 843000 400000 102000 1141000 -546000 21000 1666000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NOTE 4 — INVENTORIES, NET</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Inventories consisted of the following at December 31 (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:76.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.899%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Parts and supplies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,380 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,459 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-progress</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,858 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,532 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,896 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,093 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,134 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,084 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company has non-cancellable purchase commitments with certain of its component suppliers in the amount of approximately $68.1 million at December 31, 2020. Should production requirements fall below the level of the Company’s commitments, the Company </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">coul</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d be required to take delivery of inventory for which it has no immediate need or incur an increased cost per unit going forward.</span></div> <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:76.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.899%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Parts and supplies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,380 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,459 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-progress</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,858 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,532 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,896 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,093 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,134 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,084 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 86380000 45459000 18858000 15532000 17896000 16093000 123134000 77084000 68100000 2020-12-31 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NOTE 5 — FAIR VALUE MEASUREMENT</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    ASC 820 “Fair Value Measurement” (ASC 820) defines fair value, establishes a framework for measuring fair value under U.S. GAAP and enhances disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. ASC 820 describes a fair value hierarchy based on the following three levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last unobservable:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Level 1—Quoted prices in active markets for identical assets or liabilities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company determines the fair value of its investment portfolio assets by obtaining non-binding market prices from its third-party portfolio managers on the last day of the quarter, whose sources may use quoted prices in active markets for identical assets (Level 1 inputs) or inputs other than quoted prices that are observable either directly or indirectly (Level 2 inputs) in determining fair value. There were no transfers between Level 1, Level 2 or Level 3 measurements for the year ended December 31, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The following table represents the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2020 and 2019 (in thousands):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.851%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements as of December 31, 2020 Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money Market funds</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Equity investment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,909 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,909 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.851%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements as of December 31, 2019 Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money Market funds</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minority interest investments - long-term</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,501 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,501 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2020-12-31 2020-12-31 <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.851%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements as of December 31, 2020 Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money Market funds</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Equity investment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,909 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,909 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 707000 0 0 707000 0 0 707000 0 0 707000 0 0 22000 22000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NOTE 6 — PROPERTY AND EQUIPMENT</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Property and equipment consisted of the following at December 31 (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:76.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.899%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,189 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,486 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,784 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,471 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,034 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,916 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased software</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,981 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,621 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,081 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,924 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets on loan/rental</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,544 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,946 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,613 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,364 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117,467)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99,849)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,146 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,515 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Depreciation expense was $18.4 million and $16.5 million for the years ended December 31, 2020 and 2019, respectively.</span></div> <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:76.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.899%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,189 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,486 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,784 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,471 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,034 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,916 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased software</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,981 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,621 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,081 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,924 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets on loan/rental</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,544 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,946 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,613 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,364 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117,467)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99,849)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,146 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,515 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 181613000 165364000 117467000 99849000 64146000 65515000 18400000 16500000 2020-12-31 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NOTE 7 — GOODWILL AND OTHER INTANGIBLE ASSETS</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The changes in the carrying amount of goodwill during the period are as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:63.856%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.055%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.056%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,145 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,127 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Flow cytometry acquisition </span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,145 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,145 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2020-12-31 118145000 118127000 0 18000 118145000 118145000 A portion of the Company’s goodwill is not expected to be deductible for tax purposes. The Company’s intangible assets are reflected in the table below (in thousands, except weighted average lives):<div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:41.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.886%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finite-lived</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indefinite-lived</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology, trade secrets and know-how</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer lists and contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other identifiable intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IP R&amp;D</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2018</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,469 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,819 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,655 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,013 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,956 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Flow cytometry acquisition purchase price allocation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(428)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,154 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,016)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,406)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,353 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,391 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,809 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,997 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,550 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated amortization:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated amortization balance as of December 31, 2018</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,501)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,036)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,271)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,808)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,784)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,428)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,194)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,406)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated amortization balance as of December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,285)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,464)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,465)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,214)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net balance as of December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,068 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,927 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,344 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,997 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,336 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average life (in years)</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,353 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,391 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,809 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,997 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,550 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Completion of IPR&amp;D projects</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,687 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,687)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,040 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,391 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,809 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,310 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,550 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated amortization:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated amortization balance as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,285)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,464)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,465)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,214)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,919)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,427)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,194)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,540)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated amortization balance as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,204)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,891)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,659)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,754)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net balance as of December 31, 2020</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,836 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,500 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,150 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,310 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,796 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average life (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company currently has two IP R&amp;D projects. The first relates to the development of the next generation VERIGENE System, VERIGENE II. The Company is targeting the commercial launch of the VERIGENE II System in 2021. The second is a defensive IP R&amp;D project related to the Company’s next generation xMAP System, xMAP INTELLIFLEX, which the Company currently believes will launch commercially in the first half of 2021. The next generation Guava System (Guava Next Gen System), acquired as part of the Company’s acquisition of EMD Millipore Corporation’s flow cytometry portfolio, was launched commercially in the second quarter of 2020 and transferred from IP R&amp;D to finite-lived technology, trade secrets and know-how and is being amortized.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The estimated aggregate amortization expense for the next five fiscal years and thereafter is as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:81.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.056%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,316 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,070 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,721 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,721 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,188 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,470 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,486 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:41.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.886%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finite-lived</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indefinite-lived</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology, trade secrets and know-how</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer lists and contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other identifiable intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IP R&amp;D</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2018</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,469 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,819 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,655 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,013 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,956 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Flow cytometry acquisition purchase price allocation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(428)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,154 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,016)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,406)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,353 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,391 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,809 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,997 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,550 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated amortization:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated amortization balance as of December 31, 2018</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,501)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,036)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,271)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,808)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,784)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,428)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,194)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,406)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated amortization balance as of December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,285)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,464)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,465)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,214)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net balance as of December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,068 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,927 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,344 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,997 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,336 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average life (in years)</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,353 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,391 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,809 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,997 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,550 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Completion of IPR&amp;D projects</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,687 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,687)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,040 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,391 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,809 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,310 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,550 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated amortization:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated amortization balance as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,285)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,464)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,465)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,214)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,919)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,427)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,194)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,540)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated amortization balance as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,204)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,891)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,659)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,754)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net balance as of December 31, 2020</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,836 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,500 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,150 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,310 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,796 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average life (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr></table> 98469000 23819000 10655000 24013000 156956000 -116000 -428000 1154000 -4016000 98353000 23391000 11809000 19997000 153550000 40501000 9036000 2271000 51808000 7784000 2428000 1194000 48285000 11464000 3465000 63214000 50068000 11927000 8344000 19997000 90336000 P11Y P10Y P10Y 98353000 23391000 11809000 19997000 153550000 2687000 -2687000 -2687000 101040000 23391000 11809000 17310000 153550000 48285000 11464000 3465000 63214000 7919000 2427000 1194000 56204000 13891000 4659000 74754000 44836000 9500000 7150000 17310000 78796000 P11Y P10Y P10Y <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:81.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.056%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,316 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,070 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,721 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,721 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,188 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,470 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,486 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 11316000 10070000 9721000 9721000 8188000 12470000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NOTE 8 — OTHER COMPREHENSIVE (LOSS) INCOME</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Comprehensive loss represents a measure of all changes in equity that result from recognized transactions and other economic events other than those resulting from investments by and distributions to shareholders. Other comprehensive loss for the Company includes foreign currency translation adjustments and net unrealized holding gains and losses on available-for-sale investments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The following table presents the changes in each component of accumulated other comprehensive loss, net of tax (in thousands):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:72.360%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.440%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss Items - Foreign Currency</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,380)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> loss</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,238 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current-period other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,238 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    There are no tax benefits or expenses related to the other comprehensive loss for the twelve months ended December 31, 2020.</span></div> -1380000 1238000 -142000 2020-12-31 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NOTE 9 — ACCRUED LIABILITIES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Accrued liabilities consisted of the following as of December 31 (in thousands):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:76.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.606%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and employee benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,992 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,011 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,711 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,104 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income and other taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,058 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,538 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warranty costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,849 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,641 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,335 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,942 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,053 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes interest payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,035 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,190 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,365 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,872 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Sales of certain of the Company’s systems are subject to a warranty. System warranties typically extend for a period of twelve months from the date of installation or no more than 15 months from the date of shipment. The Company estimates the amount of warranty claims on sold products that may be incurred based on current and historical data. The actual warranty expense could differ from the estimates made by the Company based on product performance. Warranty expenses are evaluated and adjusted periodically.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The following table summarizes the changes in the warranty accrual (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:87.919%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.881%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued warranty costs at December 31, 2017</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warranty services provided</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,159)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrual for warranty costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,752 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued warranty costs at December 31, 2018</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,901 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warranty services provided</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,868)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrual for warranty costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,608 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued warranty costs at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,641 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warranty services provided</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,362)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrual for warranty costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,570 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued warranty costs at December 31, 2020</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,849 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:76.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.606%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and employee benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,992 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,011 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,711 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,104 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income and other taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,058 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,538 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warranty costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,849 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,641 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,335 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,942 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,053 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes interest payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,035 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,190 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,365 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,872 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 33992000 17011000 4711000 4104000 7058000 1538000 1849000 1641000 782000 1335000 5942000 5053000 996000 0 1035000 1190000 56365000 31872000 <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:87.919%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.881%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued warranty costs at December 31, 2017</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warranty services provided</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,159)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrual for warranty costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,752 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued warranty costs at December 31, 2018</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,901 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warranty services provided</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,868)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrual for warranty costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,608 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued warranty costs at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,641 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warranty services provided</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,362)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrual for warranty costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,570 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued warranty costs at December 31, 2020</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,849 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 1308000 2159000 2752000 1901000 2868000 2608000 1641000 2362000 2570000 1849000 <div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10 — CONVERTIBLE SENIOR NOTES</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company issued $260.0 million principal amount of Convertible Senior Notes due in May 2025 (Notes). The interest rates for the Notes is fixed at 3.00% per annum with interest payable semi-annually on May 15 and November 15 of each year, commencing on November 15, 2020. The Notes mature on May 15, 2025, unless earlier converted or repurchased in accordance with their terms prior to such date. Each $1,000 of principal amount of the Notes will initially be convertible into 22.8918 shares of the Company's common stock, which is equivalent to an initial conversion price of approximately $43.68 per share. The initial conversion price for each of the Notes is subject to adjustment upon the occurrence of certain specified events. On December 3, 2020, we announced that our Board declared an increased quarterly cash dividend of $0.10 per share of common stock to be paid to shareholders of record as of the close of business on December 23, 2020 with a payment date of January 14, 2021. This increase in the dividend adjusted the conversion price to $43.67 per share, or 22.9009 shares of the Company's common stock for each $1,000 of principal amount of the Notes.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their Notes at their option at any time prior to the close of business on the business day immediately preceding November 15, 2024 only under the following circumstances: </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">during any calendar quarter commencing after the calendar quarter ending on June 30, 2020 (and only during such calendar quarter), if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">during the five business day period after any five consecutive trading day period (Measurement Period) in which the trading price (as defined in the relevant indenture governing the Notes) per $1,000 principal amount of Notes for each trading day of the Measurement Period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day; or </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">upon the occurrence of specified corporate events as set forth in the indenture governing the Notes.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after November 15, 2024 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or any portion of their Notes at any time, regardless of the foregoing circumstances. Upon conversion, the Company will pay or deliver cash, shares of its common stock or a combination of cash and shares of its common stock, at the Company’s election. The Company currently intends to settle the principal amount of the Notes in cash, and settle any excess amount with shares of the Company’s common stock, upon conversion. As of December 31, 2020, the Notes were not yet convertible.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a fundamental change (as defined in the relevant indenture governing the Notes) occurs prior to the maturity date, holders of each of the Notes may require the Company to repurchase all or a portion of their Notes for cash at a repurchase price equal to 100% of the principal amount of the Notes, plus any accrued and unpaid interest up to, but excluding, the fundamental change repurchase date.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accounting for the issuance of the Notes, the Company separated each of the Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value, as of the date of issuance, of a similar debt without the conversion feature. The effective interest rate used for the liability component was 8.50%. The liability component of the Notes is recorded in long-term debt, and the interest payable within the next twelve months is recorded in accrued liabilities on the Condensed Consolidated Balance Sheets as of December 31, 2020. The carrying amount of the equity component representing the conversion feature was determined by deducting the fair value of the liability components from the total initial proceeds. The difference between the par amount of the Notes and the carrying amount of the liability component represents debt discounts that are amortized to interest expense over the respective terms of the Notes using the effective interest rate method. The equity components are not remeasured as long as they continue to meet the conditions for equity classification.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accounting for the $7.7 million of issuance costs related to the Notes, the Company allocated the total amount of issuance costs incurred to the liability and equity components in proportion to the allocation of the proceeds from issuance to the liability and equity components. Issuance costs attributable to the liability components are amortized to interest expense over the respective terms of the Notes using the effective interest rate method. The issuance costs attributable to the equity components were netted against the respective equity components in additional paid-in capital.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Issuance costs attributable to the liability component, totaling $6.0 million, are being amortized to expense over the expected life of the Notes using the effective interest method. Issuance costs attributable to the equity component related to the conversion feature, totaling $1.7 million, were netted with the equity component.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes consist of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.124%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Liability component:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Principal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">260,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Unamortized debt discount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(51,352)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Unamortized debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(5,512)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net carrying amount</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">203,136 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Equity component:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net carrying amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">41,950 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth total interest expense recognized related to the Notes for the years ended December 31 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:77.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.858%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contractual interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,940 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt discount </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,002 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,473 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the remaining period over which the debt discount and debt issuance costs will be amortized was 4.4 years.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Note Hedge and Warrant Transactions </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with the offering of the Notes, the Company entered into privately negotiated convertible note hedge transactions (Convertible Note Hedge Transactions) with certain financial institutions (Option Counterparties) related to the issuance of the Notes. The Convertible Note Hedge Transactions are generally expected to reduce the potential dilution to the Company’s common stock upon any conversion of Notes or offset any cash payments the Company is required to make in excess of the principal amount of converted Notes. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also entered into separate privately negotiated warrant transactions (Warrant Transactions) with each of the Option Counterparties pursuant to which the Company issued Warrants that will be exercisable into a number of shares of the Company’s common stock at a price per share equal to $69.89, subject to certain adjustments under the terms of the Warrant Transactions. The Warrant Transactions could separately have a dilutive effect on the Company’s common stock if the market value per share of the Company’s common stock exceeds the applicable strike price of the Warrants. However, subject to certain conditions, the Company may elect to settle the Warrants in cash. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Convertible Note Hedge Transactions and the Warrant Transactions are separate transactions, in each case, entered into by the Company with the same Option Counterparties and are not part of the terms of the Notes and will not affect any holder’s rights under the Notes. The holders of the Notes will not have any rights with respect to the Convertible Note Hedge Transactions or Warrant Transactions. The Company used approximately $34.7 million of the net proceeds of the issuance of the Notes to pay the costs of the Convertible Note Hedge Transactions, after such cost was partially offset by the proceeds to the Company from the sale of the Warrants in the Warrant Transactions. The Convertible Note Hedge Transactions and Warrant Transactions do not meet the criteria for derivative accounting as they are indexed to the Company's stock. The amounts paid for the Convertible Note Hedge Transactions and the proceeds received from the Warrant Transactions have been included as a net reduction to additional paid-in capital.</span></div> 0.0300 43.68 2020-12-31 260000000 51352000 5512000 11473000 0 2020-12-31 P4Y4M24D 69.89 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NOTE 11 — INCOME TAXES</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The components of income before income taxes for the years ended December 31 are as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:64.735%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.897%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.899%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,631)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,314)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,242 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,571 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,812 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,069 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,940 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,502)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,311 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the provision (benefit) for income taxes attributable to continuing operations for the years ended December 31 are as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:64.735%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.897%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.899%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,318)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,689 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">951 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current expense (benefit)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,861 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,609 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,203)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,913)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,179)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,351 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,886 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,597 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,691)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred expense (benefit)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,909 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,273)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,006 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provision (benefit) for income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,770 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,664)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,803 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision (benefit) for income taxes differs from the amount computed by applying the statutory federal rate to pretax income as follows (in percentages):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.869%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and incentive tax credit generated</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax reserves</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remeasurement U.S. deferreds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transition tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign earnings withholding tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global intangible low-taxed income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other measurement period Tax Act adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canadian income tax audit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company accounts for income taxes using the asset and liability method in accordance with ASC 740 “Income Taxes” (ASC 740)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under this method, deferred income taxes are recognized for the future tax consequences of differences between the tax and financial accounting bases of assets and liabilities at the end of each reporting period. Deferred income taxes are based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Significant components of the Company’s deferred tax assets and liabilities as of December 31 are as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:76.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.897%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.605%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities and other</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,479 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,577 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss and credit carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,966 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,141 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,119 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,023 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,060 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,023 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,542 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,791 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bond hedge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,269 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,555 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,882)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,906)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,387 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,649 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities and other</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,230)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,287)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,710)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,443)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,649)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,550)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method investment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(279)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(667)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,442)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,310)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,947)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,077 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,702 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has established a valuation allowance against a portion of its remaining deferred tax assets because it is more likely than not that certain deferred tax assets will not be realized. In determining whether deferred tax assets are realizable, the Company considered numerous factors including historical profitability, the amount of future taxable income and the existence of taxable temporary differences that can be used to realize deferred tax assets. The valuation allowance decreased approximately $1.0 million in 2020 from 2019 primarily due to releasing valuation allowance of $3.6 million against deferred tax assets of certain state net operating loss carryforwards, state research credit carryforwards, and deferred tax assets for stock compensation, and recording additional valuation allowance on the deferred tax assets of certain state net operating loss carryforwards of $2.6 million. The Company’s valuation allowance is primarily offsetting certain state net operating loss and state tax credit carryforwards, and certain stock based compensation. We anticipate portions of our deferred tax assets will not be realized under the provisions of Section 162(m) of the Tax Act which limits the deductibility of executive compensation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    At December 31, 2020, the Company had gross federal, state and foreign net operating loss carryforwards of approximately $41.9 million, $283.8 million, and $6.1 million, respectively. These losses expire beginning in 2021. Federal and state net operating losses of approximately $41.9 million and $268.9 million, respectively, were acquired as part of the acquisitions of U.S. companies. These acquired net operating losses are subject to annual limitations due to the “change of ownership” provisions of Section 382 of the Internal Revenue Code of 1986, as amended, and similar state provisions. The Company has federal, state and foreign credit carryforwards of approximately $8.6 million, $3.4 million, and $2.6 million, respectively. These credits begin to expire in 2023, except for approximately $1.1 million of state research credits which have an indefinite carryforward period. Certain of these credits are subject to annual limitations under the change in ownership provisions. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The excess of financial reporting basis over tax basis of the Company’s foreign subsidiaries is considered permanently reinvested with the exception of certain earnings of the Canadian subsidiary. The cumulative amount of excess financial reporting basis of the Company’s non-U.S. subsidiaries was approximately $14.3 million at December 31, 2020, $22.5 million at December 31, 2019 and $3.8 million at December 31, 2018. Since the Company does not intend to permanently reinvest portions of its previously taxed Canadian earnings, it has recorded a deferred tax liability of approximately $30 thousand related to state income taxes associated with the ultimate repatriation from Canada to the U.S. of these previously taxed earnings. Beginning January 1, 2018, the Tax Act implemented a territorial tax system in the U.S. such that the income earned by the Company’s non-U.S. subsidiaries will be subject to a 100% dividend received deduction, with certain exceptions. We have not recognized a deferred tax liability related to withholding taxes or state income taxes on the excess financial reporting basis of our other foreign subsidiaries because the Company currently intends to reinvest earnings of these subsidiaries in operations outside the U.S. Determination of the amount of the unrecognized deferred tax liability on these unremitted earnings is not practicable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    As of December 31, 2020 and December 31, 2019, the Company had recorded gross unrecognized tax benefits of approximately $3.7 million and $3.4 million, respectively. All of the unrecognized tax benefits as of December 31, 2020, if recognized, would impact the effective tax rate. The Company recognizes interest expense and penalties associated with uncertain tax positions as a component of income tax expense. During the years ended December 31, 2020 and 2019, the Company recognized approximately $26 thousand and $1 thousand in tax related interest and penalties, respectively. Reserves for interest and penalties as of December 31, 2020 and 2019 are not significant as the Company has net operating loss carryovers and tax credit carryforwards.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    A reconciliation of the beginning and ending balance of unrecognized tax benefits is as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,423 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,721 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for tax positions of prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,038)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,704 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,423 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, there were no unrecognized tax benefits that we expect would change significantly over the next 12 months.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">    The Company files U.S., state, and foreign income tax returns in jurisdictions with varying statutes of limitations. In the United States and Canada, the statute of limitations with respect to the federal income tax returns for tax years after 2015 are open to audit; however, since the Company has net operating losses, the taxing authority has the ability to review tax returns prior to the 2015 tax year and make adjustments to these net operating loss carryforwards. In the fourth quarter of 2020, the IRS completed its audit of the Company's 2016 tax return with no material adjustments. In addition, during 2020 the IRS began auditing the Company's 2017 tax return with respect to certain limited issues. The IRS completed its audit of the Company's 2017 tax return in the fourth quarter of 2020 with no tax adjustments. We are not under audit in any major taxing jurisdictions at this time.</span></div> <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:64.735%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.897%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.899%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,631)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,314)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,242 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,571 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,812 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,069 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,940 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,502)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,311 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> -33631000 -31314000 7242000 62571000 21812000 21069000 28940000 -9502000 28311000 <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:64.735%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.897%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.899%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,318)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,689 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">951 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current expense (benefit)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,861 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,609 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,203)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,913)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,179)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,351 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,886 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,597 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,691)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred expense (benefit)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,909 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,273)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,006 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provision (benefit) for income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,770 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,664)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,803 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> -7000 821000 -3318000 6689000 951000 515000 179000 -163000 600000 6861000 1609000 -2203000 -2913000 -10179000 6351000 8886000 4597000 5271000 936000 -1691000 384000 6909000 -7273000 12006000 13770000 -5664000 9803000 <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.869%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and incentive tax credit generated</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax reserves</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remeasurement U.S. deferreds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transition tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign earnings withholding tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global intangible low-taxed income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other measurement period Tax Act adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canadian income tax audit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table> 0.210 0.210 0.210 -0.035 0.096 0.030 -0.024 -0.016 0.026 0.102 -0.117 0.034 0.077 -0.189 0.087 0.091 0.008 0.004 0.010 0.673 0.247 0.000 0.000 -0.003 0.000 -0.053 -0.166 0.001 0.066 -0.079 0.186 -0.444 0.057 0.000 0.000 0.026 0.000 0.000 0.048 0.012 -0.010 -0.001 0.476 0.602 0.346 <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:76.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.897%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.605%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities and other</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,479 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,577 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss and credit carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,966 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,141 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,119 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,023 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,060 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,023 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,542 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,791 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bond hedge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,269 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,555 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,882)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,906)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,387 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,649 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities and other</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,230)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,287)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,710)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,443)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,649)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,550)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method investment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(279)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(667)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,442)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,310)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,947)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,077 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,702 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 7479000 4577000 40966000 52141000 2119000 1023000 4060000 5023000 7542000 7791000 12103000 0 74269000 70555000 16882000 17906000 57387000 52649000 4230000 1287000 15710000 18443000 3649000 4550000 279000 667000 36310000 24947000 21077000 27702000 2020-12-31 2020-12-31 2020-12-31 2020-12-31 2020-12-31 2020-12-31 <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,423 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,721 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for tax positions of prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,038)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,704 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,423 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 3423000 9721000 311000 342000 0 398000 30000 7038000 3704000 3423000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NOTE 12 — EARNINGS PER SHARE</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    A reconciliation of the denominators used in computing per share net income (EPS) is as follows (in thousands, except per share amounts):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:66.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.457%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.458%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,170 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,838)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,508 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allocation to participating securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(297)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(312)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common stockholders</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,873 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,773)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,196 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common stock outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,102 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,148 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,727 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share attributable to common stockholders</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.33 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.42 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,170 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,838)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,508 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allocation to participating securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(298)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(311)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,872 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,775)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,197 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common stock outstanding</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,102 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,148 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,727 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities: stock options and awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used in computing net income (loss) per share</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,820 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,148 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,291 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share attributable to common stockholders</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.32 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.41 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Basic net income (loss) per share is computed by dividing the net income (loss) for the period by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share is computed by dividing the net income (loss) for the period by the weighted average number of common and common equivalent shares outstanding during the period. Restricted stock awards (RSAs) and stock options to acquire 1,620,252 shares, 1,271,248 shares, and 619,113 shares for the years ended December 31, 2020, 2019 and 2018, respectively, were excluded from the computations of diluted earnings per share because the effect of including the RSAs and stock options would have been anti-dilutive.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    We apply the two-class method of computing earnings per share, which requires the calculation of separate earnings per share amounts for our non-vested, time-based restricted stock awards with non-forfeitable dividends and for our common stock. Our non-vested, time-based restricted stock awards with non-forfeitable dividends are considered securities which participate in undistributed earnings with common stock. Under the two-class computation method, net losses are not allocated to participating securities unless the holder of the security has a contractual obligation to share in the losses. Our non-vested, time-based restricted stock awards with non-forfeitable dividends do not have such an obligation so they are not allocated losses.</span></div> <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:66.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.457%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.458%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,170 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,838)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,508 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allocation to participating securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(297)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(312)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common stockholders</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,873 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,773)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,196 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common stock outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,102 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,148 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,727 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share attributable to common stockholders</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.33 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.42 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,170 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,838)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,508 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allocation to participating securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(298)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(311)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,872 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,775)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,197 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common stock outstanding</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,102 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,148 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,727 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities: stock options and awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used in computing net income (loss) per share</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,820 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,148 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,291 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share attributable to common stockholders</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.32 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.41 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 15170000 -3838000 18508000 -297000 65000 -312000 14873000 -3773000 18196000 45102000 44148000 43727000 0.33 -0.09 0.42 15170000 -3838000 18508000 -298000 63000 -311000 14872000 -3775000 18197000 45102000 44148000 43727000 718000 0 564000 45820000 44148000 44291000 0.32 -0.09 0.41 1620252 1271248 619113 2020-12-31 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NOTE 13 — STOCKHOLDERS’ EQUITY, EMPLOYEE BENEFIT PLANS AND STOCK-BASED COMPENSATION</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preferred Stock</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company’s Board of Directors has the authority to issue up to 5,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof, including dividend rights, dividend rates, conversion rights, voting rights, terms of redemption, redemption prices, liquidation preferences and the number of shares constituting any series or the designation of such series, without further vote or action by the Company’s stockholders. At December 31, 2020 and 2019, there was no preferred stock issued and outstanding.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">    I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n February 2017, the Board of Directors initiated a cash dividend program under which the Company began paying a regular quarterly cash dividend. The following table shows cash dividends declared, recorded, and paid (or to be paid) in the periods shown:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:19.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.458%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.458%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.458%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.551%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date Paid or <br/>To Be Paid</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dividends Declared per Share</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Twelve Months Ending</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date Declared</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date Payable</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 24, 2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 23, 2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 13, 2018</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.06 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 18, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 22, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 13, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.06 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 11, 2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 21, 2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 12, 2018</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.06 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 11, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 22, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 10, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.06 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 8, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 21, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 11, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.06 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 21, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 20, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 11, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.06 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 26, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 17, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.09 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 6, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 19, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 15, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.09 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 18, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 19, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 9, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.09 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 22, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 18, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 9, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.09 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 10, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 24, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 15, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.09 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 3, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 23, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 14, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s current intent is to pay a continuing dividend on a quarterly basis. However, future declaration of dividends is subject to the final determination of the Company’s Board of Directors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    At December 31, 2020, the Company has one stock-based employee compensation plan pursuant to which grants may be made: the Luminex Corporation 2018 Equity Incentive Plan (Equity Incentive Plan) which was approved at the Company’s Annual Meeting on May 17, 2018. No further grants shall be made pursuant to the 2000 Long-Term Incentive Plan (2000 Plan), the 2001 Broad-Based Stock Option Plan (2001 Plan) or the 2006 Equity Incentive Plan (2006 Plan). In addition, at December 31, 2020, the Company has one plan pursuant to which discount purchases may be made by the participants in such plan: the Luminex Corporation Employee Stock Purchase Plan (ESPP), which was approved at the Company’s Annual Meeting on May 17, 2012 and amended at the Company’s Annual Meeting on May 18, 2017.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Incentive Plans</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Under the Company’s Equity Incentive Plan and, the 2006 Plan, certain employees, consultants and non-employee directors have been granted RSAs, restricted stock units (RSUs) and options to purchase shares of common stock. The options, RSAs, and RSUs generally vest in installments over a three to five year period, and the options expire either seven or ten years after the date of grant. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The ESPP provides for the granting of rights to certain employees of the Company to defer an elected percentage, up to 15%, of their base salary through the purchase of the Company’s common stock, discounted by 15%. As of December 31, 2020, there were approximately 2,400,000 shares authorized for future issuance under the Company’s Equity Incentive Plan and 83,044 shares eligible for purchase pursuant to the terms and conditions of the ESPP as more fully described below.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Equity Incentive Plan, the 2006 Plan and the ESPP are administered by the Compensation Committee of the Board of Directors. The Compensation Committee has the authority to determine the terms and conditions under which awards will be granted from the Equity Incentive Plan, including the number of shares, vesting schedule and term, as applicable. Any option exercise prices, as set forth in the Equity Incentive Plan, will be equal to the fair market value on the date of grant. Under certain circumstances, the Company may repurchase previously granted RSAs and RSUs.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    On February 27, 2020 and February 21, 2019, the Compensation Committee approved awards of stock options (the Performance Options) to the Company’s named executive officers and certain other executives that vest over four years based on achievement of certain operating profit and revenue targets for each of 2020 and 2019, respectively. The Performance Options have an exercise price equal to the closing market price for the Company’s common stock on the Nasdaq Global Select Market on the date of grant (March 12, 2020 and 2019, respectively) and expire seven years from the date of grant. The Performance Options were measured over a one-year performance period ending on December 31, 2020 and 2019, respectively. Following the end of the applicable fiscal year, the Committee determined the number of Performance Options which were eligible to vest based upon the level of achievement of an established Company performance goal (the Company Financial Goal). If the Company failed to meet the threshold performance for the performance period, no Performance Options would be eligible to vest. Minimum vesting for minimum threshold performance started at 30% of the target value for the Company Financial Goal. If the Company’s performance exceeded the target performance, the recipient may receive additional Performance Options above the target number, subject to a maximum of 200% of the target award. The Company’s financial performance resulted in delivery of 200% and 83% of the number of target Performance Options granted for 2020 and 2019, respectively. The Performance Options that are eligible to vest after the determination date will vest 25% on each of the first four anniversaries of the grant date. In the event of a change of control of the Company before the end of the performance period, the Performance Options will automatically vest based on the greater of actual achievement of the pro-rated Company Financial Goal as of the date of the change of control or 100% of target performance, as determined by the Committee in its sole discretion. The Performance Options are exercisable into shares of the Company’s common stock. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting for Stock Compensation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Stock-based compensation costs are generally based on the fair value calculated from the Black-Scholes option-pricing model on the date of grant for stock options, performance options and market value on the date of grant for RSAs. The fair values of stock and stock options are amortized as compensation expense on a straight-line basis over the vesting period of the grants.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    In accordance with ASC 718, the Company evaluates the assumptions used in the Black-Scholes model at each grant date using a consistent methodology for computing expected volatility, expected term and risk-free rate of return. Calculation of expected volatility is based on historical volatility. The expected life is calculated using the contractual term of the options as well as an analysis of the Company’s historical exercises of stock options and performance options. The estimate of the risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant. The dividend yield is based on our history and expectation of dividend payouts at the time of grant. The assumptions used are summarized in the following table:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:53.951%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.397%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate of return</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life of a 10 year contractual term option</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life of a 7 year contractual term option</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.88 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.88 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value at grant date</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.69 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    As part of the requirements of ASC 718, the Company is required to estimate potential forfeitures of stock grants and adjust compensation cost recorded accordingly. The estimate of forfeitures is based on historical forfeiture performance and will be adjusted over the requisite service period to the extent that actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures will be recognized through a cumulative catch-up adjustment in the period of evaluation and will also impact the amount of stock compensation expense to be recognized in future periods.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company’s stock option activity for the year ended December 31, 2020 is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:48.826%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.476%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,793 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.17 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,508 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.09 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(998)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled or expired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(550)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,753 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.25 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.48</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,633 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested at December 31, 2020 and expected to vest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,687 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.45</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,623 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,519 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,248 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    During the years ended December 31, 2020, 2019 and 2018, the total exercise intrinsic value of stock options exercised was $16.2 million, $0.4 million and $1.3 million, respectively, and the total fair value of stock options that vested was $10.6 million, $11.9 million and $12.7 million, respectively. Exercise intrinsic value represents the difference between the market value of the Company’s common stock at the time of exercise and the price paid by the employee to exercise the options. The Company had $10.5 million of total unrecognized compensation costs related to stock options at December 31, 2020 that are expected to be recognized over a weighted-average period of 2.57 years.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company’s restricted share activity for the year ended December 31, 2020 is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.103%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.324%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted Stock Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Grant Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">810 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.28 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(295)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled or expired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">893 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.98 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:54.259%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.667%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.503%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled or expired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.09</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested at December 31, 2020 and expected to vest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.05</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    As of December 31, 2020, there was $18.7 million of unrecognized compensation cost related to RSAs and RSUs. That cost is expected to be recognized over a weighted average-period of 2.17 years. The total fair value of restricted shares vested during the year ended December 31, 2020, 2019 and 2018 was $7.3 million, $6.0 million and $6.7 million, respectively.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    RSAs and RSUs may be granted at the discretion of the Compensation Committee of the Board of Directors under the Equity Incentive Plan in connection with the hiring or retention of key employees and are subject to certain conditions. Restrictions expire at certain dates after the grant date in accordance with specific provisions in the applicable agreement. During the year ended December 31, 2020, the Company awarded 416,142 shares of RSAs, which had a fair value at the date of grant ranging from $23.05–$31.65. During the year ended December 31, 2019, the Company awarded 413,967 shares of RSAs, which had a fair value at the date of grant ranging from $20.04–$24.43. During the year ended December 31, 2018, the Company awarded 387,436 shares of RSAs, which had a fair value at the date of grant ranging from $20.33–$29.33. During the year ended December 31, 2020, the Company awarded 99,584 shares of RSUs and dividend equivalents, which had a fair value at the date of grant ranging from $23.09–$31.65. During the year ended December 31, 2019, the Company awarded 120,498 shares of RSUs and dividend equivalents, which had a fair value at the date of grant ranging from $21.01–$24.43. During the year ended December 31, 2018, the Company awarded 95,127 shares of RSUs, which had a fair value at the date of grant ranging from $21.98–$26.39. Compensation under these RSAs and RSUs was charged to expense over the restriction period and amounted to $9.2 million, $8.2 million, and $6.2 million in 2020, 2019 and 2018, respectively. There were no significant stock compensation costs capitalized into assets as of December 31, 2020, 2019 or 2018.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company received $18.0 million, $1.7 million and $2.8 million for the exercise of stock options during the years ended December 31, 2020, 2019 and 2018, respectively. Cash was not used to settle any equity instruments previously granted. The Company issued shares pursuant to grants relating to each of the Equity Incentive Plan, the 2006 Plan and 2000 Plan from reserves upon the exercise of stock options and vesting of RSAs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The following are the stock-based compensation costs recognized in the Company’s consolidated statements of comprehensive income (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:56.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.397%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,332 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,028 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,715 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,027 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,635 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,409 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,493 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,535 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,102 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation costs reflected in net income (loss) </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,852 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,198 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,226 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Stock Purchase Plan </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    In May 2012, the Company’s stockholders approved the ESPP, which provides for the purchase of up to 500,000 shares of the Company’s common stock by eligible employees. In May 2017, the Company’s stockholders approved an amendment to the ESPP Plan, which increased the shares available under the ESPP by 341,744 shares. The ESPP period is semi-annual and allows participants to purchase the Company’s common stock at 85% of the lesser of (i) the closing market value per share of the common stock on the first trading date of the option period or (ii) the closing market value per share of the common stock on the last trading date of the option period. As of December 31, 2020, 2019 and 2018, 758,700 shares, 631,553 shares and 518,111 shares, respectively had been issued out of the ESPP. The related stock-based compensation expense was $0.7 million, $0.6 million and $0.5 million for 2020, 2019 and 2018, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company uses the Black-Scholes model to estimate the fair value of shares to be issued under the ESPP as of the grant date using the following weighted average assumptions:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:53.951%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.397%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumptions:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.55 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3471</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.35</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.44</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.454 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.942 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reserved Shares of Common Stock</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    At December 31, 2020 and 2019, the Company had reserved 6,808,668 and 8,349,808 shares of common stock, respectively, for the issuance of common stock upon the exercise of options, issuance of RSAs, RSUs, purchase of common stock pursuant to the ESPP or other awards issued pursuant to the Company’s equity plans and arrangements. The following table summarizes the reserved shares by plan as of December 31, 2020:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:52.858%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.735%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.735%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options and RSUs Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares Available for Future Issuance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Shares Reserved</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,339,804 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,385,820 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,725,624 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,044 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,044 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,339,804 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,468,864 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,808,668 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Savings Plans and Other Benefit Plans</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Effective January 1, 2001, the Company began sponsoring a retirement plan authorized by section 401(k) of the Internal Revenue Code for the Company’s employees in the United States. In accordance with the 401(k) plan, all employees are eligible to participate in the plan on the first day of the month following the commencement of full time employment. For 2020, 2019 and 2018, each employee could contribute a percentage of compensation up to a maximum of $19,500, $19,000, and $18,500 per year, respectively, with the Company matching 50% of each employee’s contributions. Effective January 1, 2010, the Company began contributing to a deferred profit sharing plan for its Canadian employees. All Canadian employees are eligible to participate in the plan. The Company’s contributions to these plans for 2020, 2019 and 2018 were $5.4 million, $5.1 million and $4.0 million, respectively.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Several of the Company’s Netherlands employees are covered by a defined benefit plan. The cost and total liability to the Company is not material. Effective January 1, 2011, all of the Company’s new hires in the Netherlands are eligible to participate in a defined contribution plan.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preferred Stock</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company’s Board of Directors has the authority to issue up to 5,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof, including dividend rights, dividend rates, conversion rights, voting rights, terms of redemption, redemption prices, liquidation preferences and the number of shares constituting any series or the designation of such series, without further vote or action by the Company’s stockholders. At December 31, 2020 and 2019, there was no preferred stock issued and outstanding.</span></div> 2020-12-31 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    At December 31, 2020, the Company has one stock-based employee compensation plan pursuant to which grants may be made: the Luminex Corporation 2018 Equity Incentive Plan (Equity Incentive Plan) which was approved at the Company’s Annual Meeting on May 17, 2018. No further grants shall be made pursuant to the 2000 Long-Term Incentive Plan (2000 Plan), the 2001 Broad-Based Stock Option Plan (2001 Plan) or the 2006 Equity Incentive Plan (2006 Plan). In addition, at December 31, 2020, the Company has one plan pursuant to which discount purchases may be made by the participants in such plan: the Luminex Corporation Employee Stock Purchase Plan (ESPP), which was approved at the Company’s Annual Meeting on May 17, 2012 and amended at the Company’s Annual Meeting on May 18, 2017.</span></div> 2020-12-31 2020-12-31 0.15 2020-12-31 2400000 <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:53.951%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.397%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate of return</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life of a 10 year contractual term option</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life of a 7 year contractual term option</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.88 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.88 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value at grant date</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.69 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 0.015 0.009 0.012 0.3 0.4 0.4 0.009 0.026 0.027 P7Y P7Y P7Y P4Y9M P4Y10M17D P4Y10M17D 6.17 7.69 8.23 3793000 20.17 1508000 23.09 998000 18.18 550000 24.43 3753000 21.25 P4Y5M23D 7633000 3687000 21.22 P4Y5M12D 7623000 1519000 19.12 P3Y 6248000 16200000 400000 1300000 10600000 11900000 12700000 10500000 P2Y6M25D 810000 22.28 416000 23.26 295000 21.49 38000 22.65 893000 22.98 522000 100000 45000 7000 570000 P1Y1M2D 13000 563000 P1Y18D 13000 403000 P0Y 9000 2020-12-31 18700000 P2Y2M1D 2020-12-31 7300000 6000000.0 6700000 23.05 31.65 413967 20.04 24.43 387436 20.33 29.33 23.09 31.65 120498 21.01 24.43 95127 21.98 26.39 9200000 8200000 6200000 0 18000000.0 1700000 2800000 758700 631553 518111 700000 600000 500000 <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:53.951%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.397%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumptions:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.55 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3471</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.35</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.44</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.454 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.942 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table> 0.0018 0.0255 0.021 P0Y6M P0Y6M P0Y6M 0.3471 0.35 0.44 0.01454 0.00942 0.012 2020-12-31 6808668 8349808 2020-12-31 6808668 19500 0.50 5400000 5100000 4000000.0 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NOTE 14 — REVENUE RECOGNITION</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Contract assets are included within Accounts receivables, net and contract liabilities are included in Deferred revenue on the Company’s Balance Sheet. The following table presents the opening and closing balances of the Company’s contract assets and liabilities for the twelve months ended December 31, 2020 (in thousands): </span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:63.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.323%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.324%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at <br/>December 31, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contract assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unbilled receivables - Royalties</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,054 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contract liabilities - short-term:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue - Service </span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,346 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,771 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue - Licenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue - Instruments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue - Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Contract liabilities - short-term</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,047 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,214 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contract liabilities - long-term:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue - Service</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,190 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">968 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue - Licenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Contract liabilities - long-term</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,658 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,633 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    During the twelve months ended December 31, 2020, the Company recognized the following revenues as a result of changes in the contract asset and contract liability balances in the period (in thousands):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:63.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.323%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.324%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized in the period:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts included as contract liabilities at the beginning of the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,387 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance obligations satisfied in previous periods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> -</span></td></tr></table></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NOTE 15 — COMMITMENTS AND CONTINGENCIES</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    We have leased all of our research, manufacturing and office space and have entered into various other leases in conducting our business. Our leases have remaining lease terms of one year to six years, and some of our leases include options to extend the leases for up to ten years, tenant improvement allowances, rent holidays and rent escalation clauses. As the Company’s leases do not provide an implicit rate, we have used an estimated incremental borrowing rate of 5.75%, based on the information available at the commencement date in determining the present value of lease payments. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The components of the lease expense were as follows (in thousands):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:41.652%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.496%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Twelve Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,792 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,434 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,032 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a) Includes short-term lease expense costs, which were immaterial in the years ended December 31, 2020, 2019 and 2018</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Supplemental cash flow information related to leases was as follows (in thousands):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.469%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Twelve Months Ended</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Twelve Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,072 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,553 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases was as follows (in thousands):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.812%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,768 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,439 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.52 years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.36 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.75 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.75 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Minimum annual lease commitments as of December 31, 2020 under non-cancellable leases for each of the next five years and in the aggregate were as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:80.305%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.495%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,206 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,540 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,507 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,177 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,375 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,067)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities at December 31, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,308 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    These non-cancellable lease commitments related to facilities include certain rent escalation provisions which have been included in the minimum annual rental commitments shown above. These amounts are recorded to expense on a straight-line basis over the life of the lease. In addition, some of the Company’s leases contain options to renew the lease for five to ten years at the then prevailing market rental rate, right of first refusal to lease additional space that becomes available, or leasehold improvement incentives.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Cancellable Purchase Commitments</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    As of December 31, 2020 the Company had approximately $68.1 million in purchase commitments primarily with several of its inventory suppliers as well as other operating commitments. Certain of our supply agreements require purchase and delivery of minimum amounts of components through 2020, and purchases under these arrangements were $0.5 million, $0.8 million and $2.2 million for the years ended December 31, 2020, 2019 and 2018, respectively.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employment Contracts</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company has entered into employment contracts with certain of its key executives. Generally, certain amounts may become payable in the event the Company terminates the executives’ employment without cause or the executive resigns for good reason.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    In the normal course of business, the Company is subject to claims, lawsuits and legal proceedings. When and if it appears probable in management’s judgment, and based upon consultation with outside counsel, that we will incur monetary damages or other costs in connection with any claims or proceedings, and such costs can be reasonably estimated, we record the estimated liability in the financial statements.  If only a range of estimated losses can be estimated, we record an amount within the range that, in management’s judgment, reflects the most likely outcome; if none of the estimates within that range is a better estimate than any other amount, we record the liability at the low end of the range of estimates. Any such accrual would be charged to expense in the appropriate period. We disclose significant contingencies when the loss is not probable and/or the amount of the loss is not estimable, when we believe there is at least a reasonable possibility that a loss has been incurred. We recognize costs associated with legal proceedings in the period in which the services were provided.</span></div> 9792000 9434000 7032000 P3Y6M7D P4Y4M9D 0.0575 0.0575 <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:80.305%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.495%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,206 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,540 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,507 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,177 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,375 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,067)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities at December 31, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,308 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 7206000 5540000 4507000 3177000 945000 0 21375000 2067000 68100000 500000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NOTE 16 — GUARANTEES</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The terms and conditions of the Company’s development and supply and license agreements with its strategic partners generally provide for a limited indemnification of such partners, arising from the sale of Luminex systems and consumables, against losses, expenses and liabilities resulting from third-party claims based on an alleged infringement on an intellectual property right of such third party. The terms of such indemnification provisions generally limit the scope of and remedies for such indemnification obligations to a multiple of amounts paid by such strategic partner to Luminex during the previous annual period(s). To date, the Company has not had to reimburse any of its strategic partners for any losses arising from such indemnification obligations.</span></div> <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.210%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.703%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales to Customers</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Property and Equipment, net</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325,781 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252,381 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261,726 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,755 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,180 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,382 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,635 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,625 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,672 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,018 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,220 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,603 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,293 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,775 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,725 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,715 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,993 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,962 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,119 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,042 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417,396 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334,638 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315,818 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,146 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,515 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,288 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 2020-12-31 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NOTE 18 — RECENT ACCOUNTING PRONOUNCEMENTS</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">    Recently adopted accounting guidance</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    In June 2016, the FASB issued guidance on financial instruments and related credit losses. The guidance requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis. The statement of comprehensive income reflects the measurement of credit losses for newly recognized financial assets, as well as the expected credit losses during the period. The measurement of expected credit losses is based upon historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. Credit losses relating to available-for-sale debt securities will be recorded through an allowance for credit losses rather than as a direct write-down to the security. The updated guidance is effective for annual periods beginning after December 15, 2019, and is applicable to the Company in fiscal 2020. The Company adopted the new standard effective January 1, 2020. The primary impact for the Company was the timing of recording expected credit losses on its trade receivables. The Company does not have a history of significant credit losses and this guidance did not have a material impact on its consolidated financial statements.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">    Recent accounting guidance not yet adopted</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    In December 2019, the FASB issued final guidance that simplifies the accounting for income taxes by eliminating some exceptions to the general approach in ASC 740, Income Taxes. The guidance amended certain disclosure requirements that had become redundant, outdated or superseded. Additionally, this guidance includes provisions for investment company reporting modernization, amends accounting for the interim period effects of changes in tax laws or rates, and simplifies aspects of the accounting for franchise taxes. The guidance is effective for annual periods beginning after December 15, 2020, and is applicable for the Company in fiscal 2021. Early adoption is permitted. The Company does not anticipate that this guidance will have a material impact on its consolidated financial statements.</span></div>In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies accounting for convertible instruments by removing major separation models required under U.S. GAAP. This update also amends the guidance for the derivatives scope exception for contracts in an entity's own equity to reduce form-over-substance-based accounting conclusions and requires the application of the if-converted method for calculating diluted earnings per share. The update also requires entities to provide expanded disclosures about the terms and features of convertible instruments and how the instruments have been reported in the entity’s financial statements. The guidance is effective for interim and annual periods beginning after December 15, 2021. Early adoption is permitted, but no earlier than January 1, 2021. The Company will early adopt this guidance effective January 1, 2021 under the modified retrospective basis with the cumulative effect recognized through an adjustment to additional paid-in capital. Under this method, earnings per share amounts will not be restated in prior periods presented, but future earnings per share amounts will be impacted by the change to the if-converted method for calculating diluted earnings per share. The Company's adoption is expected to result in a decrease of approximately $42 million in additional paid in capital from the de-recognition of the bifurcated equity component and an increase of approximately $50 million in debt from the de-recognition of the discount associated with the bifurcated equity component. The Company expects to write-off the related deferred tax liabilities to additional paid in capital. 90424000 109519000 106060000 111393000 50346000 69681000 63381000 64444000 1641000 18776000 11526000 10500000 654000 12510000 1767000 239000 0.01 0.27 0.04 0.01 0.01 0.27 0.04 0.01 0.09 0.09 0.09 0.10 82408000 83056000 78673000 90501000 45807000 45227000 41840000 49865000 -3584000 -5756000 -5722000 2983000 2960000 -4931000 -5250000 3383000 0.07 -0.11 -0.12 0.08 0.07 -0.11 -0.12 0.07 0.06 0.06 0.09 0.09 XML 17 R1.htm IDEA: XBRL DOCUMENT v3.20.4
COVER PAGE Document - USD ($)
 12 Months Ended
Dec. 31, 2020
Feb. 26, 2021
Jun. 30, 2020
COVER PAGE [Abstract]      
Entity Central Index Key 0001033905    
Current Fiscal Year End Date --12-31    
Document Fiscal Year Focus 2020    
Document Fiscal Period Focus FY    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Document Annual Report true    
Document Period End Date Dec. 31, 2020    
Document Transition Report false    
Entity Shell Company false    
Entity Filer Category Large Accelerated Filer    
Entity Current Reporting Status Yes    
Title of 12(b) Security Common Stock, $0.001 par value    
City Area Code (512)    
Entity Address, Address Line One 12212 Technology Blvd.,    
Entity Incorporation, State or Country Code DE    
Document Type 10-K    
Entity File Number 000-30109    
Entity Tax Identification Number 74-2747608    
Entity Address, City or Town Austin,    
Entity Address, State or Province TX    
Entity Address, Postal Zip Code 78727    
Local Phone Number 219-8020    
Trading Symbol LMNX    
Security Exchange Name NASDAQ    
Entity Interactive Data Current Yes    
Entity Small Business false    
Entity Emerging Growth Company false    
Entity Registrant Name LUMINEX CORPORATION    
Entity Common Stock, Shares Outstanding   46,688,309  
Amendment Flag false    
Entity Public Float     $ 1,344,295,984
Adjustments to Additional Paid in Capital, Warrant Issued $ 19,968,000    
XML 18 R2.htm IDEA: XBRL DOCUMENT v3.20.4
BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 309,407 $ 59,173
Accounts Receivable, Net, Current 66,963 55,815
Inventory, Net 123,134 77,084
Other 9,527 10,398
Total current assets 509,031 202,470
Property, Plant and Equipment, Net 64,146 65,515
Intangible Assets, Net (Excluding Goodwill) 78,796 90,336
Goodwill 118,145 118,145
Operating Lease, Right-of-Use Asset 17,768 20,439
Deferred Income Tax Assets, Net 21,077 27,702
Other Assets, Noncurrent 16,500 19,122
Total assets 825,463 543,729
Current liabilities:    
Accounts payable 21,049 17,983
Accrued Liabilities, Current 56,365 31,872
Short-term unearned revenue 10,047 8,214
Total current liabilities 87,461 58,069
Long-term unearned revenue 1,658 1,633
Operating Lease, Liability, Noncurrent 13,366 17,182
Other long-term liabilities 2,131 1,985
Total liabilities 307,752 78,869
Stockholders' Equity Attributable to Parent [Abstract]    
Common Stock, Value, Outstanding 45 44
Preferred Stock, Value, Outstanding 0 0
Additional Paid in Capital 434,021 380,304
Accumulated Other Comprehensive Income (Loss), Net of Tax (142) (1,380)
Retained earnings 83,787 85,892
Stockholders' Equity Attributable to Parent 517,711 464,860
Liabilities and Equity 825,463 543,729
Long-term Debt $ 203,136 $ 0
XML 19 R3.htm IDEA: XBRL DOCUMENT v3.20.4
BALANCE SHEETS (Parenthetical) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Statement of Financial Position [Abstract]    
Common Stock, Par or Stated Value Per Share $ 0.001 $ 0.001
Common stock, shares authorized 200,000,000 200,000,000
Common Stock, Shares, Issued 45,682,687 44,325,369
Common Stock, Shares, Outstanding 45,682,687 44,325,369
Preferred Stock, Par or Stated Value Per Share $ 0.001 $ 0.001
Preferred Stock, Shares Authorized 5,000,000 5,000,000
Preferred Stock, Shares Issued 0 0
Preferred Stock, Shares Outstanding 0 0
Accounts receivable, allowance for doubtful accounts $ 1,140 $ 843
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment $ 117,467 $ 99,849
XML 20 R4.htm IDEA: XBRL DOCUMENT v3.20.4
INCOME STATEMENTS - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Income Statement [Abstract]                      
Revenues $ 111,393 $ 106,060 $ 109,519 $ 90,424 $ 90,501 $ 78,673 $ 83,056 $ 82,408 $ 417,396 $ 334,638 $ 315,818
Cost of Goods and Services Sold 46,949 42,679 39,838 40,078 40,636 36,833 37,829 36,601 169,544 151,899 120,327
Gross margin 64,444 63,381 69,681 50,346 49,865 41,840 45,227 45,807 247,852 182,739 195,491
Research and development                 53,651 56,228 47,164
Selling, General and Administrative Expense                 140,216 127,183 111,816
Amortization of Intangible Assets                 11,542 11,407 8,665
Operating Expenses 53,944 51,855 50,905 48,705 46,882 47,562 50,983 49,391 205,409 194,818 167,645
Operating income 10,500 11,526 18,776 1,641 2,983 (5,722) (5,756) (3,584) 42,443 (12,079) 27,846
Other income, net                 (11,912) 3,100 465
Income (Loss) from Equity Method Investments                 (1,591) (523) 0
Income (Loss) Attributable to Parent, before Tax                 28,940 (9,502) 28,311
Provision for income taxes                 (13,770) 5,664 (9,803)
Net Income (Loss) Attributable to Parent $ 239 $ 1,767 $ 12,510 $ 654 $ 3,383 $ (5,250) $ (4,931) $ 2,960 15,170 (3,838) 18,508
Net Income (Loss) Available to Common Stockholders, Basic                 14,873 (3,773) 18,196
Net Income (Loss) Available to Common Stockholders, Diluted                 $ 14,872 $ (3,775) $ 18,197
Earnings Per Share [Abstract]                      
Earnings Per Share, Basic $ 0.01 $ 0.04 $ 0.27 $ 0.01 $ 0.08 $ (0.12) $ (0.11) $ 0.07 $ 0.33 $ (0.09) $ 0.42
Earnings Per Share, Diluted 0.01 0.04 0.27 0.01 0.07 (0.12) (0.11) 0.07 $ 0.32 $ (0.09) $ 0.41
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]                      
Weighted Average Number of Shares Outstanding, Basic                 45,102 44,148 43,727
Weighted Average Number of Shares Outstanding, Diluted                 45,820 44,148 44,291
Common Stock, Dividends, Per Share, Declared $ 0.10 $ 0.09 $ 0.09 $ 0.09 $ 0.09 $ 0.09 $ 0.06 $ 0.06 $ 0.37 $ 0.30 $ 0.24
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax                 $ 1,238 $ (253) $ (502)
Other Comprehensive Income (Loss), Net of Tax                 1,238 (253) (502)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent                 $ 16,408 $ (4,091) $ 18,006
XML 21 R5.htm IDEA: XBRL DOCUMENT v3.20.4
INCOME STATEMENTS INCOME STATEMENTS (Parenthetical) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Income Statement [Abstract]                      
Operating Expenses $ 53,944 $ 51,855 $ 50,905 $ 48,705 $ 46,882 $ 47,562 $ 50,983 $ 49,391 $ 205,409 $ 194,818 $ 167,645
Operating Income (Loss) $ 10,500 $ 11,526 $ 18,776 $ 1,641 $ 2,983 $ (5,722) $ (5,756) $ (3,584) $ 42,443 $ (12,079) $ 27,846
XML 22 R6.htm IDEA: XBRL DOCUMENT v3.20.4
CASH FLOWS STATEMENTS - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Net Cash Provided by (Used in) Operating Activities [Abstract]      
Net Income (Loss) Attributable to Parent $ 15,170 $ (3,838) $ 18,508
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]      
Depreciation, Depletion and Amortization 30,483 28,529 23,674
Stock-based compensation expense 14,852 13,198 12,226
Increase (Decrease) in Deferred Income Taxes 6,593 (7,444) 8,159
Gain (Loss) on Disposition of Property Plant Equipment 851 641 730
Income (Loss) from Equity Method Investments, Net of Dividends or Distributions 1,592 (2,719) 0
Other Operating Activities, Cash Flow Statement 2,086 (329) (1,369)
Changes in operating assets and liabilities:      
Accounts receivable (11,139) (2,440) (1,569)
Inventories (45,973) (13,559) (6,827)
Operating Assets 4,125 4,789 (3,319)
Operating Liabilities 19,686 (5,630) 103
Accounts payable 3,184 3,370 4
Unearned revenue 1,888 (1,031) 579
Net cash from operations 49,931 13,537 50,899
Net Cash Provided by (Used in) Financing Activities [Abstract]      
Common stock issued 20,435 3,750 4,570
Payments Related to Tax Withholding for Share-based Compensation (2,373) (2,095) (2,312)
Common stock cash dividends paid (16,485) (12,153) (10,654)
Net cash used in financing 219,166 (10,498) (8,396)
Net Cash Provided by (Used in) Investing Activities [Abstract]      
Additions to property and equipment (17,910) (16,249) (21,292)
Payments to Acquire Businesses, Net of Cash Acquired 0 0 (65,381)
Payments for (Proceeds from) Previous Acquisition 0 1,916 0
Payments to Acquire Notes Receivable 0 0 (1,000)
Payments to Acquire Equity Method Investments 0 6,980 0
Proceeds from (Payments to) Noncontrolling Interests 0 734 (1,782)
Proceeds from Sale of Productive Assets 0 0 2
Payments to Acquire Intangible Assets 22 (40) (4,000)
Net cash used in investing (17,888) (20,619) (93,453)
Effect of foreign exchange rates on cash and cash equivalents (975) 312 279
Net change in cash and cash equivalents 250,234 (17,268) (50,671)
Cash and cash equivalents, end of period 309,407 59,173 76,441
Amortization of Debt Issuance Costs 6,533    
Proceeds from Convertible Debt 252,247 0 0
Payments for Hedge, Financing Activities (54,626) 0 0
Proceeds from Issuance of Warrants $ 19,968 $ 0 $ 0
XML 23 R7.htm IDEA: XBRL DOCUMENT v3.20.4
STOCKHOLDERS' EQUITY STATEMENTS - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated other comprehensive Income (loss)
Retained earnings
Stockholders' Equity Attributable to Parent $ 437,907 $ 43 $ 350,834 $ (625) $ 87,655
Common Stock, Shares, Outstanding 43,404,493        
Stock Issued During Period, Value, Stock Options Exercised $ 2,814 $ 0 2,814 0 0
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures   253,152      
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures (2,311) $ 1 (2,312) 0 0
Stock-based compensation expense $ 12,187 $ 0 12,187 0 0
Stock Issued During Period, Shares, Employee Stock Purchase Plans 518,111 83,811      
ESPP $ 1,740 $ 0 1,740 0 0
Net Income (Loss) Attributable to Parent 18,508 0 0 0 18,508
Common stock cash dividends (10,710) 0 86 0 (10,796)
Other, net (8,023) $ 0 0 0 (8,023)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period   157,754      
Stockholders' Equity Attributable to Parent 467,656 $ 44 365,349 (1,127) 103,390
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax $ (502) 0 0 (502) 0
Common Stock, Shares, Outstanding 43,899,210        
Stock Issued During Period, Value, Stock Options Exercised $ 1,698 $ 0 1,698 0 0
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures   217,620      
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures (2,095) $ 0 (2,095) 0 0
Stock-based compensation expense $ 13,198 $ 0 13,198 0 0
Stock Issued During Period, Shares, Employee Stock Purchase Plans 631,553 113,442      
ESPP $ 2,030 $ 0 2,030 0 0
Net Income (Loss) Attributable to Parent (3,838) 0 0 0 (3,838)
Common stock cash dividends (13,536) $ 0 124 0 (13,660)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period   95,097      
Stockholders' Equity Attributable to Parent 464,860 $ 44 380,304 (1,380) 85,892
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax $ (253) 0 0 (253) 0
Common Stock, Shares, Outstanding 44,325,369        
Stock Issued During Period, Value, Stock Options Exercised $ 17,989 $ 1 17,988 0 0
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures   240,100      
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures (2,373) $ 0 (2,373) 0 0
Stock-based compensation expense $ 14,852 $ 0 14,852 0 0
Stock Issued During Period, Shares, Employee Stock Purchase Plans 758,700 127,147      
ESPP $ 2,391 $ 0 2,391 0 0
Net Income (Loss) Attributable to Parent 15,170 0 0 0 15,170
Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 41,950   41,950    
Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments (41,243)   (41,243)    
Adjustments to Additional Paid in Capital, Warrant Issued 19,968   19,968    
Common stock cash dividends (17,091) $ 0 184 0 (17,275)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period   990,071      
Stockholders' Equity Attributable to Parent 517,711 $ 45 434,021 (142) 83,787
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax $ 1,238 $ 0 $ 0 $ 1,238 $ 0
Common Stock, Shares, Outstanding 45,682,687        
XML 24 R8.htm IDEA: XBRL DOCUMENT v3.20.4
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)
 12 Months Ended
Dec. 31, 2020
Equity [Abstract]  
Comprehensive Income (Loss) Note [Text Block]
NOTE 8 — OTHER COMPREHENSIVE (LOSS) INCOME

    Comprehensive loss represents a measure of all changes in equity that result from recognized transactions and other economic events other than those resulting from investments by and distributions to shareholders. Other comprehensive loss for the Company includes foreign currency translation adjustments and net unrealized holding gains and losses on available-for-sale investments.

    The following table presents the changes in each component of accumulated other comprehensive loss, net of tax (in thousands):
Accumulated Other Comprehensive Loss Items - Foreign Currency
Balance as of December 31, 2019$(1,380)
Other comprehensive loss
1,238 
Net current-period other comprehensive loss1,238 
Balance as of December 31, 2020$(142)

    There are no tax benefits or expenses related to the other comprehensive loss for the twelve months ended December 31, 2020.
XML 25 R9.htm IDEA: XBRL DOCUMENT v3.20.4
INVESTMENTS Details (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]    
Document Period End Date Dec. 31, 2020  
Other Long-term Investments $ 9,909 $ 11,501
Prepaid Expense and Other Assets, Noncurrent 1,137 1,594
Other Assets, Noncurrent 16,500 19,122
Licensing Agreements [Member]    
Finite-Lived Intangible Assets [Line Items]    
Finite-Lived Intangible Assets, Net $ 5,454 $ 6,027
XML 26 R10.htm IDEA: XBRL DOCUMENT v3.20.4
ACCUMULATED OTHER COMPREHENSIVE INCOME Details (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Accumulated Other Comprehensive Income (Loss) [Line Items]      
Accumulated Other Comprehensive Income (Loss), Net of Tax $ (142) $ (1,380)  
Other Comprehensive Income (Loss), Net of Tax $ 1,238 $ (253) $ (502)
XML 27 R11.htm IDEA: XBRL DOCUMENT v3.20.4
Investments, Equity Method and Joint Ventures
 12 Months Ended
Dec. 31, 2020
Equity Method Investments and Joint Ventures [Abstract]  
Equity Method Investments and Joint Ventures Disclosure Non-Marketable Securities and Other-Than-Temporary Impairment
    During the year ended December 31, 2018, the Company made a $1.8 million investment in Combinati, a private company. Subsequently, on October 1, 2019, the Company made an additional $7.0 million investment in Combinati, bringing the Company's ownership to approximately 28.4% of the voting interest of Combinati. The Company does not have majority control of the entity in which the investment was made, but has the ability to exercise significant influence over operating and financial policies due to its larger ownership percentage and its seat on the Board of Directors. The Company does not have unilateral decision making power, and therefore will not consolidate the investee; therefore, the Company accounts for this investment using the equity method. In the fourth quarter of 2019, we remeasured the existing, minority interest investment based on the fair value prior to the additional investment and recorded a gain of approximately $3.2 million in Other income, net in the Consolidated Statements of Comprehensive Income. The minority interest investment in Combinati is classified in equity method investments to distinguish it from other minority interest investments that take the fair value alternative. The Company's proportionate share of income or loss of approximately 28.4% is recorded in other income (expense), net in the Consolidated Statement of Comprehensive Income. This non-marketable equity investment is recorded at cost minus impairment, if any, plus or minus changes resulting from qualifying observable price changes. The Company periodically reviews this equity investment for other-than-temporary declines in fair value based on the specific identification method and writes down the investment to its fair value when it determines that an other-than-temporary decline has occurred.

    As of December 31, 2020, the carrying value of the Company’s total investment in Combinati was $9.9 million, which exceeded the Company’s share of Combinati’s net assets by $8.1 million and is not amortized. For the year ended December 31, 2020, the Company recorded the allocable share of Combinati’s net income in its Consolidated Statement of Comprehensive Income and as an adjustment to the invested balance.
XML 28 R12.htm IDEA: XBRL DOCUMENT v3.20.4
ACCOUNTS RECEIVABLE (Notes)
 12 Months Ended
Dec. 31, 2020
Receivables [Abstract]  
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]
NOTE 3 — ACCOUNTS RECEIVABLE AND RESERVES

    Accounts receivable consisted of the following (in thousands):
 20202019
Accounts receivable$68,629 $56,956 
Less: Allowance for doubtful accounts(1,666)(1,141)
 $66,963 $55,815 

    The following table summarizes the changes in the allowance for doubtful accounts (in thousands):
Balance at December 31, 2017$1,345 
Net increases charged to costs and expenses(437)
Write-offs of uncollectible accounts(65)
Balance at December 31, 2018$843 
Net recoveries charged to costs and expenses400 
Write-offs of uncollectible accounts(102)
Balance at December 31, 20191,141 
Net recoveries charged to costs and expenses546 
Write-offs of uncollectible accounts(21)
Balance at December 31, 20201,666 
XML 29 R13.htm IDEA: XBRL DOCUMENT v3.20.4
INVENTORIES
 12 Months Ended
Dec. 31, 2020
Inventory Disclosure [Abstract]  
INVENTORIES
NOTE 4 — INVENTORIES, NET

    Inventories consisted of the following at December 31 (in thousands):
 20202019
Parts and supplies$86,380 $45,459 
Work-in-progress18,858 15,532 
Finished goods17,896 16,093 
 $123,134 $77,084 

    The Company has non-cancellable purchase commitments with certain of its component suppliers in the amount of approximately $68.1 million at December 31, 2020. Should production requirements fall below the level of the Company’s commitments, the Company could be required to take delivery of inventory for which it has no immediate need or incur an increased cost per unit going forward.
XML 30 R14.htm IDEA: XBRL DOCUMENT v3.20.4
FAIR VALUE (Notes)
 12 Months Ended
Dec. 31, 2020
Fair Value Disclosures [Abstract]  
Fair Value Disclosures [Text Block]
NOTE 5 — FAIR VALUE MEASUREMENT

    ASC 820 “Fair Value Measurement” (ASC 820) defines fair value, establishes a framework for measuring fair value under U.S. GAAP and enhances disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. ASC 820 describes a fair value hierarchy based on the following three levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last unobservable:

    Level 1—Quoted prices in active markets for identical assets or liabilities.

    Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

    Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

    The Company determines the fair value of its investment portfolio assets by obtaining non-binding market prices from its third-party portfolio managers on the last day of the quarter, whose sources may use quoted prices in active markets for identical assets (Level 1 inputs) or inputs other than quoted prices that are observable either directly or indirectly (Level 2 inputs) in determining fair value. There were no transfers between Level 1, Level 2 or Level 3 measurements for the year ended December 31, 2020.

    The following table represents the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2020 and 2019 (in thousands):
 Fair Value Measurements as of December 31, 2020 Using
 Level 1Level 2Level 3Total
Assets:    
Money Market funds$707 $— $— $707 
 Equity investment$— $— $9,909 $9,909 
 Fair Value Measurements as of December 31, 2019 Using
 Level 1Level 2Level 3Total
Assets:    
Money Market funds$707 $— $— $707 
Minority interest investments - long-term$— $— $22 $22 
Equity investment$— $— $11,501 $11,501 
XML 31 R15.htm IDEA: XBRL DOCUMENT v3.20.4
PROPERTY, PLANT AND EQUIPMENT (Notes)
 12 Months Ended
Dec. 31, 2020
Property, Plant and Equipment [Abstract]  
Property, Plant and Equipment Disclosure [Text Block]
NOTE 6 — PROPERTY AND EQUIPMENT

    Property and equipment consisted of the following at December 31 (in thousands):
 20202019
Laboratory equipment$70,189 $60,486 
Leasehold improvements45,784 43,471 
Computer equipment4,034 3,916 
Purchased software22,981 22,621 
Furniture and fixtures6,081 5,924 
Assets on loan/rental32,544 28,946 
181,613 165,364 
Less: Accumulated depreciation(117,467)(99,849)
 $64,146 $65,515 

    Depreciation expense was $18.4 million and $16.5 million for the years ended December 31, 2020 and 2019, respectively.
XML 32 R16.htm IDEA: XBRL DOCUMENT v3.20.4
GOODWILL
 12 Months Ended
Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill Disclosure [Text Block]
NOTE 7 — GOODWILL AND OTHER INTANGIBLE ASSETS

    The changes in the carrying amount of goodwill during the period are as follows (in thousands):
 December 31, 2020December 31, 2019
Balance at beginning of period$118,145 $118,127 
Flow cytometry acquisition $— $18 
Balance at end of period$118,145 $118,145 
XML 33 R17.htm IDEA: XBRL DOCUMENT v3.20.4
INTANGIBLE ASSETS
 12 Months Ended
Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets Disclosure [Text Block] A portion of the Company’s goodwill is not expected to be deductible for tax purposes. The Company’s intangible assets are reflected in the table below (in thousands, except weighted average lives):
 Finite-livedIndefinite-lived 
 Technology, trade secrets and know-howCustomer lists and contractsOther identifiable intangible assetsIP R&DTotal
2019     
Balance as of December 31, 2018$98,469 $23,819 $10,655 $24,013 $156,956 
Flow cytometry acquisition purchase price allocation adjustments(116)(428)1,154 (4,016)(3,406)
Balance as of December 31, 201998,353 23,391 11,809 19,997 153,550 
Less: accumulated amortization:     
Accumulated amortization balance as of December 31, 2018(40,501)(9,036)(2,271)— (51,808)
Amortization expense(7,784)(2,428)(1,194)— (11,406)
Accumulated amortization balance as of December 31, 2019(48,285)(11,464)(3,465)— (63,214)
Net balance as of December 31, 2019$50,068 $11,927 $8,344 $19,997 $90,336 
Weighted average life (in years)111010  
2020     
Balance as of December 31, 2019$98,353 $23,391 $11,809 $19,997 $153,550 
Completion of IPR&D projects2,687 (2,687)— 
Balance as of December 31, 2020101,040 23,391 11,809 17,310 153,550 
Less: accumulated amortization:     
Accumulated amortization balance as of December 31, 2019(48,285)(11,464)(3,465)— (63,214)
Amortization expense(7,919)(2,427)(1,194)— (11,540)
Accumulated amortization balance as of December 31, 2020(56,204)(13,891)(4,659)— (74,754)
Net balance as of December 31, 2020$44,836 $9,500 $7,150 $17,310 $78,796 
Weighted average life (in years)111010  

    The Company currently has two IP R&D projects. The first relates to the development of the next generation VERIGENE System, VERIGENE II. The Company is targeting the commercial launch of the VERIGENE II System in 2021. The second is a defensive IP R&D project related to the Company’s next generation xMAP System, xMAP INTELLIFLEX, which the Company currently believes will launch commercially in the first half of 2021. The next generation Guava System (Guava Next Gen System), acquired as part of the Company’s acquisition of EMD Millipore Corporation’s flow cytometry portfolio, was launched commercially in the second quarter of 2020 and transferred from IP R&D to finite-lived technology, trade secrets and know-how and is being amortized.

    The estimated aggregate amortization expense for the next five fiscal years and thereafter is as follows (in thousands):
2020$11,316 
202110,070 
20229,721 
20239,721 
20248,188 
Thereafter12,470 
 $61,486 
XML 34 R18.htm IDEA: XBRL DOCUMENT v3.20.4
ACCRUED LIABILITIES (Notes)
 12 Months Ended
Dec. 31, 2020
Payables and Accruals [Abstract]  
Accounts Payable and Accrued Liabilities Disclosure [Text Block]
NOTE 9 — ACCRUED LIABILITIES

    Accrued liabilities consisted of the following as of December 31 (in thousands):
20202019
Compensation and employee benefits$33,992 $17,011 
Dividends payable4,711 4,104 
Income and other taxes7,058 1,538 
Warranty costs1,849 1,641 
Royalties payable782 1,335 
Current operating lease liabilities5,942 5,053 
Convertible notes interest payable996 — 
Other1,035 1,190 
$56,365 $31,872 

    Sales of certain of the Company’s systems are subject to a warranty. System warranties typically extend for a period of twelve months from the date of installation or no more than 15 months from the date of shipment. The Company estimates the amount of warranty claims on sold products that may be incurred based on current and historical data. The actual warranty expense could differ from the estimates made by the Company based on product performance. Warranty expenses are evaluated and adjusted periodically.

    The following table summarizes the changes in the warranty accrual (in thousands):
Accrued warranty costs at December 31, 2017$1,308 
Warranty services provided(2,159)
Accrual for warranty costs2,752 
Accrued warranty costs at December 31, 20181,901 
Warranty services provided(2,868)
Accrual for warranty costs2,608 
Accrued warranty costs at December 31, 20191,641 
Warranty services provided(2,362)
Accrual for warranty costs2,570 
Accrued warranty costs at December 31, 2020$1,849 
XML 35 R19.htm IDEA: XBRL DOCUMENT v3.20.4
Debt
 12 Months Ended
Dec. 31, 2020
Debt Disclosure [Abstract]  
Long-term Debt
NOTE 10 — CONVERTIBLE SENIOR NOTES

In May 2020, the Company issued $260.0 million principal amount of Convertible Senior Notes due in May 2025 (Notes). The interest rates for the Notes is fixed at 3.00% per annum with interest payable semi-annually on May 15 and November 15 of each year, commencing on November 15, 2020. The Notes mature on May 15, 2025, unless earlier converted or repurchased in accordance with their terms prior to such date. Each $1,000 of principal amount of the Notes will initially be convertible into 22.8918 shares of the Company's common stock, which is equivalent to an initial conversion price of approximately $43.68 per share. The initial conversion price for each of the Notes is subject to adjustment upon the occurrence of certain specified events. On December 3, 2020, we announced that our Board declared an increased quarterly cash dividend of $0.10 per share of common stock to be paid to shareholders of record as of the close of business on December 23, 2020 with a payment date of January 14, 2021. This increase in the dividend adjusted the conversion price to $43.67 per share, or 22.9009 shares of the Company's common stock for each $1,000 of principal amount of the Notes.

Holders may convert their Notes at their option at any time prior to the close of business on the business day immediately preceding November 15, 2024 only under the following circumstances:

•during any calendar quarter commencing after the calendar quarter ending on June 30, 2020 (and only during such calendar quarter), if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day;

•during the five business day period after any five consecutive trading day period (Measurement Period) in which the trading price (as defined in the relevant indenture governing the Notes) per $1,000 principal amount of Notes for each trading day of the Measurement Period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day; or

•upon the occurrence of specified corporate events as set forth in the indenture governing the Notes.

On or after November 15, 2024 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or any portion of their Notes at any time, regardless of the foregoing circumstances. Upon conversion, the Company will pay or deliver cash, shares of its common stock or a combination of cash and shares of its common stock, at the Company’s election. The Company currently intends to settle the principal amount of the Notes in cash, and settle any excess amount with shares of the Company’s common stock, upon conversion. As of December 31, 2020, the Notes were not yet convertible.

If a fundamental change (as defined in the relevant indenture governing the Notes) occurs prior to the maturity date, holders of each of the Notes may require the Company to repurchase all or a portion of their Notes for cash at a repurchase price equal to 100% of the principal amount of the Notes, plus any accrued and unpaid interest up to, but excluding, the fundamental change repurchase date.

In accounting for the issuance of the Notes, the Company separated each of the Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value, as of the date of issuance, of a similar debt without the conversion feature. The effective interest rate used for the liability component was 8.50%. The liability component of the Notes is recorded in long-term debt, and the interest payable within the next twelve months is recorded in accrued liabilities on the Condensed Consolidated Balance Sheets as of December 31, 2020. The carrying amount of the equity component representing the conversion feature was determined by deducting the fair value of the liability components from the total initial proceeds. The difference between the par amount of the Notes and the carrying amount of the liability component represents debt discounts that are amortized to interest expense over the respective terms of the Notes using the effective interest rate method. The equity components are not remeasured as long as they continue to meet the conditions for equity classification.

In accounting for the $7.7 million of issuance costs related to the Notes, the Company allocated the total amount of issuance costs incurred to the liability and equity components in proportion to the allocation of the proceeds from issuance to the liability and equity components. Issuance costs attributable to the liability components are amortized to interest expense over the respective terms of the Notes using the effective interest rate method. The issuance costs attributable to the equity components were netted against the respective equity components in additional paid-in capital.
Issuance costs attributable to the liability component, totaling $6.0 million, are being amortized to expense over the expected life of the Notes using the effective interest method. Issuance costs attributable to the equity component related to the conversion feature, totaling $1.7 million, were netted with the equity component.

The Notes consist of the following:
As of December 31, 2020
Liability component:
Principal$260,000 
Unamortized debt discount(51,352)
Unamortized debt issuance costs(5,512)
Net carrying amount$203,136 
Equity component:
Net carrying amount$41,950 

The following table sets forth total interest expense recognized related to the Notes for the years ended December 31 (in thousands):
20202019
Contractual interest expense$4,940 $— 
Amortization of debt issuance costs531 — 
Amortization of debt discount 6,002 — 
Total$11,473 $— 

As of December 31, 2020, the remaining period over which the debt discount and debt issuance costs will be amortized was 4.4 years.

Convertible Note Hedge and Warrant Transactions

Concurrent with the offering of the Notes, the Company entered into privately negotiated convertible note hedge transactions (Convertible Note Hedge Transactions) with certain financial institutions (Option Counterparties) related to the issuance of the Notes. The Convertible Note Hedge Transactions are generally expected to reduce the potential dilution to the Company’s common stock upon any conversion of Notes or offset any cash payments the Company is required to make in excess of the principal amount of converted Notes.

The Company also entered into separate privately negotiated warrant transactions (Warrant Transactions) with each of the Option Counterparties pursuant to which the Company issued Warrants that will be exercisable into a number of shares of the Company’s common stock at a price per share equal to $69.89, subject to certain adjustments under the terms of the Warrant Transactions. The Warrant Transactions could separately have a dilutive effect on the Company’s common stock if the market value per share of the Company’s common stock exceeds the applicable strike price of the Warrants. However, subject to certain conditions, the Company may elect to settle the Warrants in cash.

The Convertible Note Hedge Transactions and the Warrant Transactions are separate transactions, in each case, entered into by the Company with the same Option Counterparties and are not part of the terms of the Notes and will not affect any holder’s rights under the Notes. The holders of the Notes will not have any rights with respect to the Convertible Note Hedge Transactions or Warrant Transactions. The Company used approximately $34.7 million of the net proceeds of the issuance of the Notes to pay the costs of the Convertible Note Hedge Transactions, after such cost was partially offset by the proceeds to the Company from the sale of the Warrants in the Warrant Transactions. The Convertible Note Hedge Transactions and Warrant Transactions do not meet the criteria for derivative accounting as they are indexed to the Company's stock. The amounts paid for the Convertible Note Hedge Transactions and the proceeds received from the Warrant Transactions have been included as a net reduction to additional paid-in capital.
XML 36 R20.htm IDEA: XBRL DOCUMENT v3.20.4
INCOME TAXES
 12 Months Ended
Dec. 31, 2020
Income Tax Disclosure [Abstract]  
Income Tax Disclosure [Text Block]
NOTE 11 — INCOME TAXES
 
    The components of income before income taxes for the years ended December 31 are as follows (in thousands):
 202020192018
Domestic$(33,631)$(31,314)$7,242 
Foreign62,571 21,812 21,069 
Total$28,940 $(9,502)$28,311 
    
The components of the provision (benefit) for income taxes attributable to continuing operations for the years ended December 31 are as follows (in thousands):
 202020192018
Current:   
Federal$(7)$821 $(3,318)
Foreign6,689 951 515 
State179 (163)600 
Total current expense (benefit)$6,861 $1,609 $(2,203)
Deferred:   
Federal(2,913)(10,179)6,351 
Foreign8,886 4,597 5,271 
State936 (1,691)384 
Total deferred expense (benefit)6,909 (7,273)12,006 
Total provision (benefit) for income taxes$13,770 $(5,664)$9,803 
    
The provision (benefit) for income taxes differs from the amount computed by applying the statutory federal rate to pretax income as follows (in percentages):
 Year Ended December 31,
 202020192018
Statutory tax rate21.0 %21.0 %21.0 %
State taxes, net of federal benefit(3.5)%9.6 %3.0 %
Permanent items(2.4)%(1.6)%2.6 %
Effect of foreign operations10.2 %(11.7)%3.4 %
Research and incentive tax credit generated(7.7)%18.9 %(8.7)%
Valuation allowance9.1 %0.8 %0.4 %
Income tax reserves1.0 %67.3 %24.7 %
Remeasurement U.S. deferreds0.0 %0.0 %(0.3)%
Transition tax0.0 %(5.3)%(16.6)%
Foreign earnings withholding tax0.1 %6.6 %(7.9)%
Global intangible low-taxed income18.6 %(44.4)%5.7 %
Other measurement period Tax Act adjustments0.0 %0.0 %2.6 %
Canadian income tax audit0.0 %0.0 %4.8 %
Other1.2 %(1.0)%(0.1)%
 47.6 %60.2 %34.6 %

    The Company accounts for income taxes using the asset and liability method in accordance with ASC 740 “Income Taxes” (ASC 740). Under this method, deferred income taxes are recognized for the future tax consequences of differences between the tax and financial accounting bases of assets and liabilities at the end of each reporting period. Deferred income taxes are based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized.
    Significant components of the Company’s deferred tax assets and liabilities as of December 31 are as follows (in thousands):
 20202019
Deferred tax assets: 
Accrued liabilities and other$7,479 $4,577 
Net operating loss and credit carryforwards40,966 52,141 
Deferred revenue2,119 1,023 
Operating lease liability4,060 5,023 
Stock compensation and other7,542 7,791 
Bond hedge12,103 — 
Gross deferred tax assets74,269 70,555 
Valuation allowance(16,882)(17,906)
Total deferred tax assets$57,387 $52,649 
Deferred tax liabilities:  
Accrued liabilities and other$(4,230)$(1,287)
Depreciation and amortization(15,710)(18,443)
Operating lease right-of-use assets(3,649)(4,550)
Equity method investment(279)(667)
Convertible debt(12,442)
Total deferred tax liabilities(36,310)(24,947)
Net deferred tax assets$21,077 $27,702 
    
The Company has established a valuation allowance against a portion of its remaining deferred tax assets because it is more likely than not that certain deferred tax assets will not be realized. In determining whether deferred tax assets are realizable, the Company considered numerous factors including historical profitability, the amount of future taxable income and the existence of taxable temporary differences that can be used to realize deferred tax assets. The valuation allowance decreased approximately $1.0 million in 2020 from 2019 primarily due to releasing valuation allowance of $3.6 million against deferred tax assets of certain state net operating loss carryforwards, state research credit carryforwards, and deferred tax assets for stock compensation, and recording additional valuation allowance on the deferred tax assets of certain state net operating loss carryforwards of $2.6 million. The Company’s valuation allowance is primarily offsetting certain state net operating loss and state tax credit carryforwards, and certain stock based compensation. We anticipate portions of our deferred tax assets will not be realized under the provisions of Section 162(m) of the Tax Act which limits the deductibility of executive compensation.

    At December 31, 2020, the Company had gross federal, state and foreign net operating loss carryforwards of approximately $41.9 million, $283.8 million, and $6.1 million, respectively. These losses expire beginning in 2021. Federal and state net operating losses of approximately $41.9 million and $268.9 million, respectively, were acquired as part of the acquisitions of U.S. companies. These acquired net operating losses are subject to annual limitations due to the “change of ownership” provisions of Section 382 of the Internal Revenue Code of 1986, as amended, and similar state provisions. The Company has federal, state and foreign credit carryforwards of approximately $8.6 million, $3.4 million, and $2.6 million, respectively. These credits begin to expire in 2023, except for approximately $1.1 million of state research credits which have an indefinite carryforward period. Certain of these credits are subject to annual limitations under the change in ownership provisions.
    The excess of financial reporting basis over tax basis of the Company’s foreign subsidiaries is considered permanently reinvested with the exception of certain earnings of the Canadian subsidiary. The cumulative amount of excess financial reporting basis of the Company’s non-U.S. subsidiaries was approximately $14.3 million at December 31, 2020, $22.5 million at December 31, 2019 and $3.8 million at December 31, 2018. Since the Company does not intend to permanently reinvest portions of its previously taxed Canadian earnings, it has recorded a deferred tax liability of approximately $30 thousand related to state income taxes associated with the ultimate repatriation from Canada to the U.S. of these previously taxed earnings. Beginning January 1, 2018, the Tax Act implemented a territorial tax system in the U.S. such that the income earned by the Company’s non-U.S. subsidiaries will be subject to a 100% dividend received deduction, with certain exceptions. We have not recognized a deferred tax liability related to withholding taxes or state income taxes on the excess financial reporting basis of our other foreign subsidiaries because the Company currently intends to reinvest earnings of these subsidiaries in operations outside the U.S. Determination of the amount of the unrecognized deferred tax liability on these unremitted earnings is not practicable.

    As of December 31, 2020 and December 31, 2019, the Company had recorded gross unrecognized tax benefits of approximately $3.7 million and $3.4 million, respectively. All of the unrecognized tax benefits as of December 31, 2020, if recognized, would impact the effective tax rate. The Company recognizes interest expense and penalties associated with uncertain tax positions as a component of income tax expense. During the years ended December 31, 2020 and 2019, the Company recognized approximately $26 thousand and $1 thousand in tax related interest and penalties, respectively. Reserves for interest and penalties as of December 31, 2020 and 2019 are not significant as the Company has net operating loss carryovers and tax credit carryforwards.

    A reconciliation of the beginning and ending balance of unrecognized tax benefits is as follows (in thousands):
20202019
Balance at beginning of year$3,423 $9,721 
Additions based on tax positions related to the current year311 342 
Additions for tax positions of prior years— 398 
Reductions for tax positions of prior years(30)(7,038)
Balance at end of year$3,704 $3,423 
    
As of December 31, 2020, there were no unrecognized tax benefits that we expect would change significantly over the next 12 months.

    The Company files U.S., state, and foreign income tax returns in jurisdictions with varying statutes of limitations. In the United States and Canada, the statute of limitations with respect to the federal income tax returns for tax years after 2015 are open to audit; however, since the Company has net operating losses, the taxing authority has the ability to review tax returns prior to the 2015 tax year and make adjustments to these net operating loss carryforwards. In the fourth quarter of 2020, the IRS completed its audit of the Company's 2016 tax return with no material adjustments. In addition, during 2020 the IRS began auditing the Company's 2017 tax return with respect to certain limited issues. The IRS completed its audit of the Company's 2017 tax return in the fourth quarter of 2020 with no tax adjustments. We are not under audit in any major taxing jurisdictions at this time.
XML 37 R21.htm IDEA: XBRL DOCUMENT v3.20.4
EARNINGS PER SHARE
 12 Months Ended
Dec. 31, 2020
Earnings Per Share [Abstract]  
EARNINGS PER SHARE
NOTE 12 — EARNINGS PER SHARE

    A reconciliation of the denominators used in computing per share net income (EPS) is as follows (in thousands, except per share amounts):
 Year Ended December 31,
 202020192018
Basic:   
Net income (loss)$15,170 $(3,838)$18,508 
Less: allocation to participating securities(297)65 (312)
Net income (loss) attributable to common stockholders$14,873 $(3,773)$18,196 
Weighted average common stock outstanding45,102 44,148 43,727 
Net income (loss) per share attributable to common stockholders$0.33 $(0.09)$0.42 
Diluted:   
Net income (loss)$15,170 $(3,838)$18,508 
Less: allocation to participating securities(298)63 (311)
Net income (loss) attributable to common stockholders$14,872 $(3,775)$18,197 
Weighted average common stock outstanding45,102 44,148 43,727 
Effect of dilutive securities: stock options and awards718 — 564 
Weighted-average shares used in computing net income (loss) per share45,820 44,148 44,291 
Net income (loss) per share attributable to common stockholders$0.32 $(0.09)$0.41 

    Basic net income (loss) per share is computed by dividing the net income (loss) for the period by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share is computed by dividing the net income (loss) for the period by the weighted average number of common and common equivalent shares outstanding during the period. Restricted stock awards (RSAs) and stock options to acquire 1,620,252 shares, 1,271,248 shares, and 619,113 shares for the years ended December 31, 2020, 2019 and 2018, respectively, were excluded from the computations of diluted earnings per share because the effect of including the RSAs and stock options would have been anti-dilutive.

    We apply the two-class method of computing earnings per share, which requires the calculation of separate earnings per share amounts for our non-vested, time-based restricted stock awards with non-forfeitable dividends and for our common stock. Our non-vested, time-based restricted stock awards with non-forfeitable dividends are considered securities which participate in undistributed earnings with common stock. Under the two-class computation method, net losses are not allocated to participating securities unless the holder of the security has a contractual obligation to share in the losses. Our non-vested, time-based restricted stock awards with non-forfeitable dividends do not have such an obligation so they are not allocated losses.
XML 38 R22.htm IDEA: XBRL DOCUMENT v3.20.4
STOCKHOLDERS' EQUITY
 12 Months Ended
Dec. 31, 2020
Equity [Abstract]  
Shareholders' Equity and Share-based Payments [Text Block]
NOTE 13 — STOCKHOLDERS’ EQUITY, EMPLOYEE BENEFIT PLANS AND STOCK-BASED COMPENSATION

Preferred Stock

    The Company’s Board of Directors has the authority to issue up to 5,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof, including dividend rights, dividend rates, conversion rights, voting rights, terms of redemption, redemption prices, liquidation preferences and the number of shares constituting any series or the designation of such series, without further vote or action by the Company’s stockholders. At December 31, 2020 and 2019, there was no preferred stock issued and outstanding.

Dividends

    In February 2017, the Board of Directors initiated a cash dividend program under which the Company began paying a regular quarterly cash dividend. The following table shows cash dividends declared, recorded, and paid (or to be paid) in the periods shown:
Date Paid or
To Be Paid		Dividends Declared per Share
Twelve Months EndingDate DeclaredDate Payable
December 31, 2018
January 24, 2018March 23, 2018April 13, 2018$0.06 
May 18, 2018June 22, 2018July 13, 2018$0.06 
September 11, 2018September 21, 2018October 12, 2018$0.06 
December 11, 2018December 22, 2018January 10, 2019$0.06 
December 31, 2019
February 8, 2019March 21, 2019April 11, 2019$0.06 
May 21, 2019June 20, 2019July 11, 2019$0.06 
July 31, 2019September 26, 2019October 17, 2019$0.09 
December 6, 2019December 19, 2019January 15, 2020$0.09 
December 31, 2020
February 18, 2020March 19, 2020April 9, 2020$0.09 
May 22, 2020June 18, 2020July 9, 2020$0.09 
September 10, 2020September 24, 2020October 15, 2020$0.09 
December 3, 2020December 23, 2020January 14, 2021$0.10 
    
The Company’s current intent is to pay a continuing dividend on a quarterly basis. However, future declaration of dividends is subject to the final determination of the Company’s Board of Directors.

Stock-Based Compensation

    At December 31, 2020, the Company has one stock-based employee compensation plan pursuant to which grants may be made: the Luminex Corporation 2018 Equity Incentive Plan (Equity Incentive Plan) which was approved at the Company’s Annual Meeting on May 17, 2018. No further grants shall be made pursuant to the 2000 Long-Term Incentive Plan (2000 Plan), the 2001 Broad-Based Stock Option Plan (2001 Plan) or the 2006 Equity Incentive Plan (2006 Plan). In addition, at December 31, 2020, the Company has one plan pursuant to which discount purchases may be made by the participants in such plan: the Luminex Corporation Employee Stock Purchase Plan (ESPP), which was approved at the Company’s Annual Meeting on May 17, 2012 and amended at the Company’s Annual Meeting on May 18, 2017.

Equity Incentive Plans

    Under the Company’s Equity Incentive Plan and, the 2006 Plan, certain employees, consultants and non-employee directors have been granted RSAs, restricted stock units (RSUs) and options to purchase shares of common stock. The options, RSAs, and RSUs generally vest in installments over a three to five year period, and the options expire either seven or ten years after the date of grant.

    The ESPP provides for the granting of rights to certain employees of the Company to defer an elected percentage, up to 15%, of their base salary through the purchase of the Company’s common stock, discounted by 15%. As of December 31, 2020, there were approximately 2,400,000 shares authorized for future issuance under the Company’s Equity Incentive Plan and 83,044 shares eligible for purchase pursuant to the terms and conditions of the ESPP as more fully described below.

    The Equity Incentive Plan, the 2006 Plan and the ESPP are administered by the Compensation Committee of the Board of Directors. The Compensation Committee has the authority to determine the terms and conditions under which awards will be granted from the Equity Incentive Plan, including the number of shares, vesting schedule and term, as applicable. Any option exercise prices, as set forth in the Equity Incentive Plan, will be equal to the fair market value on the date of grant. Under certain circumstances, the Company may repurchase previously granted RSAs and RSUs.
    On February 27, 2020 and February 21, 2019, the Compensation Committee approved awards of stock options (the Performance Options) to the Company’s named executive officers and certain other executives that vest over four years based on achievement of certain operating profit and revenue targets for each of 2020 and 2019, respectively. The Performance Options have an exercise price equal to the closing market price for the Company’s common stock on the Nasdaq Global Select Market on the date of grant (March 12, 2020 and 2019, respectively) and expire seven years from the date of grant. The Performance Options were measured over a one-year performance period ending on December 31, 2020 and 2019, respectively. Following the end of the applicable fiscal year, the Committee determined the number of Performance Options which were eligible to vest based upon the level of achievement of an established Company performance goal (the Company Financial Goal). If the Company failed to meet the threshold performance for the performance period, no Performance Options would be eligible to vest. Minimum vesting for minimum threshold performance started at 30% of the target value for the Company Financial Goal. If the Company’s performance exceeded the target performance, the recipient may receive additional Performance Options above the target number, subject to a maximum of 200% of the target award. The Company’s financial performance resulted in delivery of 200% and 83% of the number of target Performance Options granted for 2020 and 2019, respectively. The Performance Options that are eligible to vest after the determination date will vest 25% on each of the first four anniversaries of the grant date. In the event of a change of control of the Company before the end of the performance period, the Performance Options will automatically vest based on the greater of actual achievement of the pro-rated Company Financial Goal as of the date of the change of control or 100% of target performance, as determined by the Committee in its sole discretion. The Performance Options are exercisable into shares of the Company’s common stock.

Accounting for Stock Compensation

    Stock-based compensation costs are generally based on the fair value calculated from the Black-Scholes option-pricing model on the date of grant for stock options, performance options and market value on the date of grant for RSAs. The fair values of stock and stock options are amortized as compensation expense on a straight-line basis over the vesting period of the grants.

    In accordance with ASC 718, the Company evaluates the assumptions used in the Black-Scholes model at each grant date using a consistent methodology for computing expected volatility, expected term and risk-free rate of return. Calculation of expected volatility is based on historical volatility. The expected life is calculated using the contractual term of the options as well as an analysis of the Company’s historical exercises of stock options and performance options. The estimate of the risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant. The dividend yield is based on our history and expectation of dividend payouts at the time of grant. The assumptions used are summarized in the following table:
 202020192018
Dividend yield1.5 %0.9 %1.2 %
Expected volatility0.3 0.4 0.4 
Risk-free rate of return0.9 %2.6 %2.7 %
Expected life of a 10 year contractual term option7 years7 years7 years
Expected life of a 7 year contractual term option4.75 years4.88 years4.88 years
Weighted average fair value at grant date$6.17 $7.69 $8.23 

    As part of the requirements of ASC 718, the Company is required to estimate potential forfeitures of stock grants and adjust compensation cost recorded accordingly. The estimate of forfeitures is based on historical forfeiture performance and will be adjusted over the requisite service period to the extent that actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures will be recognized through a cumulative catch-up adjustment in the period of evaluation and will also impact the amount of stock compensation expense to be recognized in future periods.
    The Company’s stock option activity for the year ended December 31, 2020 is as follows:
Stock OptionsShares
(in thousands)		Weighted Average Exercise PriceWeighted Average Remaining Contractual Life (in years)Aggregate Intrinsic Value (in thousands)
Outstanding at December 31, 20193,793 $20.17   
Granted1,508 23.09   
Exercised(998)18.18   
Canceled or expired(550)24.43   
Outstanding at December 31, 20203,753 $21.25 4.48$7,633 
Vested at December 31, 2020 and expected to vest3,687 $21.22 4.45$7,623 
Exercisable at December 31, 20201,519 $19.12 3.00$6,248 

    During the years ended December 31, 2020, 2019 and 2018, the total exercise intrinsic value of stock options exercised was $16.2 million, $0.4 million and $1.3 million, respectively, and the total fair value of stock options that vested was $10.6 million, $11.9 million and $12.7 million, respectively. Exercise intrinsic value represents the difference between the market value of the Company’s common stock at the time of exercise and the price paid by the employee to exercise the options. The Company had $10.5 million of total unrecognized compensation costs related to stock options at December 31, 2020 that are expected to be recognized over a weighted-average period of 2.57 years.

    The Company’s restricted share activity for the year ended December 31, 2020 is as follows:
Restricted Stock AwardsShares
(in thousands)		Weighted Average Grant Price
Non-vested at December 31, 2019810 $22.28 
Granted416 23.26 
Vested(295)21.49 
Cancelled or expired(38)22.65 
Non-vested at December 31, 2020893 $22.98 
Restricted Stock UnitsShares
(in thousands)		Weighted Average Remaining Contractual Life (in years)Aggregate Intrinsic Value (in thousands)
Non-vested at December 31, 2019522 
Granted100 
Vested(45)
Cancelled or expired(7)
Non-vested at December 31, 2020570 1.09$13 
Vested at December 31, 2020 and expected to vest563 1.05$13 
Exercisable at December 31, 2020403 0.00$9 

    As of December 31, 2020, there was $18.7 million of unrecognized compensation cost related to RSAs and RSUs. That cost is expected to be recognized over a weighted average-period of 2.17 years. The total fair value of restricted shares vested during the year ended December 31, 2020, 2019 and 2018 was $7.3 million, $6.0 million and $6.7 million, respectively.
    RSAs and RSUs may be granted at the discretion of the Compensation Committee of the Board of Directors under the Equity Incentive Plan in connection with the hiring or retention of key employees and are subject to certain conditions. Restrictions expire at certain dates after the grant date in accordance with specific provisions in the applicable agreement. During the year ended December 31, 2020, the Company awarded 416,142 shares of RSAs, which had a fair value at the date of grant ranging from $23.05–$31.65. During the year ended December 31, 2019, the Company awarded 413,967 shares of RSAs, which had a fair value at the date of grant ranging from $20.04–$24.43. During the year ended December 31, 2018, the Company awarded 387,436 shares of RSAs, which had a fair value at the date of grant ranging from $20.33–$29.33. During the year ended December 31, 2020, the Company awarded 99,584 shares of RSUs and dividend equivalents, which had a fair value at the date of grant ranging from $23.09–$31.65. During the year ended December 31, 2019, the Company awarded 120,498 shares of RSUs and dividend equivalents, which had a fair value at the date of grant ranging from $21.01–$24.43. During the year ended December 31, 2018, the Company awarded 95,127 shares of RSUs, which had a fair value at the date of grant ranging from $21.98–$26.39. Compensation under these RSAs and RSUs was charged to expense over the restriction period and amounted to $9.2 million, $8.2 million, and $6.2 million in 2020, 2019 and 2018, respectively. There were no significant stock compensation costs capitalized into assets as of December 31, 2020, 2019 or 2018.

    The Company received $18.0 million, $1.7 million and $2.8 million for the exercise of stock options during the years ended December 31, 2020, 2019 and 2018, respectively. Cash was not used to settle any equity instruments previously granted. The Company issued shares pursuant to grants relating to each of the Equity Incentive Plan, the 2006 Plan and 2000 Plan from reserves upon the exercise of stock options and vesting of RSAs.

    The following are the stock-based compensation costs recognized in the Company’s consolidated statements of comprehensive income (in thousands):
 Year Ended December 31,
 202020192018
Cost of revenue$2,332 $2,028 $1,715 
Research and development2,027 1,635 1,409 
Selling, general and administrative10,493 9,535 9,102 
Stock-based compensation costs reflected in net income (loss) $14,852 $13,198 $12,226 

Employee Stock Purchase Plan

    In May 2012, the Company’s stockholders approved the ESPP, which provides for the purchase of up to 500,000 shares of the Company’s common stock by eligible employees. In May 2017, the Company’s stockholders approved an amendment to the ESPP Plan, which increased the shares available under the ESPP by 341,744 shares. The ESPP period is semi-annual and allows participants to purchase the Company’s common stock at 85% of the lesser of (i) the closing market value per share of the common stock on the first trading date of the option period or (ii) the closing market value per share of the common stock on the last trading date of the option period. As of December 31, 2020, 2019 and 2018, 758,700 shares, 631,553 shares and 518,111 shares, respectively had been issued out of the ESPP. The related stock-based compensation expense was $0.7 million, $0.6 million and $0.5 million for 2020, 2019 and 2018, respectively.

    The Company uses the Black-Scholes model to estimate the fair value of shares to be issued under the ESPP as of the grant date using the following weighted average assumptions:
 202020192018
Assumptions:
Risk-free interest rates0.18 %2.55 %2.1 %
Expected life0.5 years0.5 years0.5 years
Expected volatility0.34710.350.44
Dividend yield1.454 %0.942 %1.2 %
Reserved Shares of Common Stock

    At December 31, 2020 and 2019, the Company had reserved 6,808,668 and 8,349,808 shares of common stock, respectively, for the issuance of common stock upon the exercise of options, issuance of RSAs, RSUs, purchase of common stock pursuant to the ESPP or other awards issued pursuant to the Company’s equity plans and arrangements. The following table summarizes the reserved shares by plan as of December 31, 2020:
 Options and RSUs OutstandingShares Available for Future IssuanceTotal Shares Reserved
Equity Incentive Plan4,339,804 2,385,820 6,725,624 
ESPP— 83,044 83,044 
 4,339,804 2,468,864 6,808,668 

Employee Savings Plans and Other Benefit Plans

    Effective January 1, 2001, the Company began sponsoring a retirement plan authorized by section 401(k) of the Internal Revenue Code for the Company’s employees in the United States. In accordance with the 401(k) plan, all employees are eligible to participate in the plan on the first day of the month following the commencement of full time employment. For 2020, 2019 and 2018, each employee could contribute a percentage of compensation up to a maximum of $19,500, $19,000, and $18,500 per year, respectively, with the Company matching 50% of each employee’s contributions. Effective January 1, 2010, the Company began contributing to a deferred profit sharing plan for its Canadian employees. All Canadian employees are eligible to participate in the plan. The Company’s contributions to these plans for 2020, 2019 and 2018 were $5.4 million, $5.1 million and $4.0 million, respectively.

    Several of the Company’s Netherlands employees are covered by a defined benefit plan. The cost and total liability to the Company is not material. Effective January 1, 2011, all of the Company’s new hires in the Netherlands are eligible to participate in a defined contribution plan.
Preferred Stock [Text Block]
Preferred Stock

    The Company’s Board of Directors has the authority to issue up to 5,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof, including dividend rights, dividend rates, conversion rights, voting rights, terms of redemption, redemption prices, liquidation preferences and the number of shares constituting any series or the designation of such series, without further vote or action by the Company’s stockholders. At December 31, 2020 and 2019, there was no preferred stock issued and outstanding.
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]
Stock-Based Compensation

    At December 31, 2020, the Company has one stock-based employee compensation plan pursuant to which grants may be made: the Luminex Corporation 2018 Equity Incentive Plan (Equity Incentive Plan) which was approved at the Company’s Annual Meeting on May 17, 2018. No further grants shall be made pursuant to the 2000 Long-Term Incentive Plan (2000 Plan), the 2001 Broad-Based Stock Option Plan (2001 Plan) or the 2006 Equity Incentive Plan (2006 Plan). In addition, at December 31, 2020, the Company has one plan pursuant to which discount purchases may be made by the participants in such plan: the Luminex Corporation Employee Stock Purchase Plan (ESPP), which was approved at the Company’s Annual Meeting on May 17, 2012 and amended at the Company’s Annual Meeting on May 18, 2017.
XML 39 R23.htm IDEA: XBRL DOCUMENT v3.20.4
CONTINGENCIES
 12 Months Ended
Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Disclosure [Text Block]
NOTE 15 — COMMITMENTS AND CONTINGENCIES

Leases

    We have leased all of our research, manufacturing and office space and have entered into various other leases in conducting our business. Our leases have remaining lease terms of one year to six years, and some of our leases include options to extend the leases for up to ten years, tenant improvement allowances, rent holidays and rent escalation clauses. As the Company’s leases do not provide an implicit rate, we have used an estimated incremental borrowing rate of 5.75%, based on the information available at the commencement date in determining the present value of lease payments.

    The components of the lease expense were as follows (in thousands):
Twelve Months Ended December 31,
202020192018
Operating lease cost(a)
$9,792 $9,434 $7,032 
(a) Includes short-term lease expense costs, which were immaterial in the years ended December 31, 2020, 2019 and 2018

    Supplemental cash flow information related to leases was as follows (in thousands):
Twelve Months EndedTwelve Months Ended
December 31, 2020December 31, 2019
Cash paid for amounts included in the measurement of lease liabilities$7,072 $6,553 
    
Supplemental balance sheet information related to leases was as follows (in thousands):
December 31, 2020December 31, 2019
Operating leases:
Operating lease right-of-use assets$17,768 $20,439 
Operating lease liabilities$19,308 $22,235 
Weighted average remaining lease term3.52 years4.36 years
Weighted average discount rate5.75 %5.75 %

    Minimum annual lease commitments as of December 31, 2020 under non-cancellable leases for each of the next five years and in the aggregate were as follows (in thousands):
Operating Leases
2021$7,206 
20225,540 
20234,507 
20243,177 
2025945 
Thereafter— 
Total lease payments21,375 
Less: imputed interest(2,067)
Lease liabilities at December 31, 2020$19,308 
    These non-cancellable lease commitments related to facilities include certain rent escalation provisions which have been included in the minimum annual rental commitments shown above. These amounts are recorded to expense on a straight-line basis over the life of the lease. In addition, some of the Company’s leases contain options to renew the lease for five to ten years at the then prevailing market rental rate, right of first refusal to lease additional space that becomes available, or leasehold improvement incentives.

Non-Cancellable Purchase Commitments

    As of December 31, 2020 the Company had approximately $68.1 million in purchase commitments primarily with several of its inventory suppliers as well as other operating commitments. Certain of our supply agreements require purchase and delivery of minimum amounts of components through 2020, and purchases under these arrangements were $0.5 million, $0.8 million and $2.2 million for the years ended December 31, 2020, 2019 and 2018, respectively.

Employment Contracts

    The Company has entered into employment contracts with certain of its key executives. Generally, certain amounts may become payable in the event the Company terminates the executives’ employment without cause or the executive resigns for good reason.

Legal Proceedings

    In the normal course of business, the Company is subject to claims, lawsuits and legal proceedings. When and if it appears probable in management’s judgment, and based upon consultation with outside counsel, that we will incur monetary damages or other costs in connection with any claims or proceedings, and such costs can be reasonably estimated, we record the estimated liability in the financial statements.  If only a range of estimated losses can be estimated, we record an amount within the range that, in management’s judgment, reflects the most likely outcome; if none of the estimates within that range is a better estimate than any other amount, we record the liability at the low end of the range of estimates. Any such accrual would be charged to expense in the appropriate period. We disclose significant contingencies when the loss is not probable and/or the amount of the loss is not estimable, when we believe there is at least a reasonable possibility that a loss has been incurred. We recognize costs associated with legal proceedings in the period in which the services were provided.
XML 40 R24.htm IDEA: XBRL DOCUMENT v3.20.4
GUARANTEES (Notes)
 12 Months Ended
Dec. 31, 2020
Guarantees and Product Warranties [Abstract]  
Guarantees [Text Block]
NOTE 16 — GUARANTEES

    The terms and conditions of the Company’s development and supply and license agreements with its strategic partners generally provide for a limited indemnification of such partners, arising from the sale of Luminex systems and consumables, against losses, expenses and liabilities resulting from third-party claims based on an alleged infringement on an intellectual property right of such third party. The terms of such indemnification provisions generally limit the scope of and remedies for such indemnification obligations to a multiple of amounts paid by such strategic partner to Luminex during the previous annual period(s). To date, the Company has not had to reimburse any of its strategic partners for any losses arising from such indemnification obligations.
XML 41 R25.htm IDEA: XBRL DOCUMENT v3.20.4
GEOGRAPHIC INFORMATION (Notes)
 12 Months Ended
Dec. 31, 2020
Segment Reporting [Abstract]  
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]
 Sales to CustomersProperty and Equipment, net
 202020192018202020192018
Domestic$325,781 $252,381 $261,726 $61,755 $63,180 $63,382 
Foreign:      
Europe48,635 36,625 21,672 89 178 394 
Asia30,018 32,220 21,603 577 442 519 
Canada5,293 4,775 1,725 1,715 1,993 
Other12,962 8,119 6,042 — — — 
 $417,396 $334,638 $315,818 $64,146 $65,515 $66,288 
XML 42 R26.htm IDEA: XBRL DOCUMENT v3.20.4
RECENT ACCOUNTING (Notes)
 12 Months Ended
Dec. 31, 2020
Accounting Changes and Error Corrections [Abstract]  
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]
NOTE 18 — RECENT ACCOUNTING PRONOUNCEMENTS

    Recently adopted accounting guidance

    In June 2016, the FASB issued guidance on financial instruments and related credit losses. The guidance requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis. The statement of comprehensive income reflects the measurement of credit losses for newly recognized financial assets, as well as the expected credit losses during the period. The measurement of expected credit losses is based upon historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. Credit losses relating to available-for-sale debt securities will be recorded through an allowance for credit losses rather than as a direct write-down to the security. The updated guidance is effective for annual periods beginning after December 15, 2019, and is applicable to the Company in fiscal 2020. The Company adopted the new standard effective January 1, 2020. The primary impact for the Company was the timing of recording expected credit losses on its trade receivables. The Company does not have a history of significant credit losses and this guidance did not have a material impact on its consolidated financial statements.

    Recent accounting guidance not yet adopted

    In December 2019, the FASB issued final guidance that simplifies the accounting for income taxes by eliminating some exceptions to the general approach in ASC 740, Income Taxes. The guidance amended certain disclosure requirements that had become redundant, outdated or superseded. Additionally, this guidance includes provisions for investment company reporting modernization, amends accounting for the interim period effects of changes in tax laws or rates, and simplifies aspects of the accounting for franchise taxes. The guidance is effective for annual periods beginning after December 15, 2020, and is applicable for the Company in fiscal 2021. Early adoption is permitted. The Company does not anticipate that this guidance will have a material impact on its consolidated financial statements.
In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies accounting for convertible instruments by removing major separation models required under U.S. GAAP. This update also amends the guidance for the derivatives scope exception for contracts in an entity's own equity to reduce form-over-substance-based accounting conclusions and requires the application of the if-converted method for calculating diluted earnings per share. The update also requires entities to provide expanded disclosures about the terms and features of convertible instruments and how the instruments have been reported in the entity’s financial statements. The guidance is effective for interim and annual periods beginning after December 15, 2021. Early adoption is permitted, but no earlier than January 1, 2021. The Company will early adopt this guidance effective January 1, 2021 under the modified retrospective basis with the cumulative effect recognized through an adjustment to additional paid-in capital. Under this method, earnings per share amounts will not be restated in prior periods presented, but future earnings per share amounts will be impacted by the change to the if-converted method for calculating diluted earnings per share. The Company's adoption is expected to result in a decrease of approximately $42 million in additional paid in capital from the de-recognition of the bifurcated equity component and an increase of approximately $50 million in debt from the de-recognition of the discount associated with the bifurcated equity component. The Company expects to write-off the related deferred tax liabilities to additional paid in capital.
XML 43 R27.htm IDEA: XBRL DOCUMENT v3.20.4
REVENUE RECOGNITION (Notes)
 12 Months Ended
Dec. 31, 2020
Revenue Recognition and Deferred Revenue [Abstract]  
Revenue Recognition, Deferred Revenue [Policy Text Block]
NOTE 14 — REVENUE RECOGNITION

    Contract assets are included within Accounts receivables, net and contract liabilities are included in Deferred revenue on the Company’s Balance Sheet. The following table presents the opening and closing balances of the Company’s contract assets and liabilities for the twelve months ended December 31, 2020 (in thousands):
 Balance at
December 31, 2020		 Balance at December 31, 2019
Contract assets:
Unbilled receivables - Royalties$12,054 $12,257 
Contract liabilities - short-term:
Deferred revenue - Service $9,346 $7,771 
Deferred revenue - Licenses197 207 
Deferred revenue - Instruments78 2 
Deferred revenue - Other426 234 
Total Contract liabilities - short-term$10,047 $8,214 
Contract liabilities - long-term:  
Deferred revenue - Service$1,190 $968 
Deferred revenue - Licenses468 665 
Total Contract liabilities - long-term$1,658 $1,633 
    During the twelve months ended December 31, 2020, the Company recognized the following revenues as a result of changes in the contract asset and contract liability balances in the period (in thousands):
 Year Ended December 31, 2020
Revenue recognized in the period:
Amounts included as contract liabilities at the beginning of the period$9,387 
Performance obligations satisfied in previous periods -
XML 44 R28.htm IDEA: XBRL DOCUMENT v3.20.4
ACCOUNTING POLICIES (Policies)
 12 Months Ended
Dec. 31, 2020
Accounting Policies [Abstract]  
Business Description and Accounting Policies [Text Block]
NOTE 1 — DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Description of Business

    Luminex Corporation, the “Company” or “Luminex,” develops, manufactures and sells proprietary biological testing technologies and products with applications throughout the life sciences industries, including diagnostics, pharmaceutical and research. These industries depend on a broad range of tests, called assays, to perform diagnostic testing and conduct life science research. The Company established a position in several segments of the life sciences industries by developing and delivering products that satisfy a variety of customer needs in specific market segments, including multiplexing, accuracy, precision, sensitivity, specificity, reduction of labor and ability to test for proteins and nucleic acids. These needs are addressed by the Company’s proprietary technologies.

    Multiplexing, the foundation of the Company, allows the end user in a laboratory to generate multiple laboratory results from a single sample with a single assay. This is important because the Company’s end user customers, which include laboratory professionals performing discovery and research and clinical laboratories performing tests on patients as ordered by physicians and other laboratories, have a fundamental need to perform high quality testing as efficiently as possible. Until the availability of multiplexing technology, the laboratory professional had to perform one assay at a time in a sequential manner, and if additional testing was required on a sample, a second assay would be performed to generate the second result, and so on until all the necessary tests were performed.

    The Company primarily serves the life sciences industries by marketing products, including our specific testing equipment and assays, to various types of testing laboratories. As of December 31, 2020, the Company had 82 strategic partners, 54 of which have released commercialized reagent-based products utilizing the Company’s technology. Luminex and these partners have sold approximately 17,900 xMAP-based instruments in laboratories worldwide as of December 31, 2020, some of which may be retired or otherwise not in use. The Company’s remaining partners are in various stages of development and commercialization of products incorporating the Company’s technology.

    A primary focus for the Company’s growth is the development and sale of molecular diagnostic assays utilizing the Company’s proprietary MultiCode and VERIGENE technologies for use on the Company’s installed base of systems. The Company utilizes a direct sales model for sales of these products, which is intended to take advantage of the Company’s increasing installed base of instruments. Luminex’s assays are primarily focused on multiplexed applications for the human molecular clinical diagnostics market. Luminex’s assays are currently focused on three segments of the molecular diagnostic testing market: infectious disease, personalized medicine and human genetics.

Principles of Consolidation

    The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany transactions and balances have been eliminated upon consolidation.

Use of Estimates

    The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual amounts and results could differ from those estimates, and such differences could be material to the financial statements.

Cash and Cash Equivalents

    Cash and cash equivalents consist of cash deposits and highly liquid investments with original maturities of three months or less when purchased.

Investments

    The Company determines the appropriate classification of its investments in equity securities at the time of purchase and reevaluates such determinations at each balance sheet date.
Fair Value of Financial Instruments

    The fair values of financial instruments are determined by obtaining non-binding market prices from the Company’s third-party portfolio managers on the last day of the quarter, whose sources may use quoted prices in active markets for identical assets or inputs other than quoted prices that are observable either directly or indirectly in determining fair value. The Company’s financial instruments include cash and cash equivalents, short-term investments, accounts receivable, equity-method investments, long-term investments, accounts payable and accrued liabilities. The fair values of these financial instruments were not materially different from their carrying or contract values at December 31, 2020 and 2019. See Note 6 for further details concerning fair value measurements.

Supplemental Cash Flow Statement Information (in thousands)
Year Ended December 31,
 202020192018
Cash paid during the period for taxes$2,141 $1,206 $2,214 
Cash paid during the period for interest and penalties3,969 29 17 
Effect of acquisitions:
Fair value of tangible assets acquired— 2,657 13,262 
Liabilities assumed— (1,915)(5,082)
Cost in excess of fair value of assets acquired— 18 32,647 
Acquired identifiable intangible assets— 609 26,797 
Deferred tax liabilities, net— 731 (4,433)
In-process research and development— (4,016)6,703 
Total purchase price — (1,916)69,894 
Less cash and cash equivalents acquired— — 4,513 
Net cash paid for business acquisition$— $(1,916)$65,381 

Concentration of Credit Risk

    Financial instruments which potentially subject the Company to concentrations of credit risk consist of short-term and long-term investments and trade receivables. The Company provides credit, in the normal course of business, to a number of its customers geographically dispersed primarily throughout the U.S. The Company attempts to limit its credit risk by performing ongoing credit evaluations of its customers and maintaining adequate allowances for potential credit losses, but the Company does not require collateral.

    One customer accounted for 10%, 12% and 14% of our total revenues in 2020, 2019 and 2018, respectively. Another customer accounted for 4%, 5% and 15% of our total revenues in 2020, 2019 and 2018, respectively. No other customer accounted for more than 10% of our total revenues in 2020, 2019 or 2018.
Inventories

    Inventories, consisting primarily of raw materials and purchased components, are stated at the lower of cost or net realizable value, with cost determined according to the standard cost method, which approximates the first-in, first-out method. Net realizable value is defined as the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. As a developer and manufacturer of high technology medical equipment, the Company may be exposed to a number of economic and industry factors that could result in portions of inventory becoming either obsolete or in excess of anticipated usage. These factors include, but are not limited to, technological changes in the Company’s markets, ability to meet changing customer requirements, competitive pressures on products and prices, and reliability and replacement of and the availability of key components from suppliers. The Company’s policy is to establish inventory reserves when conditions exist that suggest that inventory may be in excess of anticipated demand or is obsolete based upon the Company’s assumptions about future demand for products and market conditions. The Company regularly evaluates the ability to realize the value of inventory based on a combination of factors including the following: historical usage rates, forecasted sales or usage, product expiration or end of life dates, estimated current and future market values and new product introductions. Assumptions used in determining the Company’s estimates of future product demand may prove to be incorrect, in which case the provision required for excess and obsolete inventory would have to be adjusted. If inventory is determined to be above the lower of cost or net realizable value, excess or obsolete, the Company would be required to record impairment charges within cost of goods sold at the time of such determination. Although considerable effort is made to ensure the accuracy of forecasts of future product demand, any significant unanticipated changes in demand or expected usage could have a significant negative impact on the value of inventory and the Company’s operating results. When recorded, reserves are intended to reduce the carrying value of inventory to its net realizable value.

Property and Equipment

    Property and equipment are carried at cost less accumulated amounts for amortization and depreciation. Property and equipment are typically amortized or depreciated on a straight-line basis over the useful lives of the assets, which typically range from two to seven years. Leasehold improvements and equipment under capital leases are amortized on a straight-line basis over the shorter of the remaining term of the lease or the estimated useful life of the improvements and equipment. The Company classifies the carrying value of Luminex’s xMAP, ARIES and VERIGENE Systems placed within the reagent rental program and the instruments on loan to customers in property and equipment as “Assets on loan/rental.”

Leases

With the adoption of the new lease guidance effective January 1, 2019, the Company determines whether an agreement represents a lease and at commencement we evaluate each lease agreement to determine whether the lease is an operating or financing lease. The Company recorded an operating lease right-of-use asset and an operating lease liability on its balance sheet. Right-of-use lease assets represent the Company’s right to use the underlying asset for the lease term and the lease obligation represents the Company’s commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. The right-of-use lease asset includes any lease payments made prior to commencement and excludes any lease incentives. The lease term may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or expectations regarding the terms. Variable lease costs such as common area costs and property taxes are expensed as incurred. For all lease agreements we combine lease and non-lease components. Leases with an initial term of twelve months or less are not recorded on the balance sheet.
Goodwill and Other Intangible Assets

    Goodwill represents the excess of the cost over the fair value of the assets of the acquired business. In accordance with Accounting Standards Codification (ASC) 350 “Goodwill and Other” (ASC 350), goodwill is reviewed for impairment at least annually at the beginning of the fourth quarter, or more frequently if impairment indicators arise, tested at our sole reporting unit level. Events or circumstances that could trigger an impairment test include, but are not limited to, a significant adverse change in the business climate, significant changes in our use of the acquired assets, significant negative industry or economic trends, significant under-performance relative to operating performance indicators and significant changes in competition. The Company determined that no triggering events occurred during the year ended December 31, 2020. In 2020 and 2019, the Company estimated the fair value of the reporting unit using a fair-value-based approach based on the market capitalization. Determining the fair value of goodwill is subjective in nature and often involves the use of estimates and assumptions including, without limitation, use of estimates of future prices and volumes for the Company’s products, capital needs, economic trends and other factors which are inherently difficult to forecast. The Company’s annual test did not result in an impairment charge in 2020, as the estimated fair value of the reporting unit continued to exceed the carrying value by a significant enough amount such that any reasonably likely change in the assumptions used in the analysis would not cause the carrying value to exceed the estimated fair value for the reporting unit. No goodwill impairments were recorded in 2020, 2019 or 2018.

    Intangible assets are amortized on a straight-line basis over their respective estimated useful lives ranging from 9 to 15 years. Any in-process research and development will be an indefinite-lived intangible asset until completion or abandonment, at which point it will be accounted for as a finite-lived intangible asset or written off if abandoned.

Impairment of Long-Lived Assets

    Long-lived assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that their net book value may not be recoverable. When such factors and circumstances exist, the Company compares the projected undiscounted future cash flows associated with the related asset or group of assets over their estimated useful lives against their respective carrying amounts. Impairment, if any, is based on the excess of the carrying amount over the fair value of those assets and is recorded in the period in which the determination was made.

Revenue Recognition, Receivables and Allowance for Doubtful Accounts

    Performance Obligations: Revenue is generated primarily from the sale of the Company’s products and related services, which are primarily support and maintenance services on the Company’s systems. The Company recognizes revenue when the customer obtains control of promised products or services, in an amount that reflects the consideration which the Company expects to receive in exchange for these products or services. To determine revenue recognition for arrangements, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract, identifies the performance obligations and assesses whether each promised good or service is distinct. The Company allocates the total transaction price to each performance obligation in an amount based on the estimated relative standalone selling prices of the promised goods or service underlying each performance obligation and recognizes as revenue when such performance obligation is satisfied. Revenue recognition typically occurs upon shipment or delivery to the customer depending upon the shipping terms. We treat shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost. Our customers do not typically have any contractual rights of return outside of our warranty provisions. The Company has allowed few returns to date and believes that returns of its products will be minimal in the future.

    Royalties:  For arrangements that include sales-based royalties, including minimum payments, the Company recognizes revenue at the later of: (i) when the related sales occur, or (ii) when the performance obligation, to which some or all of the royalty has been allocated, has been satisfied. Royalty payments are typically received when our strategic partners report the end-user sales to the Company.
    Reagent Rentals: The Company provides systems and certain other hardware to customers through reagent rental agreements, under which the customers commit to purchasing minimum quantities of assays at a stated price over a defined contract term, which is normally two to three years. Instead of rental payments, the Company recovers the cost of providing the system and other hardware in the amount charged for assays. Revenue is recognized over the defined contract term as assays are shipped. The depreciation costs associated with the system and other hardware are charged to cost of sales on a straight-line basis over the estimated life of the system. The costs to maintain these instruments in the field are charged to cost of sales as incurred. Under the guidance, the Company reclassified the portion of reagent rental revenue associated with the recovery of the cost of providing the system and other hardware in reagent rental agreements from assay revenue to system revenue.

    Warranties: The Company provides a limited, assurance-type warranty, typically for twelve months from installation for the systems sold to end customers and fifteen months for the systems sold to partners. The Company accrues for the estimated cost of initial product warranties at the time revenue is recognized. While the Company engages in product quality programs and processes, the Company’s warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. While the Company believes that adequate reserve has been made in the consolidated financial statements for product warranties, should actual product failure rates, material usage or service delivery costs differ from the Company’s estimates, revisions to the estimated warranty liability would be required. Warranty expenses are evaluated and adjusted periodically.

    License Revenues: The Company enters into out-licensing agreements, under which it licenses certain rights to its technology to third parties. These licenses are typically not distinct, as the customer cannot benefit from the license on its own, and do not have significant standalone functionality, but represent single performance obligations together with the sales of our consumables, systems and assays. The terms of these arrangements typically include payment to the Company of non-refundable, up-front license fees and can extend up to twenty years. Each of these payments results in license revenues which are recognized ratably over time and are included in other revenues, except for revenues from royalties on net sales of licensed products, which are classified as royalty revenues. Deferred revenues related to these out-licensing agreements are shown in contract liabilities in Note 18, “Revenue Recognition”.

    Service Agreements: Revenue from extended service agreements is deferred when payment is received in advance of the performance obligation being satisfied or completed. Luminex provides an integrated service of maintenance and related activities for equipment sold to customers, where the nature of the overall promise is to provide a stand-ready service. As such, the performance obligation is recognized as a series of distinct service periods and the service revenue is recognized ratably over the term of each agreement. The extended service agreements typically range from one to four years and payment is typically received up-front.

    Reserves for Variable Consideration: Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from discounts and any other allowances that are offered within contracts between the Company and its customers relating to the Company’s sales of its products. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable. Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as the Company’s historical experience, current contractual requirements, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of each contract. The amount of variable consideration which is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company will adjust these estimates, which would affect net product revenue and earnings in the period when such variances become known.
    Receivables and Allowance for Doubtful Accounts: We recognize receivables when we have an unconditional right to payment, which represents the amount we expect to collect in a transaction and is most often equal to the transaction price in the contract. The Company adopted the new credit loss standard effective January 1, 2020. The primary impact for the Company was the timing of recording expected credit losses on its trade receivables. The Company’s allowance for doubtful accounts is based upon its expected credit losses, which is based upon its historical loss experience. Management prepared an analysis of partner versus non-partner credit loss experience and noted that its loss experience between partners and non-partners was very comparable. These receivables have been pooled together, as similar risk characteristics exist between them. On the rare occasion that interest is charged on trade receivables, it is recognized when received and there are no related fees and costs. Receivable balances are written off to the allowance for doubtful accounts when, in the judgment of management, they are considered uncollectible. The Company's credit losses have historically been within the Company’s expectations, but there can be no assurance that the Company will continue to experience the same level of credit losses that it has in the past. A significant change in the liquidity or financial position of any one of the Company’s significant customers, or a deterioration in the economic environment in general, could have a material adverse impact on the collectability of the Company’s accounts receivable and its future operating results, including a reduction in future revenues and additional allowances for doubtful accounts.

Product-Related Expenses

    The Company provides for the estimated cost of initial product warranties at the time revenue is recognized. While the Company engages in product quality programs and processes, the Company’s warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. Should actual product failure rates, material usage or service delivery costs differ from the Company’s estimates, revisions to the estimated warranty liability would be required. Shipping and handling costs associated with product sales are included in cost of sales. Advertising costs are charged to operations as incurred. The Company does not have any direct-response advertising.  Advertising expenses, which include trade shows and conventions, were approximately $1.4 million, $3.5 million and $2.8 million for 2020, 2019 and 2018, respectively, and were included in selling, general and administrative expense in the Consolidated Statements of Comprehensive Income.

Research and Development Costs

    Research and development costs are expensed in the period incurred. Nonrefundable advance payments for research and development activities for materials, equipment, facilities and purchased intangible assets that have an alternative future use are deferred and capitalized. In addition, the Company capitalizes certain internally developed products used for evaluation during development projects that also have alternative future uses. These internally developed assets are generally depreciated on a straight-line basis over the useful life of the assets, which range from one to five years.

Foreign Currency Translation

    The financial statements of the Company’s foreign subsidiaries are translated in accordance with ASC 830, “Foreign Currency Matters.” The reporting currency for the Company is the U.S. dollar. With the exception of its Canadian subsidiary, whose functional currency is the U.S. dollar, the functional currency of the Company’s foreign subsidiaries is their local currency. Accordingly, assets and liabilities of these subsidiaries are translated at the exchange rate in effect at each balance sheet date. Before translation, the Company re-measures foreign currency denominated assets and liabilities, including inter-company accounts receivable and payable, into the functional currency of the respective entity, resulting in unrealized gains or losses recorded in selling, general and administrative expenses in the Consolidated Statement of Comprehensive Income. Revenues and expenses are translated using average exchange rates during the respective period. Foreign currency translation adjustments are accumulated as a component of other comprehensive income as a separate component of stockholders’ equity. Gains and losses arising from transactions denominated in foreign currencies are included in selling, general and administrative expenses in the Consolidated Statement of Comprehensive Income and to date have not been material.

Incentive Compensation

    Management incentive plans are tied to various financial and non-financial performance metrics. Bonus accruals made throughout the year related to the various incentive plans are based on management’s best estimate of the achievement of the specific metrics. Adjustments to the accruals are made on a quarterly basis as forecasts of performance are updated. At year-end, the accruals are adjusted to reflect the actual results achieved.
Income Taxes

    The Company accounts for income taxes under the asset and liability method.  Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.  Deferred tax balances are adjusted to reflect tax rates based on currently enacted tax laws, which will be in effect in the years in which the temporary differences are expected to reverse.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period of the enactment date.  A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets unless it is more likely than not that those assets will be realized.

    The Company accounts for uncertain tax positions in accordance with ASC 740, “Income Taxes”, which clarifies the accounting for uncertainty in tax positions. These provisions require recognition of the impact of a tax position in the Company’s financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense.

Earnings Per Share

    Basic net income per share is computed by dividing the net income for the period by the weighted average number of common shares outstanding during the period. Diluted net income per share is computed by dividing the net income for the period by the weighted average number of common shares and potential common shares from outstanding stock options, restricted stock units (RSUs) and contingently issuable shares resulting from an award subject to performance or market conditions determined by applying the treasury stock method. In periods with a net loss, potentially dilutive securities composed of incremental common shares issuable upon the exercise of stock options and warrants, and common shares issuable on conversion of preferred stock, would be excluded from historical diluted loss per share because of their anti-dilutive effect.

Stock-Based Compensation

    The Company accounts for stock-based employee compensation plans under the fair value recognition and measurement provisions of ASC 718 “Stock Compensation” (ASC 718). ASC 718 requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based payments including stock options, restricted stock units and shares issued under the Company’s employee stock purchase plan. Pursuant to ASC 718, stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as expense over the requisite service period.
Business Description and Basis of Presentation [Text Block]
Description of Business

    Luminex Corporation, the “Company” or “Luminex,” develops, manufactures and sells proprietary biological testing technologies and products with applications throughout the life sciences industries, including diagnostics, pharmaceutical and research. These industries depend on a broad range of tests, called assays, to perform diagnostic testing and conduct life science research. The Company established a position in several segments of the life sciences industries by developing and delivering products that satisfy a variety of customer needs in specific market segments, including multiplexing, accuracy, precision, sensitivity, specificity, reduction of labor and ability to test for proteins and nucleic acids. These needs are addressed by the Company’s proprietary technologies.

    Multiplexing, the foundation of the Company, allows the end user in a laboratory to generate multiple laboratory results from a single sample with a single assay. This is important because the Company’s end user customers, which include laboratory professionals performing discovery and research and clinical laboratories performing tests on patients as ordered by physicians and other laboratories, have a fundamental need to perform high quality testing as efficiently as possible. Until the availability of multiplexing technology, the laboratory professional had to perform one assay at a time in a sequential manner, and if additional testing was required on a sample, a second assay would be performed to generate the second result, and so on until all the necessary tests were performed.

    The Company primarily serves the life sciences industries by marketing products, including our specific testing equipment and assays, to various types of testing laboratories. As of December 31, 2020, the Company had 82 strategic partners, 54 of which have released commercialized reagent-based products utilizing the Company’s technology. Luminex and these partners have sold approximately 17,900 xMAP-based instruments in laboratories worldwide as of December 31, 2020, some of which may be retired or otherwise not in use. The Company’s remaining partners are in various stages of development and commercialization of products incorporating the Company’s technology.
    A primary focus for the Company’s growth is the development and sale of molecular diagnostic assays utilizing the Company’s proprietary MultiCode and VERIGENE technologies for use on the Company’s installed base of systems. The Company utilizes a direct sales model for sales of these products, which is intended to take advantage of the Company’s increasing installed base of instruments. Luminex’s assays are primarily focused on multiplexed applications for the human molecular clinical diagnostics market. Luminex’s assays are currently focused on three segments of the molecular diagnostic testing market: infectious disease, personalized medicine and human genetics.
Principles of Consolidation
Principles of Consolidation

    The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany transactions and balances have been eliminated upon consolidation.
Estimates and Assumptions
Use of Estimates

    The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual amounts and results could differ from those estimates, and such differences could be material to the financial statements.
Cash and Cash Equivalents, Policy [Policy Text Block]
Cash and Cash Equivalents

    Cash and cash equivalents consist of cash deposits and highly liquid investments with original maturities of three months or less when purchased.
Investments Investments    The Company determines the appropriate classification of its investments in equity securities at the time of purchase and reevaluates such determinations at each balance sheet date.
Fair Value Measurements
Fair Value of Financial Instruments

    The fair values of financial instruments are determined by obtaining non-binding market prices from the Company’s third-party portfolio managers on the last day of the quarter, whose sources may use quoted prices in active markets for identical assets or inputs other than quoted prices that are observable either directly or indirectly in determining fair value. The Company’s financial instruments include cash and cash equivalents, short-term investments, accounts receivable, equity-method investments, long-term investments, accounts payable and accrued liabilities. The fair values of these financial instruments were not materially different from their carrying or contract values at December 31, 2020 and 2019. See Note 6 for further details concerning fair value measurements.
Concentration Risk, Credit Risk, Policy [Policy Text Block]
Concentration of Credit Risk

    Financial instruments which potentially subject the Company to concentrations of credit risk consist of short-term and long-term investments and trade receivables. The Company provides credit, in the normal course of business, to a number of its customers geographically dispersed primarily throughout the U.S. The Company attempts to limit its credit risk by performing ongoing credit evaluations of its customers and maintaining adequate allowances for potential credit losses, but the Company does not require collateral.
    One customer accounted for 10%, 12% and 14% of our total revenues in 2020, 2019 and 2018, respectively. Another customer accounted for 4%, 5% and 15% of our total revenues in 2020, 2019 and 2018, respectively. No other customer accounted for more than 10% of our total revenues in 2020, 2019 or 2018.
Inventory, Policy [Policy Text Block] Inventories    Inventories, consisting primarily of raw materials and purchased components, are stated at the lower of cost or net realizable value, with cost determined according to the standard cost method, which approximates the first-in, first-out method. Net realizable value is defined as the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. As a developer and manufacturer of high technology medical equipment, the Company may be exposed to a number of economic and industry factors that could result in portions of inventory becoming either obsolete or in excess of anticipated usage. These factors include, but are not limited to, technological changes in the Company’s markets, ability to meet changing customer requirements, competitive pressures on products and prices, and reliability and replacement of and the availability of key components from suppliers. The Company’s policy is to establish inventory reserves when conditions exist that suggest that inventory may be in excess of anticipated demand or is obsolete based upon the Company’s assumptions about future demand for products and market conditions. The Company regularly evaluates the ability to realize the value of inventory based on a combination of factors including the following: historical usage rates, forecasted sales or usage, product expiration or end of life dates, estimated current and future market values and new product introductions. Assumptions used in determining the Company’s estimates of future product demand may prove to be incorrect, in which case the provision required for excess and obsolete inventory would have to be adjusted. If inventory is determined to be above the lower of cost or net realizable value, excess or obsolete, the Company would be required to record impairment charges within cost of goods sold at the time of such determination. Although considerable effort is made to ensure the accuracy of forecasts of future product demand, any significant unanticipated changes in demand or expected usage could have a significant negative impact on the value of inventory and the Company’s operating results. When recorded, reserves are intended to reduce the carrying value of inventory to its net realizable value.
Property, Plant and Equipment, Policy [Policy Text Block]
Property and Equipment

    Property and equipment are carried at cost less accumulated amounts for amortization and depreciation. Property and equipment are typically amortized or depreciated on a straight-line basis over the useful lives of the assets, which typically range from two to seven years. Leasehold improvements and equipment under capital leases are amortized on a straight-line basis over the shorter of the remaining term of the lease or the estimated useful life of the improvements and equipment. The Company classifies the carrying value of Luminex’s xMAP, ARIES and VERIGENE Systems placed within the reagent rental program and the instruments on loan to customers in property and equipment as “Assets on loan/rental.”

Leases
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]
Goodwill and Other Intangible Assets

    Goodwill represents the excess of the cost over the fair value of the assets of the acquired business. In accordance with Accounting Standards Codification (ASC) 350 “Goodwill and Other” (ASC 350), goodwill is reviewed for impairment at least annually at the beginning of the fourth quarter, or more frequently if impairment indicators arise, tested at our sole reporting unit level. Events or circumstances that could trigger an impairment test include, but are not limited to, a significant adverse change in the business climate, significant changes in our use of the acquired assets, significant negative industry or economic trends, significant under-performance relative to operating performance indicators and significant changes in competition. The Company determined that no triggering events occurred during the year ended December 31, 2020. In 2020 and 2019, the Company estimated the fair value of the reporting unit using a fair-value-based approach based on the market capitalization. Determining the fair value of goodwill is subjective in nature and often involves the use of estimates and assumptions including, without limitation, use of estimates of future prices and volumes for the Company’s products, capital needs, economic trends and other factors which are inherently difficult to forecast. The Company’s annual test did not result in an impairment charge in 2020, as the estimated fair value of the reporting unit continued to exceed the carrying value by a significant enough amount such that any reasonably likely change in the assumptions used in the analysis would not cause the carrying value to exceed the estimated fair value for the reporting unit. No goodwill impairments were recorded in 2020, 2019 or 2018.

    Intangible assets are amortized on a straight-line basis over their respective estimated useful lives ranging from 9 to 15 years. Any in-process research and development will be an indefinite-lived intangible asset until completion or abandonment, at which point it will be accounted for as a finite-lived intangible asset or written off if abandoned.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]
Impairment of Long-Lived Assets

    Long-lived assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that their net book value may not be recoverable. When such factors and circumstances exist, the Company compares the projected undiscounted future cash flows associated with the related asset or group of assets over their estimated useful lives against their respective carrying amounts. Impairment, if any, is based on the excess of the carrying amount over the fair value of those assets and is recorded in the period in which the determination was made.
Revenue Recognition, Policy [Policy Text Block] Performance Obligations: Revenue is generated primarily from the sale of the Company’s products and related services, which are primarily support and maintenance services on the Company’s systems. The Company recognizes revenue when the customer obtains control of promised products or services, in an amount that reflects the consideration which the Company expects to receive in exchange for these products or services. To determine revenue recognition for arrangements, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract, identifies the performance obligations and assesses whether each promised good or service is distinct. The Company allocates the total transaction price to each performance obligation in an amount based on the estimated relative standalone selling prices of the promised goods or service underlying each performance obligation and recognizes as revenue when such performance obligation is satisfied. Revenue recognition typically occurs upon shipment or delivery to the customer depending upon the shipping terms. We treat shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost. Our customers do not typically have any contractual rights of return outside of our warranty provisions. The Company has allowed few returns to date and believes that returns of its products will be minimal in the future.     Royalties:  For arrangements that include sales-based royalties, including minimum payments, the Company recognizes revenue at the later of: (i) when the related sales occur, or (ii) when the performance obligation, to which some or all of the royalty has been allocated, has been satisfied. Royalty payments are typically received when our strategic partners report the end-user sales to the Company.
    Reagent Rentals: The Company provides systems and certain other hardware to customers through reagent rental agreements, under which the customers commit to purchasing minimum quantities of assays at a stated price over a defined contract term, which is normally two to three years. Instead of rental payments, the Company recovers the cost of providing the system and other hardware in the amount charged for assays. Revenue is recognized over the defined contract term as assays are shipped. The depreciation costs associated with the system and other hardware are charged to cost of sales on a straight-line basis over the estimated life of the system. The costs to maintain these instruments in the field are charged to cost of sales as incurred. Under the guidance, the Company reclassified the portion of reagent rental revenue associated with the recovery of the cost of providing the system and other hardware in reagent rental agreements from assay revenue to system revenue.

    Warranties: The Company provides a limited, assurance-type warranty, typically for twelve months from installation for the systems sold to end customers and fifteen months for the systems sold to partners. The Company accrues for the estimated cost of initial product warranties at the time revenue is recognized. While the Company engages in product quality programs and processes, the Company’s warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. While the Company believes that adequate reserve has been made in the consolidated financial statements for product warranties, should actual product failure rates, material usage or service delivery costs differ from the Company’s estimates, revisions to the estimated warranty liability would be required. Warranty expenses are evaluated and adjusted periodically.

    License Revenues: The Company enters into out-licensing agreements, under which it licenses certain rights to its technology to third parties. These licenses are typically not distinct, as the customer cannot benefit from the license on its own, and do not have significant standalone functionality, but represent single performance obligations together with the sales of our consumables, systems and assays. The terms of these arrangements typically include payment to the Company of non-refundable, up-front license fees and can extend up to twenty years. Each of these payments results in license revenues which are recognized ratably over time and are included in other revenues, except for revenues from royalties on net sales of licensed products, which are classified as royalty revenues. Deferred revenues related to these out-licensing agreements are shown in contract liabilities in Note 18, “Revenue Recognition”.

    Service Agreements: Revenue from extended service agreements is deferred when payment is received in advance of the performance obligation being satisfied or completed. Luminex provides an integrated service of maintenance and related activities for equipment sold to customers, where the nature of the overall promise is to provide a stand-ready service. As such, the performance obligation is recognized as a series of distinct service periods and the service revenue is recognized ratably over the term of each agreement. The extended service agreements typically range from one to four years and payment is typically received up-front.

    Reserves for Variable Consideration: Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from discounts and any other allowances that are offered within contracts between the Company and its customers relating to the Company’s sales of its products. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable. Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as the Company’s historical experience, current contractual requirements, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of each contract. The amount of variable consideration which is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company will adjust these estimates, which would affect net product revenue and earnings in the period when such variances become known.
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block] Receivables and Allowance for Doubtful Accounts: We recognize receivables when we have an unconditional right to payment, which represents the amount we expect to collect in a transaction and is most often equal to the transaction price in the contract. The Company adopted the new credit loss standard effective January 1, 2020. The primary impact for the Company was the timing of recording expected credit losses on its trade receivables. The Company’s allowance for doubtful accounts is based upon its expected credit losses, which is based upon its historical loss experience. Management prepared an analysis of partner versus non-partner credit loss experience and noted that its loss experience between partners and non-partners was very comparable. These receivables have been pooled together, as similar risk characteristics exist between them. On the rare occasion that interest is charged on trade receivables, it is recognized when received and there are no related fees and costs. Receivable balances are written off to the allowance for doubtful accounts when, in the judgment of management, they are considered uncollectible. The Company's credit losses have historically been within the Company’s expectations, but there can be no assurance that the Company will continue to experience the same level of credit losses that it has in the past. A significant change in the liquidity or financial position of any one of the Company’s significant customers, or a deterioration in the economic environment in general, could have a material adverse impact on the collectability of the Company’s accounts receivable and its future operating results, including a reduction in future revenues and additional allowances for doubtful accounts.
Cost of Sales, Policy [Policy Text Block]
Product-Related Expenses

    The Company provides for the estimated cost of initial product warranties at the time revenue is recognized. While the Company engages in product quality programs and processes, the Company’s warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. Should actual product failure rates, material usage or service delivery costs differ from the Company’s estimates, revisions to the estimated warranty liability would be required. Shipping and handling costs associated with product sales are included in cost of sales. Advertising costs are charged to operations as incurred. The Company does not have any direct-response advertising.  Advertising expenses, which include trade shows and conventions, were approximately $1.4 million, $3.5 million and $2.8 million for 2020, 2019 and 2018, respectively, and were included in selling, general and administrative expense in the Consolidated Statements of Comprehensive Income.
Research and Development Expense, Policy [Policy Text Block]
Research and Development Costs

    Research and development costs are expensed in the period incurred. Nonrefundable advance payments for research and development activities for materials, equipment, facilities and purchased intangible assets that have an alternative future use are deferred and capitalized. In addition, the Company capitalizes certain internally developed products used for evaluation during development projects that also have alternative future uses. These internally developed assets are generally depreciated on a straight-line basis over the useful life of the assets, which range from one to five years.
Foreign Currency Transactions and Translations Policy [Policy Text Block]
Foreign Currency Translation

    The financial statements of the Company’s foreign subsidiaries are translated in accordance with ASC 830, “Foreign Currency Matters.” The reporting currency for the Company is the U.S. dollar. With the exception of its Canadian subsidiary, whose functional currency is the U.S. dollar, the functional currency of the Company’s foreign subsidiaries is their local currency. Accordingly, assets and liabilities of these subsidiaries are translated at the exchange rate in effect at each balance sheet date. Before translation, the Company re-measures foreign currency denominated assets and liabilities, including inter-company accounts receivable and payable, into the functional currency of the respective entity, resulting in unrealized gains or losses recorded in selling, general and administrative expenses in the Consolidated Statement of Comprehensive Income. Revenues and expenses are translated using average exchange rates during the respective period. Foreign currency translation adjustments are accumulated as a component of other comprehensive income as a separate component of stockholders’ equity. Gains and losses arising from transactions denominated in foreign currencies are included in selling, general and administrative expenses in the Consolidated Statement of Comprehensive Income and to date have not been material.
Compensation Related Costs, Policy [Policy Text Block]
Incentive Compensation

    Management incentive plans are tied to various financial and non-financial performance metrics. Bonus accruals made throughout the year related to the various incentive plans are based on management’s best estimate of the achievement of the specific metrics. Adjustments to the accruals are made on a quarterly basis as forecasts of performance are updated. At year-end, the accruals are adjusted to reflect the actual results achieved.
Income Taxes
Income Taxes

    The Company accounts for income taxes under the asset and liability method.  Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.  Deferred tax balances are adjusted to reflect tax rates based on currently enacted tax laws, which will be in effect in the years in which the temporary differences are expected to reverse.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period of the enactment date.  A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets unless it is more likely than not that those assets will be realized.

    The Company accounts for uncertain tax positions in accordance with ASC 740, “Income Taxes”, which clarifies the accounting for uncertainty in tax positions. These provisions require recognition of the impact of a tax position in the Company’s financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense.
Earnings Per Share
Earnings Per Share

    Basic net income per share is computed by dividing the net income for the period by the weighted average number of common shares outstanding during the period. Diluted net income per share is computed by dividing the net income for the period by the weighted average number of common shares and potential common shares from outstanding stock options, restricted stock units (RSUs) and contingently issuable shares resulting from an award subject to performance or market conditions determined by applying the treasury stock method. In periods with a net loss, potentially dilutive securities composed of incremental common shares issuable upon the exercise of stock options and warrants, and common shares issuable on conversion of preferred stock, would be excluded from historical diluted loss per share because of their anti-dilutive effect.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]
Stock-Based Compensation

    The Company accounts for stock-based employee compensation plans under the fair value recognition and measurement provisions of ASC 718 “Stock Compensation” (ASC 718). ASC 718 requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based payments including stock options, restricted stock units and shares issued under the Company’s employee stock purchase plan. Pursuant to ASC 718, stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as expense over the requisite service period.
XML 45 R29.htm IDEA: XBRL DOCUMENT v3.20.4
INVESTMENTS (Tables)
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Investments, Debt and Equity Securities [Abstract]    
Other Investments Not Readily Marketable [Table Text Block]
 20202019
Purchased technology rights (net of accumulated amortization of $8,872 and $8,300 in 2020 and 2019, respectively)$5,454 $6,027 
Minority interest and equity method investments9,909 11,501 
Other1,137 1,594 
 $16,500 $19,122 
  
Marketable Securities [Table Text Block]
 Amortized CostGains in Accumulated Other Comprehensive IncomeLosses in Accumulated Other Comprehensive IncomeEstimated Fair Value
Current:    
Money Market funds$707 $— $— $707 
Total current securities707 — — 707 
Noncurrent:    
Total noncurrent securities— — — — 
Total available-for-sale securities$707 $— $— $707 
 Amortized CostGains in Accumulated Other Comprehensive IncomeLosses in Accumulated Other Comprehensive IncomeEstimated Fair Value
Current:    
Money Market funds$707 $— $— $707 
Total current securities707 — — 707 
Noncurrent:    
Total noncurrent securities— — — — 
Total available-for-sale securities$707 $— $— $707 
Cost-method Investments, Description [Text Block] In August 2018, the Company exercised its purchase option on a second private company and acquired 100% of its capital stock in a non-cash transaction involving (i) a prior investment of $2.0 million being applied to the purchase option, (ii) the forgiveness and application of a $2.4 million note and related interest receivable to the purchase option and (iii) a tax impact of $0.1 million. This acquisition was accounted for as an asset acquisition rather than a business combination, as substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset, a next generation technology. The Company recorded the $4.3 million asset acquisition as a defensive, in-process research and development (IP R&D) intangible asset. There were no gains or losses recognized as part of this transaction.    The Company owned a minority interest in another private company based in the U.S. through its initial investment of $1.0 million in the third quarter of 2012. We were informed that this private company will be dissolving and ceasing operations in the first quarter of 2020. We received cash representing the majority of our investment in the fourth quarter of 2019 and recorded an impairment of $205,000 in Other income, net in the Consolidated Statements of Comprehensive Income during 2019 based upon these circumstances. We received the final cash payment for the remainder of this minority interest in the first quarter of 2020, recorded in cash flows from investing activities in the Consolidated Statements of Cash Flows.    These minority interest investments do not have readily determinable fair values. Therefore, the Company has elected the measurement alternative for its minority interests and the investments are recorded at cost, less any impairment, including changes resulting from observable price changes. The Company regularly evaluates the carrying value of its investment for impairment and whether any events or circumstances are identified that would significantly harm the fair value of the investment. The primary indicators the Company utilizes to identify these events and circumstances are the investee’s ability to remain in business, such as the investee’s liquidity and rate of cash use, and the investee’s ability to secure additional funding and the value of that additional funding. In the event a decline in fair value is less than the investment’s carrying value, the Company will record an impairment charge in Other income, net in the Consolidated Statements of Comprehensive Income. Other than the $205,000 impairment in 2019 discussed above, the Company has not recorded any impairment charges related to these non-marketable investments.  
Investments and Other Noncurrent Assets [Text Block]  
NOTE 2 — INVESTMENTS AND OTHER ASSETS

    Marketable Securities

    The Company determines the appropriate classification of any investments in debt and equity securities at the time of purchase and re-evaluates such determinations at each balance sheet date.

    Available-for-sale securities consisted of the following as of December 31, 2020 (in thousands):
 Amortized CostGains in Accumulated Other Comprehensive IncomeLosses in Accumulated Other Comprehensive IncomeEstimated Fair Value
Current:    
Money Market funds$707 $— $— $707 
Total current securities707 — — 707 
Noncurrent:    
Total noncurrent securities— — — — 
Total available-for-sale securities$707 $— $— $707 
    Available-for-sale securities consisted of the following as of December 31, 2019 (in thousands):
 Amortized CostGains in Accumulated Other Comprehensive IncomeLosses in Accumulated Other Comprehensive IncomeEstimated Fair Value
Current:    
Money Market funds$707 $— $— $707 
Total current securities707 — — 707 
Noncurrent:    
Total noncurrent securities— — — — 
Total available-for-sale securities$707 $— $— $707 
    There were no proceeds from the sales of available-for-sale securities for the years ended December 31, 2020 and December 31, 2019. Realized gains and losses on sales of investments are determined using the specific identification method and are included in other income (expense) in the Consolidated Statement of Comprehensive Income. There were no available-for-sale debt securities as of December 31, 2020 or December 31, 2019.
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Marketable Securities
    The Company determines the appropriate classification of any investments in debt and equity securities at the time of purchase and re-evaluates such determinations at each balance sheet date.

    Available-for-sale securities consisted of the following as of December 31, 2020 (in thousands):
 Amortized CostGains in Accumulated Other Comprehensive IncomeLosses in Accumulated Other Comprehensive IncomeEstimated Fair Value
Current:    
Money Market funds$707 $— $— $707 
Total current securities707 — — 707 
Noncurrent:    
Total noncurrent securities— — — — 
Total available-for-sale securities$707 $— $— $707 
    Available-for-sale securities consisted of the following as of December 31, 2019 (in thousands):
 Amortized CostGains in Accumulated Other Comprehensive IncomeLosses in Accumulated Other Comprehensive IncomeEstimated Fair Value
Current:    
Money Market funds$707 $— $— $707 
Total current securities707 — — 707 
Noncurrent:    
Total noncurrent securities— — — — 
Total available-for-sale securities$707 $— $— $707 
    There were no proceeds from the sales of available-for-sale securities for the years ended December 31, 2020 and December 31, 2019. Realized gains and losses on sales of investments are determined using the specific identification method and are included in other income (expense) in the Consolidated Statement of Comprehensive Income. There were no available-for-sale debt securities as of December 31, 2020 or December 31, 2019. 		 
XML 46 R30.htm IDEA: XBRL DOCUMENT v3.20.4
ACCOUNTS RECEIVABLE (Tables)
 12 Months Ended
Dec. 31, 2020
Receivables [Abstract]  
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]
 20202019
Accounts receivable$68,629 $56,956 
Less: Allowance for doubtful accounts(1,666)(1,141)
 $66,963 $55,815 
Allowance for Credit Losses on Financing Receivables [Table Text Block]
Balance at December 31, 2017$1,345 
Net increases charged to costs and expenses(437)
Write-offs of uncollectible accounts(65)
Balance at December 31, 2018$843 
Net recoveries charged to costs and expenses400 
Write-offs of uncollectible accounts(102)
Balance at December 31, 20191,141 
Net recoveries charged to costs and expenses546 
Write-offs of uncollectible accounts(21)
Balance at December 31, 20201,666 
XML 47 R31.htm IDEA: XBRL DOCUMENT v3.20.4
INVENTORIES (Tables)
 12 Months Ended
Dec. 31, 2020
Inventory Disclosure [Abstract]  
Components of Inventories
 20202019
Parts and supplies$86,380 $45,459 
Work-in-progress18,858 15,532 
Finished goods17,896 16,093 
 $123,134 $77,084 
XML 48 R32.htm IDEA: XBRL DOCUMENT v3.20.4
FAIR VALUE (Tables)
 12 Months Ended
Dec. 31, 2020
Fair Value Disclosures [Abstract]  
Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]
 Fair Value Measurements as of December 31, 2020 Using
 Level 1Level 2Level 3Total
Assets:    
Money Market funds$707 $— $— $707 
 Equity investment$— $— $9,909 $9,909 
XML 49 R33.htm IDEA: XBRL DOCUMENT v3.20.4
PROPERTY, PLANT AND EQUIPMENT (Tables)
 12 Months Ended
Dec. 31, 2020
Property, Plant and Equipment [Abstract]  
Property, Plant and Equipment [Table Text Block]
 20202019
Laboratory equipment$70,189 $60,486 
Leasehold improvements45,784 43,471 
Computer equipment4,034 3,916 
Purchased software22,981 22,621 
Furniture and fixtures6,081 5,924 
Assets on loan/rental32,544 28,946 
181,613 165,364 
Less: Accumulated depreciation(117,467)(99,849)
 $64,146 $65,515 
XML 50 R34.htm IDEA: XBRL DOCUMENT v3.20.4
INTANGIBLE ASSETS (Tables)
 12 Months Ended
Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Intangible Assets and Goodwill [Table Text Block]
 Finite-livedIndefinite-lived 
 Technology, trade secrets and know-howCustomer lists and contractsOther identifiable intangible assetsIP R&DTotal
2019     
Balance as of December 31, 2018$98,469 $23,819 $10,655 $24,013 $156,956 
Flow cytometry acquisition purchase price allocation adjustments(116)(428)1,154 (4,016)(3,406)
Balance as of December 31, 201998,353 23,391 11,809 19,997 153,550 
Less: accumulated amortization:     
Accumulated amortization balance as of December 31, 2018(40,501)(9,036)(2,271)— (51,808)
Amortization expense(7,784)(2,428)(1,194)— (11,406)
Accumulated amortization balance as of December 31, 2019(48,285)(11,464)(3,465)— (63,214)
Net balance as of December 31, 2019$50,068 $11,927 $8,344 $19,997 $90,336 
Weighted average life (in years)111010  
2020     
Balance as of December 31, 2019$98,353 $23,391 $11,809 $19,997 $153,550 
Completion of IPR&D projects2,687 (2,687)— 
Balance as of December 31, 2020101,040 23,391 11,809 17,310 153,550 
Less: accumulated amortization:     
Accumulated amortization balance as of December 31, 2019(48,285)(11,464)(3,465)— (63,214)
Amortization expense(7,919)(2,427)(1,194)— (11,540)
Accumulated amortization balance as of December 31, 2020(56,204)(13,891)(4,659)— (74,754)
Net balance as of December 31, 2020$44,836 $9,500 $7,150 $17,310 $78,796 
Weighted average life (in years)111010  
Estimated Future Amortization Expense Related to Intangible Assets
2020$11,316 
202110,070 
20229,721 
20239,721 
20248,188 
Thereafter12,470 
 $61,486 
XML 51 R35.htm IDEA: XBRL DOCUMENT v3.20.4
ACCRUED LIABILITIES (Tables)
 12 Months Ended
Dec. 31, 2020
Payables and Accruals [Abstract]  
Schedule of Accrued Liabilities [Table Text Block]
20202019
Compensation and employee benefits$33,992 $17,011 
Dividends payable4,711 4,104 
Income and other taxes7,058 1,538 
Warranty costs1,849 1,641 
Royalties payable782 1,335 
Current operating lease liabilities5,942 5,053 
Convertible notes interest payable996 — 
Other1,035 1,190 
$56,365 $31,872 
Schedule of Product Warranty Liability [Table Text Block]
Accrued warranty costs at December 31, 2017$1,308 
Warranty services provided(2,159)
Accrual for warranty costs2,752 
Accrued warranty costs at December 31, 20181,901 
Warranty services provided(2,868)
Accrual for warranty costs2,608 
Accrued warranty costs at December 31, 20191,641 
Warranty services provided(2,362)
Accrual for warranty costs2,570 
Accrued warranty costs at December 31, 2020$1,849 
XML 52 R36.htm IDEA: XBRL DOCUMENT v3.20.4
INCOME TAXES Tables (Tables)
 12 Months Ended
Dec. 31, 2020
Income Tax Disclosure [Abstract]  
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]
 202020192018
Domestic$(33,631)$(31,314)$7,242 
Foreign62,571 21,812 21,069 
Total$28,940 $(9,502)$28,311 
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]
 202020192018
Current:   
Federal$(7)$821 $(3,318)
Foreign6,689 951 515 
State179 (163)600 
Total current expense (benefit)$6,861 $1,609 $(2,203)
Deferred:   
Federal(2,913)(10,179)6,351 
Foreign8,886 4,597 5,271 
State936 (1,691)384 
Total deferred expense (benefit)6,909 (7,273)12,006 
Total provision (benefit) for income taxes$13,770 $(5,664)$9,803 
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]
 Year Ended December 31,
 202020192018
Statutory tax rate21.0 %21.0 %21.0 %
State taxes, net of federal benefit(3.5)%9.6 %3.0 %
Permanent items(2.4)%(1.6)%2.6 %
Effect of foreign operations10.2 %(11.7)%3.4 %
Research and incentive tax credit generated(7.7)%18.9 %(8.7)%
Valuation allowance9.1 %0.8 %0.4 %
Income tax reserves1.0 %67.3 %24.7 %
Remeasurement U.S. deferreds0.0 %0.0 %(0.3)%
Transition tax0.0 %(5.3)%(16.6)%
Foreign earnings withholding tax0.1 %6.6 %(7.9)%
Global intangible low-taxed income18.6 %(44.4)%5.7 %
Other measurement period Tax Act adjustments0.0 %0.0 %2.6 %
Canadian income tax audit0.0 %0.0 %4.8 %
Other1.2 %(1.0)%(0.1)%
 47.6 %60.2 %34.6 %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]
 20202019
Deferred tax assets: 
Accrued liabilities and other$7,479 $4,577 
Net operating loss and credit carryforwards40,966 52,141 
Deferred revenue2,119 1,023 
Operating lease liability4,060 5,023 
Stock compensation and other7,542 7,791 
Bond hedge12,103 — 
Gross deferred tax assets74,269 70,555 
Valuation allowance(16,882)(17,906)
Total deferred tax assets$57,387 $52,649 
Deferred tax liabilities:  
Accrued liabilities and other$(4,230)$(1,287)
Depreciation and amortization(15,710)(18,443)
Operating lease right-of-use assets(3,649)(4,550)
Equity method investment(279)(667)
Convertible debt(12,442)
Total deferred tax liabilities(36,310)(24,947)
Net deferred tax assets$21,077 $27,702 
Summary of Positions for which Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Table Text Block]
20202019
Balance at beginning of year$3,423 $9,721 
Additions based on tax positions related to the current year311 342 
Additions for tax positions of prior years— 398 
Reductions for tax positions of prior years(30)(7,038)
Balance at end of year$3,704 $3,423 
XML 53 R37.htm IDEA: XBRL DOCUMENT v3.20.4
EARNINGS PER SHARE (Tables)
 12 Months Ended
Dec. 31, 2020
Earnings Per Share [Abstract]  
Basic and Diluted Earnings Per Share
 Year Ended December 31,
 202020192018
Basic:   
Net income (loss)$15,170 $(3,838)$18,508 
Less: allocation to participating securities(297)65 (312)
Net income (loss) attributable to common stockholders$14,873 $(3,773)$18,196 
Weighted average common stock outstanding45,102 44,148 43,727 
Net income (loss) per share attributable to common stockholders$0.33 $(0.09)$0.42 
Diluted:   
Net income (loss)$15,170 $(3,838)$18,508 
Less: allocation to participating securities(298)63 (311)
Net income (loss) attributable to common stockholders$14,872 $(3,775)$18,197 
Weighted average common stock outstanding45,102 44,148 43,727 
Effect of dilutive securities: stock options and awards718 — 564 
Weighted-average shares used in computing net income (loss) per share45,820 44,148 44,291 
Net income (loss) per share attributable to common stockholders$0.32 $(0.09)$0.41 
XML 54 R38.htm IDEA: XBRL DOCUMENT v3.20.4
STOCKHOLDERS' EQUITY (Tables)
 12 Months Ended
Dec. 31, 2020
Equity [Abstract]  
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
 202020192018
Dividend yield1.5 %0.9 %1.2 %
Expected volatility0.3 0.4 0.4 
Risk-free rate of return0.9 %2.6 %2.7 %
Expected life of a 10 year contractual term option7 years7 years7 years
Expected life of a 7 year contractual term option4.75 years4.88 years4.88 years
Weighted average fair value at grant date$6.17 $7.69 $8.23 
Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]
 202020192018
Assumptions:
Risk-free interest rates0.18 %2.55 %2.1 %
Expected life0.5 years0.5 years0.5 years
Expected volatility0.34710.350.44
Dividend yield1.454 %0.942 %1.2 %
XML 55 R39.htm IDEA: XBRL DOCUMENT v3.20.4
COMMITMENTS AND CONTINGENCIES (Tables)
 12 Months Ended
Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]
Operating Leases
2021$7,206 
20225,540 
20234,507 
20243,177 
2025945 
Thereafter— 
Total lease payments21,375 
Less: imputed interest(2,067)
Lease liabilities at December 31, 2020$19,308 
XML 56 R40.htm IDEA: XBRL DOCUMENT v3.20.4
ACCOUNTS RECEIVABLE (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Receivables [Abstract]        
Accounts Receivable, Gross, Current $ 68,629 $ 56,956    
Allowance for Doubtful Accounts Receivable (1,666) (1,141) $ (843) $ (1,345)
Allowance for Doubtful Accounts Receivable, Period Increase (Decrease) (546) 400 (437)  
Allowance for Doubtful Accounts Receivable, Write-offs (21) (102) $ (65)  
Accounts Receivable, Net, Current $ 66,963 $ 55,815    
XML 57 R41.htm IDEA: XBRL DOCUMENT v3.20.4
INVENTORIES (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Inventory Disclosure [Abstract]    
Inventory, Raw Materials and Purchased Parts, Net of Reserves $ 86,380 $ 45,459
Inventory, Work in Process, Net of Reserves 18,858 15,532
Inventory, Finished Goods, Net of Reserves 17,896 16,093
Inventory, Net $ 123,134 $ 77,084
XML 58 R42.htm IDEA: XBRL DOCUMENT v3.20.4
FAIR VALUE (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure $ 707 $ 707
Cost Method Investments, Fair Value Disclosure   22
Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure 707 707
Cost Method Investments, Fair Value Disclosure 0 0
Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure 0 0
Cost Method Investments, Fair Value Disclosure 0 0
Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and Cash Equivalents, Fair Value Disclosure $ 0 0
Cost Method Investments, Fair Value Disclosure   $ 22
XML 59 R43.htm IDEA: XBRL DOCUMENT v3.20.4
PROPERTY, PLANT AND EQUIPMENT (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Property, Plant and Equipment [Abstract]    
Property, Plant and Equipment, Gross $ 181,613 $ 165,364
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment (117,467) (99,849)
Depreciation 18,400 16,500
Property, Plant and Equipment, Net $ 64,146 $ 65,515
XML 60 R44.htm IDEA: XBRL DOCUMENT v3.20.4
GOODWILL (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]      
Goodwill $ 118,145 $ 118,145 $ 118,127
Goodwill, Acquired During Period $ 0 $ 18  
XML 61 R45.htm IDEA: XBRL DOCUMENT v3.20.4
INTANGIBLE ASSETS (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Finite-Lived Intangible Assets [Line Items]      
Finite-Lived Intangible Assets, Accumulated Amortization $ (74,754) $ (63,214) $ (51,808)
Indefinite-lived Intangible Assets (Excluding Goodwill) 17,310 19,997 24,013
Finite-Lived Intangible Assets, Amortization Expense, after Year Five 12,470    
Finite-Lived Intangible Assets, Amortization Expense, Year Three 9,721    
Finite-Lived Intangible Assets, Amortization Expense, Year Two 10,070    
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months 11,316    
Finite-Lived Intangible Assets, Amortization Expense, Year Four 9,721    
Finite-Lived Intangible Assets, Amortization Expense, Year Five 8,188    
Intangible Assets, Net (Excluding Goodwill) 78,796 90,336  
Intangible Assets, Gross (Excluding Goodwill) 153,550 153,550 156,956
Indefinite-lived Intangible Assets, Period Increase (Decrease)   (4,016)  
Indefinite-lived Intangible Assets Acquired (2,687)    
Amortization of Intangible Assets (11,542) (11,407) (8,665)
Technology-Based Intangible Assets [Member]      
Finite-Lived Intangible Assets [Line Items]      
Finite-Lived Intangible Assets, Accumulated Amortization (56,204) (48,285) (40,501)
Finite-Lived Intangible Assets, Gross 101,040 98,353 98,469
Finite-Lived Intangible Assets, Net $ 44,836 $ 50,068  
Finite-Lived Intangible Asset, Useful Life 11 years 11 years  
Finite-Lived Intangible Assets, Period Increase (Decrease)   $ (116)  
Finite-lived Intangible Assets Acquired $ 2,687    
Amortization of Intangible Assets (7,919) (7,784)  
Customer-Related Intangible Assets [Member]      
Finite-Lived Intangible Assets [Line Items]      
Finite-Lived Intangible Assets, Accumulated Amortization (13,891) (11,464) (9,036)
Finite-Lived Intangible Assets, Gross 23,391 23,391 23,819
Finite-Lived Intangible Assets, Net $ 9,500 $ 11,927  
Finite-Lived Intangible Asset, Useful Life 10 years 10 years  
Finite-Lived Intangible Assets, Period Increase (Decrease)   $ (428)  
Finite-lived Intangible Assets Acquired    
Amortization of Intangible Assets (2,427) (2,428)  
Other Intangible Assets [Member]      
Finite-Lived Intangible Assets [Line Items]      
Finite-Lived Intangible Assets, Accumulated Amortization (4,659) (3,465) (2,271)
Finite-Lived Intangible Assets, Gross 11,809 11,809 $ 10,655
Finite-Lived Intangible Assets, Net $ 7,150 $ 8,344  
Finite-Lived Intangible Asset, Useful Life 10 years 10 years  
Finite-Lived Intangible Assets, Period Increase (Decrease)   $ 1,154  
Finite-lived Intangible Assets Acquired    
Amortization of Intangible Assets $ (1,194) $ (1,194)  
XML 62 R46.htm IDEA: XBRL DOCUMENT v3.20.4
ACCRUED LIABILITIES (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Payables and Accruals [Abstract]        
Employee-related Liabilities, Current $ 33,992 $ 17,011    
Taxes Payable, Current 7,058 1,538    
Product Warranty Accrual, Current 1,849 1,641 $ 1,901 $ 1,308
Accrued Royalties, Current 782 1,335    
Operating Lease, Liability, Current 5,942 5,053    
Standard and Extended Product Warranty Accrual, Decrease for Payments (2,362) (2,868) (2,159)  
Standard and Extended Product Warranty Accrual, Increase for Warranties Issued 2,570 2,608 $ 2,752  
Dividends Payable, Current 4,711 4,104    
Other Accrued Liabilities, Current 1,035 1,190    
Accrued Liabilities, Current 56,365 31,872    
Interest Payable, Current $ 996 $ 0    
XML 63 R47.htm IDEA: XBRL DOCUMENT v3.20.4
Debt (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Debt Disclosure [Abstract]    
Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate 3.00%  
Debt Instrument, Convertible, Conversion Price $ 43.68  
Long-term Debt, Gross $ 260,000  
Debt Instrument, Unamortized Discount (51,352)  
Unamortized Debt Issuance Expense (5,512)  
Interest Expense, Debt $ 11,473 $ 0
Debt Instrument, Convertible, Remaining Discount Amortization Period 4 years 4 months 24 days  
Debt Instrument, Convertible, Stock Price Trigger $ 69.89  
XML 64 R48.htm IDEA: XBRL DOCUMENT v3.20.4
Income Taxes - Additional Information (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Income Tax Disclosure [Abstract]      
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities $ 7,479 $ 4,577  
Deferred Tax Assets, Operating Loss Carryforwards 40,966 52,141  
Deferred Tax Assets, Deferred Income 2,119 1,023  
Deferred Tax Assets, Tax Deferred Expense, Other 4,060 5,023  
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other 7,542 7,791  
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Other 12,103 0  
Deferred Tax Assets, Gross 74,269 70,555  
Deferred Tax Assets, Valuation Allowance (16,882) (17,906)  
Deferred Tax Assets, Net of Valuation Allowance 57,387 52,649  
Deferred Tax Liabilities, Other (4,230) (1,287)  
Deferred Tax Liabilities, Deferred Expense (15,710) (18,443)  
Deferred Tax Liabilities, Leasing Arrangements (3,649) (4,550)  
Deferred Tax Liabilities, Investment in Noncontrolled Affiliates (279) (667)  
Deferred Tax Liabilities, Gross (36,310) (24,947)  
Unrecognized Tax Benefits 3,423 9,721  
Unrecognized Tax Benefits 3,704 3,423 $ 9,721
Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions 311 342  
Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions 0 398  
Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions (30) (7,038)  
Current Federal Tax Expense (Benefit) (7) 821 (3,318)
Income (Loss) from Continuing Operations before Income Taxes, Domestic $ (33,631) $ (31,314) $ 7,242
Effective tax rate 47.60% 60.20% 34.60%
U.S. federal statutory tax rate 21.00% 21.00% 21.00%
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent (3.50%) 9.60% 3.00%
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent (2.40%) (1.60%) 2.60%
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent 10.20% (11.70%) 3.40%
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent (7.70%) 18.90% (8.70%)
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent 9.10% 0.80% 0.40%
Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent 1.00% 67.30% 24.70%
Effective Income Tax Rate Reconciliation, Deduction, Other, Percent 0.10% 6.60% (7.90%)
Effective Income Tax Rate Reconciliation, Tax Exempt Income, Percent 18.60% (44.40%) 5.70%
Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent 0.00% 0.00% 2.60%
Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent 0.00% (5.30%) (16.60%)
Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 0.00% 0.00% (0.30%)
Effective Income Tax Rate Reconciliation, Tax Settlement, Foreign, Percent 0.00% 0.00% 4.80%
Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent 1.20% (1.00%) (0.10%)
Provision for income taxes $ 13,770 $ (5,664) $ 9,803
Income (Loss) from Continuing Operations before Income Taxes, Foreign 62,571 21,812 21,069
Income (Loss) Attributable to Parent, before Tax 28,940 (9,502) 28,311
Current Foreign Tax Expense (Benefit) 6,689 951 515
Current State and Local Tax Expense (Benefit) 179 (163) 600
Current Income Tax Expense (Benefit) 6,861 1,609 (2,203)
Deferred Federal Income Tax Expense (Benefit) (2,913) (10,179) 6,351
Deferred Foreign Income Tax Expense (Benefit) 8,886 4,597 5,271
Deferred State and Local Income Tax Expense (Benefit) 936 (1,691) 384
Deferred Income Tax Expense (Benefit) 6,909 (7,273) $ 12,006
Deferred Tax Assets, Net $ 21,077 $ 27,702  
XML 65 R49.htm IDEA: XBRL DOCUMENT v3.20.4
EARNINGS PER SHARE Details (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Earnings Per Share [Abstract]                      
Participating Securities, Distributed and Undistributed Earnings (Loss), Basic                 $ (297) $ 65 $ (312)
Net Income (Loss) Available to Common Stockholders, Basic                 $ 14,873 $ (3,773) $ 18,196
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount                 1,620,252 1,271,248 619,113
Net Income (Loss) Available to Common Stockholders, Diluted                 $ 14,872 $ (3,775) $ 18,197
Weighted Average Number of Shares Outstanding, Basic                 45,102,000 44,148,000 43,727,000
Earnings Per Share, Basic $ 0.01 $ 0.04 $ 0.27 $ 0.01 $ 0.08 $ (0.12) $ (0.11) $ 0.07 $ 0.33 $ (0.09) $ 0.42
Net Income (Loss) Attributable to Parent $ 239 $ 1,767 $ 12,510 $ 654 $ 3,383 $ (5,250) $ (4,931) $ 2,960 $ 15,170 $ (3,838) $ 18,508
Participating Securities, Distributed and Undistributed Earnings (Loss), Diluted                 $ (298) $ 63 $ (311)
Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements                 718,000 0 564,000
Weighted Average Number of Shares Outstanding, Diluted                 45,820,000 44,148,000 44,291,000
Earnings Per Share, Diluted $ 0.01 $ 0.04 $ 0.27 $ 0.01 $ 0.07 $ (0.12) $ (0.11) $ 0.07 $ 0.32 $ (0.09) $ 0.41
XML 66 R50.htm IDEA: XBRL DOCUMENT v3.20.4
STOCKHOLDERS' EQUITY Details (Details) - USD ($)
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Document Period End Date Dec. 31, 2020    
Common Stock, Capital Shares Reserved for Future Issuance 6,808,668 8,349,808  
Allocated Share-based Compensation Expense $ 9,200,000 $ 8,200,000 $ 6,200,000
Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount 0    
Proceeds from Stock Options Exercised 18,000,000.0 1,700,000 2,800,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 16,200,000 400,000 1,300,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options 10,500,000    
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options 18,700,000    
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount $ 19,500    
Defined Contribution Plan, Employer Matching Contribution, Percent of Match 50.00%    
Defined Contribution Plan, Administrative Expense $ 5,400,000 $ 5,100,000 $ 4,000,000.0
Stock Issued During Period, Shares, Employee Stock Purchase Plans 758,700 631,553 518,111
Stock Issued During Period, Value, Employee Stock Ownership Plan $ 700,000 $ 600,000 $ 500,000
Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date 15.00%    
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 1.50% 0.90% 1.20%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 30.00% 40.00% 40.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 0.90% 2.60% 2.70%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term 7 years 7 years 7 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term 4 years 9 months 4 years 10 months 17 days 4 years 10 months 17 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value $ 6.17 $ 7.69 $ 8.23
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized 2,400,000    
Restricted Stock Units (RSUs) [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number 570,000 522,000  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms 1 year 1 month 2 days    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 100,000 120,498 95,127
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit $ 23.09 $ 21.01 $ 21.98
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit $ 31.65 $ 24.43 $ 26.39
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (45,000)    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period (7,000)    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term 0 years    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value $ 9,000    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value $ 7,300,000 $ 6,000,000.0 $ 6,700,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition 2 years 2 months 1 day    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested $ 13,000    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term 1 year 18 days    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $ 13,000    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number 563,000    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number 403,000    
Restricted Stock [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number 893,000 810,000  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $ 22.98 $ 22.28  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 416,000 413,967 387,436
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit $ 23.05 $ 20.04 $ 20.33
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit 31.65 $ 24.43 $ 29.33
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value $ 23.26    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (295,000)    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value $ 21.49    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period (38,000)    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value $ 22.65    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value $ 10,600,000 $ 11,900,000 $ 12,700,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition 2 years 6 months 25 days    
Employee Stock Option [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term 3 years    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value $ 6,248,000    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 3,753,000 3,793,000  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price $ 21.25 $ 20.17  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term 4 years 5 months 23 days    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $ 7,633,000    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 1,508,000    
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price $ 23.09    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (998,000)    
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price $ 18.18    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period (550,000)    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price $ 24.43    
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 1.454% 0.942% 1.20%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 34.71% 35.00% 44.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 0.18% 2.55% 2.10%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term 6 months 6 months 6 months
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term 4 years 5 months 12 days    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $ 7,623,000    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number 3,687,000    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $ 21.22    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number 1,519,000    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price $ 19.12    
XML 67 R51.htm IDEA: XBRL DOCUMENT v3.20.4
COMMITMENTS AND CONTINGENCIES (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]      
Operating Lease, Weighted Average Remaining Lease Term 3 years 6 months 7 days 4 years 4 months 9 days  
Lease, Cost $ 9,792 $ 9,434 $ 7,032
Purchase Obligation 68,100    
Recorded Unconditional Purchase Obligation 500    
Operating Leases, Future Minimum Payments Due, Next Twelve Months 7,206    
Operating Leases, Future Minimum Payments, Due in Two Years 5,540    
Operating Leases, Future Minimum Payments, Due in Three Years 4,507    
Operating Leases, Future Minimum Payments, Due in Four Years 3,177    
Operating Leases, Future Minimum Payments, Due in Five Years 945    
Operating Leases, Future Minimum Payments, Due Thereafter 0    
Operating Leases, Future Minimum Payments Due $ 21,375    
Operating Lease, Weighted Average Discount Rate, Percent 5.75% 5.75%  
Unrecorded Unconditional Purchase Obligation, Imputed Interest $ (2,067)    
EXCEL 68 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 69 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 70 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 71 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 83 425 1 false 14 0 false 5 false false R1.htm 0001001 - Document - COVER PAGE Document Sheet http://www.luminexcorp.com/role/COVERPAGEDocument COVER PAGE Document Cover 1 false false R2.htm 1001002 - Statement - BALANCE SHEETS Sheet http://www.luminexcorp.com/role/BALANCESHEETS BALANCE SHEETS Statements 2 false false R3.htm 1002003 - Statement - BALANCE SHEETS (Parenthetical) Sheet http://www.luminexcorp.com/role/BALANCESHEETSParenthetical BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - INCOME STATEMENTS Sheet http://www.luminexcorp.com/role/INCOMESTATEMENTS INCOME STATEMENTS Statements 4 false false R5.htm 1004005 - Statement - INCOME STATEMENTS INCOME STATEMENTS (Parenthetical) Sheet http://www.luminexcorp.com/role/INCOMESTATEMENTSINCOMESTATEMENTSParenthetical INCOME STATEMENTS INCOME STATEMENTS (Parenthetical) Statements 5 false false R6.htm 1005006 - Statement - CASH FLOWS STATEMENTS Sheet http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS CASH FLOWS STATEMENTS Statements 6 false false R7.htm 1006007 - Statement - STOCKHOLDERS' EQUITY STATEMENTS Sheet http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYSTATEMENTS STOCKHOLDERS' EQUITY STATEMENTS Statements 7 false false R8.htm 1108109 - Statement - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) Sheet http://www.luminexcorp.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSS ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) Statements 8 false false R9.htm 1407402 - Statement - INVESTMENTS Details (Details) Sheet http://www.luminexcorp.com/role/INVESTMENTSDetailsDetails INVESTMENTS Details (Details) Statements 9 false false R10.htm 1409409 - Statement - ACCUMULATED OTHER COMPREHENSIVE INCOME Details (Details) Sheet http://www.luminexcorp.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEDetailsDetails ACCUMULATED OTHER COMPREHENSIVE INCOME Details (Details) Statements 10 false false R11.htm 2106102 - Disclosure - Investments, Equity Method and Joint Ventures Sheet http://www.luminexcorp.com/role/InvestmentsEquityMethodandJointVentures Investments, Equity Method and Joint Ventures Notes 11 false false R12.htm 2107103 - Disclosure - ACCOUNTS RECEIVABLE (Notes) Notes http://www.luminexcorp.com/role/ACCOUNTSRECEIVABLENotes ACCOUNTS RECEIVABLE (Notes) Notes 12 false false R13.htm 2110104 - Disclosure - INVENTORIES Sheet http://www.luminexcorp.com/role/INVENTORIES INVENTORIES Notes 13 false false R14.htm 2113105 - Disclosure - FAIR VALUE (Notes) Notes http://www.luminexcorp.com/role/FAIRVALUENotes FAIR VALUE (Notes) Notes 14 false false R15.htm 2116106 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Notes) Notes http://www.luminexcorp.com/role/PROPERTYPLANTANDEQUIPMENTNotes PROPERTY, PLANT AND EQUIPMENT (Notes) Notes 15 false false R16.htm 2119107 - Disclosure - GOODWILL Sheet http://www.luminexcorp.com/role/GOODWILL GOODWILL Notes 16 false false R17.htm 2121108 - Disclosure - INTANGIBLE ASSETS Sheet http://www.luminexcorp.com/role/INTANGIBLEASSETS INTANGIBLE ASSETS Notes 17 false false R18.htm 2124110 - Disclosure - ACCRUED LIABILITIES (Notes) Notes http://www.luminexcorp.com/role/ACCRUEDLIABILITIESNotes ACCRUED LIABILITIES (Notes) Notes 18 false false R19.htm 2127111 - Disclosure - Debt Sheet http://www.luminexcorp.com/role/Debt Debt Notes 19 false false R20.htm 2130112 - Disclosure - INCOME TAXES Sheet http://www.luminexcorp.com/role/INCOMETAXES INCOME TAXES Notes 20 false false R21.htm 2133113 - Disclosure - EARNINGS PER SHARE Sheet http://www.luminexcorp.com/role/EARNINGSPERSHARE EARNINGS PER SHARE Notes 21 false false R22.htm 2136114 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://www.luminexcorp.com/role/STOCKHOLDERSEQUITY STOCKHOLDERS' EQUITY Notes 22 false false R23.htm 2139115 - Disclosure - CONTINGENCIES Sheet http://www.luminexcorp.com/role/CONTINGENCIES CONTINGENCIES Notes 23 false false R24.htm 2142116 - Disclosure - GUARANTEES (Notes) Notes http://www.luminexcorp.com/role/GUARANTEESNotes GUARANTEES (Notes) Notes 24 false false R25.htm 2145117 - Disclosure - GEOGRAPHIC INFORMATION (Notes) Notes http://www.luminexcorp.com/role/GEOGRAPHICINFORMATIONNotes GEOGRAPHIC INFORMATION (Notes) Notes 25 false false R26.htm 2148118 - Disclosure - RECENT ACCOUNTING (Notes) Notes http://www.luminexcorp.com/role/RECENTACCOUNTINGNotes RECENT ACCOUNTING (Notes) Notes 26 false false R27.htm 2151119 - Disclosure - REVENUE RECOGNITION (Notes) Notes http://www.luminexcorp.com/role/REVENUERECOGNITIONNotes REVENUE RECOGNITION (Notes) Notes 27 false false R28.htm 2201201 - Disclosure - ACCOUNTING POLICIES (Policies) Sheet http://www.luminexcorp.com/role/ACCOUNTINGPOLICIESPolicies ACCOUNTING POLICIES (Policies) Policies 28 false false R29.htm 2305301 - Disclosure - INVESTMENTS (Tables) Sheet http://www.luminexcorp.com/role/INVESTMENTSTables INVESTMENTS (Tables) Tables 29 false false R30.htm 2308302 - Disclosure - ACCOUNTS RECEIVABLE (Tables) Sheet http://www.luminexcorp.com/role/ACCOUNTSRECEIVABLETables ACCOUNTS RECEIVABLE (Tables) Tables http://www.luminexcorp.com/role/ACCOUNTSRECEIVABLENotes 30 false false R31.htm 2311303 - Disclosure - INVENTORIES (Tables) Sheet http://www.luminexcorp.com/role/INVENTORIESTables INVENTORIES (Tables) Tables http://www.luminexcorp.com/role/INVENTORIES 31 false false R32.htm 2314304 - Disclosure - FAIR VALUE (Tables) Sheet http://www.luminexcorp.com/role/FAIRVALUETables FAIR VALUE (Tables) Tables http://www.luminexcorp.com/role/FAIRVALUENotes 32 false false R33.htm 2317305 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables) Sheet http://www.luminexcorp.com/role/PROPERTYPLANTANDEQUIPMENTTables PROPERTY, PLANT AND EQUIPMENT (Tables) Tables http://www.luminexcorp.com/role/PROPERTYPLANTANDEQUIPMENTNotes 33 false false R34.htm 2322306 - Disclosure - INTANGIBLE ASSETS (Tables) Sheet http://www.luminexcorp.com/role/INTANGIBLEASSETSTables INTANGIBLE ASSETS (Tables) Tables http://www.luminexcorp.com/role/INTANGIBLEASSETS 34 false false R35.htm 2325307 - Disclosure - ACCRUED LIABILITIES (Tables) Sheet http://www.luminexcorp.com/role/ACCRUEDLIABILITIESTables ACCRUED LIABILITIES (Tables) Tables http://www.luminexcorp.com/role/ACCRUEDLIABILITIESNotes 35 false false R36.htm 2331309 - Disclosure - INCOME TAXES Tables (Tables) Sheet http://www.luminexcorp.com/role/INCOMETAXESTablesTables INCOME TAXES Tables (Tables) Tables 36 false false R37.htm 2334310 - Disclosure - EARNINGS PER SHARE (Tables) Sheet http://www.luminexcorp.com/role/EARNINGSPERSHARETables EARNINGS PER SHARE (Tables) Tables http://www.luminexcorp.com/role/EARNINGSPERSHARE 37 false false R38.htm 2337311 - Disclosure - STOCKHOLDERS' EQUITY (Tables) Sheet http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYTables STOCKHOLDERS' EQUITY (Tables) Tables http://www.luminexcorp.com/role/STOCKHOLDERSEQUITY 38 false false R39.htm 2340312 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) Sheet http://www.luminexcorp.com/role/COMMITMENTSANDCONTINGENCIESTables COMMITMENTS AND CONTINGENCIES (Tables) Tables 39 false false R40.htm 2409403 - Disclosure - ACCOUNTS RECEIVABLE (Details) Sheet http://www.luminexcorp.com/role/ACCOUNTSRECEIVABLEDetails ACCOUNTS RECEIVABLE (Details) Details http://www.luminexcorp.com/role/ACCOUNTSRECEIVABLETables 40 false false R41.htm 2412404 - Disclosure - INVENTORIES (Details) Sheet http://www.luminexcorp.com/role/INVENTORIESDetails INVENTORIES (Details) Details http://www.luminexcorp.com/role/INVENTORIESTables 41 false false R42.htm 2415405 - Disclosure - FAIR VALUE (Details) Sheet http://www.luminexcorp.com/role/FAIRVALUEDetails FAIR VALUE (Details) Details http://www.luminexcorp.com/role/FAIRVALUETables 42 false false R43.htm 2418406 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Details) Sheet http://www.luminexcorp.com/role/PROPERTYPLANTANDEQUIPMENTDetails PROPERTY, PLANT AND EQUIPMENT (Details) Details http://www.luminexcorp.com/role/PROPERTYPLANTANDEQUIPMENTTables 43 false false R44.htm 2420407 - Disclosure - GOODWILL (Details) Sheet http://www.luminexcorp.com/role/GOODWILLDetails GOODWILL (Details) Details http://www.luminexcorp.com/role/GOODWILL 44 false false R45.htm 2423408 - Disclosure - INTANGIBLE ASSETS (Detail) Sheet http://www.luminexcorp.com/role/INTANGIBLEASSETSDetail INTANGIBLE ASSETS (Detail) Details http://www.luminexcorp.com/role/INTANGIBLEASSETSTables 45 false false R46.htm 2426410 - Disclosure - ACCRUED LIABILITIES (Details) Sheet http://www.luminexcorp.com/role/ACCRUEDLIABILITIESDetails ACCRUED LIABILITIES (Details) Details http://www.luminexcorp.com/role/ACCRUEDLIABILITIESTables 46 false false R47.htm 2429411 - Disclosure - Debt (Details) Sheet http://www.luminexcorp.com/role/DebtDetails Debt (Details) Details http://www.luminexcorp.com/role/Debt 47 false false R48.htm 2432412 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://www.luminexcorp.com/role/IncomeTaxesAdditionalInformationDetail Income Taxes - Additional Information (Detail) Details 48 false false R49.htm 2435413 - Disclosure - EARNINGS PER SHARE Details (Details) Sheet http://www.luminexcorp.com/role/EARNINGSPERSHAREDetailsDetails EARNINGS PER SHARE Details (Details) Details 49 false false R50.htm 2438414 - Disclosure - STOCKHOLDERS' EQUITY Details (Details) Sheet http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails STOCKHOLDERS' EQUITY Details (Details) Details 50 false false R51.htm 2441415 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://www.luminexcorp.com/role/COMMITMENTSANDCONTINGENCIESDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://www.luminexcorp.com/role/COMMITMENTSANDCONTINGENCIESTables 51 false false All Reports Book All Reports lmnx-20201231.htm lmnx-12312020xexhibit1053.htm lmnx-12312020xexhibit1054.htm lmnx-12312020xexhibit231.htm lmnx-12312020xexhibit311.htm lmnx-12312020xexhibit312.htm lmnx-12312020xexhibit321.htm lmnx-12312020xexhibit322.htm lmnx-20201231.xsd lmnx-20201231_cal.xml lmnx-20201231_def.xml lmnx-20201231_lab.xml lmnx-20201231_pre.xml lmnx-20201231_g1.jpg lmnx-20201231_g2.jpg http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2020-01-31 true true JSON 74 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "lmnx-20201231.htm": { "axisCustom": 0, "axisStandard": 4, "contextCount": 83, "dts": { "calculationLink": { "local": [ "lmnx-20201231_cal.xml" ] }, "definitionLink": { "local": [ "lmnx-20201231_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "lmnx-20201231.htm" ] }, "labelLink": { "local": [ "lmnx-20201231_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "lmnx-20201231_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml" ] }, "schema": { "local": [ "lmnx-20201231.xsd" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd" ] } }, "elementCount": 439, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 92, "http://xbrl.sec.gov/dei/2019-01-31": 9, "total": 101 }, "keyCustom": 0, "keyStandard": 425, "memberCustom": 0, "memberStandard": 14, "nsprefix": "lmnx", "nsuri": "http://www.luminexcorp.com/20201231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityWellKnownSeasonedIssuer", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - COVER PAGE Document", "role": "http://www.luminexcorp.com/role/COVERPAGEDocument", "shortName": "COVER PAGE Document", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityWellKnownSeasonedIssuer", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i5e0213c224a645fbaa3892f030bb30e8_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1409409 - Statement - ACCUMULATED OTHER COMPREHENSIVE INCOME Details (Details)", "role": "http://www.luminexcorp.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEDetailsDetails", "shortName": "ACCUMULATED OTHER COMPREHENSIVE INCOME Details (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106102 - Disclosure - Investments, Equity Method and Joint Ventures", "role": "http://www.luminexcorp.com/role/InvestmentsEquityMethodandJointVentures", "shortName": "Investments, Equity Method and Joint Ventures", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107103 - Disclosure - ACCOUNTS RECEIVABLE (Notes)", "role": "http://www.luminexcorp.com/role/ACCOUNTSRECEIVABLENotes", "shortName": "ACCOUNTS RECEIVABLE (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110104 - Disclosure - INVENTORIES", "role": "http://www.luminexcorp.com/role/INVENTORIES", "shortName": "INVENTORIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113105 - Disclosure - FAIR VALUE (Notes)", "role": "http://www.luminexcorp.com/role/FAIRVALUENotes", "shortName": "FAIR VALUE (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116106 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Notes)", "role": "http://www.luminexcorp.com/role/PROPERTYPLANTANDEQUIPMENTNotes", "shortName": "PROPERTY, PLANT AND EQUIPMENT (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2119107 - Disclosure - GOODWILL", "role": "http://www.luminexcorp.com/role/GOODWILL", "shortName": "GOODWILL", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2121108 - Disclosure - INTANGIBLE ASSETS", "role": "http://www.luminexcorp.com/role/INTANGIBLEASSETS", "shortName": "INTANGIBLE ASSETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2124110 - Disclosure - ACCRUED LIABILITIES (Notes)", "role": "http://www.luminexcorp.com/role/ACCRUEDLIABILITIESNotes", "shortName": "ACCRUED LIABILITIES (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2127111 - Disclosure - Debt", "role": "http://www.luminexcorp.com/role/Debt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i5e0213c224a645fbaa3892f030bb30e8_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - BALANCE SHEETS", "role": "http://www.luminexcorp.com/role/BALANCESHEETS", "shortName": "BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i5e0213c224a645fbaa3892f030bb30e8_I20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OtherAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2130112 - Disclosure - INCOME TAXES", "role": "http://www.luminexcorp.com/role/INCOMETAXES", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2133113 - Disclosure - EARNINGS PER SHARE", "role": "http://www.luminexcorp.com/role/EARNINGSPERSHARE", "shortName": "EARNINGS PER SHARE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2136114 - Disclosure - STOCKHOLDERS' EQUITY", "role": "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITY", "shortName": "STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2139115 - Disclosure - CONTINGENCIES", "role": "http://www.luminexcorp.com/role/CONTINGENCIES", "shortName": "CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GuaranteesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2142116 - Disclosure - GUARANTEES (Notes)", "role": "http://www.luminexcorp.com/role/GUARANTEESNotes", "shortName": "GUARANTEES (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GuaranteesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2145117 - Disclosure - GEOGRAPHIC INFORMATION (Notes)", "role": "http://www.luminexcorp.com/role/GEOGRAPHICINFORMATIONNotes", "shortName": "GEOGRAPHIC INFORMATION (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2148118 - Disclosure - RECENT ACCOUNTING (Notes)", "role": "http://www.luminexcorp.com/role/RECENTACCOUNTINGNotes", "shortName": "RECENT ACCOUNTING (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueRecognitionDeferredRevenue", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2151119 - Disclosure - REVENUE RECOGNITION (Notes)", "role": "http://www.luminexcorp.com/role/REVENUERECOGNITIONNotes", "shortName": "REVENUE RECOGNITION (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueRecognitionDeferredRevenue", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2201201 - Disclosure - ACCOUNTING POLICIES (Policies)", "role": "http://www.luminexcorp.com/role/ACCOUNTINGPOLICIESPolicies", "shortName": "ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherInvestmentsNotReadilyMarketableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - INVESTMENTS (Tables)", "role": "http://www.luminexcorp.com/role/INVESTMENTSTables", "shortName": "INVESTMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherInvestmentsNotReadilyMarketableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i5e0213c224a645fbaa3892f030bb30e8_I20201231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - BALANCE SHEETS (Parenthetical)", "role": "http://www.luminexcorp.com/role/BALANCESHEETSParenthetical", "shortName": "BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "div", "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308302 - Disclosure - ACCOUNTS RECEIVABLE (Tables)", "role": "http://www.luminexcorp.com/role/ACCOUNTSRECEIVABLETables", "shortName": "ACCOUNTS RECEIVABLE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "div", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311303 - Disclosure - INVENTORIES (Tables)", "role": "http://www.luminexcorp.com/role/INVENTORIESTables", "shortName": "INVENTORIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2314304 - Disclosure - FAIR VALUE (Tables)", "role": "http://www.luminexcorp.com/role/FAIRVALUETables", "shortName": "FAIR VALUE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2317305 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables)", "role": "http://www.luminexcorp.com/role/PROPERTYPLANTANDEQUIPMENTTables", "shortName": "PROPERTY, PLANT AND EQUIPMENT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2322306 - Disclosure - INTANGIBLE ASSETS (Tables)", "role": "http://www.luminexcorp.com/role/INTANGIBLEASSETSTables", "shortName": "INTANGIBLE ASSETS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2325307 - Disclosure - ACCRUED LIABILITIES (Tables)", "role": "http://www.luminexcorp.com/role/ACCRUEDLIABILITIESTables", "shortName": "ACCRUED LIABILITIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2331309 - Disclosure - INCOME TAXES Tables (Tables)", "role": "http://www.luminexcorp.com/role/INCOMETAXESTablesTables", "shortName": "INCOME TAXES Tables (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2334310 - Disclosure - EARNINGS PER SHARE (Tables)", "role": "http://www.luminexcorp.com/role/EARNINGSPERSHARETables", "shortName": "EARNINGS PER SHARE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2337311 - Disclosure - STOCKHOLDERS' EQUITY (Tables)", "role": "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYTables", "shortName": "STOCKHOLDERS' EQUITY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2340312 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)", "role": "http://www.luminexcorp.com/role/COMMITMENTSANDCONTINGENCIESTables", "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "ic3cac44c62f7442190932d1f1a7379a1_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - INCOME STATEMENTS", "role": "http://www.luminexcorp.com/role/INCOMESTATEMENTS", "shortName": "INCOME STATEMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "ic3cac44c62f7442190932d1f1a7379a1_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "div", "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i5e0213c224a645fbaa3892f030bb30e8_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccountsReceivableGrossCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409403 - Disclosure - ACCOUNTS RECEIVABLE (Details)", "role": "http://www.luminexcorp.com/role/ACCOUNTSRECEIVABLEDetails", "shortName": "ACCOUNTS RECEIVABLE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "div", "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i5e0213c224a645fbaa3892f030bb30e8_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccountsReceivableGrossCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i5e0213c224a645fbaa3892f030bb30e8_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsAndPurchasedPartsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412404 - Disclosure - INVENTORIES (Details)", "role": "http://www.luminexcorp.com/role/INVENTORIESDetails", "shortName": "INVENTORIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i5e0213c224a645fbaa3892f030bb30e8_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsAndPurchasedPartsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i5e0213c224a645fbaa3892f030bb30e8_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415405 - Disclosure - FAIR VALUE (Details)", "role": "http://www.luminexcorp.com/role/FAIRVALUEDetails", "shortName": "FAIR VALUE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i5e0213c224a645fbaa3892f030bb30e8_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i5e0213c224a645fbaa3892f030bb30e8_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418406 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Details)", "role": "http://www.luminexcorp.com/role/PROPERTYPLANTANDEQUIPMENTDetails", "shortName": "PROPERTY, PLANT AND EQUIPMENT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i5e0213c224a645fbaa3892f030bb30e8_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:GoodwillDisclosureTextBlock", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i5e0213c224a645fbaa3892f030bb30e8_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420407 - Disclosure - GOODWILL (Details)", "role": "http://www.luminexcorp.com/role/GOODWILLDetails", "shortName": "GOODWILL (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:GoodwillDisclosureTextBlock", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i83681890f3e84ca4bc7853c27a826aef_I20181231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i5e0213c224a645fbaa3892f030bb30e8_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423408 - Disclosure - INTANGIBLE ASSETS (Detail)", "role": "http://www.luminexcorp.com/role/INTANGIBLEASSETSDetail", "shortName": "INTANGIBLE ASSETS (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i5e0213c224a645fbaa3892f030bb30e8_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i5e0213c224a645fbaa3892f030bb30e8_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426410 - Disclosure - ACCRUED LIABILITIES (Details)", "role": "http://www.luminexcorp.com/role/ACCRUEDLIABILITIESDetails", "shortName": "ACCRUED LIABILITIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i5e0213c224a645fbaa3892f030bb30e8_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i5e0213c224a645fbaa3892f030bb30e8_I20201231", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtPercentageBearingFixedInterestRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429411 - Disclosure - Debt (Details)", "role": "http://www.luminexcorp.com/role/DebtDetails", "shortName": "Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i5e0213c224a645fbaa3892f030bb30e8_I20201231", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtPercentageBearingFixedInterestRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i5e0213c224a645fbaa3892f030bb30e8_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2432412 - Disclosure - Income Taxes - Additional Information (Detail)", "role": "http://www.luminexcorp.com/role/IncomeTaxesAdditionalInformationDetail", "shortName": "Income Taxes - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i5e0213c224a645fbaa3892f030bb30e8_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2435413 - Disclosure - EARNINGS PER SHARE Details (Details)", "role": "http://www.luminexcorp.com/role/EARNINGSPERSHAREDetailsDetails", "shortName": "EARNINGS PER SHARE Details (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingExpenses", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - INCOME STATEMENTS INCOME STATEMENTS (Parenthetical)", "role": "http://www.luminexcorp.com/role/INCOMESTATEMENTSINCOMESTATEMENTSParenthetical", "shortName": "INCOME STATEMENTS INCOME STATEMENTS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R50": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentPeriodEndDate", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2438414 - Disclosure - STOCKHOLDERS' EQUITY Details (Details)", "role": "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails", "shortName": "STOCKHOLDERS' EQUITY Details (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i5e0213c224a645fbaa3892f030bb30e8_I20201231", "decimals": "0", "lang": "en-US", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i5e0213c224a645fbaa3892f030bb30e8_I20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2441415 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "role": "http://www.luminexcorp.com/role/COMMITMENTSANDCONTINGENCIESDetails", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i5e0213c224a645fbaa3892f030bb30e8_I20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - CASH FLOWS STATEMENTS", "role": "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS", "shortName": "CASH FLOWS STATEMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i524b745eb4994e668324c47c08ddbf42_I20171231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - STOCKHOLDERS' EQUITY STATEMENTS", "role": "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYSTATEMENTS", "shortName": "STOCKHOLDERS' EQUITY STATEMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i524b745eb4994e668324c47c08ddbf42_I20171231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1108109 - Statement - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)", "role": "http://www.luminexcorp.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSS", "shortName": "ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i8f9840ebabb044608049a7c731d49619_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentPeriodEndDate", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1407402 - Statement - INVESTMENTS Details (Details)", "role": "http://www.luminexcorp.com/role/INVESTMENTSDetailsDetails", "shortName": "INVESTMENTS Details (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfOtherInvestmentsNotReadilyMarketableTextBlock", "div", "body", "html" ], "baseRef": "lmnx-20201231.htm", "contextRef": "i5e0213c224a645fbaa3892f030bb30e8_I20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OtherLongTermInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } } }, "segmentCount": 14, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.luminexcorp.com/role/COVERPAGEDocument" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.luminexcorp.com/role/COVERPAGEDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.luminexcorp.com/role/COVERPAGEDocument" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r459" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.luminexcorp.com/role/COVERPAGEDocument" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.luminexcorp.com/role/COVERPAGEDocument" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.luminexcorp.com/role/COVERPAGEDocument" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.luminexcorp.com/role/COVERPAGEDocument", "http://www.luminexcorp.com/role/INVESTMENTSDetailsDetails", "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r458" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.luminexcorp.com/role/COVERPAGEDocument" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.luminexcorp.com/role/COVERPAGEDocument" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.luminexcorp.com/role/COVERPAGEDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.luminexcorp.com/role/COVERPAGEDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.luminexcorp.com/role/COVERPAGEDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.luminexcorp.com/role/COVERPAGEDocument" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r460" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.luminexcorp.com/role/COVERPAGEDocument" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.luminexcorp.com/role/COVERPAGEDocument" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.luminexcorp.com/role/COVERPAGEDocument" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r460" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.luminexcorp.com/role/COVERPAGEDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.luminexcorp.com/role/COVERPAGEDocument" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r460" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.luminexcorp.com/role/COVERPAGEDocument" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.luminexcorp.com/role/COVERPAGEDocument" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r461" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.luminexcorp.com/role/COVERPAGEDocument" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.luminexcorp.com/role/COVERPAGEDocument" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r460" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.luminexcorp.com/role/COVERPAGEDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r460" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.luminexcorp.com/role/COVERPAGEDocument" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r460" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.luminexcorp.com/role/COVERPAGEDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r460" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.luminexcorp.com/role/COVERPAGEDocument" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.luminexcorp.com/role/COVERPAGEDocument" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.luminexcorp.com/role/COVERPAGEDocument" ], "xbrltype": "yesNoItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.luminexcorp.com/role/COVERPAGEDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.luminexcorp.com/role/COVERPAGEDocument" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.luminexcorp.com/role/COVERPAGEDocument" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.luminexcorp.com/role/COVERPAGEDocument" ], "xbrltype": "tradingSymbolItemType" }, "lmnx_COVERPAGEAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "COVER PAGE [Abstract]", "label": "COVER PAGE [Abstract]", "terseLabel": "COVER PAGE [Abstract]" } } }, "localname": "COVERPAGEAbstract", "nsuri": "http://www.luminexcorp.com/20201231", "xbrltype": "stringItemType" }, "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Changes and Error Corrections [Abstract]", "terseLabel": "Accounting Changes and Error Corrections [Abstract]" } } }, "localname": "AccountingChangesAndErrorCorrectionsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r41" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/ACCRUEDLIABILITIESNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r40" ], "calculation": { "http://www.luminexcorp.com/role/BALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/BALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableGrossCurrent": { "auth_ref": [ "r181", "r182" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, before Allowance for Credit Loss, Current", "terseLabel": "Accounts Receivable, Gross, Current" } } }, "localname": "AccountsReceivableGrossCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/ACCOUNTSRECEIVABLEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r4", "r20", "r181", "r182" ], "calculation": { "http://www.luminexcorp.com/role/BALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts Receivable, Net, Current" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/ACCOUNTSRECEIVABLEDetails", "http://www.luminexcorp.com/role/BALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r44" ], "calculation": { "http://www.luminexcorp.com/role/BALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued Liabilities, Current" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/ACCRUEDLIABILITIESDetails", "http://www.luminexcorp.com/role/BALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedRoyaltiesCurrent": { "auth_ref": [ "r7", "r8", "r44" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Royalties, Current", "terseLabel": "Accrued Royalties, Current" } } }, "localname": "AccruedRoyaltiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/ACCRUEDLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r38", "r227" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTerseLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "terseLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/BALANCESHEETSParenthetical", "http://www.luminexcorp.com/role/PROPERTYPLANTANDEQUIPMENTDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": { "auth_ref": [ "r55", "r58", "r59", "r60", "r376" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.", "label": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax", "terseLabel": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEDetailsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r23", "r58", "r59", "r60", "r430", "r446", "r449" ], "calculation": { "http://www.luminexcorp.com/role/BALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEDetailsDetails", "http://www.luminexcorp.com/role/BALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r380", "r381", "r382", "r383", "r384", "r386" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEDetailsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r57", "r60", "r61", "r111", "r112", "r113", "r364", "r442", "r443" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "verboseLabel": "Accumulated other comprehensive Income (loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYSTATEMENTS" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r21", "r309" ], "calculation": { "http://www.luminexcorp.com/role/BALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional Paid in Capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/BALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r111", "r112", "r113", "r305", "r306", "r307" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYSTATEMENTS" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt": { "auth_ref": [ "r244" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.", "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt", "terseLabel": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of subsequent adjustments to additional paid in capital for convertible financial instruments where a component of equity and a component of debt are recognized.", "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments", "terseLabel": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid-in capital (APIC) for recognition of cost for employee stock purchase program (ESPP) award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition", "terseLabel": "ESPP" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r270", "r272", "r312", "r313" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r243", "r251", "r252" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "terseLabel": "Adjustments to Additional Paid in Capital, Warrant Issued" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/COVERPAGEDocument", "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r272", "r300", "r311" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Allocated Share-based Compensation Expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock": { "auth_ref": [ "r183", "r200" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allowance for credit loss on financing receivable.", "label": "Financing Receivable, Allowance for Credit Loss [Table Text Block]", "terseLabel": "Allowance for Credit Losses on Financing Receivables [Table Text Block]" } } }, "localname": "AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/ACCOUNTSRECEIVABLETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r184", "r196", "r197", "r199" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss", "negatedTerseLabel": "Allowance for Doubtful Accounts Receivable" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/ACCOUNTSRECEIVABLEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r27", "r184", "r196" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/BALANCESHEETSParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease": { "auth_ref": [ "r200" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease)", "terseLabel": "Allowance for Doubtful Accounts Receivable, Period Increase (Decrease)" } } }, "localname": "AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/ACCOUNTSRECEIVABLEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": { "auth_ref": [ "r198" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.", "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff", "negatedTerseLabel": "Allowance for Doubtful Accounts Receivable, Write-offs" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/ACCOUNTSRECEIVABLEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r76", "r97", "r389" ], "calculation": { "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of Debt Issuance Costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r97", "r211", "r219" ], "calculation": { "http://www.luminexcorp.com/role/INCOMESTATEMENTS": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "negatedTerseLabel": "Amortization of Intangible Assets", "terseLabel": "Amortization of Intangible Assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INCOMESTATEMENTS", "http://www.luminexcorp.com/role/INTANGIBLEASSETSDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r144" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/EARNINGSPERSHAREDetailsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r105", "r166", "r169", "r175", "r191", "r361", "r365", "r378", "r413", "r428" ], "calculation": { "http://www.luminexcorp.com/role/BALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/BALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/BALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r6", "r54", "r105", "r191", "r361", "r365", "r378" ], "calculation": { "http://www.luminexcorp.com/role/BALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/BALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/BALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r273", "r303" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r110", "r160" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Business Description and Accounting Policies [Text Block]", "terseLabel": "Business Description and Accounting Policies [Text Block]" } } }, "localname": "BusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/ACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r1", "r110", "r160" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]", "terseLabel": "Business Description and Basis of Presentation [Text Block]" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/ACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r34", "r99" ], "calculation": { "http://www.luminexcorp.com/role/BALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash and cash equivalents, end of period", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/BALANCESHEETS", "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash and Cash Equivalents, Fair Value Disclosure" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/FAIRVALUEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": { "auth_ref": [], "calculation": { "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.", "label": "Cash and Cash Equivalents, Period Increase (Decrease)", "totalLabel": "Net change in cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r11", "r100", "r102" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents, Policy [Policy Text Block]" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/ACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r231", "r232", "r235", "r236" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies Disclosure [Text Block]" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/CONTINGENCIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Common Stock, Capital Shares Reserved for Future Issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r252" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Common Stock, Dividends, Per Share, Declared" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INCOMESTATEMENTS" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r111", "r112" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYSTATEMENTS" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common Stock, Par or Stated Value Per Share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/BALANCESHEETSParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/BALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common Stock, Shares, Issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/BALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r19", "r251" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common Stock, Shares, Outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/BALANCESHEETSParenthetical", "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYSTATEMENTS" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValueOutstanding": { "auth_ref": [ "r19" ], "calculation": { "http://www.luminexcorp.com/role/BALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.", "label": "Common Stock, Value, Outstanding", "terseLabel": "Common Stock, Value, Outstanding" } } }, "localname": "CommonStockValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/BALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "auth_ref": [ "r101", "r276" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.", "label": "Compensation Related Costs, Policy [Policy Text Block]", "terseLabel": "Compensation Related Costs, Policy [Policy Text Block]" } } }, "localname": "CompensationRelatedCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/ACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r64", "r66", "r67", "r74", "r420", "r438" ], "calculation": { "http://www.luminexcorp.com/role/INCOMESTATEMENTS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INCOMESTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r73", "r84", "r419", "r437" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "Comprehensive Income (Loss) Note [Text Block]" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r154", "r424" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration Risk, Credit Risk, Policy [Policy Text Block]" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/ACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r102", "r363" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/ACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r254", "r255", "r256" ], "calculation": { "http://www.luminexcorp.com/role/BALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Short-term unearned revenue" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/BALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r254", "r255", "r256" ], "calculation": { "http://www.luminexcorp.com/role/BALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Contract with Customer, Liability, Noncurrent", "terseLabel": "Long-term unearned revenue" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/BALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostMethodInvestmentsDescriptionTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments accounted for under the cost-method. The carrying amount of such investments may be adjusted, for example, distributions in excess of cost (return of capital) or for other-than-temporary impairments. The cost method and lower-of-cost or market, an adaptation of the cost method, is generally followed for most investments in noncontrolled corporations, in some corporate joint ventures, and to a lesser extent in unconsolidated subsidiaries in which the entity does not have the ability to exercise significant influence.", "label": "Cost-method Investments, Description [Text Block]", "terseLabel": "Cost-method Investments, Description [Text Block]" } } }, "localname": "CostMethodInvestmentsDescriptionTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INVESTMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_CostMethodInvestmentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of investments accounted under the cost method.", "label": "Cost Method Investments, Fair Value Disclosure", "terseLabel": "Cost Method Investments, Fair Value Disclosure" } } }, "localname": "CostMethodInvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/FAIRVALUEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r79", "r403" ], "calculation": { "http://www.luminexcorp.com/role/INCOMESTATEMENTS": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of Goods and Services Sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INCOMESTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesPolicyTextBlock": { "auth_ref": [ "r261" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.", "label": "Cost of Goods and Service [Policy Text Block]", "terseLabel": "Cost of Sales, Policy [Policy Text Block]" } } }, "localname": "CostOfSalesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/ACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r106", "r339", "r349" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Federal Tax Expense (Benefit)", "terseLabel": "Current Federal Tax Expense (Benefit)" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r108", "r339" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Foreign Tax Expense (Benefit)", "terseLabel": "Current Foreign Tax Expense (Benefit)" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r106", "r339", "r349", "r351" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense (Benefit)", "terseLabel": "Current Income Tax Expense (Benefit)" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r106", "r339", "r349" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "Current State and Local Tax Expense (Benefit)" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerRelatedIntangibleAssetsMember": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "Customer-related asset, including, but not limited to, customer lists, and noncontractual customer relationships.", "label": "Customer-Related Intangible Assets [Member]", "terseLabel": "Customer-Related Intangible Assets [Member]" } } }, "localname": "CustomerRelatedIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INTANGIBLEASSETSDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r15", "r245", "r415", "r426" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "terseLabel": "Long-term Debt, Gross" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r248" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price", "terseLabel": "Debt Instrument, Convertible, Conversion Price" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/DebtDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Convertible, Remaining Discount Amortization Period", "terseLabel": "Debt Instrument, Convertible, Remaining Discount Amortization Period" } } }, "localname": "DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/DebtDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtInstrumentConvertibleStockPriceTrigger": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of the entity's common stock which would be required to be attained for the conversion feature embedded in the debt instrument to become effective.", "label": "Debt Instrument, Convertible, Stock Price Trigger", "terseLabel": "Debt Instrument, Convertible, Stock Price Trigger" } } }, "localname": "DebtInstrumentConvertibleStockPriceTrigger", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/DebtDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r388", "r390" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "negatedTerseLabel": "Debt Instrument, Unamortized Discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r106", "r340", "r349" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal Income Tax Expense (Benefit)", "terseLabel": "Deferred Federal Income Tax Expense (Benefit)" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r106", "r340", "r349" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Foreign Income Tax Expense (Benefit)", "terseLabel": "Deferred Foreign Income Tax Expense (Benefit)" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r320", "r321" ], "calculation": { "http://www.luminexcorp.com/role/BALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred Income Tax Assets, Net" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/BALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r97", "r106", "r340", "r349", "r350", "r351" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred Income Tax Expense (Benefit)" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r16", "r17", "r331", "r414", "r425" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "negatedTerseLabel": "Deferred Tax Liabilities, Gross" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r106", "r340", "r349" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "terseLabel": "Deferred State and Local Income Tax Expense (Benefit)" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsDeferredIncome": { "auth_ref": [ "r337", "r338" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.", "label": "Deferred Tax Assets, Deferred Income", "terseLabel": "Deferred Tax Assets, Deferred Income" } } }, "localname": "DeferredTaxAssetsDeferredIncome", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r332" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "terseLabel": "Deferred Tax Assets, Gross" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r334" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "terseLabel": "Deferred Tax Assets, Net" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r334" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "terseLabel": "Deferred Tax Assets, Net of Valuation Allowance" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r337", "r338" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Deferred Tax Assets, Operating Loss Carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther": { "auth_ref": [ "r337", "r338" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from compensation and benefits, classified as other.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Other", "terseLabel": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Other" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther": { "auth_ref": [ "r337", "r338" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other.", "label": "Deferred Tax Assets, Tax Deferred Expense, Other", "terseLabel": "Deferred Tax Assets, Tax Deferred Expense, Other" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": { "auth_ref": [ "r337", "r338" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities", "terseLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther": { "auth_ref": [ "r337", "r338" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other", "terseLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r333" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedTerseLabel": "Deferred Tax Assets, Valuation Allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesDeferredExpense": { "auth_ref": [ "r337", "r338" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from capitalized costs.", "label": "Deferred Tax Liabilities, Deferred Expense", "negatedTerseLabel": "Deferred Tax Liabilities, Deferred Expense" } } }, "localname": "DeferredTaxLiabilitiesDeferredExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates": { "auth_ref": [ "r337", "r338" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from investments in unconsolidated subsidiaries and investments in other affiliates which are not controlled nor consolidated.", "label": "Deferred Tax Liabilities, Investment in Noncontrolled Affiliates", "negatedTerseLabel": "Deferred Tax Liabilities, Investment in Noncontrolled Affiliates" } } }, "localname": "DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": { "auth_ref": [ "r337", "r338" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.", "label": "Deferred Tax Liabilities, Leasing Arrangements", "negatedTerseLabel": "Deferred Tax Liabilities, Leasing Arrangements" } } }, "localname": "DeferredTaxLiabilitiesLeasingArrangements", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesOther": { "auth_ref": [ "r337", "r338" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.", "label": "Deferred Tax Liabilities, Other", "negatedTerseLabel": "Deferred Tax Liabilities, Other" } } }, "localname": "DeferredTaxLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome": { "auth_ref": [ "r337", "r338" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from tax deferred revenue or income classified as other.", "label": "Deferred Tax Liabilities, Tax Deferred Income", "negatedTerseLabel": "Deferred Tax Liabilities, Tax Deferred Income" } } }, "localname": "DeferredTaxLiabilitiesTaxDeferredIncome", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanAdministrativeExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of administrative expense incurred by defined contribution plan.", "label": "Defined Contribution Plan, Administrative Expense", "terseLabel": "Defined Contribution Plan, Administrative Expense" } } }, "localname": "DefinedContributionPlanAdministrativeExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage employer matches of the employee's percentage contribution matched.", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match", "terseLabel": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Maximum amount the employee may contribute to a defined contribution plan.", "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount", "terseLabel": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount" } } }, "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r97", "r225" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/PROPERTYPLANTANDEQUIPMENTDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r97", "r163" ], "calculation": { "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation, Depletion and Amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted": { "auth_ref": [ "r130" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a new accounting pronouncement that has been issued but not yet adopted.", "label": "Description of New Accounting Pronouncements Not yet Adopted [Text Block]", "terseLabel": "Description of New Accounting Pronouncements Not yet Adopted [Text Block]" } } }, "localname": "DescriptionOfNewAccountingPronouncementsNotYetAdopted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/RECENTACCOUNTINGNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITY" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Text Block [Abstract]", "terseLabel": "Disclosure Text Block [Abstract]" } } }, "localname": "DisclosureTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/RECENTACCOUNTINGDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r252" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "Dividends, Common Stock, Cash", "negatedLabel": "Common stock cash dividends" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPayableCurrent": { "auth_ref": [ "r8", "r44" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Dividends Payable, Current", "terseLabel": "Dividends Payable, Current" } } }, "localname": "DividendsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/ACCRUEDLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INCOMESTATEMENTS" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r75", "r120", "r121", "r122", "r123", "r124", "r131", "r134", "r141", "r142", "r143", "r147", "r148", "r421", "r439" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Earnings Per Share, Basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/EARNINGSPERSHAREDetailsDetails", "http://www.luminexcorp.com/role/INCOMESTATEMENTS" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r75", "r120", "r121", "r122", "r123", "r124", "r134", "r141", "r142", "r143", "r147", "r148", "r421", "r439" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Earnings Per Share, Diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/EARNINGSPERSHAREDetailsDetails", "http://www.luminexcorp.com/role/INCOMESTATEMENTS" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r102", "r144", "r145" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Earnings Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/ACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r144", "r145", "r146", "r149" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "EARNINGS PER SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/EARNINGSPERSHARE" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": { "auth_ref": [ "r379" ], "calculation": { "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS": { "order": 4.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.", "label": "Effect of Exchange Rate on Cash and Cash Equivalents", "terseLabel": "Effect of foreign exchange rates on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateOnCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r323", "r353" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "U.S. federal statutory tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r323", "r353" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "terseLabel": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": { "auth_ref": [ "r323", "r353" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.", "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent", "terseLabel": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther": { "auth_ref": [ "r323", "r353" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other deductions.", "label": "Effective Income Tax Rate Reconciliation, Deduction, Other, Percent", "terseLabel": "Effective Income Tax Rate Reconciliation, Deduction, Other, Percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationDeductionsOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r323", "r353" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent", "terseLabel": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": { "auth_ref": [ "r323", "r353" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent", "terseLabel": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r323", "r353" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "terseLabel": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.", "label": "Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent", "terseLabel": "Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes": { "auth_ref": [ "r323", "r353" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.", "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent", "terseLabel": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings": { "auth_ref": [ "r323", "r353" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the repatriation of foreign earnings.", "label": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent", "terseLabel": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r323", "r353" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "terseLabel": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": { "auth_ref": [ "r323", "r353" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent", "negatedTerseLabel": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome": { "auth_ref": [ "r323", "r353" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income (loss) exempt from income taxes.", "label": "Effective Income Tax Rate Reconciliation, Tax Exempt Income, Percent", "terseLabel": "Effective Income Tax Rate Reconciliation, Tax Exempt Income, Percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxExemptIncome", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign": { "auth_ref": [ "r323", "r353" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax settlement.", "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Foreign, Percent", "terseLabel": "Effective Income Tax Rate Reconciliation, Tax Settlement, Foreign, Percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r44" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Employee-related Liabilities, Current" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/ACCRUEDLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": { "auth_ref": [ "r301" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost capitalized for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Amount Capitalized", "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r302" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r302" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Employee Stock Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r111", "r112", "r113", "r117", "r125", "r127", "r151", "r193", "r251", "r252", "r305", "r306", "r307", "r342", "r343", "r380", "r381", "r382", "r383", "r384", "r386", "r442", "r443", "r444" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYSTATEMENTS" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Method Investments and Joint Ventures [Abstract]" } } }, "localname": "EquityMethodInvestmentsAndJointVenturesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": { "auth_ref": [ "r192" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.", "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]", "terseLabel": "Equity Method Investments and Joint Ventures Disclosure" } } }, "localname": "EquityMethodInvestmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/InvestmentsEquityMethodandJointVentures" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/FAIRVALUEDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r367", "r368", "r369", "r373" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/FAIRVALUEDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r367", "r368" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.", "label": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]", "terseLabel": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/FAIRVALUETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r368", "r400", "r401", "r402" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/FAIRVALUEDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r367", "r368", "r370", "r371", "r374" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/FAIRVALUEDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Disclosures [Text Block]" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/FAIRVALUENotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r262", "r263", "r268", "r269", "r368", "r400" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/FAIRVALUEDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r262", "r263", "r268", "r269", "r368", "r401" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/FAIRVALUEDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r368", "r402" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/FAIRVALUEDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Fair Value, Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/FAIRVALUEDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r400", "r401", "r402" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/FAIRVALUEDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r102", "r375", "r377" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/ACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Finite-Lived Intangible Asset, Useful Life" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INTANGIBLEASSETSDetail" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r218" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Finite-Lived Intangible Assets, Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INTANGIBLEASSETSDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, after Year Five" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INTANGIBLEASSETSDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r220" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INTANGIBLEASSETSDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r220" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Year Five" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INTANGIBLEASSETSDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r220" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Year Four" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INTANGIBLEASSETSDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r220" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Year Three" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INTANGIBLEASSETSDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r220" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Year Two" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INTANGIBLEASSETSDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r212", "r215", "r218", "r222", "r404", "r408" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INTANGIBLEASSETSDetail", "http://www.luminexcorp.com/role/INVESTMENTSDetailsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r218", "r408" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Finite-Lived Intangible Assets, Gross" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INTANGIBLEASSETSDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INTANGIBLEASSETSDetail", "http://www.luminexcorp.com/role/INVESTMENTSDetailsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r212", "r217" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INTANGIBLEASSETSDetail", "http://www.luminexcorp.com/role/INVESTMENTSDetailsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r218", "r404" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Finite-Lived Intangible Assets, Net", "verboseLabel": "Finite-Lived Intangible Assets, Net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INTANGIBLEASSETSDetail", "http://www.luminexcorp.com/role/INVESTMENTSDetailsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Period Increase (Decrease)", "terseLabel": "Finite-Lived Intangible Assets, Period Increase (Decrease)" } } }, "localname": "FiniteLivedIntangibleAssetsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INTANGIBLEASSETSDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "auth_ref": [ "r213" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.", "label": "Finite-lived Intangible Assets Acquired", "terseLabel": "Finite-lived Intangible Assets Acquired" } } }, "localname": "FinitelivedIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INTANGIBLEASSETSDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r102", "r387" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency Transactions and Translations Policy [Policy Text Block]" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/ACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r97" ], "calculation": { "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedTerseLabel": "Gain (Loss) on Disposition of Property Plant Equipment" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r205", "r206", "r411" ], "calculation": { "http://www.luminexcorp.com/role/BALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/BALANCESHEETS", "http://www.luminexcorp.com/role/GOODWILLDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r207" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "terseLabel": "Goodwill, Acquired During Period" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/GOODWILLDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "auth_ref": [ "r102", "r208" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "terseLabel": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]" } } }, "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/ACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillDisclosureTextBlock": { "auth_ref": [ "r209" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill.", "label": "Goodwill Disclosure [Text Block]", "terseLabel": "Goodwill Disclosure [Text Block]" } } }, "localname": "GoodwillDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/GOODWILL" ], "xbrltype": "textBlockItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r78", "r105", "r166", "r168", "r171", "r174", "r176", "r191", "r378" ], "calculation": { "http://www.luminexcorp.com/role/INCOMESTATEMENTS": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross margin" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INCOMESTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_GuaranteesAndProductWarrantiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Guarantees and Product Warranties [Abstract]", "terseLabel": "Guarantees and Product Warranties [Abstract]" } } }, "localname": "GuaranteesAndProductWarrantiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_GuaranteesTextBlock": { "auth_ref": [ "r242" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for each guarantee obligation, or each group of similar guarantee obligations, including (a) the nature of the guarantee, including its term, how it arose, and the events or circumstances that would require the guarantor to perform under the guarantee; (b) the maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee; (c) the current carrying amount of the liability, if any, for the guarantor's obligations under the guarantee; and (d) the nature of any recourse provisions under the guarantee, and any assets held either as collateral or by third parties, and any relevant related party disclosure. Excludes disclosures about product warranties.", "label": "Guarantees [Text Block]", "terseLabel": "Guarantees [Text Block]" } } }, "localname": "GuaranteesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/GUARANTEESNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r102", "r224", "r229" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/ACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossAttributableToParent": { "auth_ref": [ "r80" ], "calculation": { "http://www.luminexcorp.com/role/INCOMESTATEMENTS": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.", "label": "Income (Loss) Attributable to Parent, before Tax", "terseLabel": "Income (Loss) Attributable to Parent, before Tax", "totalLabel": "Income (Loss) Attributable to Parent, before Tax" } } }, "localname": "IncomeLossAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INCOMESTATEMENTS", "http://www.luminexcorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r107", "r352" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "terseLabel": "Income (Loss) from Continuing Operations before Income Taxes, Domestic" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r107", "r352" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "terseLabel": "Income (Loss) from Continuing Operations before Income Taxes, Foreign" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r71", "r97", "r164", "r189", "r417", "r435" ], "calculation": { "http://www.luminexcorp.com/role/INCOMESTATEMENTS": { "order": 2.0, "parentTag": "us-gaap_IncomeLossAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Income (Loss) from Equity Method Investments", "terseLabel": "Income (Loss) from Equity Method Investments" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INCOMESTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions": { "auth_ref": [ "r97" ], "calculation": { "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.", "label": "Income (Loss) from Equity Method Investments, Net of Dividends or Distributions", "negatedTerseLabel": "Income (Loss) from Equity Method Investments, Net of Dividends or Distributions" } } }, "localname": "IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r324", "r329", "r336", "r347", "r354", "r356", "r357", "r358" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Tax Disclosure [Text Block]" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INCOMETAXES" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r106", "r126", "r127", "r165", "r322", "r348", "r355", "r441" ], "calculation": { "http://www.luminexcorp.com/role/INCOMESTATEMENTS": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedTerseLabel": "Provision for income taxes", "terseLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INCOMESTATEMENTS", "http://www.luminexcorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r68", "r102", "r318", "r319", "r329", "r330", "r335", "r341", "r451" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/ACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r96" ], "calculation": { "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r96" ], "calculation": { "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r96" ], "calculation": { "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Unearned revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": { "auth_ref": [ "r96" ], "calculation": { "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.", "label": "Increase (Decrease) in Deferred Income Taxes", "negatedTerseLabel": "Increase (Decrease) in Deferred Income Taxes" } } }, "localname": "IncreaseDecreaseInDeferredIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r96" ], "calculation": { "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r96" ], "calculation": { "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedTerseLabel": "Operating Assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r96" ], "calculation": { "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Operating Liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r135", "r136", "r137", "r143" ], "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/EARNINGSPERSHAREDetailsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r214", "r221" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INTANGIBLEASSETSDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r221" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Indefinite-lived Intangible Assets (Excluding Goodwill)" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INTANGIBLEASSETSDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r214", "r221" ], "lang": { "en-us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INTANGIBLEASSETSDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease": { "auth_ref": [ "r221" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets, Period Increase (Decrease)", "terseLabel": "Indefinite-lived Intangible Assets, Period Increase (Decrease)" } } }, "localname": "IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INTANGIBLEASSETSDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefinitelivedIntangibleAssetsAcquired": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition.", "label": "Indefinite-lived Intangible Assets Acquired", "terseLabel": "Indefinite-lived Intangible Assets Acquired" } } }, "localname": "IndefinitelivedIntangibleAssetsAcquired", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INTANGIBLEASSETSDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r223" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible Assets Disclosure [Text Block]" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INTANGIBLEASSETS" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.", "label": "Intangible Assets, Gross (Excluding Goodwill)", "terseLabel": "Intangible Assets, Gross (Excluding Goodwill)" } } }, "localname": "IntangibleAssetsGrossExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INTANGIBLEASSETSDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r210", "r216" ], "calculation": { "http://www.luminexcorp.com/role/BALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible Assets, Net (Excluding Goodwill)" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/BALANCESHEETS", "http://www.luminexcorp.com/role/INTANGIBLEASSETSDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r83", "r249" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "terseLabel": "Interest Expense, Debt" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r8", "r9", "r44" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest Payable, Current", "terseLabel": "Interest Payable, Current" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/ACCRUEDLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]", "terseLabel": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r204" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "INVENTORIES" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INVENTORIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r29", "r203" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Inventory, Finished Goods, Net of Reserves" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INVENTORIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r3", "r51" ], "calculation": { "http://www.luminexcorp.com/role/BALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory, Net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/BALANCESHEETS", "http://www.luminexcorp.com/role/INVENTORIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r10", "r52", "r102", "r150", "r201", "r202", "r204" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventory, Policy [Policy Text Block]" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/ACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterialsAndPurchasedPartsNetOfReserves": { "auth_ref": [ "r31", "r203" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of items purchased for use as components of a finished product or pieces of machinery and equipment plus any items in their natural and unrefined state. This element may be used when the reporting entity combines raw materials and purchased parts into an aggregate amount.", "label": "Inventory, Raw Materials and Purchased Parts, Net of Reserves", "terseLabel": "Inventory, Raw Materials and Purchased Parts, Net of Reserves" } } }, "localname": "InventoryRawMaterialsAndPurchasedPartsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INVENTORIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r30", "r203" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Inventory, Work in Process, Net of Reserves" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INVENTORIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r190", "r440" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/ACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments and other noncurrent assets.", "label": "Investments and Other Noncurrent Assets [Text Block]", "terseLabel": "Investments and Other Noncurrent Assets [Text Block]" } } }, "localname": "InvestmentsAndOtherNoncurrentAssetsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INVESTMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]", "terseLabel": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r188", "r409", "r423", "r450" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INVESTMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r398", "r399" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "terseLabel": "Lease, Cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r43", "r105", "r170", "r191", "r362", "r365", "r366", "r378" ], "calculation": { "http://www.luminexcorp.com/role/BALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/BALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r26", "r105", "r191", "r378", "r416", "r432" ], "calculation": { "http://www.luminexcorp.com/role/BALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Liabilities and Equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/BALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/BALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r45", "r105", "r191", "r362", "r365", "r366", "r378" ], "calculation": { "http://www.luminexcorp.com/role/BALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/BALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/BALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LicensingAgreementsMember": { "auth_ref": [ "r360" ], "lang": { "en-us": { "role": { "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).", "label": "Licensing Agreements [Member]", "terseLabel": "Licensing Agreements [Member]" } } }, "localname": "LicensingAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INVESTMENTSDetailsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": { "auth_ref": [ "r187" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.", "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]", "terseLabel": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]" } } }, "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/ACCOUNTSRECEIVABLENotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r15", "r246", "r415", "r429" ], "calculation": { "http://www.luminexcorp.com/role/BALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "terseLabel": "Long-term Debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/BALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtPercentageBearingFixedInterestRate": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate.", "label": "Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate", "terseLabel": "Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate" } } }, "localname": "LongTermDebtPercentageBearingFixedInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/DebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r250" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-term Debt [Text Block]", "terseLabel": "Long-term Debt" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_MarketableSecuritiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.", "label": "Marketable Securities [Table Text Block]", "terseLabel": "Marketable Securities [Table Text Block]" } } }, "localname": "MarketableSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INVESTMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r93" ], "calculation": { "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS": { "order": 2.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r93" ], "calculation": { "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS": { "order": 3.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r93", "r94", "r98" ], "calculation": { "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS": { "order": 1.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash from operations" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r0", "r62", "r65", "r72", "r98", "r105", "r116", "r120", "r121", "r122", "r123", "r126", "r127", "r139", "r166", "r168", "r171", "r174", "r176", "r191", "r378", "r418", "r436" ], "calculation": { "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.luminexcorp.com/role/INCOMESTATEMENTS": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net Income (Loss) Attributable to Parent" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS", "http://www.luminexcorp.com/role/EARNINGSPERSHAREDetailsDetails", "http://www.luminexcorp.com/role/INCOMESTATEMENTS", "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r120", "r121", "r122", "r123", "r131", "r132", "r140", "r143", "r166", "r168", "r171", "r174", "r176" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net Income (Loss) Available to Common Stockholders, Basic" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/EARNINGSPERSHAREDetailsDetails", "http://www.luminexcorp.com/role/INCOMESTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r133", "r140", "r143" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "terseLabel": "Net Income (Loss) Available to Common Stockholders, Diluted" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/EARNINGSPERSHAREDetailsDetails", "http://www.luminexcorp.com/role/INCOMESTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r114", "r115", "r118", "r119", "r128", "r129", "r130", "r194", "r195", "r257", "r258", "r259", "r260", "r308", "r344", "r345", "r346", "r405", "r406", "r407", "r445", "r446", "r447", "r448", "r449" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.", "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]", "terseLabel": "New Accounting Pronouncements and Changes in Accounting Principles [Text Block]" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/RECENTACCOUNTINGNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r82" ], "calculation": { "http://www.luminexcorp.com/role/INCOMESTATEMENTS": { "order": 3.0, "parentTag": "us-gaap_IncomeLossAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "terseLabel": "Other income, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INCOMESTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.luminexcorp.com/role/INCOMESTATEMENTS": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "terseLabel": "Operating Expenses", "totalLabel": "Operating Expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INCOMESTATEMENTS", "http://www.luminexcorp.com/role/INCOMESTATEMENTSINCOMESTATEMENTSParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r166", "r168", "r171", "r174", "r176" ], "calculation": { "http://www.luminexcorp.com/role/INCOMESTATEMENTS": { "order": 1.0, "parentTag": "us-gaap_IncomeLossAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Operating Income (Loss)", "totalLabel": "Operating income" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INCOMESTATEMENTS", "http://www.luminexcorp.com/role/INCOMESTATEMENTSINCOMESTATEMENTSParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r395" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating Lease, Liability, Current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/ACCRUEDLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r395" ], "calculation": { "http://www.luminexcorp.com/role/BALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating Lease, Liability, Noncurrent" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/BALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r394" ], "calculation": { "http://www.luminexcorp.com/role/BALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating Lease, Right-of-Use Asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/BALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r397", "r399" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Operating Lease, Weighted Average Discount Rate, Percent" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r396", "r399" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": { "auth_ref": [ "r391", "r392" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.", "label": "Operating Leases, Future Minimum Payments Due", "terseLabel": "Operating Leases, Future Minimum Payments Due" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": { "auth_ref": [ "r391", "r392" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months", "terseLabel": "Operating Leases, Future Minimum Payments Due, Next Twelve Months" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": { "auth_ref": [ "r391", "r392" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Five Years", "terseLabel": "Operating Leases, Future Minimum Payments, Due in Five Years" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": { "auth_ref": [ "r391", "r392" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Four Years", "terseLabel": "Operating Leases, Future Minimum Payments, Due in Four Years" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r391", "r392" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Three Years", "terseLabel": "Operating Leases, Future Minimum Payments, Due in Three Years" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r391", "r392" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Two Years", "terseLabel": "Operating Leases, Future Minimum Payments, Due in Two Years" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": { "auth_ref": [ "r391", "r392" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due Thereafter", "terseLabel": "Operating Leases, Future Minimum Payments, Due Thereafter" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r7", "r8", "r9", "r44" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other Accrued Liabilities, Current" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/ACCRUEDLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r53" ], "calculation": { "http://www.luminexcorp.com/role/BALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/BALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r39" ], "calculation": { "http://www.luminexcorp.com/role/BALANCESHEETS": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other Assets, Noncurrent" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/BALANCESHEETS", "http://www.luminexcorp.com/role/INVESTMENTSDetailsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location in other comprehensive income.", "label": "Other Comprehensive Income Location [Axis]", "terseLabel": "Other Comprehensive Income Location [Axis]" } } }, "localname": "OtherComprehensiveIncomeLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEDetailsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in other comprehensive income.", "label": "Other Comprehensive Income Location [Domain]", "terseLabel": "Other Comprehensive Income Location [Domain]" } } }, "localname": "OtherComprehensiveIncomeLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEDetailsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r55" ], "calculation": { "http://www.luminexcorp.com/role/INCOMESTATEMENTS": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INCOMESTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r63", "r66", "r69", "r73", "r251", "r380", "r385", "r386", "r419", "r437" ], "calculation": { "http://www.luminexcorp.com/role/INCOMESTATEMENTS": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Other Comprehensive Income (Loss), Net of Tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEDetailsDetails", "http://www.luminexcorp.com/role/INCOMESTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r56", "r58" ], "calculation": { "http://www.luminexcorp.com/role/INCOMESTATEMENTS": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "terseLabel": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INCOMESTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intangible assets classified as other.", "label": "Other Intangible Assets [Member]", "terseLabel": "Other Intangible Assets [Member]" } } }, "localname": "OtherIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INTANGIBLEASSETSDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r47" ], "calculation": { "http://www.luminexcorp.com/role/BALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/BALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLongTermInvestments": { "auth_ref": [ "r35", "r434" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term investments classified as other.", "label": "Other Long-term Investments", "terseLabel": "Other Long-term Investments" } } }, "localname": "OtherLongTermInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INVESTMENTSDetailsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "auth_ref": [], "calculation": { "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).", "label": "Other Operating Activities, Cash Flow Statement", "terseLabel": "Other Operating Activities, Cash Flow Statement" } } }, "localname": "OtherOperatingActivitiesCashFlowStatement", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic": { "auth_ref": [ "r138", "r140" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of earnings (loss) distributed and earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.", "label": "Participating Securities, Distributed and Undistributed Earnings (Loss), Basic", "terseLabel": "Participating Securities, Distributed and Undistributed Earnings (Loss), Basic" } } }, "localname": "ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/EARNINGSPERSHAREDetailsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted": { "auth_ref": [ "r140" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of earnings (loss) distributed and earnings (loss) allocated to participating securities for the diluted earnings (loss) per share or per unit calculation under the two-class method.", "label": "Participating Securities, Distributed and Undistributed Earnings (Loss), Diluted", "terseLabel": "Participating Securities, Distributed and Undistributed Earnings (Loss), Diluted" } } }, "localname": "ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/EARNINGSPERSHAREDetailsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]", "terseLabel": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsForHedgeFinancingActivities": { "auth_ref": [ "r92", "r95" ], "calculation": { "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a financial contract that meets the hedge criteria as either cash flow hedge, fair value hedge or hedge of net investment in foreign operations.", "label": "Payments for Hedge, Financing Activities", "negatedTerseLabel": "Payments for Hedge, Financing Activities" } } }, "localname": "PaymentsForHedgeFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromPreviousAcquisition": { "auth_ref": [ "r109" ], "calculation": { "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net cash inflow or outflow associated with the aggregate amount of adjustment to the purchase price of a previous acquisition.", "label": "Payments for (Proceeds from) Previous Acquisition", "negatedTerseLabel": "Payments for (Proceeds from) Previous Acquisition" } } }, "localname": "PaymentsForProceedsFromPreviousAcquisition", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r91" ], "calculation": { "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "Payments of Ordinary Dividends, Common Stock", "negatedTerseLabel": "Common stock cash dividends paid" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r91" ], "calculation": { "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "negatedTerseLabel": "Payments Related to Tax Withholding for Share-based Compensation" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r87" ], "calculation": { "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedTerseLabel": "Payments to Acquire Businesses, Net of Cash Acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireEquityMethodInvestments": { "auth_ref": [ "r87" ], "calculation": { "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.", "label": "Payments to Acquire Equity Method Investments", "terseLabel": "Payments to Acquire Equity Method Investments" } } }, "localname": "PaymentsToAcquireEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r88" ], "calculation": { "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedTerseLabel": "Payments to Acquire Intangible Assets" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireNotesReceivable": { "auth_ref": [ "r86" ], "calculation": { "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.", "label": "Payments to Acquire Notes Receivable", "negatedTerseLabel": "Payments to Acquire Notes Receivable" } } }, "localname": "PaymentsToAcquireNotesReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r88" ], "calculation": { "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedTerseLabel": "Additions to property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred Stock, Par or Stated Value Per Share" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/BALANCESHEETSParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred Stock, Shares Authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/BALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred Stock, Shares Issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/BALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred Stock, Shares Outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/BALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockTextBlock": { "auth_ref": [ "r253" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.", "label": "Preferred Stock [Text Block]", "terseLabel": "Preferred Stock [Text Block]" } } }, "localname": "PreferredStockTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITY" ], "xbrltype": "textBlockItemType" }, "us-gaap_PreferredStockValueOutstanding": { "auth_ref": [ "r18" ], "calculation": { "http://www.luminexcorp.com/role/BALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.", "label": "Preferred Stock, Value, Outstanding", "terseLabel": "Preferred Stock, Value, Outstanding" } } }, "localname": "PreferredStockValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/BALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent": { "auth_ref": [ "r14", "r412", "r427" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Noncurrent", "terseLabel": "Prepaid Expense and Other Assets, Noncurrent" } } }, "localname": "PrepaidExpenseAndOtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INVESTMENTSDetailsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r90" ], "calculation": { "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from Convertible Debt", "terseLabel": "Proceeds from Convertible Debt" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r89" ], "calculation": { "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Common stock issued" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "auth_ref": [ "r89" ], "calculation": { "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).", "label": "Proceeds from Issuance of Warrants", "terseLabel": "Proceeds from Issuance of Warrants" } } }, "localname": "ProceedsFromIssuanceOfWarrants", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsToMinorityShareholders": { "auth_ref": [ "r109" ], "calculation": { "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from (to) a noncontrolling interest. Excludes dividends paid to the noncontrolling interest.", "label": "Proceeds from (Payments to) Noncontrolling Interests", "terseLabel": "Proceeds from (Payments to) Noncontrolling Interests" } } }, "localname": "ProceedsFromPaymentsToMinorityShareholders", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfProductiveAssets": { "auth_ref": [ "r85" ], "calculation": { "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "Proceeds from Sale of Productive Assets", "terseLabel": "Proceeds from Sale of Productive Assets" } } }, "localname": "ProceedsFromSaleOfProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r89", "r304" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from Stock Options Exercised" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyAccrualClassifiedCurrent": { "auth_ref": [ "r44", "r237", "r238" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Product Warranty Accrual, Current", "terseLabel": "Product Warranty Accrual, Current" } } }, "localname": "ProductWarrantyAccrualClassifiedCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/ACCRUEDLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyAccrualPayments": { "auth_ref": [ "r239" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in the standard and extended product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard and extended product warranty.", "label": "Standard and Extended Product Warranty Accrual, Decrease for Payments", "negatedTerseLabel": "Standard and Extended Product Warranty Accrual, Decrease for Payments" } } }, "localname": "ProductWarrantyAccrualPayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/ACCRUEDLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyAccrualWarrantiesIssued": { "auth_ref": [ "r240" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in the standard and extended product warranty accrual from warranties issued.", "label": "Standard and Extended Product Warranty Accrual, Increase for Warranties Issued", "terseLabel": "Standard and Extended Product Warranty Accrual, Increase for Warranties Issued" } } }, "localname": "ProductWarrantyAccrualWarrantiesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/ACCRUEDLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]", "terseLabel": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r230", "r452", "r453", "r454" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property, Plant and Equipment Disclosure [Text Block]" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/PROPERTYPLANTANDEQUIPMENTNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r37", "r226" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property, Plant and Equipment, Gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/PROPERTYPLANTANDEQUIPMENTDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r12", "r13", "r228", "r433" ], "calculation": { "http://www.luminexcorp.com/role/BALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, Plant and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/BALANCESHEETS", "http://www.luminexcorp.com/role/PROPERTYPLANTANDEQUIPMENTDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r36", "r102", "r228", "r452", "r453" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property, Plant and Equipment, Policy [Policy Text Block]" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/ACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r12", "r228" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Property, Plant and Equipment [Table Text Block]" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/PROPERTYPLANTANDEQUIPMENTTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PurchaseObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.", "label": "Purchase Obligation", "terseLabel": "Purchase Obligation" } } }, "localname": "PurchaseObligation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Receivables [Abstract]", "terseLabel": "Receivables [Abstract]" } } }, "localname": "ReceivablesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": { "auth_ref": [ "r28", "r102", "r185" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.", "label": "Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]", "terseLabel": "Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]" } } }, "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/ACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RecordedUnconditionalPurchaseObligation": { "auth_ref": [ "r234" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the recorded obligation to transfer funds in the future for fixed or minimum amounts or quantities of goods or services at fixed or minimum prices (for example, as in take-or-pay contracts or throughput contracts).", "label": "Recorded Unconditional Purchase Obligation", "terseLabel": "Recorded Unconditional Purchase Obligation" } } }, "localname": "RecordedUnconditionalPurchaseObligation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r316", "r455" ], "calculation": { "http://www.luminexcorp.com/role/INCOMESTATEMENTS": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INCOMESTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r102", "r316" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Expense, Policy [Policy Text Block]" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/ACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r144" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units (RSUs) [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r22", "r252", "r309", "r431", "r445", "r449" ], "calculation": { "http://www.luminexcorp.com/role/BALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/BALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r111", "r112", "r113", "r117", "r125", "r127", "r193", "r305", "r306", "r307", "r342", "r343", "r442", "r444" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYSTATEMENTS" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueRecognitionAndDeferredRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue Recognition and Deferred Revenue [Abstract]", "terseLabel": "Revenue Recognition and Deferred Revenue [Abstract]" } } }, "localname": "RevenueRecognitionAndDeferredRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueRecognitionDeferredRevenue": { "auth_ref": [ "r102" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing unearned income or deferred revenue related to transactions involving the sale of a product or performance of services.", "label": "Revenue Recognition, Deferred Revenue [Policy Text Block]", "terseLabel": "Revenue Recognition, Deferred Revenue [Policy Text Block]" } } }, "localname": "RevenueRecognitionDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/REVENUERECOGNITIONNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r103", "r104" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue Recognition, Policy [Policy Text Block]" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/ACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r70", "r105", "r161", "r162", "r167", "r172", "r173", "r177", "r178", "r180", "r191", "r378", "r422" ], "calculation": { "http://www.luminexcorp.com/role/INCOMESTATEMENTS": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INCOMESTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/ACCOUNTSRECEIVABLETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accrued Liabilities [Table Text Block]" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/ACCRUEDLIABILITIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r341" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INCOMETAXESTablesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INCOMETAXESTablesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r143" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Basic and Diluted Earnings Per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/EARNINGSPERSHARETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INCOMETAXESTablesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r212", "r217", "r404" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INTANGIBLEASSETSDetail", "http://www.luminexcorp.com/role/INVESTMENTSDetailsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": { "auth_ref": [ "r393" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.", "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]", "terseLabel": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/COMMITMENTSANDCONTINGENCIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r107" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "terseLabel": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INCOMETAXESTablesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": { "auth_ref": [ "r208" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.", "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]", "terseLabel": "Schedule of Intangible Assets and Goodwill [Table Text Block]" } } }, "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INTANGIBLEASSETSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r10", "r31", "r32", "r33" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Components of Inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INVENTORIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherInvestmentsNotReadilyMarketableTextBlock": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of other investments not readily marketable, including, but not limited to, description of investment, fair value and value as measured by quoted price.", "label": "Other Investments Not Readily Marketable [Table Text Block]", "terseLabel": "Other Investments Not Readily Marketable [Table Text Block]" } } }, "localname": "ScheduleOfOtherInvestmentsNotReadilyMarketableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INVESTMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": { "auth_ref": [ "r241" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability.", "label": "Schedule of Product Warranty Liability [Table Text Block]", "terseLabel": "Schedule of Product Warranty Liability [Table Text Block]" } } }, "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/ACCRUEDLIABILITIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": { "auth_ref": [ "r77", "r179" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]", "terseLabel": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/GEOGRAPHICINFORMATIONNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r273", "r303" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r217" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Estimated Future Amortization Expense Related to Intangible Assets" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INTANGIBLEASSETSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r81" ], "calculation": { "http://www.luminexcorp.com/role/INCOMESTATEMENTS": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, General and Administrative Expense" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INCOMESTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r96" ], "calculation": { "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/CASHFLOWSSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "Discount rate from fair value on purchase date that participants pay for shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r283" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r287" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r287" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r298" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r290" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period", "negatedTerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r289" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r303" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r280", "r303" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r279" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r293" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r291" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r271", "r275" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r102", "r273", "r277" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/ACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit", "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit", "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r295", "r310" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r303" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r293" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r278" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": { "auth_ref": [ "r253", "r315" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).", "label": "Shareholders' Equity and Share-based Payments [Text Block]", "terseLabel": "Shareholders' Equity and Share-based Payments [Text Block]" } } }, "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITY" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r49", "r111", "r112", "r113", "r117", "r125", "r127", "r151", "r193", "r251", "r252", "r305", "r306", "r307", "r342", "r343", "r380", "r381", "r382", "r383", "r384", "r386", "r442", "r443", "r444" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYSTATEMENTS" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYSTATEMENTS" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r111", "r112", "r113", "r151", "r403" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYSTATEMENTS" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r18", "r19", "r251", "r252" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Stock Issued During Period, Shares, Employee Stock Purchase Plans" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails", "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYSTATEMENTS" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r18", "r19", "r251", "r252" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYSTATEMENTS" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r18", "r19", "r251", "r252", "r282" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails", "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYSTATEMENTS" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan": { "auth_ref": [ "r18", "r19", "r251", "r252", "r314" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate value of stock issued during the period as a result of employee stock ownership plan (ESOP).", "label": "Stock Issued During Period, Value, Employee Stock Ownership Plan", "terseLabel": "Stock Issued During Period, Value, Employee Stock Ownership Plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYDetailsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r251", "r252" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r49", "r251", "r252" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Stock Issued During Period, Value, Stock Options Exercised" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r19", "r24", "r25", "r105", "r186", "r191", "r378" ], "calculation": { "http://www.luminexcorp.com/role/BALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "terseLabel": "Stockholders' Equity Attributable to Parent", "totalLabel": "Stockholders' Equity Attributable to Parent" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/BALANCESHEETS", "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' Equity Attributable to Parent [Abstract]" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/BALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.", "label": "Stockholders' Equity, Other", "negatedLabel": "Other, net" } } }, "localname": "StockholdersEquityOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/STOCKHOLDERSEQUITYSTATEMENTS" ], "xbrltype": "monetaryItemType" }, "us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of unrecognized tax benefits for which a material change is reasonably possible in the next twelve months, typically including the nature of the uncertainty, the event(s) that could cause a material change, and an estimate of the range of the reasonably possible change or a statement that an estimate of the range cannot be made. An unrecognized tax benefit is the difference between a tax position taken in a tax return and the amounts recognized in the financial statements for which it is more likely than not, based on the technical merits of the position, that the tax position will not be sustained upon examination.", "label": "Summary of Positions for which Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Table Text Block]", "terseLabel": "Summary of Positions for which Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Table Text Block]" } } }, "localname": "SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INCOMETAXESTablesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_TaxesPayableCurrent": { "auth_ref": [ "r42" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Taxes Payable, Current", "terseLabel": "Taxes Payable, Current" } } }, "localname": "TaxesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/ACCRUEDLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TechnologyBasedIntangibleAssetsMember": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights.", "label": "Technology-Based Intangible Assets [Member]", "terseLabel": "Technology-Based Intangible Assets [Member]" } } }, "localname": "TechnologyBasedIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INTANGIBLEASSETSDetail" ], "xbrltype": "domainItemType" }, "us-gaap_UnamortizedDebtIssuanceExpense": { "auth_ref": [ "r39" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.", "label": "Unamortized Debt Issuance Expense", "negatedTerseLabel": "Unamortized Debt Issuance Expense" } } }, "localname": "UnamortizedDebtIssuanceExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r317", "r326" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Unrecognized Tax Benefits", "periodStartLabel": "Unrecognized Tax Benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r327" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "negatedTerseLabel": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r328" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "terseLabel": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r327" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "terseLabel": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecordedUnconditionalPurchaseObligationImputedInterest": { "auth_ref": [ "r233" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "If disclosed, the amount of imputed interest necessary to reduce an unconditional purchase obligation to present value on an unrecorded unconditional purchase obligation.", "label": "Unrecorded Unconditional Purchase Obligation, Imputed Interest", "negatedTerseLabel": "Unrecorded Unconditional Purchase Obligation, Imputed Interest" } } }, "localname": "UnrecordedUnconditionalPurchaseObligationImputedInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r152", "r153", "r155", "r156", "r157", "r158", "r159" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Estimates and Assumptions" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/ACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r133", "r143" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted Average Number of Shares Outstanding, Diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/EARNINGSPERSHAREDetailsDetails", "http://www.luminexcorp.com/role/INCOMESTATEMENTS" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r131", "r143" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted Average Number of Shares Outstanding, Basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/EARNINGSPERSHAREDetailsDetails", "http://www.luminexcorp.com/role/INCOMESTATEMENTS" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]", "terseLabel": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.luminexcorp.com/role/INCOMESTATEMENTS" ], "xbrltype": "stringItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=d3e31137-122693" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=SL108384541-122693" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1500-109256" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "60", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2740-109256" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258" }, "r149": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=SL6953423-111524" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5144-111524" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r187": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/subtopic&trid=2196772" }, "r188": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r192": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "323", "URI": "http://asc.fasb.org/topic&trid=2196965" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r204": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r209": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/subtopic&trid=2144439" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r223": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25376-109308" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25383-109308" }, "r235": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r236": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68070138&loc=d3e11281-110244" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12524-110249" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "((c)(2))", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "((c)(3))", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r242": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "460", "URI": "http://asc.fasb.org/topic&trid=2155896" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4724-112606" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=51819886&loc=SL6014347-161799" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031898-161870" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031898-161870" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r253": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r261": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "705", "URI": "http://asc.fasb.org/topic&trid=2122478" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f(1))", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "40", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109244457&loc=d3e16649-113920" }, "r315": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "740" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "740" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r358": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5227-128473" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5419-128473" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=SL116692626-108610" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r387": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "http://asc.fasb.org/topic&trid=2175825" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(1)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(2)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(3)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r409": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/subtopic&trid=2176304" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "820", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=35710923&loc=d3e45360-110995" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r423": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/subtopic&trid=2209399" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(f))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/subtopic&trid=2324412" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r456": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r457": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r458": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r459": { "Name": "Forms 10-K, 20-F, 40-F", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d-1" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r461": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.20)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "http://asc.fasb.org/topic&trid=2134417" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3581-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" } }, "version": "2.1" } ZIP 75 0001033905-21-000012-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001033905-21-000012-xbrl.zip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�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ʭ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�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end